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Abstract 
 
 
Pharmacological-functional imaging provides a non-invasive method by which the actions 
of neurotropic drugs on the human brain can be explored. Simply put, it assesses how 
neural activity patterns associated with cognitive functions of interest are modified by a 
drug challenge. Since one of the most widely-used cognitive-enhancing drugs in clinical 
practice are cholinesterase inhibitors, this thesis applies pharmacological functional 
imaging to the question of understanding how such drugs work - both in healthy people and 
dementia. The experiments in this thesis describe how brain activations – as revealed by 
functional magnetic resonance imaging (fMRI) – are modulated by the cholinesterase 
inhibitor physostigmine, during tasks designed to isolate sensory, attentional, and memory 
processes. While non-human and human psychophysical studies suggest that all three of 
these cognitive functions are under the control of the endogenous cortical cholinergic 
system, understanding how neurobiological models of cholinergic function translate into 
human brain activation modulations is unclear. One main question that is particularly 
relevant in this regard, that recurs through all the experiments, is how physostigmine-
induced neuromodulations differ between sensory-driven ‘bottom-up’, and task-driven 
‘top-down’, brain activations. The results are discussed with reference both to non-human 
physiological data and to existing human cholinergic-functional imaging studies (fifty 
studies published to date), which are themselves reviewed at the outset. Furthermore, 
assumptions based upon the physical and physiological principles of pharmacological 
functional imaging, being critical to interpretation, are discussed in detail within a general 
methods section. 
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the pupillary sphincter in a pinch-like manner (Anderson, 1905)  
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1. Introduction
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Purpose 
This thesis is about how one neuromodulatory system – the cortical cholinergic system – 
interacts with brain activity during normal and disease states. The question of course 
implies that there are, in very broad terms, two types of brain system that themselves are 
interconnected. On the one hand, we have the main platform for information processing – 
the cerebral cortex with its rapid and specific synaptic connections mediated by 
transmitters such as glutamate and GABA. On the other hand, we have neuromodulatory 
systems that influence information processing relatively uniformly, over broad spatial and 
temporal ranges. Instead of signalling ‘there is now a light stimulus present at 37 degrees 
East, 42 degrees North’ as a glutamatergic synapse might, neuromodulators might convey 
the request that all receptors should be ‘on guard’ for any new incoming input. 
 
Put like this, neuromodulation seems quite ancillary to cortical processing, and perhaps 
therefore plays only a minor role in brain function. Its actions, in being broad and non-
specific, make its relationship with cortical function analogous to the volume knob’s role 
in relation to a sophisticated music recording.  However, there are at least two reasons 
why we shouldn’t relegate neuromodulation just yet. Firstly, as we shall see in the next 
chapter, neuromodulators are able to orchestrate processing over wide regions and so are 
ideally placed to change the mode of cortical function to suit an animal’s currently 
required behavioural set (e.g. to be vigilant, bored, restful, etc). Rather than acting merely 
as a volume knob, neuromodulators may act more as the overall control panel switching 
between radio and CD functions! Neurophysiologists, moreover, can work backwards 
from this viewpoint by identifying all the actions of one neuromodulator as together 
 11
Chapter 1 
serving a common functional purpose (cf. the usual neurophysiological approach of 
correlating isolated neural responses with behavioural or environmental events). 
Furthermore, the conception of neuromodulators, and especially acetylcholine, as acting 
non-specifically over wide swathes of the brain is increasingly challenged (Sarter et al, 
2009) on the basis of mounting data showing ACh release patterns more temporally and 
spatially precise than previously believed.   
 
The second reason for being interested in neuromodulation is clinical. Following brain 
injury due to whatever cause, the potential for recovery is slow and usually incomplete. 
Rehabilitation therapies may extend or hasten the capacity for repair but still fall far short 
of being able to provide a return to normal function universally. One reason for this is 
that correction of brain injury, where this involves damage to specific, one-to-one 
connections of cortical circuits, would require insertion of a replica circuit – a challenge 
as good as impossible by today’s technology. Rehabilitation therapies may work by re-
creating copies, albeit imprecisely, of damaged circuitry in unaffected parts of the brain. 
But to be more successful rehab-based strategies will require a considerable advance in 
our understanding of compensatory neural mechanisms, and technological ability to 
manipulate these.  
 
A short cut to brain recovery may be provided by neuromodulation. For a start, if any 
component of brain injury includes a neuromodulatory deficit this could be conveniently 
restored through a systemically-acting drug given the properties of neuromodulators of 
acting over a distance, en masse etc. For example, Alzheimer’s disease, like many 
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neurodegenerative diseases, involves degeneration of multiple systems simultaneously, 
but of these, it is only the cholinergic deficiency that can be easily reversed (Mesulam, 
2004). Furthermore, given the usual location of diseases such as stroke and multiple 
sclerosis (Selden et al, 1998), it is likely that their associated lesions often interrupt 
cortical cholinergic pathways, again laying open the opportunity for pro-cholinergic 
therapies.  
 
 
Aims 
The first aim of this thesis is to explore how one of the most well-known class of 
neuromodulator drugs – cholinesterase inhibitors (ChEIs) – modifies cerebral processing, 
and related cognitive performance, in its principle application in dementia. ChEIs were 
first used medicinally for glaucoma after it was observed that they had a pupillary-
constricting effect (see Figure, page 9). However, it was only after the cholinergic basis 
of ChEIs actions were discovered that it became apparent that they may be of use in 
diseases characterised by impaired cholinergic neurotransmission, viz. myasthenia gravis 
and Alzheimer’s disease.  
 
Ironically, the contrast between ChEI use in these two diseases couldn’t be greater. 
Current knowledge of myasthenia gravis - an immune disorder in which autoantibodies 
are directed against neuromuscular-junction cholinergic transmission - allows for a 
comprehensive understanding of its associated peripheral cholinergic transmission 
dysfunction. The centrality of acetylcholine to its pathophysiology predictably accounts 
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for the high efficacy and universality of ChEI benefit in this patient group. By contrast, 
the same drug type in Alzheimer’s disease - a neurodegenerative disease characterized by 
early cerebral cholinergic fibre loss amongst other findings - is associated with only a 
mild benefit, on only certain cognitive and behavioural measures, and then only in certain 
patients (Giacobini, 2000). Hence, at least within the dementia community, there is a 
clinical need for an understanding into how ChEIs exert their cognitive effects. It would 
be useful to know which brain systems or neural processes can be influenced by ChEIs; 
whether these drug-induced modulations effectively reverse deficits seen in dementia, 
and whether these effects on brain activity can provide a sensitive indicator of therapeutic 
responsiveness. 
 
A second aim of the thesis is to question the effects of ChEIs in healthy subjects. On the 
one hand, a limited number of experiments have shown that such drugs may improve 
cognitive performance (Davis et al, 1978), albeit by only a small effect size and with 
wide variance (as we see with AD). On the other hand, evidence from diverse sources 
suggests that a central hypercholinergic state may be detrimental, for example by 
inducing a hypervigilant state, and may partly explain the pathogenesis of disorders such 
as anxiety and schizophrenia (Berntson et al, 2003). Only through examining brain 
activity, its relation to behavioural responses, and the effects of cholinergic modulation 
on both, might we begin to formulate models that could explain these prima facie 
conflicting sets of observations.      
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From an evolutionary perspective, we would not expect a normal-functioning biosystem 
– such as the mammalian cortical cholinergic system - to be significantly lacking along 
any dimension that could readily be corrected by a simple biochemical alteration. We 
would especially not expect any such fault to be present in a cognitive system residing in 
an organism that has excelled in its behavioural capacities. Hence it is highly likely that, 
as with virtually all other physiological parameters, the normal range of brain levels of 
acetylcholine are tightly regulated to ensure optimal functioning. Deviation from the 
norm, in either direction, is likely to entail net performance deterioration, i.e. over the 
average of behavioural states that an animal typically finds itself in.  
 
One possible explanation for the paradoxical finding of both positive and negative effects 
of a hypercholinergic state is that while a limited number of performance measures may 
improve, this is at a greater cost in the long run due to impairments on other measures. 
We might predict therefore that a low-cholinergic state may also be useful given that it 
intermittently occurs in normal people, even if when induced pharmacologically, low 
cholinergic states induce deleterious effects such as sedation and impaired attention. 
Interestingly, something similar to this has recently been found: if the muscarinic blocker 
scopolamine is administered shortly after an object-to-be-remembered is presented (i.e. 
after encoding) subsequent memory of it increases; but if scopolamine is given 
immediately before encoding then memory is decreased (Winters et al, 2007). Of course, 
real life does not resemble a controlled psychology experiment. So the problem facing an 
animal is that it does not know following a significant experience whether it should 
decrease its acetylcholine levels so as to improve subsequent recall of the event just 
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passed, or whether it should heighten acetylcholine levels so as to enhance memory of 
any subsequent, and possibly more important, experiences. Consequently, we might 
expect animals to have the facility to adjust their acetylcholine levels in line with a 
running internal estimate of environmental predictability: a prediction borne out across 
diverse animal and psychophysical studies (see Yu & Dayan, 2005).   
 
The final aim of this thesis, but perhaps one that needs to be addressed before tackling the 
first two, is to question the role and capabilities of functional imaging in psycho-
pharmacology. Until recently many of the explanations behind ChEIs’ actions have been 
circumstantial, involving extrapolations from animal models or human drug effects to 
human disease. For example, it is assumed that ChEIs produce effects in opposite 
directions to those induced by selective cholinergic lesions in non-human animals, or by 
administration of scopolamine to healthy individuals. Given that Alzheimer’s disease 
shows a loss of cholinergic cell markers it is assumed that ChEIs, in raising acetylcholine 
levels, can help to restore cholinergic control of cortical processing. However, such leaps 
of faith – e.g. from monkey lesion to human disease, or from drug model to disease 
model – do not always hold. Given the extent of cholinergic damage seen in AD, and the 
importance of acetylcholine to a wide number of cognitive actions, is it not surprising to 
observe only small benefits when ChEIs are actually used in AD? Why also do some 
patients respond well to ChEIs, while others not at all? Hence there is a calling for 
technologies that are able to go beyond mere behavioural testing, that actually probe 
brain function, and subsequently to observe how drugs modulate both neurophysiological 
processes and performance in one. 
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The advent of new non-invasive imaging technologies – fMRI, MEG, EEG, and 
radioligand-based techniques - as well as invasive recording in patients needing this for 
clinical reasons (e.g. as part of a perioperative protocol for severe epilepsy or Parkinson’s 
disease), make it increasingly possible, firstly, to examine brain function directly in 
patients themselves, and secondly to observe the effects of psychoactive drugs on these 
measures. The results of such studies will need to be complemented by the findings of 
animal studies which, in so far as they enable recording of single units in any part of the 
brain, still provide by far the best resolution of neurophysiological measurement. Yet 
animal studies have limitations: there are clear phylogenetic differences with humans in 
brain anatomy, organisation, cognitive capacities, and diseases. It is only to be expected 
that animal models of Alzheimer’s disease that recreate the biochemical and pathological 
characteristics of the human equivalent are difficult to compare at the level of cognitive 
impact. So our best understanding will most likely come from a synthesis of human-
based imaging techniques with animal-derived data.  
 
A good example of how measurements of neural responses can be compared across 
different instruments, at different scales, in different organisms is shown in the following 
example (Figure 1.1; for Details see pages 45 - 47 and 85). The effects of increasing 
acetylcholine levels, either directly or through ChEI administration, on occipital cortex 
responses to visual stimulation have been looked at using: 1) single cell recording; 2); 
voltage-sensitive dye optical imaging 3) event-related potentials; and 4) fMRI (from the 
current thesis), in cats (1,2,3) and humans (4), respectively. The animal studies seem to 
 17
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converge on showing that increasing acetylcholine concentrations decreases the overall 
level of neural activity, due to an increase in the ratio of signal (afferent input) to noise 
(including feedback or intrinsic input). The latter is demonstrated by comparing 
activation levels from layer IV (afferent input) with that of other layers that receive 
intrinsic input, which is illustrated succinctly by example (2). In humans, the blood 
oxygen level dependent (BOLD) – fMRI response in primary visual cortex, but not other 
cortical areas, was also found to be reduced by physostigmine (that increases extracellular 
acetylcholine levels) suggesting that what is seen by BOLD in humans is equivalent to 
that seen with voltage dyes and single unit recordings in animals. For certainty of this 
claim, however, it would be necessary to perform pharmacological investigations in 
animals that are simultaneously probed with electrophysiological and BOLD measures, as 
performed in monkey visual cortex (Logothetis et al, 2001). For our example, it would be 
crucial to see if cholinergic-induced changes in neural activity paralleled that observed 
with BOLD, since it is likely that factors underlying monkey and human BOLD signal 
generation are very similar – certainly more similar than the link between recordings of 
animal single units or columns and human BOLD or cerebral blood flow.  
 
Chapter 1 
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1) Single Unit (Tatano et al, 2005) 2) Cell Column (Optical Imaging) (Kimura et al, 1999)
3) Evoked Responses (Harding et al, 1983) 2) BOLD Response (Silver et al, 2008)
Cortical 
layers 
I 
II 
III 
IV 
V 
VI 
Figure 1.1: Different scales and methods by which cholinergic function can be measured.  
Chapter 1 
Layout 
Cholinesterase inhibitors work primarily by boosting the brain’s cholinergic system, and 
so the thesis Background begins with a survey of cholinergic neuroanatomy, 
neurophysiology and neuropsychology. Three broad cognitive systems can be identified 
with which endogenous and exogenous cholinergic manipulations interact: sensory, 
attention and memory. A description of cholinergic influences on these systems using 
traditional neurophysiological methods such as single-unit recordings, micro-
iontophoresis, and lesion studies is first described, before the most well-established 
models of brain cholinergic function are expounded. This section is followed by a brief 
account of cholinergic pharmacology, including a summary of physiological and 
psychological effects cholinesterase inhibitors. Finally, since the last two experiments in 
this thesis investigate effects of cholinesterase inhibitors in Alzheimer’s disease, this 
section evaluates evidence for and against a central cholinergic deficiency as a cause of 
this disease’s clinical manifestations.   
 
The experiments presented in this thesis contribute to approximately fifty cholinergic 
functional imaging studies reported in healthy human adults. These previous functional 
imaging studies are described in the Human Cholinergic Functional Imaging Review 
section, by first dividing up effects into sensory cortex, frontoparietal and memory-
associated modulations – in line with current models of cholinergic function. For each 
study is listed: the imaging methodology and paradigm; cholinergic drug employed; the 
resultant neuromodulation, and the nature of any behavioural effects concomitantly 
observed. A summary of the most consistent cholinergic functional imaging results is 
20 
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then presented, together with an attempt to link these findings with current 
neurobiological and computational models of cholinergic function.  
 
The Methods section next explains the theory and practice of functional magnetic 
resonance imaging (fMRI), both in terms of its physical basis, and in terms of the 
statistical analysis of its data. This section then questions the assumptions, criticisms and 
counter-criticisms to the application of fMRI to neuropharmacology, upon which all 
experiments in this thesis are based.  
 
Corresponding to the three divisions of brain function with which acetylcholine interacts, 
the Experiments of this thesis encompass the question: how does cholinesterase 
inhibition – using the centrally-acting drug physostigmine - modulate neural activity 
associated with sensory stimulation, attention, and memory? Since contemporary 
accounts of cholinergic function postulate a role for acetylcholine in modulating 
processes that are both bottom-up (i.e. stimulus-dependent) and top-down (i.e. dependent 
upon task or internal-set), the experiments in this thesis are designed to tease apart the 
differential effects of cholinesterase inhibition on both types of process. Thus 
Experiments 1 and 4 probe effects of physostigmine on brain activity associated with 
attentional and sensory factors, manipulated orthogonally. Similarly, Experiment 3 
contrasts effects of physostigmine on visual stimulation with that on attention and 
working memory, while also questioning cholinergic interactions with spatial-directed 
attention. Interweaving with cholinergic influences on sensory and attentional functions, 
are its effects on memory – especially since pharmacological studies show that 
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cholinergic blockade interferes primarily with stimulus encoding. Correspondingly, 
Experiments 2 and 5 question how physostigmine modulates memory-associated neural 
activity, using the functional imaging memory signatures of repetition decreases and 
subsequent memory effects, respectively. It should be noted that Experiments 2 and 5, 
involve the same general behavioural paradigm as Experiments 1 and 4, respectively 
(thus explaining their ordering), yet are analysed in ways that specifically focus on their 
memory-related factors. Finally, given evidence for differences in cholinergic status 
between healthy people and those with Alzheimer’s disease, and given the clinical role of 
pro-cholinergic drugs, Experiments 4 and 5 question whether cholinesterase inhibition 
exerts different  neuromodulatory effects between Alzheimer’s disease patients and age-
matched healthy controls.  
 
The main results of the five experiments are summarised in the General Discussion, 
before a more general interpretation of these experiments is presented in the form of six 
key findings. The thesis concludes by questioning the role and potential future 
applications of pharmacological-functional imaging. 
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2. Background 
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Cholinergic Neuroanatomy 
 
A helpful starting point in understanding the functionality of any neural system is a detail of 
its anatomy, and more specifically, what other structures it connects with. Unlike 
neuromodulators such as dopamine and serotonin which are confined to well-localised brain 
circuits (e.g. dopamine with premotor and reward pathways), neurotransmission involving 
acetylcholine occurs in virtually all parts of the brain, reflecting its purported involvement in 
nearly all cognitive domains.  
 
The localisation of cholinergic neurons in the post-mortem brain has been achieved most 
specifically through immunohistochemical identification of choline acetyltransferase (ChAT), 
the synthetic enzyme for ACh (Fig. 2.1). This has shown in the human CNS that cholinergic 
neurons occur in the following locations, some of which are assembled in cell groups, or 
nuclei, designated ‘Ch’ (Figs. 2.2, 2.3): 
 
1. Basal forebrain (Ch1-4): 
- substantia innominata = magnocellular nucleus basalis of Meynert = Ch4 
   - medial septum = Ch1 
               - vertical limb nucleus of the diagonal band = Ch2 
               - horizontal limb nucleus of the diagonal band = Ch3 
2. Striatum: interneurons  
3. Cerebral cortex: interneurons  
4. Brainstem / reticular formation:  
                - pedunculopontine tegmental nucleus (Ch5): connects diffusely to thalamus  
                - lateral dorsal pontine tegmental nucleus (Ch6): connects to specific 
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                  thalamic nuclei 
                - parabrachial nuclei (pons): connects to thalamus 
5. Habenula, medial nucleus (Ch7) (posterior thalamus) 
6. Parabigeminal nucleus (Ch8): interacts with superior colliculus 
7. Motor nuclei and parasympathetic branches of cranial nerves 
8. Motor neurons of spinal cord  
 
Animal lesion studies have shown that it is the basal forebrain, rather than other sources of 
ACh, that is most critical for higher cognitive processes such as attention and memory. The 
wide range of cognitive processes that appear to be under cholinergic influence is suggested 
by the broad connections of basal forebrain cholinergic cells with all parts of cerebral cortex, 
as well as to thalamus and brainstem. A minor input to cingulate and medial prefrontal 
cortices is also provided by pontine tegmental ACh fibres (Satoh & Fibiger, 1986). 
Cholinergic structures other than basal forebrain, e.g. in brainstem and thalamus, are 
concerned with more basic performance aspects, such as arousal. 
 
The major functional divisions of cholinergic basal forebrain are as follows (Fig. 2.2): 
1. Nucleus basalis (caudal basal forebrain; ventromedial pallidum) – Ch4 
– supplies whole of neocortex, and has broad sensory, attentional and memory 
functions 
– supplies amygdala via ventral amygdalofugal pathway and stria terminalis 
– divisible into medial and lateral cholinergic pathways (Selden et al, 1998) 
(Fig. 2.3). The medial pathway supplies the gyrus rectus, medial orbitofrontal, 
cingulate, retrosplenial and medial occipital cortices. The lateral pathway 
divides into a capsular division that courses in the white matter of the external 
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capsule and uncinate fasciculus, and a perisylvian division that travels with 
the claustrum. 
2. Medial Septum – Ch1 
– supplies hippocampus via fornix-fimbria (along with GABAergic and 
neuropeptide fibres), and has selective effects on episodic memory 
3. Vertical Limb of the Diagonal Band – Ch2 
            -    supplies cingulate cortex, as well as hippocampus, and performs a   
                 specific role in types of learning e.g. conditional discrimination 
4. Horizontal Limb of the Diagonal Band – Ch3 
            -    supplies olfactory bulb 
 
At a finer level of structural organisation, it appears that basal forebrain – corticopetal fibre 
system is clustered into longitudinal bands that separately innervate different parts of the 
cortical mantle (Zaborszky, 2002). This observation together with the fact that cholinergic 
projections to the cortex are only to a very limited degree, collateralised (Semba, 2000), 
suggests that the cholinergic basal forebrain may be divisible into functional modules with 
each modulating separate, parallel cortico-subcortical circuits. Spatially precise modes of 
cholinergic modulation within neocortex may also arise from two further anatomical 
arrangements: 1) cortico-cortical glutamatergic interactions at the termini, rather than 
(nucleus basalis) cell bodies of cholinergic fibres (Parikh et al, 2008), and 2) cortical 
cholinergic interneurons that are confined to neocortical columns (von Engelhardt et al, 
2007).  
 
For the purposes of the current thesis it cannot be underemphasised that any intravenously-
administered cholinergic-acting drug e.g. physostigmine, which crosses the blood-brain 
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barrier, would be expected to act on all of these cholinergic structures. The aim of this thesis 
is to describe how cholinergic manipulation using such a globally-acting drug – as occurs in 
real-life clinical scenarios - can alter function-related activity within specific brain regions. 
Hence the anatomical specificity provided by functional imaging, as presented in this thesis, 
applies to neural consequences that are downstream to the sites at which cholinergic 
neurotransmission occurs, and not to the exact areas at which cholinergic pathways are 
modified. This lies in contrast to various neurochemical imaging techniques that employ 
radioligands to target chemically-defined structures such as receptors or transporters, and 
which delineate the sites of neurotransmission of the very neurochemical in question.  
Figure 2.1: Schematic of cholinergic neurotransmission 
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 Figure 2.2: Principle cholinergic pathways of the human brain 
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Figure 2.3: Disposition of cholinergic cell-bodies within nucleus basalis (A), and main cholinergic corticopetal trajectories (B) in human brain 
No of Overlapping Brains
1 10
A. Probabilistic maps of the Ch4 cell groups at 
six rostro-caudal levels
Zaborsky et al, 2008 Selden et al, 1998
B. AchE-rich (cholinergic) fibre bundles in hemispheric white matter. 
Green=medial pathway; Red=lateral pathway (capsule division); 
Orange=lateral pathway (perisylvian division). 
Blue=Cholinergic Ch4 neurons of the nucleus basalis of Meynert.
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Cholinergic Neurophysiology – General vs Specific Neuromodulation 
 
Diffuse, tonic effects 
The cortical cholinergic system has traditionally been thought of as a general activator 
of cerebral activity, with the nucleus basalis being conceived as a rostral extension of 
the brainstem ascending reticular activating system. During tonic states such as 
wakefulness (Kametani & Kawamura, 1990) and REM sleep (Jasper & Tessier, 
1971), there are increases in basal forebrain activity; cortical acetylcholine release, 
and cortical EEG arousal patterns; while during inactivity or slow-wave sleep all these 
measures decrease (Detari et al, 1999). Cholinergic antagonists, or lesions of nucleus 
basalis, also induce large slow waves in the cortex similar to those seen during non-
REM sleep (Buzsaki et al, 1988). If only a partial basal forebrain lesion is made then 
only the cortical region corresponding to the denervated cholinergic fibres shows 
EEG slowing. Activating fibres from mesencephalic reticular formation to nucleus 
basalis explain cholinergic dependency of arousal-state cortical EEG patterns (Wainer 
& Mesulam, 1990), while cholinergic projections within pedunculopontine tegmental 
nucleus can induce arousal patterns of thalamocortical activation (Ye et al, 2010). 
 
Corresponding to the behavioural-EEG data are structural and physiological 
properties of cortical cholinergic cells that suggest ACh acts non-specifically to 
increase cortical responsiveness. Cholinergic fibres project to all parts of the cerebral 
cortex and access all layers (Mechawar et al, 2000). The number of cholinergic basal 
forebrain neurons is far less (e.g. ~ 7000 in the rat nucleus basalis) than the number of 
target neocortical neurons (Miettinen et al, 2002). Correspondingly, cholinergic cells 
that innervate the neocortex have extensive terminal fields implying co-activation of 
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widely divergent cortical regions (Adams et al, 1986). Furthermore, any one cortical 
region receives input from disparate nucleus basalis regions (Baskerville et al, 1997). 
Early studies suggested that the predominant response to acetylcholine is excitation 
(Krnjevic & Phillis, 1963; Sillito & Kemp et al, 1983). However, more recent studies, 
employing ACh concentrations and temporal durations matched to physiological 
modes of release, suggest that neural inhibition may be a more widespread neocortical 
response to ACh (Gulledge et al, 2007).  
 
Activation of the basal forebrain cholinergic neurons occurs in a diffuse, all-or-none 
fashion. Input connections to the basal forebrain from disparate cortical, subcortical 
and brainstem areas suggest a broad, unselective activation pattern (Zaborszky et al, 
1997). Furthermore, sampling of acetylcholine concentrations in widely separate parts 
of cortex shows no significant inter-regional difference in ACh release following 
sensory stimulation (Phillis & Chong, 1965; Collier & Mitchell, 1966), or following 
bidirectional pharmacological manipulation of basal forebrain activity (e.g. Casamenti 
et al, 1986; Moore et al, 1995).   
 
At an ultrastructural scale, it is found that acetylcholine vesicles are mostly disposed 
within axonal varicosities that, in ~90% of cases, do not make immediate contact with 
synapses (Umbriaco et al, 1994; Umbriaco et al, 1995; Descarries et al, 1997). This 
layout suggests that activation of such cells sprays ACh over a wide cortical area, 
producing postsynaptic effects over a large spatial scale (so-called ‘volume-
transmission’).  Furthermore, this structural arrangement accounts for post-synaptic 
effects of acetylcholine occurring over significantly longer time periods (~10-20 
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seconds) than classical glutamatergic or GABAergic synapses (< 1 second) (Krjnevic 
et al, 1971; Hasselmo & Fehlau, 2001).   
 
Focal, phasic effects 
In spite of many characteristics that lend favour to the traditional model of the 
cholinergic system as a mere arousal-heightening or ‘gain increase’ mechanism, a 
growing body of evidence disputes this. Anatomically, this has been suggested by 
noting that although cholinergic innervation is pervasive (see above), the regional and 
laminar arrangement of both cholinergic fibres, and cholinergic receptors, is 
heterogeneous (Lidow et al, 1989). For example, most cholinergic varicosities are 
concentrated in layers I and V, accounting for ACh’s ability to modulate columnar 
output (Mechawar et al, 2000). Furthermore, contrary to some groups showing a 
predominance of non-synaptic cholinergic varicosities in rodents (Umbriaco et al, 
1994), other groups have found in monkeys (Mrzljak et al. 1995) and humans (Smiley 
et al. 1997), as well as rodents (Turrini et al. 2001; Casu et al. 2002), that that the 
majority of corticopetal cholinergic fibres make specialised synaptic connections with 
cortical neurons (Fig. 2.4).  
 
The relative importance of volume transmission (i.e. non-synaptic and tonic) relative 
to wired transmission (i.e. synaptic and phasic) in understanding neocortical 
cholinergic modulation has also been questioned by noting that non-synaptic ACh 
concentration changes are an order of magnitude of less than that required to 
depolarise pyramidal neurons (Pepeu & Giovannini, 2004). Furthermore, basal 
forebrain cholinergic neurons can be divided into whether they modulate cortical 
activity tonically or phasically (Detari et al, 1999).  
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More recently, a sensitive electrochemical method of measuring extracellular ACh 
concentrations at a second-scale temporal resolution suggests that apparent tonic 
changes in ACh concentration, as recorded by traditional microdialysis methods 
recording at a minute-scale resolution, can in fact be at least partially accounted for by 
recurrent, but phasic, release of ACh (Parikh et al, 2007) (Fig. 2.5). Critically, these 
results show that the dependency of performance, e.g. cue detection, on acetycholine 
occurs via such phasic transmission, correlating as it does with trial-by-trial accuracy. 
If volume transmission was a major mode by which ACh acted, then bursts of 
cholinergic neuron activity would be expected to increase extracellular ACh levels – 
which in fact is not found (Giuliano et al, 2008).  
 
Increasingly, evidence is also emerging for differential activation of specific sectors 
of nucleus basalis, allowing for variation of acetylcholine release between cortical 
regions. Anatomically this is suggested by segregated topographical (Carey & Rieck, 
1987; Semba, 2000) and laminar (Rieck & Carey, 1984) organisations of basal 
forebrain cells. The significance of this arrangement is that different parts of basal 
forebrain can be selectively activated depending on task demands. For example, rats 
presented with either visual or somatosensory stimulation are found to release 
relatively more ACh in the correspondingly stimulated, than unstimulated, sensory 
cortex (Fournier et al, 2004) (Fig. 2.5). Furthermore, passive sensory stimulation 
induces ACh release in the appropriate sensory cortex without prefrontal cholinergic 
release (Laplante et al, 2005); but if the animal attends to the stimulus then 
frontoparietal ACh release also occurs (Arnold et al, 2002). Differential activation of 
nucleus basalis may itself originate from selective activation of sensory cortices, 
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possibly via indirect pathways involving prefrontal cortex (Golmayo et al, 2003; 
Rasmusson et al, 2007).  
 
The traditional model by which nucleus basalis cholinergic projections modulate 
cortical glutamatergic signalling appears in fact to be too simplistic, with evidence for 
the reverse interaction also co-existing. Specifically, phasic ACh release within 
neocortex may depend  upon  local activity within glutamatergic thalamocortical 
afferents, some of whose termini signal with cholinergic termini (Parikh et al, 2008). 
This raises the intriguing possibility that the cholinergic system has ‘evolved’ from 
being a general activator of cortical activity (e.g. for arousal) – as suggested 
anatomically – to being placed under more specific control by cortical inputs 
themselves (Sarter et al, 2009). Furthermore, while nucleus basalis activation may 
serve to deliver ACh to large and widespread areas of neocortex, the arrangement of 
cholinergic cortical interneurons allows for cortical modulation to occur in much 
more spatially-circumscribed postsynaptic fields (von Engelhardt et al, 2007).  
 
In summary, the capability of the cholinergic system to be selectively activated and, 
in turn, to direct its output towards specific neocortical targets, helps in explaining its 
modulation of functions characterised by spatially segregated patterns of activity, e.g. 
attention and learning. 
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Figure 2.4: Cholinergic neurotransmission can occur diffusely (A), or via specific synapses (B), with the latter mode predominating in humans. 
(A) Rat cortex showing a non-synaptic cholinergic varicosity (staining positive for ChAT) abutting with, but not forming synapses with, cortical 
dendrites (d). (B) Rat cortical section showing how both proximal (p) and distal (d) dendrites of a pyramidal cell (silver stained) form specialised 
synaptic contacts with cholinergic axonal varicosities (i.e. VAchT-positive; unlabelled arrows). (s) = dendrite spine. 
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Figure 2.5: (A) Apparently tonic modes of ACh release in cerebral cortex, as measured by microdialysis (a) may in fact be accounted for by 
recurrent phasic release of ACh as resolved with enzyme-plated electrodes (b). Moreover, the phasic release of Ach into prefrontal cortex 
correlates strongly with accuracy on a trial-by-trial basis.  (B) Region-specific release (% increase) of ACh is found in a paradigm in which rats 
are presented with either skin or visual stimulation; ACh was measured simultaneously in visual cortex (VC), somatosensory cortex (SC), and 
medial prefrontal cortex (MPFC).  
(Sarter et al, 2009) (Fournier et al, 2004)
A. B.                          
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Cholinergic Neurophysiology – Cellular Actions 
 
One of the earliest characterisations of electrophysiological responsiveness to 
acetylcholine was that it heightened cortical responsiveness to synaptic inputs, but did 
so in a manner quite different to the direct and fast actions of glutamate, the main 
cortical excitatory neurotransmitter. Specifically, ACh tends only to increase firing in 
cells in which there is all ready an excitatory input, but does not increase baseline 
activity (Krnjevic & Phillis, 1963; Fig. 2.6). Excitatory patterns of ACh modulation in 
neocortex include: 1) an initial temporary decrease in spontaneous activity, before 
spike frequency slowly increases for ~10-20 seconds after ACh activation has stopped 
(McCormick & Prince, 1985); 2) a reduction of spike adaptation seen in cortical cells 
following prolonged input (McCormick & Prince, 1986; Zinke et al, 2006), and 3) 
potentiation of sustained-spiking following a single depolarising event, seen 
especially in perirhinal-entorhinal cortex (Klink & Alonso, 1997; Egorov et al, 2002). 
The prolongation of input-driven activity may be of functional importance, as we 
shall see later, both in attention – by increasing the likelihood of response to brief 
stimuli (Sarter et al, 2005a), and in memory – by facilitating long-term potentiation 
and other mechanisms of synaptic strength modification (Rasmusson, 2000).  
 
More recently, groups using transient ACh stimulation (20-40 ms) to simulate a 
physiological mode of ACh release have shown net inhibitory effects of ACh in 
neocortex, especially in layer V pyramidal cells – the main output of cortical columns 
(Xiang et al, 1997; Gulledge et al, 2007; Fig. 2.6). Suppressive effects due to ACh are 
partly mediated by NMDA receptor-dependent pathways that may explain why 
cholinergic modulation of sensory processing is activity-dependent (Levy et al, 2006). 
37 
 
Chapter 2 
 
In order to reconcile these disparate effects of ACh on neural responsivity, it has been 
suggested that the initial, phasic onset of cholinergic activation may initially ‘reset’ 
populations of output cells by forcing a common hyperpolarisation potential. 
Subsequently, after a period of high-frequency and long-duration ACh stimulation, 
the net effect may be voltage-dependent excitation (Andrade, 1991; Haj-Dahmane & 
Andrade,1996; McCormick & Prince, 1985). These two serial effects may help to 
explain the well-established cholinergic property of enhancing cortical signal-to-noise 
ratio: by first suppressing background activity, and then favouring pyramidal cells that 
have the strongest synaptic input drive (Gulledge et al, 2007).   
 
A similar conclusion has also been suggested by computational models that attempt to 
account for bi-directional effects of ACh on inhibitory interneurons in hippocampus 
and sensory cortices (Behrends & ten Bruggencate, 1993). Under weak afferent input, 
ACh enhances spontaneous release of GABAergic-inhibitory neurotransmitter, 
thereby dampening background pyramidal cell activity. Conversely, under strong 
afferent input, ACh decreases pyramidal cell-driven GABA release, which suppresses 
local negative feedback, and effectively turns an asymptotic input-output function into 
an exponentially-rising one (Patil & Hasselmo, 1999).  
  
There are two further patterns by which heterogeneous cellular effects of ACh may 
converge to serve common microcircuitry functions. Firstly, opposite effects of ACh 
on two classes of cortical inhibitory interneuron produces the net effect of decreasing 
intracolumnar signalling, while facilitating intercolumnar signalling (Xiang et al, 
1997). In sensory cortex, this will tend to result in heightened ACh levels reducing 
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surround inhibition, while facilitating learning-associated enlargement of relevant 
stimulus representations (Fig. 2.7) (Froemke et al, 2007). Secondly, spatially-
segregated effects of ACh on pyramidal cell inputs has the net effect of potentiating 
cortical inputs (in cortical layer IV), whilst inhibiting intracortical neurotransmission 
(Hasselmo & Bower, 1992; Linster et al, 1999; Hsieh et al, 2000). In this way, the net 
effect of ACh can be to suppress intracortical feedback or lateral connectivity, while 
sparing, or even enhancing, thalamocortical-originating signals (Hasselmo & Cekic, 
1996; Fig. 2.8). Such patterning of information-flow by ACh has been surmised to be 
responsible for numerous functional consequences of ACh modulation depending on 
which part of neocortex is modulated, including: 1) enhancing stimulus detection and 
thereby attention (Sarter et al, 2005a); 2) favouring memory encoding over 
consolidation (Hasselmo & McGaughy, 2004), and 3) shifting perceptual inference 
towards an ‘uncertain’ mode in which bottom-up inputs outweigh top-down 
influences (Yu & Dayan, 2002).  
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Figure 2.6: (A) Cholinergic stimulation does not increase baseline firing rate of cortical neurons but does increases their response to excitatory 
input (here provided by glutamate application).  (B) Biphasic response to cholinergic stimulation in cortical pyramidal cell showing initial 
depression and later potentiation of depolarising inputs. (C) Transient cholinergic stimulation induces widespread cortical inhibition in layer 5   
pyramidal neurons of rat cortex.  
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(McCormick & Prince, 1985) (Gulledge et al, 2007)
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Figure 2.7: (A): Response to acetylcholine of cortical inhibitory interneurons (red - blue), and their differential disposition relative to pyramidal 
cells (grey) and cortical columns (bottom), results in high ACh states favouring intercolumnar over intracolumnar signalling. (B) Pairing of tone-
specific auditory input (e.g. 9kHz) with cholinergic stimulation increases lateral extent of neurons whose tuning curves peak at the input auditory 
frequency (x-axis): note that the cellular modulations of ACh observed in (A) suggest one mechanism by which this could be achieved. 
 
Low-Threshold Spiking Cell Fast Spiking Cell
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Figure 2.8: (A) Segregated effects of ACh on cortical pyramidal cells can account for pattern of enhancing columnar inputs (e.g. from thalamus) 
while decreasing feedback. (B) Modelling of single-fibre activity in piriform cortex. In the absence of ACh (Modulation OFF), pyramidal cell 
output is a combination of both afferent input (ARROWS) and feedback signals. On activating ACh modulation (Modulation ON), afferent 
inputs are favoured, while background activity is suppressed. Afferent-driven pyramidal cells are also more likely to synchronise thereby 
potentiating associative firing. 1: individual unit rasters; 2: spike histograms during spontaneous firing and afferent input activity periods. 
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Cholinergic Neurophysiology - Systems 
 
One of the greatest neuroscientific challenges is to bridge the gulf between cellular, or 
cell-network, processes on the one hand, and cognitive or behavioural phenomena, on 
the other. While the range of psychological constructs that acetylcholine has been 
shown to influence is wide, within these categories its effects are specific and well-
defined. For example, cortical cholinergic integrity is essential for sensory signal 
enhancement, but only for signals that are deemed task-relevant (Sarter et al, 2001); is 
required for attentional enhancements to novel stimulus contingencies, but not 
attentional reductions to repetitive contingencies (Chiba et al, 1995; Baxter et al, 
1997), and underlies certain aspects of memory encoding and retrieval (Everitt & 
Robbins, 1997). Reiterating the pattern of neuronal effects produced by acetylcholine, 
it is clear that the particular behavioural profile associated with cholinergic 
modulation is far from being easily captured by a simplistic, umbrella-type property 
such as ‘increasing overall efficiency’ or ‘processing speed’.  
 
In attempting to explain behavioural influences of acetylcholine it is tempting to peer 
over the ‘explanatory divide’ to cellular and network impacts of equivalent 
cholinergic manipulations, in the hope that links can be made between the two 
disciplines. One example that is commonly made in this regard is the 
neurophysiological finding, described above, that ACh enhances input-driven 
neuronal activity, whilst suppressing background noise. For behavioural phenomena, 
such as that an intact cortical cholinergic system is required for stimulus detection, 
especially of briefly-occurring events, the relationship with the neuronal observation 
seems fairly clear. Ideally, both neuronal firing and performance would need to be 
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measured in the same animal, and shown to be closely correlated, for this explanation 
to be consolidated.  
 
Extending this idea, it has been speculated that other ACh-dependent performance 
effects –such as attention-driven target detection, conditioned stimulus acquisition and 
memory encoding and retrieval - may also follow from what we know about 
cholinergic enhancement of neuronal signal-to-noise ratio (Everitt & Robbins, 1997; 
Furey et al, 2000; Gu, 2002). By this account, competition between multiple signals, 
whether originating from sensory events or stored memory traces, can be facilitated 
by processes that exaggerate differences in signal strength. The attraction of this 
account is that it helps to unite diverse behavioural phenomena by interpreting them 
as different applications of the same fundamental neural processes. In a similar 
fashion, neuronal-level, or network-level, effects of ACh, such as neuronal 
synchronisation and sustained-spiking, and regulation of cortical-laminar flow have 
been adduced as explanatory crutches for diverse effects of ACh on sensory, 
attentional and memory processing.  
 
There is another angle by which the multiple, seemingly disparate behavioural effects 
of acetylcholine can be seen to converge through common physiological processes. 
This can be appreciated by noting the types of naturalistic conditions that increase 
neocortical ACh levels (Himmelheber et al, 2000). In general the cortical cholinergic 
system becomes activated during novel or uncertain circumstances; or in response to 
emotionally salient stimuli, when attention to certain aspects of the environment has 
to be maximised, even after controlling for variables such as motor activity and 
reward (Giovannini et al, 2001). During these behavioural ‘states’, it makes 
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evolutionary sense for the animal to enhance both: 1) sensory processing and 
orienting, and 2) encoding of the current situation, so as to reduce future uncertainty 
and to enable learning of appropriate behavioural responses. The nucleus basalis - by 
virtue of its cortex-wide connectivity - is able to orchestrate this facilitation of 
sensory, attentional and memory processes. Furthermore, effects of ACh on sensory 
and perirhinal-entorhinal cortex information flow – namely, enhancing input 
processing and feedforward associativity, while suppressing feedback – are argued to 
be supportive of both of these neuromodulatory roles (Hasselmo & McGaughy, 
2004).  
 
Sensory   
Cholinergic fibres from nucleus basalis provide rich innervation to all layers of 
primary sensory cortices (Zilles et al, 1990). Following stimulus presentation, 
acetylcholine is released into sensory cortices (Laplante et al, 2005; Fournier et al, 
2004), that increases under circumstances when active sensory processing is favoured, 
i.e. – with attention (Sarter et al, 2005). About 90% of visual cortical neurons are 
responsive to acetylcholine, of which 60 – 75% show a facilitatory response (Sillito & 
Kemp, 1983; Sato et al, 1987a; Zinke et al, 2006). This facilitatory response often 
manifests itself as a reduction of usual adaptation to sustained sensory input, rather 
than as heightening of early peak activity (McCormick & Prince, 1996; Zinke et al, 
2006). Additionally, removing cholinergic input to visual cortex causes a profound 
impairment in sensitivity to visual stimuli (Sato et al, 1987b). However, cholinergic 
facilitation of cortical activity only occurs in cells in which there is all ready a 
significant synaptic input (Krjnevic & Phillis, 1963). In other cortical cells, ACh has 
the effect of decreasing baseline activity (Sato et al, 1987b).  
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By heightening stimulus-driven input while dampening background firing, 
acetylcholine is able to increase gain, or signal-to-noise ratio, rather than just 
increasing cortical activity in general (Fig. 2.9). However, signal-to-noise ratio is also 
dependent on input timing: the more synchronised inputs are, the stronger and more 
stable are the resultant postsynaptic potentials, and consequently output firing 
frequencies. Hence the finding that ACh drives synchronisation between sensory 
cortical neurons (Rodriguez et al, 2004), which itself is associated with more efficient 
signal detection (Womelsdorf et al, 2006) reveals another aspect by which ACh 
facilitates sensory responses. Cholinergic-driven cortical synchronisation occurs at 
high frequency (gamma-band: ~40Hz) which maximises the effect of concerted inputs 
on target cells over unit time. The same frequency of cortical synchronisation also 
occurs during periods of high-attention (Fries et al, 2001) suggesting that cholinergic 
actions on cortical rhythmicity may underlie sensory attention.  
 
A separate, and orthogonal, issue relates to the effects of ACh on stimulus selectivity. 
Studies examining visual cortical responses have shown that ACh increases input-
driven activity more for stimuli at non-optimal, than at optimal, orientations (Sato et 
al, 1987a; Zinke et al, 2006; Fig. 2.9), thereby broadening tuning curves (however, 
see also Sillito & Kemp, 1983; Murphy & Sillito, 1991). This has been explained with 
reference to the well-established circuitry effects of ACh noted earlier -  in which the 
net cortical response to ACh is general inhibition of all layers, except in input layer 
IV, for which inputs are facilitated (e.g. Gil et al, 1997; Kimura et al, 1999). Since 
selectivity arises from lateral or top-down, intracortical connections to layers other 
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than layer IV, their suppression by ACh would be expected to broaden sensory tuning 
curves (Zinke et al, 2006).  
 
The ability of ACh to reduce intracortical communication is also able to account for 
the finding that ACh decreases spatial summation of neighbouring receptive fields, 
thereby reducing contextual or integration effects (Roberts et al, 2005). Given that 
ACh also enhances thalamocortical input within each neuron’s own classical receptive 
field, these properties help to explain facilitatory effects of ACh on selective attention 
- when small-targets need to be detected and adjacent distractors need to be 
suppressed. Furthermore, in reducing contextual influences, while selectively 
enhancing input, ACh encourages a ‘pure, unadulterated’ mode of sensory processing, 
advantageous during periods of uncertainty (Yu & Dayan, 2002). Indeed in certain 
situations, basal forebrain activation may even potentiate weak, indirect sensory 
cortex inputs, e.g. from receptors peripheral to a sensory unit’s classical receptive 
field, more than it potentiates direct inputs that are all ready strong (Kuo et al, 2009) – 
possibly encouraging detection and encoding of unexpected input patterns. 
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Figure 2.9: (A) Response of direction-orientation specific cat visual cortical neurons in absence and presence of 40 nA ACh, showing ACh 
reduces background activity, and hence increases signal-to-noise ratio. Lower graph shows that signal also increases at non-optimal orientations 
so broadening tuning curve. (B)  Response of orientation specific marmoset visual cortical neurons in absence and presence of ACh, showing 
ACh increases visual response at later time periods, especially at non-preferred angular orientations (y-axis on grey-scale plots), thereby 
broadening tuning curve. 
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Attention  
Neocortical cholinergic lesions impair the ability to detect, identify, or localise brief 
stimuli, especially in the presence of attention-demanding challenges such as 
distractors, while not affecting overall motivational state, response rate, rule memory, 
or directional bias (Robbins et al, 1989; Moore et al, 1995; Muir et al, 1994). The fact 
that such lesions result in performance impairments that are proportionate to the 
degree to which sensory/attentional processing is taxed (Himmelheber et al, 2001), 
suggests that the cortical cholinergic system may play an important role in 
interactions of attention with sensory processing, rather than influencing either 
process in isolation (McGaughy et al, 2002). An influential model that has emerged 
from such observations relates neocortical cholinergic release with the degree of 
mismatch between motivation-driven goals and actual performance, i.e. 'attentional 
effort' (Sarter et al, 2006). For example, cortical ACh levels increase following 
challenges that degrade reward-driven performance, which itself is instrumental in 
reversing the initiating behavioral impairment (Himmelheber et al, 2000; Kozak et al, 
2006) (Fig. 2.10). This may account for correlations between ACh release and either 
sensory demands or motor response (Richardson & DeLong, 1990; Passetti et al, 
2000). 
 
Cholinergic interactions with attention are also manifest during learning paradigms. 
For example, attention shifts that normally occur in associative-conditioning, when a 
previously learnt contingency is suddenly violated, are critically dependent upon 
cholinergic inputs from nucleus basalis to posterior parietal cortex (Chiba et al, 1995; 
Bucci et al, 1998). Furthermore, learning, but not retrieval, of new feature 
conjunctions can be selectively disrupted by cortical cholinergic lesions (Botly & De 
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Rosa, 2009). To the extent that feature-binding is believed to require frontoparietal 
control (e.g. Esterman et al, 2007), and that learning of single features is found not to 
be impaired, this cholinergic-dependency is considered to be attentional, rather than 
sensory or learning per se.  
 
The functional anatomy (and effective connectivity) by which the cortical cholinergic 
system supports attention involves interactions between prefrontal, parietal and 
sensory regions (Golmayo et al, 2003; Nelson et al, 2005) (Fig. 2.11). Performance 
monitoring information from prefrontal regions combines with arousal and 
motivational information from reticular and limbic regions, as well as contingency-
violation or fear-conditioned signals from amygdala, in providing the main input to 
basal forebrain, and subsequent cortical acetylcholine release (Holland & Gallagher, 
1999; Sarter et al, 2006; Gozzi et al, 2010). In turn, cholinergic inputs to prefrontal 
and parietal regions are thought to modulate processes such as distractor suppression 
(Gill et al, 2000), or attentional shifting (Davidson & Marrocco, 2000) and 
disengagement (Bushnell et al, 1998) between spatial locations or features (Bucci et 
al, 1998). Following repeated training with an attention-taxing task, cellular mediators 
of cholinergic neurotransmission are upregulated in prefrontal regions, and correlate 
with enhanced signal detection (Apparsundaram et al, 2005). Cholinergic inputs to 
prefrontal cortex may also serve to inhibit impulsive responses via subcortical 
structures (Bushnell et al, 1998; McGaughy et al, 2002).   
 
It seems likely that that cholinergic influences on bottom-up sensory processing 
(discussed in preceding section) may complement the effects of ACh on top-down 
attentional shifting and focusing (Sarter et al, 2001), given evidence for pan-cortical 
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covariations in ACh efflux (Phillis & Chong, 1965).  This appears supported by the 
fact that selective attention-related activity (e.g. cue versus distractor associated 
neural activity) is found to be dependent upon local ACh concentrations in both 
frontoparietal (Gill et al, 2000; Broussard et al, 2009) and sensory cortices (Herrero et 
al, 2008), in a congruent fashion.  
 
A further account for cortical acetylcholine release is that it correlates with 
‘uncertainty’ regarding established stimulus-stimulus or stimulus-response 
contingencies (Bucci et al, 1998; Dalley et al, 2001). On this view, high acetylcholine 
levels favour bottom-up, over top-down, processes, and in so doing appropriately 
reduce cortical inference in times of uncertainty (Yu & Dayan, 2005). Importantly, 
this model accords with ACh efflux being related both to 'attentional effort' in the face 
of performance challenges (Sarter et al, 2006) and to novelty (Acquas et al, 1996). It 
also fits cortical slice data demonstrating that ACh promotes feedforward over 
feedback signalling (Hasselmo & McGaughy, 2004). The model successfully predicts 
that cholinergic levels are inversely correlated with cue validity in a Posner spatial-
attention paradigm, and that as ACh levels increase, the degree to which a cue focuses 
attention - i.e. the cue validity effect - decreases (Phillips et al, 2000). Furthermore, 
prefrontal ACh innervation mediates cognitive flexibility during serial contingency 
reversals, but not initial acquisition of contingency (Cabrera et al, 2006), consistent 
with ACh communicating expected, rather than unexpected, uncertainty (Yu & 
Dayan, 2005).
Chapter 2 
Figure 2.10: (A) ACh efflux in prefrontal cortex increases most intensely during a sustained attention task (i.e. requiring stimulus processing 
and response selection) rather than during tasks that control for sensorimotor and reward components. (B)  ACh efflux in frontoparietal cortex 
increases yet further following presentation of a distractor. Initially, performance worsens (as indicated by an inappropriate response bias in 
block 3), but then recovers synchronously with the peak in ACh release.   
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Figure 2.11: (A) Model of corticopetal cholinergic interactions with both ‘top-down’ and ‘bottom-up’ cortical processes. Basal forebrain (BF) 
may itself be activated either by top-down prefrontal glutamatergic inputs, or by bottom-up norepinephric (NA) inputs from locus cereleus (LC), 
as well as nucleus accumbens and amygdala (not shown). TH: thalamus. (B) Drivers of basal forebrain (BF) activity can be divided into those 
from prefrontal, including anterior cingulate cortices (PFC/ACC), which may convey error signals, and those from  limbic structures (nucleus 
accumbens, NAC; ventral tegmental area, VTA; locus cereleus, LC; and amygdala, not shown) which communicate motivational signals. 
(Sarter et al, 2001)  (Sarter et al, 2006)  
A. B. 
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Memory and Learning 
The link between acetylcholine and memory has traditionally been asserted on the 
back of two sets of robust findings (Bartus et al, 2000). Firstly, the archetypal 
memory disorder Alzheimer’s disease is characterised by early and profound losses of 
cholinergic neurons (e.g. Bowen et al, 1976). Secondly, administration of 
anticholinergic drugs, are well-known to induce memory and learning deficits (e.g. 
Plakke et al, 2008), while cholinergic enhancing drugs tend to improve memory (e.g. 
Davis et al, 1978; Stratton & Petrinovich, 1963). In support of this are anatomical 
considerations: the main structure responsible for episodic memory in the brain - the 
hippocampus – has two inputs: one from entorhinal cortex, and the other from fornix-
fimbriae, that carries predominantly cholinergic fibres from the medial septum 
division of the basal forebrain.  
 
One of the most important characteristics of the memory impairment induced by 
cholinergic blockade is that it is specific for the encoding of new information, while 
having little effect on the maintenance or retrieval on previously stored information 
(Sherman et al, 2003). For example, exploring rats forget which earlier paths they had 
visited if injected with scoplamine before the task, but not if injected at half-time 
(Buresova et al, 1986). The significance of this principle is that it directs our enquiry 
towards cholinergic interactions with systems believed to be responsible for memory 
encoding – especially sensory, prefrontal and hippocampal cortices. Given that the 
cortical cholinergic system can be divided into: 1) nucleus-basalis – neocortical, and 
2) septohippocampal components, cholinergic interactions with memory within each 
of these systems are reviewed separately, before looking at more general cholinergic 
mechanisms.  
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Nucleus basalis – Neocortical Cholinergic System 
Successful encoding requires sufficient resource allocation to sensory processing, 
accounting for the well-established dependency between attention and memory 
(Baddeley, 1990; Chun & Turk-Browne, 2007). Thus the fact that memory deficits 
following cholinergic blockade are specific for the acquisition, rather than retrieval, of 
new sensory information, is in keeping with the pro-attentional role of the nucleus 
basalis cholinergic system (Hasselmo & McGaughy, 2004). This point is made by the 
findings that pro- or anti-mnemonic effects of cholinergic drugs interact with‘depth of 
processing’ during encoding, with a greater drug effect observed under conditions 
where stimuli are most deeply processed (e.g. Warburton et al, 2001; Fitzgerald et al, 
2008). Furthermore, effects of cholinergic manipulation on working memory interact 
with information-processing load, e.g. span length, suggesting influences on attention 
(Turchi & Sarter, 1997). In this sense, many actions of ACh on memory may be 
derivative to its primary effects on sensory-attentional processing.  
 
A further question is whether ACh can influence memory directly, independent from 
its attentional effects, and if so, in which neural systems does this take place? In 
answer to this, a number of lesion studies in rats and monkeys have suggested that 
while lesions to the nucleus basalis-neocortical cholinergic system cause clear, robust 
deficts in attention, they do not in general affect memory performance (see Everitt & 
Robbins, 1997). This profile has also been used to explain why performance 
improvements in Alzheimer’s disease patients taking pro-cholinergic therapies are 
seen more consistently with attention than memory tasks (Sahakian & Coull, 1993).  
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Yet, certain paradigms, particularly in studies using highly precise cholinergic lesions, 
have suggested ACh interactions specifically with neocortically-implemented 
memory or learning systems. These are:  
1) Reversal Learning - Prefrontal Cortices  
Lesions to prefrontal cholinergic inputs result in a specific deficit in reversal learning 
- in which a double-option, stimulus-response contingency switches between the two 
contingencies after unpredictable intervals (Robbins & Roberts, 2007).  
2) Working Memory - Prefrontal Cortices  
Prefrontal cholinergic inputs are necessary in many paradigms where there is a 
relatively short (< ~1 minute) delay between exemplar exposure and response (e.g. 
Chudasama et al, 2004). Not all working memory paradigms though are cholinergic-
dependent: for example, while scopolamine impairs episodic memory formation, it 
spares aspects of short-term memory such as the recency effect of serially-ordered 
items (Crow & Grove-White, 1973), and digit-span (Beatty et al, 1986).  
3) Discrimination Learning – Extrastriate, Perirhinal and Cingulate Cortices   
Cholinergic inputs to inferotemporal cortex are required for acquisition, of 
perceptually-demanding, but not simple, visual discriminations (Fine et al, 1997). One 
mechanism by which this may occur is though ACh-induced enhancement of protein 
synthesis in visual cortex input layer (Dotigny et al, 2008). Conditional discrimination 
learning, in which both a sensory discrimination and a rule are learnt, depends 
specifically upon cholinergic innervation of the cingulate cortex (Marston et al, 1994).  
4) Recognition Memory - Perirhinal and Sensory Cortices 
Recognition memory depends upon cholinergic inputs to medial temporal regions, 
especially perirhinal cortex, during the encoding, rather than test, phase (Tang et al, 
1997). This effect is not seen with spatial memory (Winters & Bussey, 2005). 
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5) Conditioning and Receptive Field Plasticity - Sensory Cortices  
The remapping of sensory cortex so as to favour responses to behaviourally-relevant 
stimuli properties is critically dependent on basal forebrain – cholinergic inputs 
(Edeline, 1999). This is seen most readily with associative conditioning paradigms, 
where, for example, tonotopic auditory cortex neurons become increasingly ‘tuned’ to 
a specific tone, when paired with an electrical shock, whilst unpaired tones become 
progresssively less represented (Weinberger, 2007). Similar ACh-dependent effects 
have been observed in motor cortex (Conner et al, 2003)  
 
SeptoHippocampal Cholinergic System 
Cholinergic input to the hippocampus via the medial septum-fornix-fimbriae pathway 
provides a likely anatomical basis for cholinergic interactions with long-term 
memory. However, while multiple studies have demonstrated consistent correlations 
between hippocampal cholinergic activity and memory, it has been more difficult to 
prove that the cholinergic septohippocampal projection is necessary for memory or 
learning (Parent & Baxter, 2004). Learning paradigms that have been shown to be 
dependent upon this pathway include conditioning, social discrimination, and non-
match-to-sample spatial memory (e.g. McAlonan et al, 1995).  
 
Noting that cholinergic activation of hippocampus has a net inhibitory effect (Buzsaki 
et al, 1988), and that cholinergic lesions of the medial septum disrupt processes such 
as latent inhibition or blocking in which attention is reduced to stimuli in familiar 
contexts (Baxter et al, 1997), it has been suggestd that the function of the 
septohippocampal cholinergic system is to suppress processing of inputs regarded as 
irrelevant e.g. due to overexposure, thereby enabling the hippocampus to concentrate 
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its resources on a small number of relevant or novel stimuli (Everitt & Robbins, 
1997). This is supported by the finding that cholinergic lesions of the medial septum 
impair trace conditioning – where there is a delay between a conditioned and 
unconditioned stimulus, and for which stimuli generally need to be attended to be 
remembered, whereas the same lesion actually causes a paradoxical improvement in 
contextual conditioning – i.e. memory for unattended features of the environment.  
 
A further mechanism by which ACh influences memory within hippocampus is 
through its interactions with theta rhythm (4-8 Hz) that occurs selectively during 
alertness, and enhances learning (Lee et al, 1994; Allen et al, 2002). Theta rhythm is 
thought to be required for new synaptic modifications, through phase-locking of 
stimulus features. In this regard, effects of ACh on hippocampal rhythmicity may be 
analagous to ACh  influences on stimulus-binding, and attention-associated gamma 
rhythm of sensory cortices (Rodriguez et al, 2004). Recent data suggests that phasic 
hippocampal ACh release actually begins slightly after the onset of theta suggesting a 
synergistic interaction rather than a causal relationship (Zhang et al, 2010).   
 
General Memory Mechanisms of Acetylcholine in Neocortex and Hippocampus  
An important insight made by Hasslemo and colleagues is that neurophysiological 
characteristics of ACh modulation are strikingly similar between sensory, perirhinal, 
hippocampal and frontal fields. Indeed there are three main cellular-network effects of 
ACh that are observed repeatedly across these cortical regions, and which are all 
likely to facilitate memory. These mechanisms are: cortical layer feedforward-versus-
feedback regulation; sustained-spiking, and long-term potentiation. 
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The first of these cholinergic-dependent mechanisms - cortical layer feedforward-
versus-feedback regulation  - relates to a general effect of ACh on columnar circuitry 
noted under sensory mechanisms – but which equally is found in perirhinal and rhinal 
regions (Hasselmo et al, 1995) (Fig. 2.12). Specifically, the usual configuration of 
cholinergic inputs in relation to cortical pyramidal cells is such that stimulus-driven 
input activity to layer IV is preserved, or enhanced, while inputs to other layers, 
conveying feedback, are suppressed (Hasselmo & Cekic, 1996). By favouring a 
bottom-up rather then top-down (or ‘model-driven’) mode of sensory processing, high 
ACh levels, seen for example with arousal or REM sleep, enhance new 
(‘feedforward’) memory associations, while suppressing activation of previously 
stored representations (Sarter et al, 2005a). The advantage of feedback inhibition lies 
in the suppression of previously encoded associations, which can ‘proactively 
interfere’ with acquisition of new associations (Atri et al, 2004).  
 
The fact that ACh levels vary with behavioural state implies an advantage to cortical 
processing in the presence of low ambient ACh levels – typically found during rest or 
slow-wave sleep. In the foregoing model, low ACh favours a backwards shift in 
information flow from a limited-capacity hippocampus to high-capacity perirhinal and 
sensory neocortices. This fact combined with the finding that oscillatory patterns 
found during low-ACh states are conducive to the strengthening of modifiable 
synapses, suggest that the function of low-ACh states is in consolidation of memory 
traces (Ellenbogen et al, 2006).  
 
The second general cellular mechanism by which ACh may support memory is 
sustained-spiking. Sustained-spiking is found in a subset of entorhinal - perirhinal 
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neurons between the study and test phases of working-memory tasks (Young et al, 
1997; Suzuki et al, 1997), and is stimulus-specific, conferring upon it the ability to 
hold stimulus representations active following stimulus removal. Since this 
phenomenon occurs in entorhinal neurons that input hippocampus, it is likely that 
sustained-spiking is relevant for both short-term and long-term memory encoding. 
The non-specific cation current, INCM that gives rise to sustained-spiking (Fransen et 
al, 2002) is sensitive to muscarinic receptor activation (Klink & Alonso, 1997), and so 
may account for a performance susceptibility to scopolamine in tasks such as delayed 
matching, spatial working memory and fear-conditioning (Buresova et al, 1986). 
 
Finally, the most well-known cellular mechanism of long-term memory – long-term 
potentiation (LTP) – is a further target of cholinergic control in both hippocampus and 
sensory neocortex (Huerta & Lisman, 1993; Brocher et al, 1992). Since LTP requires 
repeated synchronous activity between pre- and postsynaptic membranes, ACh 
facilitates this by: 1) potentiating spontaneous oscillations, such as exploratory-
associated hippocampal theta rhythm (Anagnostaras et al, 2003); 2) enhancing the 
duration of sensory-driven inputs (McCormick & Prince, 1986); and 3) potentiating 
sustained-spiking in perirhinal-entorhinal cortices (Klink & Alonso, 1997).  
 
It is noteworthy that many of the physiological mechanisms by which ACh appears to 
influence memory – enhancing feedforward laminar flow, prolonging input-driven 
responses, and modulating rhythmicity – are either the same, or directly analogous to 
mechanisms by which ACh appears to influence sensory - attention processing.  
Chapter 2 
 
61 (Hasselmo & McGaughy, 2004) (Hasselmo & McGaughy, 2004)
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High-ACh states favour encoding by enhancing signal-to-noise, synchronisation and self-association between afferent-driven inputs (see also 
Figure 2.9). Low-ACh states favour feedback whereby representations can be shifted between cortical sites and weak synaptic connections 
strengthened. (B) Feedforward versus feedback model of ACh accounts for different patterns of neocortical and hippocampal dynamics in 
different behavioral states. During high-ACh states activity is favoured in pathways from sensory to hippocampal cortices, whereas in low-ACh 
states, flow of activity reverses. 
Figure 2.12: (A) Cholinergic effects on cortical laminar flow support different components of memory depending on ambient ACh levels. 
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Cholinergic Receptor Pharmacology  
The cognitive influences of drugs acting at cholinergic receptors can be seen through 
manipulation of either muscarinic or nicotinic receptors. Antagonism of muscarinic 
M1 receptors, with drugs such as scopolamine, produces the most consistent memory 
(Rusted & Warburton, 1988); attentional (Wesnes et al, 1988) and sensory (Erskine et 
al, 2004) impairments. Nicotinic receptor antagonism, e.g. using mecamylamine, may 
also impair memory, especially during working memory tasks (Levin et al, 1997), 
although this is less consistent than with muscarinic blockade (Green et al, 2005). 
Nicotinic antagonism also results in attentional impairments (Rezvani et al, 2002), 
yet, again, this is not as robust a finding as seen with scopolamine (McQuail & Burk, 
2006), and does not extend to sensory (Erskine et al, 2004) dysfunction. Combining 
muscarinic and nicotinic receptor antagonism worsens the memory impairment of 
either alone suggesting a synergism (Green et al, 2005). However, this same 
combination can also result in a lesser impairment than either alone, implying that 
blockade of one pathway can overstimulate the alternative pathway that is itself 
dysfunctional (Maviel & Durkin, 2003). Nicotinic receptor stimulation, e.g. with 
nicotine, can enhance memory – an effect that can be reversed with scopolamine 
(Terry et al, 1993). Furthermore, nicotine can improve both arousal and attention 
(Newhouse et al, 2004).  
 
Both muscarinic and nicotinic-mediated drug potentiation of memory occur only if 
the drug is given just before, but not after, the first presentation of study items (Atri et 
al, 2004), suggesting that cholinergic activation, acting via both sets of receptors, 
facilitates encoding selectively.  By contrast, as discussed under the memory 
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mechanisms of ACh earlier, muscarinic blockade can enhance memory if 
administered soon after the study phase (Young et al, 2005; Winters et al, 2006). 
 
Cholinergic stimulation of receptors may exert opposite effects on related receptors. 
For example, blockade of M2 receptors has been shown to improve memory, possibly 
because of presynaptic disinhibition of ACh release (Baratti et al, 1993). Additionally, 
chronic pharmacological modulation of the nicotinic receptor may exert long-lasting 
changes in memory that persist even after drug withdrawal (Levin & Simon, 1998). 
Positive effects of chronically-exposed nicotine on memory may arise via 
neurotrophic effects acting via nerve growth factor receptors (Hernandez & Terry, 
2005).  
 
Brain Cholinesterases  
Once acetylcholine has been released into the synaptic cleft, the only significant way 
its action can be terminated is through rapid hydrolysis mediated by the catalytic site 
of the enzyme cholinesterase (ChE). ChEs also have plasticity-related effects, 
including cell differentiation, process extension, and dendritic modelling. These latter 
types of actions are mediated through the enzyme’s peripheral anionic, rather than 
catalytic, site. 
 
The human brain contains two cholinesterases (ChEs): acetylcholinesterase (AChE) 
and butyrylcholinesterase (BuChE). AChE is by far the more predominant of the two, 
and is associated with cholinergic pathways (Mesulam, 2000). AChE is manufactured 
and expressed in all neurons that express cholinergic receptors. Since all cholinergic 
neurons (i.e. those containing ACh-synthesising enzyme ChAT) bear cholinergic 
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autoreceptors, it is the case that all neurons that synthesise acetylcholine also express 
AChE. AChE is synthesised in the perikaryon of cholinergic neurons, and is then 
transported to dendrites and axons where it becomes inserted into membranes as an 
ectoenzyme. The localisation of AChE enzyme activity within cholinergic cells is 
found on synaptic boutons, proximal dendrites and perikarya (reflecting the presence 
of cholinergic autoreceptors at these sites), and axonal varicosities which make 
contact with cholinoceptive neurons (Mesulam & Geula, 1991).  
 
Neurons that are cholinoceptive (i.e. bear cholinergic receptors), but non-cholinergic 
(i.e. do not express the ACh-synthetic enzyme ChAT) express most of the brain 
AChE. However, unlike cholinergic neurons, AChE in non-cholinergic neurons is 
confined to the dendrites and perikarya, and not axons, reflecting the location of 
cholinergic receptors in the two types of neurons (Mesulam & Geula, 1992). In the 
cerebral cortex, AChE is localised predominantly to the glutamatergic pyramidal cells 
of (output) layers III and V (Mesulam & Geula, 1991). These neurons respond to ACh 
through M1 and nicotinic receptors, which differs from AChE-containing neurons in 
layer VI and subcortical zone that respond via M2. Expression of ChE may also occur 
in glia, where as well as serving to mop up extraneous ACh, it may regulate cell 
growth, plasticity and blood-brain barrier regulation (Mesulam, 2000). 
 
Cholinesterase Inhibitors – Behavioural Effects 
Cholinesterase inhibitors (ChEIs), in their role as cognition-enhancing drugs, were 
first trialled in healthy young humans. First experiences were unfavourable with 
subjects becoming withdrawn, sedated and even depressed (Davis et al, 1976). 
Furthermore, short-term memory capacity as assessed by digit span tasks was 
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worsened in the presence of physostigmine, whilst long-term memory was unaffected. 
These adverse effects were felt to be due to excessive dosage (1.5 – 3mg), as a 
subsequent trial employing a lower dose (1mg given over 1 hour) showed improved 
long-term memory on a word-list task (Davis et al, 1978).  
 
Further support for a cognition-enhancing function of ChEIs comes from studies in 
aged monkeys who, in manifesting memory deficits, act as an animal model of 
Alzheimer’s disease (Bartus et al, 1982). In order to magnify the cognitive 
impairments of aged monkeys, and in order to emulate the presumed hypo-cholinergic 
basis for memory decline seen with natural ageing and Alzheimer’s disease, monkeys 
are pre-treated with the muscarinic antagonist scopolamine. Monkeys impaired in this 
way show reversibility of recall and recognition deficits following treatment with 
either physostigmine or tacrine (Rupniak et al, 1992). Subsequent studies showed that 
the performance of both aged and young monkeys in memory tasks could be 
improved by ChEIs even in the absence of scopolamine pre-treatment (O’Neill et al, 
1998), mirroring the small memory improvements observed in humans. However, the 
beneficial effects of physostigmine, e.g. on visual recognition, were found to be 
curtailed by inflicting selective lesions to the nucleus basalis (Aigner et al, 1987), 
suggesting that the benefits of ChEIs in clinical scenarios are diminished if 
cholinergic deficiency has progressed beyond a certain point.  
 
Several psychophysical experiments have tried to tease apart the processes modulated 
by ChEIs. In one of the first human studies (Davis et al, 1978), physostigmine 
improved storage of items on each of six learning trials presenting the same material, 
without interacting with trial order. This suggests that the drug interacted with initial 
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stimulus encoding, maintenance or retrieval, rather than with repetition or familiarity-
based processes. However, physostigmine was also found to benefit recall of items 
presented both before and after the drug was infused, suggesting a specific effect on 
maintenance or recall. This result has since been challenged by experimental and 
computational modelling studies suggesting that pharmacological elevation of ACh is 
more likely to interfere with retrieval (Hasselmo & McGaughy, 2006).  
 
A separate set of studies have emphasised the sensory or attentional enhancing 
properties of ChEIs. Thus, while physostigmine shows no effect on recall accuracy or 
overall speed in short-term memory tasks, the drug has been found to speed responses 
to low-contrast, as opposed to high-contrast, probe stimuli (Wetherell, 1992), 
suggesting a specific perceptual-attention benefit. Physostigmine also speeds 
responses more during selective attention than simple perceptual tasks (Furey et al, 
2008). Given that ChEIs improve memory more for items deeply-processed, than 
superficially-processed, during encoding (Fitzgerald et al, 2008), it is possible that a 
further mechanism by which ChEIs improve memory is through effects on sensory or 
attentional processing. This would be compatible with computational simulations of 
ACh influences on encoding (Hasselmo & McGaughy, 2006), and resembles the 
profile of promnemonic actions seen with nicotine (Warburton et al, 2001). 
 
Pre-clinical studies in monkeys and humans show a wide-degree of variability in 
responses to ChEIs. One of the reasons for this is that individual monkeys (Bartus et 
al, 1983), or humans (Davis et al, 1979), show different optimum drug doses with 
steep inverted U-shaped performance curves either side of the optimum. This can 
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have the effect of providing a negative result when individuals are averaged over for 
specified doses, even across the entire range of administered doses (Bartus, 2000).  
 
A further reason for inter-subject pharmacodynamic variability relates to the 
observation that cognitive improvements in healthy subjects with ChEIs or nicotine 
are more apparent in elderly than young individuals, or in subjects with relatively low 
baseline performance (Davis et al, 1979; Drachman & Sahakian, 1980; Newhouse et 
al, 2004). It is possible that this type of inverted-U shaped response arises from 
variability in subjects' cholinergic systems - with the benefits of ChEIs being realised 
more in patients, or elderly subjects, with relative cholinergic deficiencies, than in 
health. For example, working or short-term memory capacity is unaffected by ChEIs 
in healthy subjects (Davis et al, 1978; Wetherell, 1992), yet the same drugs can 
reverse memory deficits induced by scopolamine given before encoding (Mewaldt & 
Ghoneim, 1979). As well as disease and ageing, subjects may vary in the efficiency of 
their cholinergic neurotransmission, and response to ChEIs, by virtue of genetic 
polymorphisms in ApoE (Bizzarro et al, 2005), ChAT (Harold et al, 2006), and AChE 
(Scacchi et al, 2009) genes, as well as in enzymes that metabolize such drugs 
(Varsaldi et al, 2006).   
 
Cholinesterase Inhibitors – Chemical Effects 
A key assumption regarding cholinesterase inhibitors made in this thesis is that they 
increase ACh levels in the brain. The first studies to consider this were in rats, and 
showed that toxic levels of ChEIs, such as physostigmine 1mg/kg, could increase 
brain ACh levels by 50-100% (Giarman & Pepeu, 1962; Pazzagli & Pepeu, 1965). 
Microdialysis studies in rats show that ACh concentrations increase by 300-400% 
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from baseline in neocortex (Kosasa et al, 1999a) and hippocampus (Kosasa et al, 
1999b) following either direct or oral administration of a range of cholinesterase 
inhibitors. More recently using combined PET imaging and in vivo microdialysis in 
monkeys, it has been confirmed in the same animals that the ChEI donepezil: 1) 
inhibits AChE activity; 2) increases prefrontal cortex ACh levels; 3) increases 
muscarinic ACh receptor binding, and 4) improves performance in a working memory 
task (Tsukada et al, 2004). Having established relationships between these variables it 
has been possible to use PET imaging non-invasively to quantify the degree of ACh 
release, e.g. by measuring the competitive uptake of the radiolabelled nicotinic 
receptor agonist (18)F-nifene (Easwaramoorthy et al, 2007).  
 
Estimates of the level of cholinesterase inhibition required to achieve a given rise in 
brain ACh vary widely depending on drug. For example, the organophosphate DFP 
causes inhibition of 70% cholinesterase activity that is followed by a six-fold rise in 
ACh levels (van der Staay et al, 1996), whereas an 83% cholinesterase inhibition by 
paraoxon causes only a doubling of brain ACh (Wecker et al, 1977). The extent of 
ACh rise may also differ between regions with, for example, metrifonate causing a 3-
fold ACh rise in neocortex but a 4-fold ACh rise in hippocampus (Giovannini et al, 
1998). These two regions also differed in the ACh response to chronic ACh treatment 
with only neocortex showing a sustained elevation in ACh levels.  
 
The extent of ACh rise secondary to ChEI is likely to depend upon factors that alter 
cholinergic fibre density such as age. In one study, the same level of cholinesterase 
inhibition by metrifonate caused higher neocortical ACh levels in aged than young 
rats, that was associated with aged rats only showing an improvement in object 
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recognition; conversely hippocampal ACh levels were pushed up by ChEI more in 
young than aged rats (Scali et al, 1997a). The same group found that a different ChEI, 
tacrine, this time increased hippocampal ACh levels by significantly more in aged 
than young rats (sixfold versus twofold) while increasing neocortical ACh levels 
equally by age (Scali et al, 1997b). Aged rats showed improvements following tacrine 
treatment in both passive-avoidance and object recognition tasks that conceivably are 
related to the increases in ACh in hippocampal and neocortical regions respectively.     
 
Finally, it should be appreciated that ACh release may also be increase following 
cholinergic receptor blockade; for example, systemic scopolamine increases ACh 
release within hippocampus (e.g. Mishima et al, 2000), suggesting local 
autoregulation, and presumably resulting in nicotinic receptor overstimulation.  
 
Alzheimer’s Disease – ‘The Cholinergic Hypothesis’ 
 
Evidence for Cholinergic Hypofunction in Alzheimer's Disease 
Degeneration of cerebral cholinergic innervation is a well-established pathological 
hallmark of Alzheimer’s disease (Geula & Mesulam, 1989), and provides the basis of 
the ‘cholinergic hypothesis’: that a significant component of the cognitive deficits of 
Alzheimer’s disease (AD) arises from deficiency of cortical cholinergic input (Bartus 
et al, 1982). Cell loss secondary to neurofibrillary tangle accumulation occurs 
primarily in the Ch4–nucleus basalis complex (Geula & Mesulam 1999), resulting in 
degeneration of cholinergic axons that innervate wide areas of diffuse cerebral cortex. 
Since animal studies have shown that targeted lesioning of the cortical cholinergic 
system results in a profile of attentional and memory impairments similar to that seen 
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with Alzheimer’s disease, the argument is made for cholinergic deficiency being 
instrumental to, at least components, of the clinical syndrome of this disease.  
 
Neuropathological studies show that choline acetyl transferase (ChAT) activity is 
reduced by ~60-70% in AD (Perry et al, 1981) but not other dementias (Bowen et al, 
1982). Moreover, the loss of this cholinergic neural marker correlates with cognitive 
decline (Davis et al, 1999), although this relationship cannot be fully unconfounded 
from degeneration of non-cholinergic parts of the brain. A further problem with 
ChAT-measuring studies, is that it is high-affinity choline uptake, and not ChAT 
enzymatic activity, that is the rate-limiting step for ACh synthesis (Jenden et al, 
1976). Moreover, adequate ACh synthesis can occur in the face of losses of upto 90% 
of enzyme activity (Haubrich & Chippendale, 1977). Hence in itself the reduction in 
ChAT levels in AD brains neither explains the cognitive symptomatology, nor proves 
that the cholinergic system is dysfunctional, in AD. However, further pathological 
studies have shown that the density of basal forebrain cholinergic neurons is reduced 
in AD (Whitehouse et al, 1981), which might be sufficient to reduce cortical 
cholinergic input, and so account for the similarity in cognitive profile of AD to 
animals with selective cortical cholinergic lesions.  
 
The cholinergic hypothesis of AD is supported by the degree of similarity, and 
specificity, of cognitive deficits comparing AD patients to animals with precise 
lesions of the nucleus basalis or cortical cholinergic projections. For example, one of 
the attentional impairments observed in AD - the ability to disengage from invalid 
spatial cues in a spatial orientation task (Parasuraman et al., 1992) – is also seen as a 
selective deficit following restricted lesioning of the nucleus basalis and its 
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cholinergic projections (Voytko et al, 1994). Furthermore, to the extent that 
cholinesterase inhibitors reduce the deterioration of (certain) cognitive functions in 
(some) Alzheimer’s disease patients, and to the extent that such drugs act by 
enhancing endogenous acetylcholine levels, the cholinergic hypothesis receives 
independent support. For example, attentional deficits in AD can be partially reversed 
with cholinergic agonists (Sahakian et al, 1989; Sahakian et al, 1993). Conversely, it 
is well established that cholinergic antagonists administered to healthy humans and 
adults result in memory and attentional impairments (Drachmann & Leavitt, 1974). 
 
Interestingly for the cholinergic hypothesis, it is found that cortical cholinergic 
deafferentation varies consistently between regions (Geula & Mesulam, 1996; Figure 
2.21), with cortical regions subserving memory and associational processing being 
most affected. The greatest depletion of cholinergic axons occurs in the temporal 
lobes, including the hippocampus and entorhinal cortex, in which upto 80% of 
cholinergic neurons can be lost. However, neurons within these temporal areas are 
also affected by Alzheimer’s-specific plaques and tangles directly, and so it is 
difficult to know the extent that correlations between region-specific pathology and 
clinical severity (Pappas et al, 2000) are cholinergic dependent. The regional 
heterogeneity of cortical cholinergic deficiency mirrors sectorial involvement of the 
nucleus basalis, e.g. the severely affected posterior sector supplying the temporal 
lobes. Cortical areas depleted of cholinergic input also show downregulation of 
cholinergic receptors, especially M2 and nicotinic receptors (London et al. 1989).  
 
Challenges to the Cholinergic Hypothesis 
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In contrast to the dopaminergic deficiency of Parkinson’s disease, the cholinergic 
deficiency of AD is not the pre-eminent lesion, and appears neither necessary nor 
sufficient to account for the clinical syndrome (Mesulam et al, 2004). Degeneration of 
non-cholinergic neurons in associational neocortex is at least equal if not more, 
important in accounting for the clinical deficits of AD. Indeed, the relative 
contributions of neuromodulator deficiency in accounting for the symptomatology of 
Parkinson’s and Alzheimer’s diseases can be appreciated by the significantly greater 
efficacy of levodopa, relative to cholinesterase inhibitors, in the amelioration of 
symptoms of each disease, respectively.  
 
A particular challenge to the cholinergic hypothesis is that whilst loss of cholinergic 
cells undoubtedly occurs in advanced AD, evidence for cholinergic deficiency in 
early Alzheimer’s disease, as well as its precursor stage of mild cognitive impairment 
(MCI), is not as clear-cut. For example, in the study of Davis et al, 1999, that showed 
a correlation between densities of the cholinergic cell markers ChAT and AChE and 
clinical dementia severity, there was no significant difference in the level of such 
cholinergic markers in early AD compared to unaffected age-matched controls. Even 
more surprisingly, DeKosky et al (2002) showed that ChAT levels are not only not 
decreased in mild AD, but may even be raised in MCI, specifically in prefrontal and 
hippocampal cortices. This appears to argue against cholinergic lesions being 
causative of the cognitive deficits of AD, at least in early disease, and may even 
suggest that the cholinergic system is capable of a compensatory hyperactivation - as 
observed with restricted animal cholinergic lesions (McGaughy et al, 2002).  
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However, while the results of DeKosky et al and Davis et al suggest that cholinergic 
cell numbers may not alter in early AD, they are unable to inform about the possibility 
of impaired cholinergic cell function (Sarter et al, 2002; Mesulam, 2004). This might 
explain why alternative methods of evaluating cholinergic cell function – e.g. cell 
volume (Mesulam et al, 1987), synapse number (Geula & Mesulam, 1989), nerve 
growth factor receptor expression (Mufson et al, 2003) or ACh vesicle release 
(Efrange et al, 1997) have shown impairments in early AD. The distinction between 
cell number and function is also relevant given previous findings that nucleus basalis 
Ch4 neurons may suffer from neurofibrillary tangle degeneration, with secondary 
impaired cholinergic innervation, without nucleus basalis cell counts being affected 
(Mesulam 2004). In fact the use of ChAT as a reliable marker of cholinergic status 
has been questioned for several reasons, including that it does not represent a rate-
limiting step for ACh transmission (Jenden et al, 1976), its measurement can be 
confounded by changes in background protein levels, and it may be upregulated in 
response to cholinergic cell dysfunction manifest in other ways e.g. following a loss 
of cholinergic synapses in cerebral cortex (Mesulam, 2004).  
 
In common with many neurodegenerative diseases, including Parkinson’s disease, AD 
brains exhibit lesions in more than one of the brainstem-basal forebrain 
neuromodulatory systems. A loss of epinephric cells in locus ceruleus may be even 
more profound than the loss of cholinergic cells in the basal forebrain (Zarow et al, 
2003). However, comparisons of multiple neurochemical markers with progression of 
clinical disease suggest the strongest correlation with cortical acetylcholine levels 
(Perry et al ,1981; Franceis et al, 1985; Minger et al, 2000). 
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Cholinesterase inhibitors in Alzheimer’s Disease 
The use of cholinergic enhancement in AD followed rationally from: 1) histochemical 
evidence for cholinergic defiency in post-mortem AD specimens, and 2) 
psychopharmacological data showing that disruption of cholinergic neurotransmission 
in humans, or lesioning cholinergic nuclei in animals, leads to cognitive impairments 
similar to those observed in AD. In the first blinded trial of 17 AD patients with 
moderate-advanced disease, significant improvements in a wide array of cognitive 
scores was obtained following treatment with the cholinesterase inhibitor oral 
tetrohydroaminoacridine (tacrine) (Summers et al, 1986). Whilst, subsequent larger 
trials confirmed a beneficial effect for cholinesterase inhibitors it became clear that 
the effect sizes were small, and rarely would there be complete clinical reversibility. 
Pooling the effects of randomised-controlled trials over eight types of ChEIs, in over 
10,000 patients, shows that mild-to-moderate AD patients improve by ~ 5 points 
relative to both baseline, and placebo, on the 70-point cognitive and behavioral 
ADAS-Cog scale (Giacobini, 2000). By comparison, the mean annual change in 
ADAS-Cog scores in untreated AD patients is ~ 8-9 per year. Beneficial effects are 
sustained for at least 1 year (Homma et al, 2009), and may still be present in excess of 
5 years from treatment initiation (Bullock & Dengiz, 2005). There is also limited 
evidence for a disease-modifying effect of ChEIs, with a slightly better outcome for 
patients started on ChEI treatment early in their disease course, as compared to later 
on (Winblad et al, 2006). Similarly, ChEIs may delay the rate at which mild cognitive 
impairment progresses to AD (Diniz et al, 2009).   
 
One of the reasons for the relatively mild efficacy on average of ChEIs in AD is a 
high degree of inter-patient variability. Thus the ADAS-Cog response to ChEIs 
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includes 10-15% patients showing no difference relative to placebo, 35% showing a 
significant improvement and 5% showing an ADAS-Cog improvement of 
significantly more than 5 points (Giacobini, 2000). Reasons for this variability include 
patients’ baseline performance (Calabria et al, 2009) with greater benefit in patients 
with worse baselines (Wattmo et al, 2008); integrity of cholinergic fibres as measured 
by MRI (Behl et al, 2007), and genetic profile (see above). The long-term response to 
cholinesterase inhibitors may also be predictable on the basis of psychometric 
response following a single-dose challenge of the same drug. AD patients who 
improved on attentional and executive (but not memory) tests after a single tacrine 
dose, were also those who showed an improvement (defined as MMSE increase of 
≥3) after 4 weeks of tacrine treatment (Alhainen et al, 1993).   
 
The benefits of pro-cholinergic therapies in Alzheimer’s disease tend to be manifest 
more for attentional than memory deficits (Sahakian & Coull, 1993) – an observation 
that mirrors the previously discussed findings of performance deficits following 
induced basal forebrain cholinergic lesions. Additionally, administration of nicotine to 
Alzheimer’s disease resulted in a significant improvement in tests of sustained visual 
attention and perception, while not improving auditory or visual short-term memory 
(Jones et al, 1992). Where ChEIs do improve recognition performance in Alzheimer’s 
disease, this has been found from signal-detection analysis to be due to a combination 
of improved old verus new discriminability (i.e. memory storage), and a greater 
likelihood for saying that an item was old (i.e. change in the criterion) (Mohs & 
Davis, 1982).  
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One of the reasons why ChEIs may not be that effective is because they act through 
tonic stimulation rather than though enhancing normal release patterns (as levodopa is 
able to). Hence pharmacologically suppressing GABA-mediated inhibition of nucleus 
basalis, e.g. with the benzodiazepine antagonist beta-carboline, might be better than a 
ChEI strategy (Sarter et al, 1990). Other theoretical problems with ChEIs are that they 
depend upon a minimum of baseline cortical ACh transmission, as well as a minimum 
of ChE activity. In AD, axonal cholinesterase activity decreases early in the disease 
course (Davies et al, 1976) since axonally-located AChE occurs exclusively in 
cholinergic neurons. However, total AChE levels do not decrease until AD is 
advanced since the enzyme is found not only axonally but also in cholinoceptive 
perikarya, neuroglia, and the plaques and tangles of AD. 
 
It is likely that neurological diseases other than Alzheimer’s disease involve 
deficiencies in central cholinergic neurotransmission, and so might be amenable to 
pro-cholinergic therapies including ChEIs. There are a multitude of case-reports or 
case-series showing positive effects of physostigmine on memory in various 
neurological scenarios, including: herpes simplex encephalitis (Catsman-Berrevoets et 
al, 1986), Huntington’s disease (Nutt, 1983; Davis et al, 1979), traumatic brain injury 
(Poole & Agrawal, 2008), and delirium (Rose & Moulthrop, 1986). Furthermore, 
based upon neuropathological evidence for lesions in nucleus basalis and cortical 
cholinergic fibre disruptions in cortical Lewy Body disease, Parkinson’s disease-
dementia and vascular dementia, ChEIs have been trialled in these diseases with 
modest therapeutic gains (Liepelt et al, 2007; Ballard et al, 2008; Dichgans et al, 
2008).  
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3. Human Cholinergic 
Functional Neuroimaging Review 
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Role of Pharmacological - Functional Imaging 
 
Functional neuroimaging has increasingly established itself as a valid and informative tool 
for studying activation patterns across the whole brain in different cognitive and/or 
pharmacological contexts, to complement more invasive methodologies such as single-unit 
or lesion-based techniques. Multiple examples exist where functional neuroimaging 
activations provide reliable ‘signatures’ of processes previously characterised at (and thus 
cross-validated by) other levels of neural recording, including invasive animal work. Such 
examples include: retinotopic (e.g. DeYoe et al, 1994) and category-specific (e.g. 
Kanwisher et al, 1997) mappings of visual cortex; attentional influences on sensory 
cortices (e.g. Martinez et al, 2001); attentional control signals in frontoparietal regions (e.g. 
Hopfinger et al, 2000); learning-related plasticity of sensory cortex (e.g. Morris et al, 
1998); repetition suppression (e.g. Henson & Rugg, 2003); working memory-delay activity 
(e.g. Courtney et al, 1997); and subsequent-memory effects in medial temporal cortex (e.g. 
Wagner et al, 1999).  
 
Such convergence has arisen even though most functional neuroimaging measures 
primarily reflect regional metabolic or vascular responses, as indirect indices of associated 
neural activity (Logothetis, 2002); and despite the restricted spatial resolution of existing 
functional neuroimaging approaches (on the order of sub centimetre) compared with 
others. Assumptions inherent in the interpretation of functional imaging recordings, in 
relation to the vascular - metabolic origin of its datum; and interactions of this with 
systemic pharmacological interventions are discussed subsequently in Methods. 
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From the standpoint of this thesis, it is notable that many such functional imaging 
paradigms probe neural mechanisms that non-human studies have shown to be under 
cholinergic control. Consequently, it becomes meaningful to ask whether or not 
cholinergic manipulations alter functional neuroimaging activation patterns in directions 
consistent with existing accounts; and furthermore whether human neuroimaging can 
provide new data to help refine existing models of cholinergic function. Pharmacological 
functional imaging provides a methodological strategy of asking whether patterns of brain 
function observed under well-characterised cognitive paradigms interact with a 
pharmacological manipulation of interest.  
 
Pharmacological functional imaging has the potential to complement more traditional 
physiological and psychological approaches for the following reasons: 1) It may provide 
independent corroboration of existing neuropharmacological theoretical models, firstly by 
measurement of a neural activity at a grosser spatiotemporal scale than that achieved by 
single-unit studies, and secondly by opening up neurophysiological enquiry to healthy 
humans. 2) If offers testing of predictions of existing neuropharmacological models that 
are not easily testable given the constraints of traditional neurophysiological techniques. 
For example, functional imaging provides the advantage of sampling neural activity over 
the entire brain in order to explore interactions, and connectivity relationships, between 
sensory, attentional and memory systems. Furthermore, testing in humans can provide 
more naturalistic contexts, with short-duration testing intervals, than many animal 
paradigms in which animals often need to be trained for many weeks before achieving a 
behavioural criterion. 3) It may help explain the psychotropic effects of a multitude of 
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drugs, by filling an explanatory gap between neurophysiology-based models of 
endogenous neuromodulator function and psychophysics. 4) It may explain some of the 
inter-individual variance in behavioural responsiveness to drugs either in terms of the brain 
response to a single drug challenge, or in terms of the pattern of brain activation prior to 
drug exposure (e.g. Giessing et al, 2007). 5) It can provide models of neuropathological 
states characterised by hypo- or hyperfunctioning neuromodulatory systems, e.g. as found 
with dopamine antagonists inducing activation patterns similar to those observed in 
Parkinson’s disease (Honey et al, 2003),  or with amphetamine in its capacity to model 
features of mania (Willson et al, 2004) and drug-addiction (Vollm et al, 2004). 
 
Types of Pharmacological Functional Imaging 
 
The type of pharmacological functional imaging studies reviewed here need to be 
distinguished from two other types of physiological study probing neuromodulatory 
systems in humans.  
 
The first distinction lies between measuring brain activity during a set of precisely-
controlled tasks versus imaging the resting state. Resting state studies have the advantage 
of not being confounded by performance, as may affect patient studies (Geaney et al, 
1990), and may still be related to function through correlations with performance (Ebmeier 
et al 1992), or other physiological variables, e.g. EEG (Gustafson et al, 1987). This is 
supported by studies showing changes in baseline cerebral metabolism after prolonged 
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treatment with a drug, typically a cholinesterase inhibitor (Staff et al, 2000), which itself 
correlates with clinical response to that drug (Venneri et al, 2002).  
 
Certain functional imaging data collected with subjects at rest suggest mechanisms of 
action. For example, the fact that nicotine enhances activation of thalamic nuclei and 
reticular formation, but not neocortex (McNamara et al, 1990), while scopolamine 
decreases thalamic activity (Blin et al, 1994), specifically during rest, suggests that many 
instances of cholinergic interactions with performance could be subcortically mediated. 
Differences between nicotinic and muscarinic contributions to memory have also been 
suggested by reductions in temporoparietal and prefrontal resting-state blood flow 
following mecamylamine and scopolamine, respectively (Gitelman & Prohovnik, 1992). 
Moreoever, correlations between nicotine-induced “rush” or “high” feelings and 
activations enhancements in frontal and limbic structures supports models implicating 
these regions in mediating drug reinforcement and dependency (Stein et al, 1998).  
 
Cholinergic modulation of resting-state activity may also been analysed in terms of fractal 
complexity, and inter-regional correlations, rather than merely amplitude, thereby 
providing information on cholinergic modulation of functional connectivity (Suckling et al, 
2008). For example, scopolamine is found to decrease the fractal complexity of resting-
state activity (which can be thought of as similar to the number of superimposed wavelets 
that make up a time-series), while increasing the low-frequency coherence between 
hippocampus and frontotemporal regions, both of which may characterise age-related 
memory impairment (Wink et al, 2006). 
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A second important distinction of pharmacological functional imaging is between 
metabolism-related functional imaging and neurotransmitter-related imaging. The first sort 
of study explores downstream consequences of cholinergic manipulation – including 
effects of cholinergic drugs on other neuromodulatory systems such as dopamine 
(Svensson & Giacobini, 2000). By contrast, neurotransmitter-related imaging informs 
about the particular upstream cholinergic pathway at which the drug is acting upon. For the 
latter type of inquiry, use is made of radioligand methods that measure aspects of 
cholinergic function, such as receptor occupancy (Easwaramoorthy et al, 2007), high-
affinity choline uptake (Zheng et al, 2007), vesicular ACh transporter uptake (Mazere et al, 
2008), and acetylcholinesterase (Kikuchi et al, 2007). The anatomical disposition of 
cholinergic receptors or AChE may account for regional variations in functional 
modulation secondary to drugs. For example, a concentration of nicotinic receptors within 
thalamus and basal ganglia (Paterson & Nordberg, 2000) is congruent with strong nicotinic 
influences on fMRI or PET responses in these same regions (e.g.  Jacobsen et al, 2004).  
 
Literature Review of Cholinergic Functional Imaging  
 
As a background to the human cholinergic-functional neuroimaging experiments of this 
thesis, a comprehensive listing of existing studies employing similar methodology is 
presented (Tables 1 -3), and then interpreted. An exhaustive search for human cholinergic 
functional imaging studies was performed using the PubMed database with combinations 
of the search terms [cholinergic OR acetylcholine OR nicotine OR scopolamine OR 
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cholinesterase] AND [functional imaging OR fMRI OR PET] up to July 2010. PubMed-
suggested ‘Related Articles’, references and citations of relevant articles were also 
interrogated. Selected studies were those in which: 1) functional neuroimaging measures 
were obtained in healthy humans during a stimulus-driven and/or behavioural activation 
paradigm; and 2) the effects of a systemic cholinergic manipulation on brain activation 
patterns were examined. The vast majority of such studies actually scanned subjects over at 
least two behavioural conditions, sometimes including a resting state. Hence the results of 
such studies often take the form of interactions between drug and task- (or stimulus-) 
determined conditions in determining regional brain activations.  
 
Cholinergic functional neuroimaging studies in patient groups (for which the vast majority 
have been in Alzheimer’s disease or mild cognitive impairment) are not included because 
of differences in the general methodology of such studies. The majority of such clinical 
studies observe changes in neural activation over a long course of treatment (typically 
many months), rather than using placebo-controlled, single drug challenges, as employed 
by the experiments in this thesis. Moreover many published clinical cholinergic functional 
imaging studies measured only resting-state metabolic profiles, rather than task and/or 
stimulation-related activations which are of main interest here. Two more clinically-
focused, cholinergic functional neuroimaging reviews can be found elsewhere (see 
Dickerson, 2006; Nordberg, 2004). Resting-state studies are also omitted from the list, 
having been discussed above. 
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In order to assist exposition, and in line with the various functional conceptualisations of 
acetylcholine summarised in the Background chapter (viz. sensory, attention and memory 
functions), studies are categorised according to whether the critical effects primarily arose 
in sensory, frontoparietal or medial temporal cortical regions. Activations in other brain 
regions (e.g. lateral temporal cortex and subcortical structures) are listed alongside 
frontoparietal effects for convenience. Furthermore, within each anatomical division, 
effects are secondarily classified according to the broad cognitive construct putatively 
tested (e.g. passive viewing, attention-demanding or memory task). Then for each study 
and anatomical region we tabulate: a more accurate description of the behavioural 
paradigm; the drug administered; the imaging modality; plus the critical functional 
neuroimaging and behavioural results. Studies are duplicated across tables where, for 
example, both sensory and frontoparietal regions were studied. 
 
The general format of all studies is that of a randomised-controlled trial in which subjects 
receive drug or placebo, sometimes as part of a within-subject design, other times as a 
between-subject design. The predominant cholinergic drugs used were the muscarinic 
receptor antagonist scopolamine; the nicotinic receptor stimulant nicotine; the 
cholinesterase inhibitor physostigmine (that is given intravenously and has a well-
documented pharmacokinetic time-course); or the cholinesterase inhibitor donepezil. 
Mecamylamine has also been used as a nicotinic receptor antagonist. In all the non-clinical 
studies reviewed here, the manipulation involved a single-challenge of drug, with most 
studies adopting a placebo-controlled within-subject cross-over design. 
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Table 1: Cholinergic functional imaging studies – sensory cortices 
A: No task / 
irrelevant task 
Scanning task  Drug  Effect of drug on functional activations  Effect of drug on performance 
Cohen (94)* 
PET‐FDG 
Auditory 
discrimination 
Scopolamine  ↓es primary visual, parieto‐occipital cx (i.e. 
irrelevant sensory cx); N.B. no control task 
Poorer target discrimination. 
Performance inversely correlated with 
parieto‐occipital cx activity 
Grasby (95) 
PET‐rCBF 
Auditory word:  
5‐ & 15‐spans 
Scopolamine  ↑es bilateral lateral occipital cx (i.e. irrelevant 
sensory cx), in sub‐ and suprascan tasks 
Memory impairment on supraspan 
task only 
Bahro (99) 
PET‐rCBF 
Auditory – 
eyeblink 
conditioning 
Scopolamine  ↑es occipital‐temporal, especially lateral, cx 
(i.e. irrelevant sensory cx); N.B. no direct 
comparison with placebo group 
Not measured 
Thiel (01) 
 
Word‐stem 
completion 
Scopolamine  No effect in primary visual cortex  No effect on performance 
independent of repetition 
Sperling (02)  Face‐name 
pairs 
Scopolamine  No effect in primary visual cortex  Memory impaired 
Jacobsen (02)  Chequerboard  Nicotine  No effect in sensory cortices  Not measured 
Hahn (07)  Chequerboard  Nicotine  No effect in sensory cortices  Not measured 
Hahn (09)  Chequerboard  Nicotine  No effect in sensory cortices  Not measured 
Mentis (01) 
PET‐rCBF 
Alternating eye 
light flash 
Physostigmine 
± Scopolamine 
Physostigmine ↓es middle occipital, 
Physo + Scop ↑es middle occipital; 
No effect of physo in primary visual cx 
Physo + Scop ↓es primary visual cx 
Not measured 
Furey (00a)  Face WM   Physostigmine  No effect on control stimuli in extrastriate cx  Not measured 
Silver (08)  Chequerboard  Donepezil  ↓es primary visual cortex extent & magnitude  Not measured 
 
 
 
* All studies are fMRI except where indicated under study first author 
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Table 1: Continued – sensory cortices 
B. Attention‐
demanding task 
       
Thienel (09a)  Attention 
Network Task 
Mecamylamine  ↓es superior occipital cx; ↑es anterior 
fusiform cx. ‐ orienting;  
↓es calcarine cx – conflict 
Slowing across all trial types; no 
interactions 
Thienel (09b)  ANT  Scopolamine  ↑es middle occipital cx – alerting;  
↓es lingual gyrus, inf temporal cx ‐ conflict 
Slowing of responses 
Ghatan (98) 
PET‐rCBF 
Visual Maze  Nicotine  ↑es occipital‐temporal‐parietal cx more during 
difficult than control task 
No effect 
Thiel (05)  Alerting / 
Spatial cues 
Nicotine  ↓es L lateral occipito‐temporal, R medial 
occipital cx ‐ alerting 
↓es post occip, post fusiform cx, but ↑es ant 
occip, ant fusiform cx  ‐ orienting 
Speeding of invalidly‐cued trials; 
alerting numerically but insignificantly 
speeded   
Hahn (07)  Spatial cues  Nicotine 
(smokers) 
↑es cuneus in valid precise‐cueing trials, but 
↓es cuneus in valid imprecise‐cueing trials; 
↑es lingual gyrus in invalid low‐intensity target 
trials, but ↓es lingual gyrus in invalid high‐
intensity target trials 
Speeding in precise‐cueing trials 
Thiel (08)  Spatial cues  Nicotine  No effect in occipital cx  Less slowing in invalidly cued trials 
Vossel (08)  Spatial cues  Nicotine  ↓es anterior lingual gyrus to invalid vs valid 
cues in high versus low‐predictability blocks 
Reduced invalidity effect 
Hahn (09)  Visual angle; 
colour; signal‐
detection 
Nicotine 
(smokers) 
↓es occipital‐temporal cx across all tasks  
(i.e. high‐ and low‐attention) 
Speeding in selective‐attention and 
signal‐detection tasks, but not divided 
attention 
C. Memory 
(Encoding) 
       
Rosier (99) 
PET‐rCBF 
Shape 
recognition 
Scopolamine (at  
encoding); scan 
3 days later 
↓es bilateral fusiform cx., esp. L (both tasks), 
and middle occipital cx. (during sensory‐
challenge rather than standard conditions) 
Impaired recognition accuracy. 
Fusiform activity correlates with 
memory accuracy.  
Sperling (02)  Face‐name 
pairs 
Scopolamine  ↓es fusiform cx  Activity correlates with subsequent 
memory 
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Table 1: Continued – sensory cortices 
C. Memory 
(Encoding) 
       
Bullmore (03) 
 
Object‐
location  
Scopolamine  ↓ lateral occipital; inferior temporal; cuneus 
during task independent of memory load 
No effect 
Schon (05)  Delayed 
match‐to‐
sample 
Scopolamine  ↓es bilat mid‐fusiform, parahippocampus 
(delay‐period of WM);↓es R fusiform, (delay‐
period of subsequently remembered trials) 
Impairs performance on control task, 
WM task and subsequent memory 
Lawrence (02)  Visual number 
WM (RVIP)  
Nicotine  ↑es middle occipital, fusiform cx. in RVIP and 
visuomotor control task 
Improved accuracy on RVIP task 
(dependent on treatment order) 
Hong (09)  RVIP  Nicotine  ↑es cuneus, fusiform, parahippocampal cx  Improved accuracy on RVIP task 
Jacobsen (04)  Auditory n‐
back; dichotic 
vs binaural 
Nicotine  ↑es posterior sup. Temporal cx during 2‐back, 
not 1‐back; ↓es medial occipital (i.e. irrelevant 
sensory cx) during dichotic presentation 
Accuracy worsened in hardest 
condition (2‐back, dichotic) 
Jacobsen (06)  Auditory n‐
back 
Nicotine  ↓es sup. temporal cx during 2‐back, dichotic;  
↓es occip., fusiform (i.e. irrelevant sensory cx) 
Accuracy worsened in hardest 
condition (2‐back, dichotic) 
Furey (97) 
PET‐rCBF 
Face WM  Physostigmine  ↓es lateral temporo‐occipital cx. in WM vs 
control tasks 
Speeded responses 
Furey (00b) 
PET‐rCBF 
Face WM  Physostigmine  ↑es medial occipital correlates with RT 
decreases  
Speeded responses, and correlation 
with activation increases 
Furey (00a)  Face WM  Physostigmine  ↑es amplitude in fusiform, occipital, parietal 
cx. (encoding phase); ↑es activation volume in 
occipital, inf temporal cx. (encoding and delay)  
Trend to speeded responses 
Freo (05) 
PET‐rCBF 
Face WM 
 
Physostigmine  ↑es medial occipital (in elderly); ↓es lateral 
occipital, ventral temporal cx. (esp in young)   
Speeded responses 
Furey (08) 
PET‐rCBF 
Face WM  Physostigmine  ↓es lateral occipital cx.  (1, 6, 16s delays) 
↑es medial occipital cx. (6 – 16s delays) 
Speeded responses independent of 
delay 
Chuah (08) 
(Sleep‐deprived) 
Visual color 
WM 
Donepezil  ↑es visual extrastriate cx. in sleep‐deprived, 
independent of item number 
Improved performance; correlated 
with activation enhancements 
Ricciardi (09) 
PET‐rCBF (Young 
& Old) 
Face WM  Physostigmine  ↓es lateral occipital, ventral temporal cx.  
(young) for long delays; ↑es lateral occipital 
(elderly) for long delays 
↑es medial occipital cx. (all) for long delays 
Speeded responses independent of 
delay 
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Table 1: Continued – sensory cortices 
Memory 
(Conditioning) 
       
Thiel (02a)  Auditory fear 
conditioning 
Scopolamine  ↓es auditory cx plasticity due to ↓ response 
to CS+  or ↑ response to CS‐  
Reduced speeding of responses to CS+ 
(paired) relative to CS‐ (unpaired tone) 
Thiel (02b)  Auditory fear 
conditioning 
Physostigmine  ↓es auditory cx plasticity due to ↑ CS‐ 
response (unpaired tone) 
No effect 
Memory  
(Priming) 
       
Thiel (01) 
 
Word stem‐
cell 
completion 
Scopolamine  ↓es L lateral occipital repetition decrease due 
to ↑ed response to repeated stimulus. 
No effect in primary visual cortex. 
Reduced priming (accuracy) for 
previously presented words 
Thiel (02c)  Faces –  
judging 
famousness 
Scopolamine  ↓es R fusiform cx repetition decrease to 
famous face repetition, mostly due to higher 
signal with repeated face; also overall ↓ in 
response to all face types in L fusiform cx. 
Reduced priming (RT) for repeated 
famous faces; no effect if drug given 
after study phase 
Abbreviations: WM: working memory; ANT: attention network task; RVIP: rapid visual information processing task; cx: cortex; PFC : prefrontal 
cortex; RT: reaction time; sup.: superior; occip.: occipital 
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Table 2: Cholinergic functional imaging studies – task‐related activations in fronto‐parietal‐temporal cortices, and subcortical, regions 
 
A. Sensory 
Judgement 
Scanning task  Drug  Effect of drug on functional activations  Effect of drug on performance 
Cohen (94) 
PET‐FDG 
Auditory 
Discrimination 
Scopolamine  ↓es thalamus, R PFC, cingulate, inf parietal cx; 
↑ L anterior prefrontal, superior parietal cx  
Poorer discrimination of targets. 
Correlation between R PFC and score  
Thienel (09a)  Attention 
Network Task 
Mecamylamine  ↑es orbitofrontal cx during alerting;  
↓es bilat superior frontal during orientation;     
   (and ↑es during no‐orientation trials);  
↓es precuneus, sup parietal during conflict; 
↑es L inf parietal during conflict 
Slowing across all trial types; no 
interactions 
Thienel (09b)  Attention 
Network Task 
Scopolamine  ↑es R middle temporal during alerting; 
↓es L superior prefrontal during orientation  
    (and ↑es during alerting trials); 
↓es ant cing, OFC, R superior frontal, 
precuneus, during conflict  
    (and ↑es during no‐conflict trials);  
↑es L inf parietal during conflict 
Slowing across all trial types; greater 
slowing for incongruent (conflict) 
trials; also reduced interaction of 
alerting with conflict 
Ghatan (98) 
PET‐rCBF 
Visual maze  Nicotine  ↓es ant cing, basal ganglia, thalamus, cbllm  No effect 
Mentis (01) 
PET‐rCBF 
Alternating eye 
light flash 
Physostigmine ± 
Scopolamine 
Physo ↓es inf parietal; ↑es thalamus; 
Scopolamine did not affect this 
Not measured 
Thiel (05)  Alerting / 
Spatial Cues 
Nicotine  ↑es rt angular gyrus and rt prefrontal during 
alerting trials (and ↓es during no‐cue trials) 
↓es lt lateral occipito‐temporal during alerting 
↓es left parietal, precuneus during invalid‐cue 
Speeding of invalidly‐cued trials, esp 
in subjects with large validity effect at 
baseline; alerting and false‐alarm rate 
not affected 
Giessing (06)  Visual spatial 
cues 
Nicotine  ↓es right posterior parietal during invalidly 
cued trials, esp when cues highly reliable; 
↑es right posterior parietal during validly cued 
trials when cues poorly reliable 
 No effect 
Thiel (07)  Auditory / 
visual alerting 
Nicotine  ↓es cued trials; ↑uncued trials in R parieto‐
occipital, frontal, sup temporal, ant cingulate; 
↑es cue trials in R angular gyrus (visual trials); 
↓es uncued trials (both modalities) 
Trend to speeding for cued visual 
trials and uncued auditory trials 
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Table 2: Continued – task‐related activations in fronto‐parietal‐temporal cortices, and subcortical regions 
Thiel (08)  Spatial cues  Nicotine  ↓es right parietal, left inferior frontal, bilat 
middle temporal during invalid trials 
Speeding of invalidly cued trials 
Vossell (08)  Spatial cues  Nicotine  ↓es R parietal, temporal, parietal, ant cing in 
invalid trials (and ↑es in valid trial) in 90% 
valid block, but ↑es R parietal during invalid 
trials (and ↓es in valid trial) in 60% valid block 
Speeding of invalidly cued trials in 
90%‐valid block, but slight slowing in 
60%‐valid block 
Hahn (07) 
 
Spatial cues   Nicotine 
(smokers; but 
no difference 
with non‐
smokers) 
Enhances deactivations in medial PFC ‐ 
parietal, L angular gyrus. ↓es target‐related 
activity in thalamus (valid), precuneus (invalid); 
but ↑es R PFC. ↓es invalid trials in R PFC and 
L parietal for high‐intensity targets, but ↑es in 
these regions for low‐intensity targets.  
Speeding in precise‐cue, high‐
intensity target trials only, and in 
invalid trials. Improved accuracy with 
high‐intensity targets. Correlation 
between RT ↓ and nicotine‐induced 
BOLD deactivations 
Hahn (09) 
 
Visual angle; 
colour 
sequence; 
signal‐detection  
Nicotine 
(smokers; no 
difference with 
non‐smokers) 
↓es dorsal prefrontal during low‐attention, 
but ↑es during high‐attention; also main‐
effect ↓es (enhances deactivation) in ant cing, 
medial PFC, parahippocampal cx 
Speeding of high and low‐attention 
tasks. Correlations of RT ↓ with 
thalamus, PFC deactivations in signal‐
detection task 
Ettinger (09)  Pro‐ and Anti‐
Saccades 
Nicotine  ↓es dorsal prefrontal during anti‐saccades; 
↓es posterior cingulate, precuneus, R sup 
temp gyrus during pro‐saccades 
Speeding of anti‐saccades 
Azizian (09) 
 
Color‐word 
Stroop task 
Nicotine vs 
smoking 
withdrawal 
↓es anterior cingulate; 
↑es middle frontal 
Speeding independent of congruency 
B. Working 
memory  
       
Grasby (95) 
PET‐rCBF 
Auditory word 
lists:  
5‐ & 15‐words 
Scopolamine  ↓es bilat PFC, ant cing. (supraspan task);  
↓es premotor, R thalamus, precuneus, and 
↑es OFC in supra‐ and subspan tasks  
Memory impairment on supraspan 
task only 
Dumas(08) 
 
Visual verbal n‐
back WM 
Scopolamine /  
Mecamylamine 
↓es R prefrontal (either drug);  
↓es precuneus (scopolamine) 
No effect 
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Table 2: Continued – task‐related activations in fronto‐parietal‐temporal cortices, and subcortical regions 
Ernst (01) 
PET‐rCBF 
 
Visual letter  
2‐back WM 
Nicotine  ↑es L lateral PFC; bilat parietal cx;  
↓es ant. cingulate (in ex‐smokers); 
↓es frontoparietal, ant. cingulated (smokers) 
Improves accuracy in smokers;  
accuracy correlates positively with 
PFC, cingulate activity under nicotine 
Lawrence (02)  RVIP and target 
detection 
Nicotine  ↑es bilat. parietal, post. cingulate, caudate, 
thalamus (RVIP); enhances insula deactivations 
Improved accuracy on RVIP task 
(dependent on treatment order) 
Hong (09)  RVIP  Nicotine  ↑es bilat. prefrontal, cingulate, parietal, cx; 
     insula, thalamus; striatum; midbrain, cbllm. 
Improved accuracy on RVIP task; 
correlated with activity in prefrontal, 
parietal, striatal, cingulate, brainstem 
Kumari (03)  n‐back WM  Nicotine  ↑es dorsofronto‐parietal, ant cingulate, esp at 
1‐back; ↓es R dorsal parietal for 3‐back 
Increased accuracy. Cing, parietal 
effects covary with performance. 
Speeding in 3‐back 
Jacobsen (04)  Auditory 1‐ or 
2‐back 
Nicotine  ↓es R frontal, pallidum and thalamus during 
dichotic (high‐attention) or 2‐back conditions 
Impaired accuracy during dichotic, 2‐
back condition 
Jacobsen (06)  Auditory 1‐ or 
2‐back 
Nicotine  ↓es L prefrontal, posterior cingulate during 
dichotic 2‐back condition 
Impaired accuracy during dichotic, 2‐
back (more so in 957T carriers) 
Furey (97) 
PET‐rCBF 
Face WM  Physostigmine  ↓es R prefrontal cx.    Speeded responses and correlation 
with prefrontal reductions 
Furey (00b) 
PET‐rCBF 
Face WM  Physostigmine  ↓es in R prefrontal cx.  ant cingulate, L lateral 
temporal cx. correlates with RT decreases 
Speeded responses and correlations 
with activation decreases 
Furey (00c) 
PET‐rCBF 
Face WM  Physostigmine  ↓es in R prefrontal cx.    Speeded responses  
Furey (00a)  Face WM  Physostigmine  ↓es anterior dorsal prefrontal cx,; ↑es 
inferior PFC, to all phases of task 
Speeded responses 
Freo (05) 
PET‐rCBF 
(Young & Old) 
Face WM  Physostigmine  ↓es dorsal (young) and anterior, inferior 
(elderly) PFC,; trend to ↑ in ant. cingulate cx.; 
greater deactivations in insula, medial frontal 
Speeded responses in both young and 
elderly 
Furey (08) 
PET‐rCBF 
Face WM  Physostigmine  ↓es anterior, inferior prefrontal cx., esp. at 
longer WM delays;  ↓es sup. PFC at all delays 
Speeded responses independent of 
delay 
Ricciardi (09) 
PET‐rCBF  
Face WM  Physostigmine  ↓es anterior prefrontal cx  Speeded responses independent of 
delay 
Chuah (08) 
(Sleep‐deprived) 
Visual color 
WM  
Donepezil  ↑es R intraparietal sulcus. L prefrontal in 
sleep‐deprived 
Improved performance; correlated 
with activation enhancements 
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Table 2: Continued – task‐related activations in fronto‐parietal‐temporal cortices, and subcortical regions 
C. Short‐Term 
Memory 
       
Rosier (99) 
PET‐rCBF 
Shape 
recognition 
Scopolamine 
(drug given 
during 
encoding); scan 
3 days later 
↑es posterior thalamus, bilat parietal   Impaired recognition accuracy.  
No effect on stimulus discrimination 
or detection control tasks (at time 
drug given) 
Thiel (01) 
 
Word stem‐cell 
completion 
Scopolamine  ↓es inferior and middle PFC repetition 
decrease due to ↓ed response to new items 
Reduced priming for previously 
presented words 
Sperling (02)  Face‐name 
pairs  
Scopolamine  ↓ inferior, dorsolateral, orbital PFC; 
deactivations in lateral parietal, precuneus, 
lateral temporal cx. 
Slowed responses to gender 
judgement.  
Impaired subsequent memory.  
Bullmore (03)  Object‐location 
learning 
Scopolamine  ↓ bilateral dorsolateral PFC, ant. cingulate, 
striatum for high memory loads; ↓ 
 parietal for high and low memory loads 
No effect 
Bozzali (06)  Word retrieval  Scopolamine  ↓ bilateral PFC in exclusion condition (i.e. 
source not familiarity memory) for New but 
not Old items 
No overall effect. Correlation of ↓ in 
left PFC activity with score on New 
items 
Craig (09)  Subsequent 
memory effect 
for written 
words  
Scopolamine  ↓es L inferior frontal in subgroup treated with 
GnRH (reduces estrogen release) 
Impaired recognition  
Abbreviations: WM: working memory; ANT: attention network task; RVIP: rapid visual information processing task; cx: cortex; PFC : prefrontal 
cortex; RT: reaction time; cbllm: cerebellum 
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Table 3: Cholinergic functional imaging studies – Medial temporal areas  
 
A. Memory    Scanning task  Drug  Effect of drug on functional activations  Effect of drug on performance 
Sperling (02)  Face‐name 
pairs 
Scopolamine  ↓es fusiform cx, anterior hippocampus  Correlates with memory impairment 
Bullmore (03) 
 
Object‐
locations  
Scopolamine  ↓ hippocampal, parahippocampal cx. For 
higher memory load 
No effect 
Schon (05) 
 
 
 
Scenes: 
delayed 
match‐to‐
sample 
Scopolamine  ↓es bilat mid‐fusiform, parahippocampus 
during delay‐period of WM, not control. 
↓es right‐fusiform, bilat parahippocampus,  
hippocampus in delay‐period of subsequently 
remembered items presented once;  
↑es bilat hippocampus subsequent memory 
effect for stimuli previously presented twice 
Impairs accuracy and speed on visual 
control task and WM task. Impairs 
subsequent confident memory 
Bozzali (06)  Word retrieval  Scopolamine  ↓ left perirhinal cx in exclusion condition (i.e. 
source not familiarity memory) for New but not 
Old items 
No overall effect. Correlation of ↓ in 
left perirhinal cx activity with score on 
New items 
Kukolja (09) 
 
Item & Spatial 
Source 
Memory 
 
Physostigmine  ↑es R hippocampal for successful spatial 
source encoding;  
↓es R amygdala during item encoding 
regardless of subsequent source memory 
↓es R amygdala for successful spatial source 
retrieval 
Trend for reduction in spatial source 
memory accuracy. 
Baseline item memory accuracy 
negatively correlated with effect of 
cholinergic stimulation on item 
memory accuracy. 
B. Other         
Dumas(08)  Visual verbal 
n‐back WM 
Scopolamine /  
Mecamylamine 
↑es R parahippocampal cx (mecamylamine)  No effect 
Thienel (09a)  ANT  Mecamylamine  ↑es L parahippocampal cx during orienting  Slowing of responses 
Thienel (09b)  ANT  Scopolamine  ↓es L hippocampus during alerting   Slowing of responses 
Lawrence (02) 
 
RVIP   Nicotine  Enhances L parahippocampal, amygdala 
deactivations 
Improved performance 
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Table 5: Continued ‐ Medial temporal areas  
Hong (09)  RVIP  Nicotine ↑es parahippocampal cx  Improved accuracy 
Vossel (08)  Spatial cues  Nicotine  ↓es R hippocampus to invalid vs valid cues   Reduced invalidity effect 
Hahn (09)  Several 
attention tasks 
Nicotine  Enhances L parahippocampal deactivations  Speeding of responses 
Furey (00a)  Face WM  Physostigmine  ↓es L hippocampus correlates with RT ↓  Speeding of responses 
 
Abbreviations: WM: working memory; ANT: attention network task; RVIP: rapid visual information processing task; cx: cortex; PFC : prefrontal 
cortex 
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Interpretation 
Sensory cortex modulations 
Directionality of cholinergic modulation of sensory cortex is task-dependent 
One pattern that emerges on comparing Table 1A with that of Table 1B and 1C  is that 
the direction of modulation of cholinergic drugs on sensory cortex activity depends upon 
whether or not subjects attend to the stimulus. When stimuli are observed passively, or 
are irrelevant to task, cholinergic stimulation (with nicotine or cholinesterase inhibition) 
generally either elicits no effect (e.g. Jacobsen et al, 2002), or else suppresses sensory 
cortex activity, both in higher (e.g. Furey et al, 2000b) and early processing areas (e.g. 
Silver et al, 2008). By contrast, the muscarinic receptor antagonist scopolamine results 
either in enhanced activations (e.g. Mentis et al, 2001) or in no influence (e.g. Thiel et al, 
2001) within early sensory cortices during similar similar low-attention conditions. 
Resting-state studies support this general pattern with scopolamine tending to increase, 
but physostigmine tending to decrease, sensory cortical regional glucose consumption 
(Blin et al, 1994; Blin et al, 1997). Together, these findings suggest that stimulation of 
cholinergic receptors, especially muscarinic-type, can lead to net suppression of activity 
within sensory cortical regions, for stimuli that are task-irrelevant. 
 
In contrast, in situations where the stimulus is relevant to the task – either because of an 
instructed sensory judgement (Table 1B) or encoding for later memory (1C) - the 
opposite pattern is typically found. Thus, stimulus-evoked visual cortex activity is 
enhanced by physotigmine (e.g. Furey et al, 2000a), but suppressed by scopolamine or 
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mecamylamine (e.g. Sperling et al, 2002; Thienel et al, 2009a; Thienel et al, 2009b), 
selectively in tasks requiring stimulus processing. Nicotine too induces higher visual or 
auditory cortex activity during demanding spatial orienting, or working memory tasks, 
but not in sensorimotor control tasks (Hahn et al, 2007; Ghatan et al, 1998; Lawrence et 
al, 2002; Jacobsen et al, 2004).  
 
A related observation is that subjects who show attentional impairments – e.g. through 
sleep-deprivation (Chuah & Chee, 2008), age (Freo et al, 2005; Ricciardi et al, 2009) or 
disease (Kumari et al, 2006; Goekoop et al, 2006) - can exhibit a greater enhancement of 
(task-dependent) sensory cortex activity with cholinergic stimulation than for unimpaired 
subjects. This dependency upon state/trait also appears to be reflected in a greater 
performance response to cholinergic stimulation among poorly performing subjects 
(Kukolja et al, 2009). Presumably less able subjects will experience greater difficulty 
than more typical healthy subjects for a given task, so that their characteristic response to 
cholinergic stimulation can be thought of as reflecting increased task demands.   
 
From the perspective of existing accounts of cholinergic impacts on sensory processing 
that recognise separable influences for bottom-up and top-down processes (Sarter et al, 
2001), the results of cholinergic functional imaging can be summarized as: 1) cholinergic 
stimulation typically suppresses (or cholinergic blockade enhances) net sensory 
activations under conditions in which bottom-up processing predominates – e.g. with 
passive or task-irrelevant sensory stimulation, or alerting but non-orienting cues;  while 
2) cholinergic stimulation instead typically enhances (or cholinergic blockade decreases) 
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net sensory cortical activations under conditions in which top-down influences are strong, 
e.g. with demanding perceptual discrimination, higher attentional load, or deeper 
encoding for later memory.  Furthermore, cholinergic modulation of task-dependent 
sensory cortex activity correlates with drug effects on working memory (Furey et al, 
2000b; Chuah & Chee, 2008) or short-term memory performance (Sperling et al, 2002; 
Schon et al, 2005). This apparently supports models in which cholinergic influences on 
sensory cortices also go on to influence attentional and memory functions (Hasselmo & 
McGaughy, 2004; Sarter et al, 2005).   
 
Can we relate the profile of cholinergic modulation of sensory cortex activations, as 
found with PET or fMRI, to electrophysiological studies?  As discussed in the 
Background chapter, the effects of ACh stimulation in sensory cortices as studied 
electrophysiologically are varied, with some potentiation of activity restricted to 
stimulus-driven units in layer IV, but the predominant modulation among other cortical 
layers, subserving feedback or lateral interactions, being suppressive instead (Gil et al, 
1997; Roberts et al, 2005). The net effect from such combined modulation is suggested 
by voltage-sensitive optical imaging, which demonstrates that ACh generally suppresses 
overall strength and propagation of afferent-driven electrical activity across and between 
columns within cat visual cortex (Kimura et al, 1999). From a functional perspective, 
widespread neural suppression may 'reset' sensory processing (Gulledge et al, 2007), 
thereby heightening signal-to-noise ratio specifically for sensory, i.e. thalamocortical 
inputs (Sato et al, 1987b), while reducing lateral or feedback influences (Roberts et al, 
2005). On comparison with the above functional imaging review, it is apparent that pro-
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cholinergic drugs can also be associated with reduced sensory activations (or vice versa 
for anti-cholinergics), albeit specifically when attention to the stimulus is absent or low. 
Following the schema of Sarter et al (2001) (Fig. 2.11A), and bearing in mind that most 
electrophysiological studies measure stimulus-evoked responses divorced from top-down 
inputs, the functional neuroimaging findings of pro-cholinergic sensory suppression may 
correspond to the electrophysiological findings of ACh-induced net suppression in 
sensory cortex - that itself is thought to reflect enhanced bottom-up (relative to top-down 
or lateral) processing.  
 
If decreases in sensory cortex activation induced by cholinergic stimulatory drugs reflect 
net neural suppression as seen following ACh application to cortical slices, then what 
neurophysiological events do pro-cholinergic drug-induced increases in sensory 
activation relate to, as we have generally found in high-attention conditions within 
neuroimaging paradigms? To recap, a critical role for the cholinergic system is to 
maintain sensory processing in the face of performance challenges such as distractors 
(Sarter et al, 2006). Thus we would expect ACh to potentiate neural correlates of 
selective attention, in which sensory processing is biased towards task-relevant stimulus 
features, and away from task-irrelevant ones. In keeping with this, two recent studies in 
awake monkeys and rats respectively, indicate that cholinergic input to sensory (Herrero 
et al, 2008) and parietal (Broussard et al, 2009) cortices can potentiate neural correlates 
of selective attention by disproportionately increasing weighting of task-relevant versus 
task-irrelevant inputs. However, of relevance here, is that acetylcholine application also 
increased the overall level of visual neural activity, both in cells coding for task-relevant 
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and task-irrelevant locations, specifically during target detection. Accordingly during 
attention-demanding relative to baseline conditions, as listed in Tables 1B and 1C, we 
might expect pro-cholinergic treatments to enhance stimulus-evoked responses at the 
spatial scale of fMRI or PET, that integrate activity over thousands of such units 
(potentially including both task-relevant and task-irrelevant).  
 
Combining neurophysiological accounts of cholinergic modulation on bottom-up (e.g. 
Hasselmo & McGaughy, 2004) and top-down (e.g. Herrero et al, 2008) processes within 
sensory cortices, one can propose an account that accommodates the task-dependent 
profile of cholinergic impact on sensory activations studied with neuroimaging (see 
Figure 10.1). Whenever a stimulus is presented, regardless of task, cholinergic 
stimulation facilitates bottom-up circuitry, whilst reducing feedback and horizontal 
influences - the net metabolic signature of which seems to be a decrease in sensory cortex 
activation (e.g. Kimura et al, 1999). Conversely, in a subset of sensory paradigms, in 
which attention is focused towards the stimulus, top-down glutamatergic-mediated 
signals will enhance activity in selected, task-relevant sensory regions. Given that ACh 
potentiates neural activity of task-relevant, as well as (to a lesser extent) task-irrelevant 
regions (Herrero et al, 2008) during active sensory processing, the functional imaging 
correlate of this would be an increase in sensory cortex activations following pro-
cholinergic drug administration. This would also fit with findings that pro-cholinergic 
enhancement of sensory activations is more apparent in subjects with poorer baseline 
performance - for in these subjects it is plausible that a greater top-down 'attentional 
effort' is operative in order to sustain error-free performance (Sarter et al, 2006). 
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Figure 3.1. Model that links effects of acetylcholine on attentional and sensory systems 
based upon animal studies, with effects of systemic cholinergic stimulation or antagonism 
on functional imaging in three scenarios: A) pro-cholinergic drug modulation of sensory 
stimulation in passive / low-attention paradigms, relative to no drug ; B) selective 
attention paradigm (X versus Y) under normal cholinergic tone, relative to cholinergic 
inhibition or deficiency; C) selective attention under pro-cholinergic drug modulation 
versus no drug. Effects of ACh on the basic cortical circuit are known for ex vivo slices 
and so are more relevant for passive-stimulation functional imaging paradigms (A). 
Conversely, effects of ACh on attention have been determined from in vivo recordings, 
and do not accurately delineate laminar-specific effects. Effects of endogenous ACh on 
attention (B) are suggested by functional imaging studies employing cholinergic 
antagonists, or comparing untreated with treated Alzheimer’s disease patients. 
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Frontoparietal cortex modulations 
Hypercholinergic or hypocholinergic states reduce neural markers of top-down 
orienting  
A consistent pattern of parietal modulations by nicotine is observed in a series of studies 
employing a spatial cueing (Posner) task, in which detection of lateralised targets is 
enhanced by prior cues that signal the likely location of an upcoming target. Nicotine 
decreases inferior parietal cortex activations specifically during invalidly-cued trials - i.e. 
in a minority of 'catch' trials when the cue incorrectly predicts the subsequent target 
location, and for which there is a need for reorienting away from a cued location (Thiel et 
al, 2005; Thiel et al, 2007; Thiel et al, 2008). Since nicotine also decreases the 
performance-cost of invalid cues (Phillips et al, 2000), this decreased parietal activation 
during invalid trials seems not to reflect impaired reorienting, but rather implies a 
processing benefit. Further variations of this paradigm reveal that nicotine-induced 
decreases in parietal responses to invalid cues are diminished when cue-derived 
expectation is reduced (Vossel et al, 2008; Giessing et al, 2006). This suggests that 
nicotine decreases cue-elicited spatial biasing - which secondarily reduces parietal-
mediated reorientation. Moreover, the fact that performance may be enhanced by nicotine 
on invalid trials suggests that it broadens attention: i.e. that it favours bottom-up over top-
down processing, in keeping with a key prediction of a computational model, that 
foresees ACh as signalling expected uncertainty (Yu & Dayan, 2005).   
 
Other patterns of frontoparietal modulation by cholinergic drugs support an account of 
reduced top-down orienting. First, nicotine reduces anterior cingulate, as well as parietal 
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cortex, activity during invalid trials, coincident with speeding and reduced response 
variability (Vossel et al, 2008). Given that anterior cingulate reflects a source of 
attentional control (Sarter et al, 2006), a nicotinic-induced reduction in its activity might 
reflect reduced ‘attentional effort’ and/or error detection, on invalidly cued trials, due to 
less of a preceding top-down bias towards the cued location, as proposed above. Second, 
nicotine powerfully decreases right angular gyrus (parietal) activations during uncued 
relative to cued (i.e. ‘alerting’) trials (Thiel et al, 2005; Thiel et al, 2007). Since this 
region appears to mediate reorienting to unattended stimuli (Yantis et al, 2002), this 
suggests that nicotine reduces the 'surprise' element of uncued stimuli, possibly by 
heightening vigilance (Wesnes & Warburton, 1984), and thus reducing the subsequent 
need to reorient. Third, activity in supramodal superior temporal gyrus –  thought to be a 
node within a stimulus-driven, bottom-up ‘interrupt’ system (Corbetta et al, 2000) – is 
increased by nicotine in uncued trials but decreased in cued trials, effectively resulting in 
a ‘levelling out’ of responses (Thiel et al, 2007). This too indicates that cholinergic 
stimulation can enhance processing for less attended stimuli (e.g. as for 
uncued/unexpected targets), to the detriment of top-down influences (e.g. as for 
cued/expected targets).   
 
Mirroring pro-cholinergic reductions in parietal activity, studies exploring attentional 
effects of cholinergic antagonists (with either anti-muscarinic scopolamine or anti-
nicotinic mecamylamine) have demonstrated increases in parietal activity, with 
associated impaired performance (Thienel et al, 2009a; Thienel et al, 2009b). Since these 
drug-induced hyperactivations occurred selectively with target-distractor conflict, when 
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parietal activity might reflect attentional refocusing (Corbetta et al, 2000), this can be 
interpreted in terms of the anticholinergics having decreased selective attention to the 
cued target location prior to target appearance. Thus both ACh-deficient and 
hypercholinergic states can be associated with parietal modulations and behavioral 
accompaniments that suggest impairment in top-down processing.   
 
Hypercholinergic reductions in activity may reflect enhanced processing efficiency    
When a drug reduces task-related cerebral activity, and yet is accompanied by improved 
performance, one parsimonious account is that the drug enhances cortical processing 
efficiency. Across a wide range of many (non-pharmacological) functional imaging 
paradigms, better performance often correlates with reductions in prefrontal activations 
(Rypma et al, 2006), arguably because of reduced processing times and/or metabolic 
demands.  Regional hypoactivation may reflect improved processing efficiency within the 
region itself; in remote region(s); or in the interconnections between them.  
 
Numerous examples exist where pro-cholinergic drugs improve performance while 
decreasing frontoparietal activations (Table 2). For example, physostigmine-induced 
reductions in dorsal prefrontal cortex activity, during encoding and maintenance-phases 
of a working memory task (Furey et al, 2000a), have been interpreted in terms of reduced 
task effort, on account of a correlation of this with drug-induced speeded responses 
(Furey et al, 1997). One explanation for this is that physostigmine produces a more robust 
neural representation of studied stimuli - indexed by enhanced responses in visual 
extrastriate regions during encoding (Furey et al, 2000a) - thereby necessitating less 
prefrontal-mediated activity during a subsequent working memory delay period. Since 
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such drug effects on BOLD responses and performance are more marked at longer 
memory delays (Furey et al, 2008a; Ricciardi et al, 2009), the benefit appears to be 
specific for memory processes, perhaps reflecting efficiency of encoding into memory, 
and/or stimulus-specific sustained-spiking in higher sensory cortices (Schon et al, 2005). 
The idea that drug-induced facilitation of memory-related sensory processing may 
secondarily decrease task-related prefrontal activations seems complementary to other 
findings that more taxing sensory conditions increase prefrontal activations during 
encoding (Grady et al, 1996). Furthermore, scopolamine consistently decreases fusiform 
cortex activations, at the same time as increasing thalamic and parietal activations, during 
the recollection stage of a visual pattern memory task (Rosier et al, 1999). In this case, 
enhancements of thalamus and parietal cortex were interpreted as ‘effortful’ 
compensatory strategies secondary to non-specific, drug-induced impairments in stimulus 
encoding, found as they were with both scopolamine and diazepam.  
 
Diminutions in prefrontal activity, in association with improved performance, have also 
been found following nicotine (Hahn et al, 2009; Ettinger et al, 2009). Similar to the 
profile for physostigmine, nicotine-induced reductions in prefrontal activity during a 
perceptual task are associated with increased posterior cortical activations (Ghatan et al, 
1998), suggesting that nicotine may primarily be enhancing sensory processing 
efficiency. Alternatively, such findings may reflect increased efficiency within prefrontal 
cortex itself, by, for example, facilitating presynaptic neurotransmitter release, without 
increasing presynaptic electrical activity (Lambe et al, 2003; Wonnacott et al, 2006). 
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Deactivations in frontoparietal cortex secondary to pro-cholinergic drugs, and their 
associated performance enhancements, occur with varying levels of functional specificity 
across paradigms. On the one hand, nicotine-induced deactivations of frontoparietal 
cortices or thalamus correlate with response speeding, yet do not interact with cue 
accuracy in a spatial attention task (Hahn et al, 2007; Hahn et al, 2009). This suggests 
that in certain situations, nicotine exerts a general preparatory or alerting effect in 
frontoparietal regions, rather than interacting with spatial orienting per se. However, in 
numerous other cases, pro-cholinergic treatments induce modulations that are specific to 
task or stimulus properties. Examples of this include parietal deactivations to invalid 
trials during sessions of high, but not low, cue-predictability (Vossell et al, 2008), or 
deactivations of medial prefrontal cortex seen only with imprecise, but not precise, cued 
trials (Hahn et al, 2007). Hence to the extent that nicotine or cholinesterase inhibition 
enhances cortical processing efficiency, this may be manifest only under certain 
functional states (e.g. during invalidly cued trials), and is not simply proportionate to the 
degree of task-induced cortical activation in the absence of drug. It should be noted, from 
a methodological point of view, that both the specificity of drug-induced deactivations, 
and correlations of these with corresponding behavioural effects in these studies strongly 
argue against a purely vascular ‘epiphenomenon’ account for these results.  
 
Challenges to an ‘increased efficiency’ account for pro-cholinergic drug effects in 
frontoparietal areas come from further data showing that nicotine or cholinesterase 
inhibition can sometimes reduce prefrontal activity while accompanied by performance 
impairment (Ernst et al, 2001; Jacobsen et al, 2004); or improve performance in the 
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absence of frontoparietal effects (Ettinger et al, 2009); or be associated with performance 
improvements plus prefrontal activation increases (Chuah & Chee, 2008). Furthermore, 
cholinergic blockade can also decreases prefrontal activations during rest (Honer et al, 
1988), attention (Thienel et al, 2009a; Thienel et al, 2009b), and memory tasks (e.g. 
Sperling et al, 2002; Bullmore et al, 2003; Craig et al, 2009), often while impairing 
performance, suggesting that prefrontal cholinergic stimulation is required for normal 
functioning. Taken together, the overall pattern of results indicates an inverted U-shaped 
function response profile, such that both hyper- and hypo-cholinergic stimulation can 
impair performance, and can reduce task-related frontal-parietal activiations. 
 
An alternative to efficiency-based accounts has been considered in the context of 
recently-withdrawn smokers. In these cases, nicotine can induce reductions in prefrontal 
activity while improving performance (Ernst et al, 2001; Azizian et al, 2009). Since 
nicotine reduces withdrawal symptoms, that aspect alone may improve performance 
while correspondingly reducing prefrontal activations that signify ‘attentional effort’. 
More generally, performance improvements due to a drug may alter the level of 
attentional demand for a given task, which may itself cause a secondary modification of 
cerebral activations. It therefore becomes important to consider the relation between 
drug-induced brain activations and changes in performance wherever possible, regressing 
out behavioural change when appropriate.  
 
Hypercholinergic-induced deactivations of the ‘default network’ may reflect a shift 
from internal to external processing   
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Many of the fronto-parietal-temporal regions whose activity is suppressed by pro-
cholinergic treatments are either medially-located (e.g. cingulate, precuneus, and 
parahippocampal gyri), or involve superior–middle temporal, and angular gyri (Ghatan et 
al, 1998; Hahn et al, 2007; Hahn et al, 2009; Ettinger et al, 2009; Azizian et al, 2009). 
These regions overlap with the so-called ‘default’ or ‘resting-state’ network (Raichle & 
Snyder, 2007), and as such suggest another mechanism by which the cholinergic system 
and cholinergic drugs may act. Cholinergic stimulation typically exaggerates 
deactivations within these regions, seen without drug during attention-demanding tasks, 
while not affecting activity at rest. At the same time, many of these studies also show that 
cholinergic stimulation increases task-related activity in dorsolateral frontoparietal or 
posterior regions, suggesting a reciprocal shift in the balance of processing or activation 
between ‘resting-state’ and ‘attentional-sensory’ cortices. Conversely, in the resting state, 
or for low-attention tasks, nicotine can increase activations in medial frontoparietal 
regions (Stein et al, 1998; Lawrence et al, 2002; Kumari et al, 2003).  
 
Given the similarity between locations showing nicotinic-mediated, task-related 
hypoactivations and the ‘resting-state’ network, this pattern of cholinergic modulation 
may represent a switch in processing from an internally-focused state to one where 
sensory processing is required (Hahn et al, 2007) (Fig. 3.2C). The fact that such drug-
induced hypoactivations are independent of the level or type of attention (Hahn et al, 
2009) implies that cholinergic modulation may act generally to focus attention towards 
any externally-specified task. Furthermore, positive correlations of nicotine-induced 
deactivations with performance are in keeping with the idea that performance depends 
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upon the efficiency with which the resting-state network can be deactivated, possibly 
because of a reciprocal enhancement of task-relevant processing (Polli et al, 2005).  
 
Such cholinergic-mediated transition from a resting-state, internally-focused network to 
one favouring processing of external stimuli appears analogous at the cortical column 
level to the well-recognised tendency for acetylcholine to switch cortical dynamics from 
a cortico-cortical, or feedback state, to one that favours thalamocortical, or input-driven, 
signaling (Gil et al, 1997). Hence to extend our earlier discussion of sensory cortex 
effects, the neuroimaging signature of cholinergic-driven biasing of sensory over internal 
processing may include both deactivations of sensory regions (Silver et al, 2008), and 
enhanced deactivations of a default network. 
 
As a caveat on the above account, it should be considered whether nicotine-induced 
response speeding may itself have led to some of the relevant deactivations, (e.g. Herath 
et al, 2002), especially where BOLD-behavioural correlations were found, including 
within thalalmus (Hahn et al, 2007; Hahn et al, 2009). Furthermore, nicotine-induced 
hyperactivations of anterior cingulate can be associated with positive performance effects 
(Ernst et al, 2001; Kumari et al, 2003), while cholinergic blockade is associated both with 
hypoactivations in similar regions and with performance impairment (Grasby et al, 1995; 
Thienel et al, 2009a; Thienel et al, 2009b), indicating that not all medial cortical regions 
respond homogeneously. Furthermore, nicotine-induced hypoactivations of medial 
prefrontal regions may occur specifically in conflict scenarios (Hahn et al, 2007; Vossel 
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et al, 2008), while speeding responses (Hasenfratz & Battig, 1992), suggesting a more 
specific interpretation than a ‘default network’ account alone would suggest. 
  
Hypercholinergic-mediated increases in frontoparietal activity may reflect recruitment 
of cortical processes   
Certain studies clearly show that pro-cholinergic drugs can increase activations in 
frontoparietal regions (Ernst et al, 2001; Lawrence et al, 2002; Kumari et al, 2003; Thiel 
et al, 2005; Chuah & Chee, 2009; Hahn et al, 2009), in contrast to nicotine or 
physostigmine-induced deactivations discussed in the preceding sections. Many of these 
drug-induced increases correlate positively with performance improvements. 
Consistently, multiple studies demonstrate that cholinergic blockade can engender task-
related, frontoparietal hypoactivations, concomitant with performance decrements (Cohen 
et al, 1994; Sperling et al, 2002; Grasby et al, 1995; Bullmore et al, 2003; Bozzali et al, 
2006; Thienel et al, 2009a; Thienel et al, 2009b). One of the factors that may resolve the 
apparent discrepancy of these ‘activating’ results versus the ‘deactivating’ patterns 
described earlier is anatomical. Pro-cholinergic deactivations tend to occur 
predominantly in medial prefrontal-parietal locations; whereas increased activations 
induced by cholinergic stimulants are often in dorsolateral frontoparietal cortices (Fig. 
3.2C). This supports the suggestion that ACh facilitates the reciprocal balance of resting-
state/default versus task-engaged processes (Hahn et al, 2007).  
 
But a different sort of explanation is required to account for situations in which the same 
frontoparietal regions can show either cholinergic-dependent activation increases or 
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decreases, depending upon condition. A notable pattern is that pro-cholinergic increases 
often occur specifically during the most challenging stimulus or task conditions, with 
accompanying performance improvements (e.g. Lawrence et al, 2002; Hahn et al, 2007; 
Hahn et al, 2009); while anti-cholinergics typically reduce activations in these regions 
and impair performance during the most challenging conditions (Bullmore et al, 2003; 
Bozzali et al, 2006; Thienel et al, 2009a). One interpretation of these findings is that ACh 
mediates recruitment of frontoparietal processes when resources are pushed to near-
maximum use (Fig. 3.2D), or with ‘attentional effort’ (Sarter et al, 2006). This is 
consistent with single-unit studies in rats showing that prefrontal cholinergic inputs are 
essential for both increases in prefrontal activity, and maintenance of performance in the 
face of distracters (Gill et al, 2000). Furthermore, rat studies showing that co-activation 
of a prefrontal – cholinergic basal forebrain loop is essential for sensory cortex 
potentiation and performance (Golmayo et al, 2003), finds similarity in human 
neuroimaging studies showing positive correlations between cholinergic-mediated 
enhancement (or depression) of frontoparietal cortices, visual cortices and accuracy 
(Chuah & Chee, 2008; Thienel et al, 2009a; Thienel et al, 2009b).  
 
Frontoparietal hyperactivations due to cholinergic stimulation are also found to interact 
with the relative contingency of a cue-target relationship, with nicotine tending to 
increase trial-related frontoparietal activations selectively during periods of low cue 
reliability (Giessing et al, 2006; Vossel et al, 2008), or when no cue occurs. These effects 
complement findings discussed above of nicotine-induced parietal hypoactivations during 
periods of high cue reliability (on invalid trials), and may be interpreted in terms of high-
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ACh states favouring bottom-up processing (that predominate when cues are poorly 
informative or absent). The fact that nicotine-induced hyperactivation of dorsolateral 
prefrontal cortex during a high cue reliability condition correlates negatively with 
performance (Hahn et al, 2007) further indicates that nicotine does not benefit top-down 
processing.  
 
Finally, the fact that cholinergic stimulants induce frontoparietal hyperactivations during 
a highly circumscribed set of task parameters argues against explanations in terms of the 
cholinergic system's proposed role in general arousal (see Section 1). This assertion is 
supported by the facts that frontoparietal hyperactivations due to donepezil do not 
correlate with arousal (Chuah & Chee, 2009), in contrast to activations induced by 
nicotine specifically within the midbrain (Kumari et al, 2003).  
 
Figure 3.2: Explanations for modulations of frontoparietal activations in cholinergic - 
functional imaging studies.  
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Memory-associated modulations 
 
Medial temporal regions 
Given a strong evidence base for cholinergic influences on memory performance (e.g. 
Kopelman, 1986), plus anatomical considerations regarding cholinergic innervation of 
hippocampus and surrounding structures (see Background), it is reassuring that numerous 
neuroimaging studies demonstrate direct associations between cholinergic modulation of 
medial temporal structures and memory encoding (Fig. 3.3). Hence scopolamine reduces 
activations of hippocampal and parahippocampal cortices, specifically during working 
memory delay periods, while decreasing subsequent memory success (Sperling et al, 2002; 
Schon et al, 2005). This has been interpreted in terms of sustained-spiking multi-unit 
activity, that is observed in perirhinal and entorhinal cortex neurons during, and after, 
encoding (Young et al, 1997); is stimulus-specific (Egorov et al, 2002) and cholinergic-
dependent (Fransen et al, 2002). Importantly, cholinergic-dependent, delay-period BOLD 
activity predicts not only working memory success, but also subsequent confident memory 
on a later surprise recognition test (Schon et al, 2005), thereby suggesting a role for 
sustained-spiking activity in encoding of long-term, recollection-based memory, as 
predicted by computational models (Koene et al, 2003). Consistently, cholinesterase 
inhibition increases hippocampal responses to stimuli subsequently remembered versus 
forgotten (Kukolja et al, 2009). 
 
Complementary findings are found with scopolamine, that reduces perirhinal activity 
specifically for new, rather than old, words (Bozzali et al, 2006). In Alzheimer's disease or 
mild cognitive impairment, the pro-cholinergic enhancements of memory-related 
hippocampal activity are even more apparent (Potkin et al, 2001; Goekoop et al, 2004; Gron 
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et al, 2006; Teipel et al, 2006), implying that cholinesterase inhibitors are able to partially 
reverse hippocampal dysfunction due specifically to a cholinergic deficiency. 
 
Not all examples of cholinergic neuromodulation of memory accord to this simple pattern, 
however. As well as increasing right hippocampal responses to stimuli at encoding, 
physostigmine decreases activity in adjacent right amygdala at retrieval (Kukolja et al, 
2009). Moreover, in the same study, physostigmine caused a trend for worse memory 
accuracy relative to placebo. Donepezil has also been found to decrease hippocampal 
activity at rest, but to induce the opposite pattern during stimulus presentation (Teipel et al, 
2006). 
 
This dependency of cholinergic-functional imaging data on the phase of memory testing is 
important since it mirrors behavioral and neurophysiological studies (see Background). For 
instance, scopolamine impairs memory when administered prior to, but not after, encoding 
(Rasch et al, 2006); whereas cholinesterase inhibition enhances encoding but impairs 
retrieval (Gais & Born, 2004). Moreover, cortical-layer studies (Hasselmo & McGaughy, 
2004) indicate that elevated ACh levels increase feedforward, encoding-associated activity, 
but decrease feedback, retrieval-associated activity in medial temporal cortices. On this 
account, physostigmine would be expected to enhance novel stimulus-driven responses, but 
suppress responses to retrieval prompts of the same stimuli – as was indeed found in human 
hippocampus and amygdala (Kukolja et al, 2009). 
 
In the earlier discussion of frontoparietal cholinergic-functional imaging modulations, it was 
noted that pro-cholinergic drugs may suppress task-related activity in a 'resting-state 
network' that includes also medial temporal regions (e.g. Furey et al, 2000a; Lawrence et al, 
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2002; Hahn et al, 2007). However, unlike paradigms such as those just described where the 
same drug types enhanced hippocampal activity (e.g. Schon et al, 2005; Kukolja et al, 2009) 
- when memory was a task requirement - those studies showing pro-cholinergic 
hippocampal decreases typically did not make memory demands, and used simple, abstract 
stimuli that are less likely to engage parahippocampal regions than scene or face stimuli 
used in memory paradigms. Hence the pattern of cholinergic modulation in medial temporal 
regions seems likely to depend upon task (e.g. whether or not memory is an explicit aim); 
phase (e.g. encoding or retrieval); and the specific contrasts performed (e.g. whether as a 
function of subsequent memory, or task type).  
 
Sensory cortex 
In one influential model of memory, cholinergic influences within sensory cortices 
complement similar modulations within hippocampal - perirhinal cortices in supporting 
encoding and retrieval (Hasselmo & McGaughy, 2004). Functional neuroimaging studies 
support this by demonstrating that scopolamine suppresses hippocampal and fusiform cortex 
conjointly, specifically during visual memory-delay periods (Sperling et al, 2002; Bullmore 
et al, 2003; Schon et al, 2005); and impairs long-term fusiform cortex plasticity (Rosier et 
al, 1999); in both cases matched by impaired subsequent recognition. Conversely, 
physostigmine increases extrastriate visual activations during visual working memory delay-
periods (Furey et al, 2000a), with greater modulation for longer delays (Furey et al, 2008a; 
Ricciardi et al, 2009), suggesting a cholinergic interaction with a memory, rather than 
merely sensory, process. Presumably, recognised influences of ACh on neural processes 
such as feedforward associativity, long-term potentiation, and sustained-spiking, found 
within sensory as well as perirhinal - entorhinal cortices, may underlie many of these effects 
(Gu, 2003).  
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Accounts of cholinergic influences on memory processes within sensory cortices need to 
dovetail with models of cholinergic impacts on attentional processing in similar regions 
(Sarter et al, 2005). In this regard, modelling has suggested that cholinergic influnces on 
sensory cortex circuits - viz. enhancing feedforward relative to feedback connectivity (Gil et 
al, 1997)  - serve both to enhance signal detection (and therefore certain aspects of 
attentional performance) and formation of novel input associations, likely to be critical for 
memory encoding (Hasselmo & McGaughy, 2004). One prediction that stems from this, is 
that cholinergic modulations of memory will be greater during high- relative to low-
attention conditions. Psychopharmacological studies (Warburton et al, 2001; Fitzgerald et 
al, 2008), employing depth-of-processing paradigms, appear to support this, with nicotine or 
cholinesterase inhibition boosting memory selectively for deeply, relative to superficially, 
encoded items.  
 
Cholinergic drugs are also found to interact with two well-recognised functional imaging 
signatures of implicit memory within sensory cortices – viz. conditioning-associated sensory 
remapping, and repetition priming - often with congruent effects on behaviour (Table 3C). 
The finding that scopolamine impairs conditioning-associated remapping of tonotopic 
auditory cortex in a human functional imaging paradigm (Thiel et al, 2002a), represents a 
neat translation of investigations in rats showing cholinergic dependency of a very similar 
sensory cortex plasticity mechanism (Weinberger, 2007). Perhaps unexpectedly though was 
the additional finding in humans that physostigmine also impairs conditioning-related 
sensory remapping (Thiel et al, 2002b). There were subtle differences in the manner by 
which scopolamine and physostigmine disrupted sensory cortex remapping, since 
scopolamine reduced differential sensory responses by suppressing responses to relevant 
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conditioned stimuli (CS+) (Thiel et al, 2002a) – while physostigmine heightens responses 
specifically to irrelevant non-conditioned stimuli (CS-). One possible explanation for this is 
that physostigmine reduced differential activations in sensory cortex because of this drug’s 
tendency to increase ACh levels tonically, rather than phasically - which might then 
encourage pairing of both CS+ and CS- stimuli with the unconditioned (i.e. noxious) 
stimulus, in the presence of high ACh levels (Thiel et al, 2002a). However, another possible 
interpretation is that, in line with effects of nicotine on spatial orienting (see above), and 
computational models of ACh emphasising its enhancement of bottom-up processing (Yu & 
Dayan, 2005), physostigmine induced a hypervigilant state in which processing of stimuli 
were enhanced regardless of top-down attention  (which in a conditioning paradigm is based 
upon previous experience of CS+ relevance).  
 
Repetition suppression and priming are also found to be disrupted by scopolamine (Thiel et 
al, 2001; Thiel et al, 2000a). This manifests itself through visual extrastriate cortex 
activation being increased selectively to old items under scopolamine, in contrast to the 
normal reduction of activation with repetition under placebo. Given that concomitant effects 
on behaviour are also selective for old items, this suggests that scopolamine reduces 
memory storage (i.e. maintenance of a particular representation), or reactivation, within 
sensory cortices. However, the additional findings of reduced new-item activity in 
prefrontal cortex (Thiel et al, 2001), and an absence of drug effect on priming if given after 
the item-study phase (Thiel et al, 2002c), suggests that encoding too may be disrupted, as is 
more generally recognised (Hasselmo & McGaughy, 2004). While repetition suppression 
recorded electrically amongst monkey inferior temporal cortex neurons has not been found 
to be cholinergic-dependent (Miller & Desimone, 1993), the discrepancy of this with 
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pharmacological-neuroimaging results may have arisen because of restricted neural 
sampling, or shorter lag times, in the electrophysiological study.  
 
Prefrontal cortex  
Cholinergic modulations of prefrontal activity during working memory tasks have been 
discussed earlier in the context of attentional effects (Sections 6.2 and 6.4), where it was 
noted that both cholinergic blockade and stimulation may decrease activity, albeit with 
different performance accompaniments. Prefrontal modulations related to long-term 
memory have also been observed, although in an analogous pattern to cholinergic 
neuromodulation of medial temporal regions (Kukolja et al, 2009), effects may vary 
depending on task and phase. Thus scopolamine-induced suppression of prefrontal cortex is 
associated with impaired performance when given prior to encoding (Sperling et al, 2002; 
Craig et al, 2009); but with improved performance when given afterwards (Bozzali et al, 
2006). Prefrontal modulations may reflect both direct actions, e.g. due to scopolamine 
disrupting semantic processing of encoded words (Craig et al, 2009); and/or indirect actions, 
e.g. secondary to cholinergic potentiation of sensory or perirhinal cortices (Furey et al, 
2008a).  
 
Scopolamine-induced reductions of memory-related frontoparietal (and sensory) cortex 
activity, as well as of performance, resemble those induced by benzodiazepines within the 
same experimental paradigm (Thiel et al, 2001; Rosier et al, 1999; Sperling et al, 2002), 
thereby implying a non-specific sedation effect. Arguing against this though is that these 
studies found no correlations between drug-induced modulations of memory-associated 
activations and vigilance scores (Thiel et al, 2001; Sperling et al, 2002). Strong 
interdependencies between cholinergic and GABAergic neurotransmission in many brain 
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regions, including critically the septohippocampal pathway (Parent & Baxter, 2004), may 
account for such overlap in neuromodulatory responses between benzodiazepines and anti-
cholinergics. Furthermore, the profile of behavioural and neural responses in a priming 
paradigm (Thiel et al, 2001) suggested a tendency for a greater relative effect of 
scopolamine on item storage, but for lorazepam on initial item encoding.  
 
Figure 3.3: Overview of memory-related activations modulated by cholinergic drugs. Note 
that functional imaging studies support the general proposal that high ACh levels facilitate 
encoding (A, B, C) while suppressing retrieval (D), as previously modeled computationally, 
based upon slice-recording data (Hasselmo & McGaughy, 2004).
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               Figure 3.3 
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Questions Addressed by the Experiments of this Thesis  
 
From the growing number of human cholinergic functional imaging studies certain common 
patterns emerge that are categorizable, and moreover, are interpretable within the theoretical 
frameworks of cholinergic function derived mostly from non-human physiological or human 
psychophysical studies. The experiments described in this thesis aim to consolidate further 
bridges between human and non-human data, by testing important hypotheses that arise 
from contemporary neurobiological models of cholinergic function. More specifically, the 
experiments test the effects of inducing a hypercholinergic state in humans with the 
cholinesterase inhibitor physostigmine, in both healthy subjects and Alzheimer’s disease. 
Several of the questions are addressed in more than one experiment so that the degree to 
which findings can be replicated is also assessed. These questions are: 
 
1.  How does the hypercholinergic state influence both sensory-driven (bottom-up) and 
attention –driven (top-down) modulation of visual cortices? (Experiment 1, 3, 4) 
2. Does the hypercholinergic state increase or decrease attention-driven selectivity of 
sensory cortices e.g. as observed in retinotopic visual cortex by spatial cueing? 
(Experiments 1, 3, 4) 
3. Does the hypercholinergic state influence neural reponses to emotional stimuli? 
(Experiment 1) 
4. Are there differences in how the hypercholinergic state modulates spatial attention 
and spatial working memory? (Experiment 3) 
5. Is repetition suppression - one mechanism by which priming may occur - increased 
or decreased by a hypercholinergic state? (Experiment 2) 
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6. Do effects of a hypercholinergic state on sensory activations have knock-on effects 
on subsequent recognition memory? (Experiment 5) 
7. Do effects of a hypercholinergic state on activations related to sensory, attentional 
and memory function differ between healthy elderly subjects and Alzheimer’s 
disease? (Experiments 4, 5) 
 
Prior to describing the specific experiments, and their results, a general account of the 
methodology of pharmacological-functional MRI, with specific reference to using the 
cholinesterase inhibitor physostigmine, is described. 
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4. Methods 
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Introduction 
Functional magnetic resonance imaging (fMRI) is the methodology used in this thesis. In 
brief, fMRI enables measurement of a surrogate marker of population neural activity in 
conscious humans, whose only imposition for subjects is the need to lie horizontally with 
the head kept immobile. The method rests upon the biophysical principle that there is a 
relatively consistent relationship between brain neural activity and a secondary 
haemodynamic response. The spatiotemporal resolution of the technique is therefore 
related to the anatomical and dynamic properties of the brain’s microvasculature.  
 
Given a relatively tight spatial coupling between neural activity and arteriolar dilatation, 
the spatial resolution of fMRI can be in the order of millimeters, or ~105 neurons. This is 
superior to any other contemporary human neurophysiological technique with only the 
exception of clinically-justified deep-brain recordings. The temporal resolution of fMRI, 
paralleling dynamic properties of microvascular patency and blood redistribution, is in 
the order of seconds. Compared to techniques such as electroencephalography (EEG) or 
magnetoencephalography (MEG), whose temporal resolution is ~1 – 20 milliseconds, this 
is poor, yet by modeling the hamodynamic response function it is still possible to resolve 
activity between different behavioral trials (so called, event-related fMRI). It is important 
that we appreciate the temporal range of the measuring technique employed given what 
was discussed in the Background: namely, that cholinergic modulation occurs at different 
time-scales, with both tonic, or session-related, effects, and phasic, or trial-related, 
influences (Sarter et al, 2009).    
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Unlike potentiometric or ammeteric measurements of neural electrical activity, the 
physical processes proposed to underlie fMRI measurements are far from 
straightforward. An account of what is actually measured with fMRI starts with the 
magnetic properties of atomic nuclei; relates this to interactions with local electron and 
applied magnetic fields; which is fortuitously relevant to different chemical states of 
haemoglobin, which itself is found to be an accurate reflection of regional neural activity. 
Yet, whilst only achieveing an indirect measure, combined fMRI-electophysiological 
recordings demonstrate that the fMRI signal is in general tightly coupled to neural 
activity (Logothetis et al, 2001; although see Ekstrom, 2010, for counterexamples). 
Moreover, similarities of fMRI results with those from more classical neurophysiological 
approaches, e.g. spatiotopic mapping of sensory cortices (Tootell et al, 1995; Rees et al, 
2000), engender confidence that the technique is a valid and reliable measure of neural 
activity.  The development of increasingly sophisticated methods and statistical analyses 
enables fMRI to dissect cognitive factors of interest (Friston et al, 1998), as well as to 
model inter-regional brain activity (Friston et al, 1997; Stephan et al, 2008).  
 
However, an inherent weakness of fMRI lies precisely in the long-windedness of its 
multiple biophysical assumptions. In particular, if variations occur in the core 
relationships between neural activity, haemodynamic parameters, and induced MR signal, 
then it becomes impossible to discern ‘interesting’ effects on neural activation from 
‘uninteresting’ differences in vascular phenomena. Such variations in neurovascular 
coupling have been shown to occur between individuals, or between anatomical regions 
within the same individual. Furthermore, of relevance for this thesis, aging, disease and 
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drugs may also influence blood flow response, and consequently on the size and 
distribution of fMRI signal, to a given change in neural activity.  
 
Considerations of the biophysical principles underlying fMRI are essential therefore for 
increasingly-popular clinical and pharmacological fMRI-studies that ask the generic 
question: how does disease X, or drug Y, influence neural activity during task T, (or 
cognitive process P)? The next sections discuss the physics of fMRI; pre-processing 
analysis and statistical techniques; the relationship of the fMRI signal to hemodynamic 
and neural physiology; evidence for clinical and pharmacological variation of the critical 
neurovascular relationship, and, finally, ways in which these problems can be addressed.  
 
Functional Magnetic Resonance Imaging (fMRI) 
 
MRI – Physical Principles 
The principle of MRI, including functional MRI, rests upon two fundamental physical 
properties: 1) a magnetic dipole inherent in all nucleus-located protons, from which the 
MRI signal is derived, and 2) magnetism of electron clouds that varies between 
biological molecules and tissue types, and which crucially can modify the strength of the 
MRI signal itself (either through a direct magnetic interaction, or indirectly by causing 
differing amounts of molecular motion). Both electromagnetic properties are subject to a 
fundamental quantum physical law, the constancy of which all examples of MR 
signalling are predicated upon: namely, that subatomic particles can exist in one of two 
states, and a fixed amount of energy is required to be absorbed, or released, moving from 
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a low to high, or high to low, energy-state, respectively. The two states are referred to as 
‘spins’ because it is usually electromagnetic radiation, in the form of photons travelling at 
a specific frequency, that constitute the means by which energy is absorbed or released.  
 
Most protons in everyday matter are paired off into complementary high and low energy 
states, or up and down-pointing magnetic dipole moments, that exert no net external force 
and so are effectively ‘silent’. However, certain biological substances possess protons 
and/or electrons that are unpaired, and it is here that subatomic electromagnetic processes 
can be ‘tapped’ and applied to useful biological measurement. The commonest 
occurrences of naturally-occurring unpaired protons are hydrogen nuclei, (i.e. single 
protons) found in water and organic compounds e.g. fat, protein. By being unpaired, their 
magnetic dipole moment is susceptible to an externally applied magnetic field, and 
transitions in their energy states can be measured by an electromagnetic receiver coil.  
 
As mentioned, the energy state, or spins, of protons can be flipped from low to high, or 
vice versa, by the exchange of electromagnetic radiation. The amount of input or output 
energy associated with such flipping is directly proportional to the frequency of the 
applied, or received, radiation, as asserted by Planck’s law:  
 
               Energy = h * frequency      (h = 6.62 * 10-34 Joules / sec) 
 
In MRI, a baseline energy state can be achieved through application of an external 
magnetic field B0 that is applied along the longitudinal body axis (i.e rostral – caudally). 
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In this state, all proton-related magnetic dipole moments will align themselves either in 
the same direction (low-energy states), or in the opposite direction (high-energy states), 
to the applied field. While approximately similar numbers of protons align themselves 
into one of these two states, approximately one excess proton in a million will align itself 
in the same direction as B0, meaning that the net magnetic dipole moment over the entire 
body is also in the direction of B0. This configuration of protons is considered to be a net 
low energy state for the system (i.e. of body within magnetic field). With the protons still 
aligned in B0, one can transmit an electromagnetic pulse into the body that injects 
sufficient energy to flip half of those one in a million excess protons into the high energy 
state, so that there is no net longitudinal magnetism.  
 
Figure 4.1: Effects of RF pulse on proton alignment in a magnetic field 
A. Baseline: 
 
 B0:         Individual protons:    = net:  
 
B. Following transmitted radiofrequency pulse: 
 
B0:         Individual protons:    = net: 0 
             ‘flipped’ 
 
The amount of energy required to flip the extra protons so as to achieve a net zero 
magnetic dipole moment is determined by the strength of B0: 
129 
Chapter 4 
 
             Energy = 2 * magnetic dipole moment * B0  
 
Relating this to Planck’s law above:  
 
           Energy = 2* magnetic dipole moment * B0  = h * frequency,   or : 
 
           Frequency = 2 * magnetic dipole moment    * B0                   (Larmor Equation) 
                                                    h 
 
The expression   2 * magnetic dipole moment    is known as the gyromagnetic ratio, γ.                                     
                                            h 
 
It is constant for any nucleus type, e.g. for hydrogen, γ = 42.6 MHz/T. So in a 1.5 Tesla 
MRI scanner, the frequency required to flip protons is given by: 
 
              Frequency = γ * B0 = 42.6 * 1.5 = 64 MHz.  
 
MRI - Signal 
So far we have discussed: 1) how the protons of hydrogen nuclei within the body can be 
aligned by an external magnetic field B0, and 2) how aligned protons can be flipped by a 
specific radiofrequency so that the net magnetic dipole moment shifts from a longitudinal 
vector (in the direction of B0) to zero. There are two further electromagnetic properties of 
protons that can take us from these facts to understanding how a MR signal can be 
generated, and how such signals can discern different tissue types. These facts are:  
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1) In addition to the longitudinal component of the magnetic dipole moment of protons, 
that aligns itself to B0, is constant, and can be theoretically measured along the z-axis (of 
a 3D-coordinate system), there is also a transverse component, which oscillates at the 
frequency governed by the Larmor equation, and can be measured along either the x or y-
axis as a sinusoidal wave. The summed longitudinal and oscillating transverse vectors 
can be depicted as if the proton traced out the path of a spinning top, and this pattern of 
movement is referred as ‘precession’.  
 
The relevance of the transverse component is that it enables us to measure a MRI signal. 
Although, at baseline, there is an induced longitudinal net magnetic moment in the z-axis, 
this cannot be measured practically in the presence of the applied magnetic field B0 as 
the latter is several orders of magnitude stronger than that which is induced, and acts in 
the same (z-axis) direction. However, if the induced longitudinal magnetic field can be 
flipped into an orthogonal axis, this field is potentially measurable by a coil sensitive 
only to induced magnetic fields acting along the x- (or y-) axis. At baseline, in the 
longitudinally-applied external magnetic field B0, the transverse components of the 
magnetic dipole moments of separate protons are all in different phases, but on average 
cancel each other out, and so there is nothing measurable in the x- (or y-) axis. The 
transmission of a radiofrequency (RF) pulse enables us to measure something, providing 
it is at the Larmor frequency for protons given field strength B0, because it: i) flips the 
net longitudinal magnetic dipole moment into the transverse plane; and ii) synchronizes 
the transverse component of magnetic dipole moments across all individual protons. Note 
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that the rotating transverse components of magnetic dipole moments, when synchronized, 
can be measured along one axis of the x-y plane by a receiver coil as a sinusoidal 
waveform.    
 
Figure 4.2: Transverse components of proton spins combine to generate signal  
A. Baseline:  
 
B0:     Individual                                               = net:         = Signal:  
                  protons: 
 
            Note how transverse components of individual precessions cancel each other out, 
            due to protons being in different phases, and so no net measurable MR signal.  
 
B. Following transmitted 90° radiofrequency pulse: 
 
B0:      Individual:                                         = net:                  = Signal:   
                   protons: 
 
       
            Note how transverse components of individual precessions are now in phase, thus  
generating net measurable sinusoidal MR signal. In fact, the size of the transverse 
vector just after the onset of the pulse is the same as that of the net longitudinal 
vector just before the pulse (thus the net magnetic dipole vector is ‘flipped’ 90°).   
 
2) As discussed, an RF pulse causes both: i) conversion of the longitudinal magnetic 
dipole moment into a transverse component, and ii) synchronization of the transverse 
components of precessing protons. When the RF pulse stops, these two processes reverse, 
and, importantly, the rates at which each of them reverses, or their relaxation rates, 
depend upon tissue type. The rate at which net longitudinal magnetic component is 
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restored from zero occurs with an exponentially decreasing rate, described by the 
relaxation time constant T1. The rate at which net transverse magnetic component 
decreases, due to cumulative proton-proton dephasing, also occurs at an exponentially 
decreasing rate, albeit with a time constant T2* that is independent of T1.  
 
Following a single 90° RF pulse, the longitudinal magnetic moment starts from zero and 
increases gradually to time TR. If then at time TR (repetition time), a second 90° RF 
pulse is transmitted, the intensity of the transverse vector at that time becomes the 
intensity of the longitudinal moment at time TR. Thus after two pulses, the net signal 
intensity received at time TE (time to echo) relates to both T1 and T2* time constants. 
Furthermore, while the received signal is a cosine wave (maximal at time=0 or TR), the 
intensity of this wave decreases according to an envelope that decreases exponentially.  
 
Figure 4.3:  Relaxation of protons following two 90° RF pulses separated by time TR  
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As a further refinement of relaxation rates, it should be noted that T2*-characterised 
relaxation – i.e. proton dephasing – can be divided into dephasing due to 1) external 
magnetic field inhomogeneities, including due to local changes in magnetic susceptibility 
within the surrounding tissues, and 2) intrinsic spin-spin lattice interactions that vary 
according to physical properties of the tissues itself (e.g. solid / liquid). The first kind of 
dephasing can be neutralized by following the initial 90° RF pulse with repeated 180° 
flips of the direction of net induced transverse magnetism (this combination of pulses is 
called a spin-echo sequence). The resultant relaxation rate, characterized by T2 time 
constant, is a purer quantification of tissue type being less subject to external magnetic 
inhomogeneities (i.e. noise) and so is commonly used for structural MRI scans. However, 
in functional MRI, it is precisely these external magnetic inhomogeneities, acting over a 
microscopic range to modify local proton T2* values, that need to be measured, 
reflecting as they do different tissue metabolic states (see below). Thus, for functional 
MRI, the pulse sequence and measurement times are designed specifically to be sensitive 
to differences in T2* relaxation rate.    
 
Functional MRI – Signal Contrast  
The key objective with MRI is the ability to discriminate different tissue types, or 
different physicochemical states of a single tissue type. This is achievable because the 
relaxation time constants of protons (within hydrogen nuclei) differ depending upon the 
physical properties of the tissue-type they form part of, or because of electromagnetic 
influences of nearby chemicals. For example, tissue in which protons are packed close 
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together e.g. fat-containing white matter, show rapid T2 relaxation because the protons 
easily interfere with one another and so dephase readily. By contrast, in water-based 
cerebrospinal fluid, protons are far apart, and so dephasing is slow, and T2 is long.  
 
With functional MRI, the T2* contrast of interest reflects interesting differences in 
physiological activity. Specifically, a natural MR contrast is found between two 
metabolic states of haemoglobin – oxyHb and deoxyHb - whose local relative 
concentrations are a surrogate marker of regional neural activity (see page 166). The 
chemical basis for this is that the iron atom within haemoglobin possesses an unpaired 
electron when not bound to oxygen (i.e. Fe2+-deoxyHb), which becomes paired off with 
the binding of oxygen (i.e. Fe3+- oxyHb). The presence of an unpaired electron in Fe2+-
deoxyHb enables it to become weakly magnetic in the presence of an external magnetic 
field, itself causing local magnetic-field inhomogeneities, which facilitates dephasing of 
adjacent protons. This selective property of deoxy-Hb is referred to as paramagnetism, 
and is distinct from the magnetically-neutral properties of oxy-Hb that is referred to as 
diamagnetism. Since deoxyHb dephases more quickly than oxyHb, the T2* time constant 
is shorter for deoxyHb than for oxyHb. Thus when we measure the signal at time TE after 
a 90° RF pulse, the intensity of the received signal will be greater from tissue with high, 
relative to low, oxyHb:deoxyHb ratios. This explains why the signal is also referred to as 
being blood oxygen level dependent (BOLD) (Ogawa & Tso-Ming, 1990). 
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Figure 4.4: Signal contrast employed in fMRI 
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The ability to localize signal within MRI is achieved through application of the Larmor 
equation, which as discussed earlier, is a derivation of Planck’s law. To recap, a precise 
amount of energy is required to ‘flip’ protons from a low-to-high energy state, and this 
amount, expressed as an RF pulse frequency, depends upon the strength of the externally-
applied magnetic field, B0:     Frequency = γ * B0, where γ is a constant for hydrogen.   
 
1) Slice-Select Gradient (z-axis). The baseline magnetic field, B0, is varied linearly 
along the z-axis (i.e. longitudinally), so that a specific-frequency RF pulse only flips 
protons in that slice where there is a specific magnetic field strength as defined by the 
Larmor relationship. In order to sample a volume of protons this slice cannot be infinitely 
thin, and so the transmitted RF pulse is actually a range of frequencies within a narrow 
bandwidth, the width of which determines the slice thickness.   
 
Figure 4.5. Slice-Select Gradient 
 
B0 
(Tesla) 
1.6
1.5
RF frequency (MHz) 68 64 
Calculations: 
1. Frequency = γ * B0 = 42.6 * 1.57 = 66.9 MHz 
2. Frequency = γ * B0 = 42.6 * 1.55 = 66.0 MHz 
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2) Phase-Encoding Gradient (y-axis). Immediately after an RF pulse has been 
transmitted, protons within a slice are ‘flipped’ and their transverse magnetic dipole 
moments in that instant are synchronised, i.e. in phase. These protons subsequently 
dephase due to T2* time constants of the various tissues within this slice. However, 
dephasing can also be induced by subjecting the slice to an additional magnetic gradient, 
this time within the slice plane. This gradient is therefore switched on just after the RF 
pulse and is conventionally applied along the y-axis (antero-posterior direction). 
 
The way in which the Gy gradient is able to dephase protons is again related to the 
Larmor equation. This time though the applied magnetic field modifies the frequency of 
the received signal, rather than determining what frequency we set the transmitted signal 
at. Protons in those rows of the slice in which the local field strength is relatively high 
spin faster, whereas those protons in low-field strength rows spin slower. The net effect is 
that the stronger the Gy gradient, the more dephasing, and the lower is the overall 
received signal (which is the sum of signal from all rows).  
 
The extent to which the Gy gradient dephases protons will depend upon the degree of 
spatial variation in T2* relaxation times along the y-axis before the Gy gradient is turned 
on. For example, by using a 45º Gy the intensity of the signal from peripheral, relative to 
central, protons is cosine(45º) = 0.7, enabling differential weighting of signals by 
location.   
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Figure 4.6. Phase-Encoding Gradient: two Gy gradients can distinguish two possible 
spatial conformations along the the y-axis from differences in the net signal intensity. 
 
Voxel 
SI 
Zero 
Gy 
 + 45° 
Gy  
y 
1 
1 
1 
  3 
  1  *  1  = 1 
  1  *  1  = 1 
  1  *  1  = 1 
  1  *  2  =    2 
  1  *  0.5  = 0.5 
  1  *  0.5  = 0.5 
  3 
 
  2.4 
0.7*1 =  0.7 
 
  1  *  1  = 1  
 
0.7*1 = 0.7  
 y 
0.5 
2 
0.5  0.7*0.5 = 0.35 
  1  *  2  = 2 
0.7*0.5 = 0.35 
  2.7 
 
 
 
 
 
In fact, it can be shown that the number of different Gy gradients employed determines 
the spatial resolution in the Gy direction. In standard MRI sequences each Gy gradient 
has to be applied to a separate RF pulse, meaning that if a standard spatial resolution of 
256 is required, and a typical TR is 1 second, then the entire sequence for just a single 
slice would be 256 seconds, or about 4 minutes. Thus the biggest time constraint for MRI 
data collection derives from phase-encoding. Different strategies exist to reduce the 
overall acquisition time required, and these are of particular importance for fMRI where 
as narrow a sampling time as possible is required.   
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3) Frequency-Encoding Gradient (x-axis). The phase–encoding gradient, Gy, is turned 
off some time before the signal is measured, meaning that while different protons are in 
different phases as a result of Gy, their frequency is constant (and equal to the original 
transmitted RF pulse frequency). This allows for a further spatial manipulation during the 
measurement phase itself. This is performed by applying a magnetic gradient in the x-
axis (right-left direction) during read-out, which similar to the effect of Gy earlier on, 
modifies spin frequency according to the Larmor equation. Consequently, the final signal 
is a mixture of frequencies, and decomposing it into its component frequencies enables 
spatial decoding in the x-axis direction.  
 
Figure 4.7. Frequency-Encoding gradient 
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Functional MRI – Pulse Sequence   
In functional MRI we wish to create a sequence that is both sensitive to T2* effects (since 
this discriminates deoxyHb from oxyHb), and enables rapid data acquisition (to gain a 
temporal resolution similar to that of the time-scale in which neural-driven vascular 
changes occur). The theoretically most simple, and quickest, way of T2* weighting is to 
sample the signal emitted soon after a 90° RF pulse – the so-called ‘free induction decay’ 
(Figure 3). However, this is impractical as it occurs too soon (< 10ms) after the RF pulse, 
and allows insufficient time to prepare the phase-encoding and frequency-encoding 
gradients by which the signal can be localised. One way of inserting a time delay, as 
described earlier, is to use a spin echo sequence (90° RF followed by one or more 
subsequent 180° RF pulses) that essentially regenerates the original signal after ~40ms. 
However, in using 180° refocusing pulses, spin-echo selectively neutralizes dephasing 
due to external inhomogeneities and so is insensitive to T2* effects.  
 
An alternative method of inserting adequate time delay between the RF pulse and signal 
measurement is to use a gradient-recalled echo (GRE) sequence. In this technique, the 
frequency-encoding gradient Gx is applied just before and during readout, albeit in 
opposite directions. The effect of -Gx just before readout is to induce systematic 
dephasing in the x-axis direction (just as Gy, applied before -Gx, causes systematic 
dephasing along the y-axis). However, by then applying +Gx in the reverse direction, this 
rephases the spins along the x-axis, so that after an amount of time equal to the initial 
dephasing gradient -Gx, there is a maximal echo.  
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As well as spacing apart the echo from the RF pulse, the initial negative-phase serves to 
ensure that protons are maximally refocused half-way through the readout period, which 
is set as the duration of the positive-phase.   
 
Figure 4.8. Gradient-Recalled Echo (GRE) Pulse-Sequence Diagram 
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The pulse sequence diagram depicts the order in which the various linear magnetic 
gradients are activated in relation to the RF pulses and data acquisition. The slice-select 
gradient Gz is turned on immediately before and during the RF pulse so as to excite only 
a slice-worth of protons. Within this slice, in thie z direction, there will be dephasing 
which is not measured, and which acts to reduce the overall signal intensity. To minimize 
this, a refocusing –Gz gradient is activated immediately after  +Gz is turned off.  
 
After the RF pulse is applied, a phase-encoding gradient Gy is applied. The strength of 
Gy varies with every repetition of the RF pulse (as indicated by the dotted boxcars). Then 
finally the bi-lobed Gx gradient is activated, with data acquisition occurring during the 
second, positive-phase.  
 
At the time of signal measurement, that dephasing which was induced by -Gx has been 
neutralized by the new gradient +Gx. But there still has also been dephasing because of 
both spin-spin interactions and external inhomogeneities. Thus the intensity of the signal 
at TE in gradient-recalled echo is a reflection of T2*, rather than T2 as it is with spin 
echo.   
 
A major drawback of the gradient-recall echo sequence, as shown, is that a new RF pulse 
is required for every phase-encoding step. So for each slice, we need to wait the length of 
TR, and then repeat this however many times we wish to resolve spatially in the y- 
direction. A way round this is to perform multiple phase-encoding and frequency-
encoding steps following each RF pulse so that spatial information from the entire slice is 
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obtained with a single-shot. This sequence is termed echo-planar imaging (EPI), and by 
being the fastest means of T2* data acquisition, is the standard fMRI sequence. 
 
There are two further time-saving steps often employed in EPI that enable shorter 
repetition times. Firstly, instead of performing a separate bi-lobed Gx gradient for each 
Gy step, the Gx gradient is simply reversed between each Gy step. This way, the readout 
Gx for one step acts as a primer for the next step. While the Gy gradient is turned 
momentarily on, the Gx gradient is turned off – this being referred to as ‘blipped phase-
encoding’.  Secondly, the flip angle is reduced to < 90º, so that less time is required for 
protons to relax to their starting value of longitudinal magnetization, allowing for a 
shorter TR. By contrast, if a short TR is selected for a 90º pulse, then protons will have 
only regained a fraction of their starting longitudinal magnetization, such that the induced 
transverse magnetization following subsequent pulses will be small, and signal-to-noise 
ratio low. Small flip angles also reduce T1 contrasts more than they do T2* contrasts, 
rendering it better suited for functional imaging.    
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Figure 4.9. Echo-Planar Imaging Pulse-Sequence Diagram 
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The repeated application of a constant, small-amplitude Gy blip serves to increment the 
net phase-encoding gradient successively with each echo, because unlike the case for Gx, 
there are no refocusing pulses. In order to weight the image optimally for T2* effects, the 
baseline and subsequent Gy blips are set so that the smallest net dephasing – i.e. strongest 
signal - is selected at the time, TEeffective when the greatest T2* contrast occurs (~30-
60ms). 
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Variations of EPI sequences exist, for example sinusoidally-varying Gx and Gy 
gradients, but the principle of obtaining all phase-encoding (y-axis) and frequency-
encoding (Gz) information for each slice following a single RF pulse is the same for 
these.  
 
Echo-Planar Imaging – Advantages and Disadvantages   
The EPI sequence enables both rapid data acquisition (typically, 100ms per slice) and 
T2* sensitivity. The first of these benefits also means that movement-related error is less 
than standard MR sequences.  
 
However, EPI has several shortcomings. Firstly, by limiting the number of echoes to a 
single-shot, the number of phase-encoding steps, and thus spatial resolution in the y-axis 
direction, is limited. Typically, the field of view obtained is 64x64 or 128x128, compared 
to 256x256 for routine MRI. The limitation on this parameter is the speed with which 
magnetic gradients can be reversed (characterised by the slew-rate = gradient / rise time, 
where gradient ~ 20mT/m, and rise time ~ 300µs).  
 
A second problem relates to the incremental way in which phase-encoding information is 
acquired (see above). If an error occurs in one of the early phase-encoding steps, then 
every subsequent measurement carries forward that error – i.e. artifact propagation.  
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Thirdly, artifacts are more likely to occur in the first place with EPI, because of i) the use 
of rapidly alternating magnetic fields, and ii) its high sensitivity to magnetic 
susceptibility (T2*) effects. The use of a high slew rate makes artifacts of the main image 
more likely to appear along the phase axis, during either the odd or even echoes (hence 
called “N/2 ghosts”). They occur because of eddy currents, imperfect gradients or field 
non-uniformities, and mismatch between the timing of odd and even echoes. Artifacts 
also occur because of a difference in proton precessional frequency between water and 
fat. This can be avoided by using a preceding 180° RF pulse, and timing TE so that the 
signal from fat is approximately zero (i.e. suppressed) at the time of the 90° RF pulse. 
 
fMRI Image Processing 
 
Introduction  
In a typical fMRI experiment, a time-series of EPI volumes is acquired and related in a 
time-corresponding fashion to recorded behavioral events. So far we have noted that EPI 
images are sensitive to T2* relaxation effects, of which changes in the local ratio of 
oxyHb:deoxyHb, or blood oxygen level dependent (BOLD) signal - provide one 
contribution. For functional imaging, we are not interested in anatomical variations in 
T2*, and aim only to observe dynamic T2* variation that correlates with behavioral (or 
cognitive) variation. Thus a critical part of fMRI data analysis is comparison of images 
between selected time points, or covariation of images with a behavioral measure of 
interest.  
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As shall be discussed, the comparison of image signal intensities, across many spatial 
locations (or ‘voxels’), involves the same statistical methods, such as t-tests and 
correlations, as are employed in any other scientific setting. However, before such 
comparisons can be made, a number of pre-processing steps need to be undertaken so as 
to make the assumptions of subsequent statistical tests valid.  
 
One of the biggest issues that needs to be addressed is that of signal specification. The 
data set we collect is a four-dimensional construct – i.e. the brain volume replicated 
approximately several 100 times along a continuous time-line – which itself is often 
repeated in different sessions or subjects. Thus for each data-point it is essential that we 
are confident of its spatial and temporal ‘address’, so that grouping or comparison with 
equivalent data-points can be performed reliably. To achieve this, we perform several 
steps that regiment the data into a common spatial-temporal framework that allows, not 
only data pooling and constrasting within the one study, but also permits cross-
comparison with other studies employing similar methods (including those using 
different imaging modalities).  
 
The pre-processing steps performed are:- 
1. Spatial registration and realignment: this adjusts the 3D coordinates of each 
EPI volume so that the brain is spatially aligned between images. 
2. Slice-timing correction: this adjusts for timing of each scan to account for the 
different times at which each slice (along the Gz axis) is acquired in a single 
volume. 
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3. Spatial normalization: this adjusts the 3D coordinates of each EPI volume so 
that the brain is ‘fitted’ into a standard brain template that permits between-
subject or between-study comparison. 
4. Spatial smoothing: this step takes a Gaussian-shaped, weighted average of signal 
at each voxel, thereby reducing the relative influence of outlying values, and so 
increases signal-to-noise. It is also a requirement for subsequent statistical 
comparisons in 3D space as set by random field theory. 
5. Co-Registration: this enables EPI data to be cross-compared with an alternative 
imaging modality e.g. to enable detailed anatomical localization by overlaying 
activation data on a structural scan.     
 
The pre-processing and subsequent statistical analyses performed were all implemented 
within the computer package Statistical Parametric Mapping (versions 2 and 5 were used 
in this thesis; available from www.fil.ion.ucl.ac.uk/spm). 
 
Spatial Registration and Realignment  
In spite of securing subjects’ heads within a transmitter / receiver head coil, small 
amounts of head movement inevitably occur during a scanning run that can take upto 30 
minutes or so, This problem is often magnified in elderly subjects, especially with 
dementia. When we come to model the time-series of signal intensities, we need to be 
confident that changes in BOLD signal reflect experimental manipulation, rather than 
movement artifact. Movement correction is achieved by two steps. 
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Firstly, we assume that a rigid-body spatial transformation matrix exists that maps each 
brain volume in a time series onto the first such volume. This matrix is set to have six 
unknown ‘affine’ parameters that correspond to magnitudes of movement in six possible 
ways: x, y, and z translations, and rotations around each of these axes (or pitch, roll and 
yaw). An iterative procedure, such as Gauss-Newton optimization, estimates these six 
parameters by using the principle of least squared differences, applied over all voxels of 
two scans (Friston et al, 1995a). Once these parameters are estimated, the original 
volumes can be rewritten (realigned) using signal interpolation where necessary.    
 
Secondly, even having aligned the scans, it is possible that the signal intensity was 
modified as a result of the movement itself. For example, had the head moved in the z-
axis direction, a true activation could be missed by failing to be excited by the RF pulse. 
Moreover, movement during slice acquisition results in a phase shift that propagates to 
the remainder rows for that slice. Movement can also alter the timing relationship 
between the RF pulse and T1 relaxation which can have knock-on effects on the 
subsequent signal. Certain EPI-related artifacts such as N/2 ghosts do not behave as rigid 
bodies with head motion and may further confound the realignment stage. So as to reduce 
the variance of BOLD signal associated with movement, we save the movement 
parameters generated from the realignment step, and apply these as covariate ‘factors of 
no interest’ to our eventual multiregressive statistical model (see below).   
 
Temporal Realignment 
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In experiments where TR (or strictly speaking, acquisition time) is set to longer than 2 
seconds, the separation in time of data acquisition from different slices becomes 
methodologically significant. In other words a brain volume labeled as occurring at time 
t, in fact contains slices that were collected at t±1s (or greater). This will result in brain 
activity being imperfectly modeled with respect to behavioral events.  
 
In order to correct for these timing errors, a sinc-interpolation procedure is conducted. In 
this step, the central slice of each brain volume is set as the reference time point, and the 
timing of other slices is calculated from knowledge of the sequence - usually interleaved, 
and timing, with which slices were acquired. Interpolation can then be performed 
between temporally-offset voxels and their equivalent voxels on the previous, or 
subsequent, scan.  
 
Slice-timing correction is avoided where TRs are less than 2 seconds to avoid the 
introduction of interpolation and re-writing errors. Skipping this step also enables 
realignment parameters from the first spatial registration stage to be carried forwards to 
the normalization step. 
 
Spatial Normalization 
The principle of normalization is similar to that of spatial registration, only now we are 
interested in aligning equivalent voxels between, rather than within, subjects or sessions. 
The reference scan, rather than simply being the first scan of a session, is now based upon 
an internationally-recognised brain template into which the vast majority of studies now 
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render their images. This template is known by its origin - the Montreal Neurological 
Institute (MNI) – and was created by averaging the structural scans of 305 healthy 
volunteers. The spatial coordinates of the template approximate to those of Talairach 
space (Talairach & Tournoux, 1988). In SPM, the templates are necessarily MRI scans at 
different MR weightings (T1, T2, EPI, etc.). The SPM template used within this thesis is 
an averaged EPI from 13 different subjects, that itself has previously been normalized 
into MNI space.   
 
In order to incorporate variations in brain size and shape between individuals, the 
transformation matrix has to be expanded from the six parameters we had used for rigid-
body registration, to twelve parameters that now include 3 shear and 3 zoom components. 
The difference between source image (i.e. that which needs to be fitted) and template 
image is also approximated by the coefficients of a 3D low spatial frequency cosine basis 
set. In SPM, the usual approach is to select the mean spatially-realigned EPI as the source 
image, and an EPI template that is inbuilt within the software as the template image  
 
Normalization proceeds as an iterative process in which a set of parameters and 
coefficients are estimated; then applied to the source image, and the mean squared 
difference between this and the template is calculated. This difference is referred to as the 
cost function, and the process proceeds until this is minimized. The process is also 
regularized by incorporating Bayesian model priors. The priors weight different possible 
transformations by the likelihood that each is found to occur during previous 
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transformations. This regularizes the procedure by preventing overfitting to local 
features.  
 
In the experiments described in this thesis, the mean spatially-realigned EPI over all 
sessions was selected as the source image. Following normalization, the resultant 
parameter set was then applied to all the coregistered and realigned EPI images for that 
subject, including over sessions. Furthermore, the same parameter set was also applied to 
the T1 structural scan for each subject, having previously coregistered it (see below).  
 
Spatial Smoothing 
Smoothing entails averaging the intensity of each voxel with those of its neighbours, with 
greater weightings afforded to nearby than distant voxels. The spatial pattern of 
weightings assumes a Gaussian profile whose maximum (i.e. 1.0) is centered on the voxel 
to be smoothed (this then being replicated for all voxels using the original data only). The 
extent of smoothing can be varied, and this can be characterized by a ‘full-width half 
maximum’ (FWHM) kernel parameter that specifies, for 3D space, the width of a sphere 
of voxels, within which the weighting average for the centre voxel, is at least 0.5.   
 
The main effect of smoothing is to ‘iron out’ small voxel-to-voxel variations, while 
enhancing effects that occur systematically over a large number of nearby voxels. Since 
physiological changes in BOLD occur over a spatial scale (~10mm) greater than that of a 
single voxel (3-5mm), we would like to take into account only those variations where 
such a change is observed in a spatial cluster of voxels at least as large as that expected 
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physiologically. In fact for optimal sensitivity, the matched filter theorem states that the 
data smoothing kernel should match the smoothing kernel of the thing that you ultimately 
wish to measure. A similar rationale explains neural processes (regularized by 
acetylcholine) that optimize signal-to-noise ratio within sensory networks. For fMRI, the 
FWHM smoothing kernel is usually set to 8 or 12mm given what is known about the 
spatial scale of haemodynamic responses to regional neural activity. By reducing the 
influences of non-physiological signal intensity variation, smoothing serves to decrease 
inter-subject variability. 
 
Smoothing also increases the validity of subsequent statistical analyses. The central limit 
theorem implies that the distribution of errors from smoothed data will be more normal, 
which itself is an assumption of parametric statistical methods such as t-tests and 
regression. Furthermore, inferences based upon Gaussian random field theory (see below) 
are predicated on the assumption that the error terms conform approximately to a lattice 
approximation of an underlying smooth Gaussian field.   
 
Co-Registration 
Co-registration is used to fit two different types of scan into the same anatomical space. 
Similar to normalization, its ultimate aim is to estimate the 12-parameter affine 
transformation matrix required to fit one volume into another, except that these volumes 
are derived from different imaging modalities. For further optimization of this fitting, 
after co-registration, spatial normalization is usually performed on both types of co-
registered scans. This can be done by applying the normalization parameters for one scan 
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type to the co-registered image of the second scan type. In this thesis, co-registration was 
performed so as to enable functional activations (derived from EPI scans) to be 
superimposed on detailed T1 structural scans for each subject. This enables more precise 
anatomical localization of group and individual functional effects.   
 
The co-registration process is very different from simple spatial registration since a 
difference image cannot be used when different scan types are being compared. This is 
because there is no simple linear relationship between signal intensities of equivalent 
anatomical regions comparing imaging modalities (e.g. between T1 and T2-weighted 
scans). The comparison procedure is therefore based upon maximizing mutual 
information between the two images. This process involves plotting a 2D joint-histogram 
in which the intensity values for each image are plotted along each axis. Two images that 
are maximally aligned are defined by a joint histogram in which there is a precise one-to-
one relationship – i.e. depicted as a sharp line on the 2D plane - between the intensity 
values of the two images. Images that are progressively less well aligned are 
characterized by joint histograms that are progressively more dispersed, or possess higher 
joint entropies, in their inter-intensities. Co-registration is an iterative process that 
estimates the 12 affine transformation parameters required to minimize joint-entropy. 
 
Statistical Analysis of fMRI Time Series 
 
Introduction  
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The standard functional imaging paradigm involves a comparison of neural activation 
patterns between two behavioral states A and B, say. This is repeated over multiple 
subjects enabling us to estimate an average difference in neural activation between A and 
B, as well as to test hypotheses, such as that the activation difference between A and B is 
greater than zero, or greater than the activation difference between states C and D, etc. In 
this abstract sense, the statistical analysis required by fMRI (and PET, MEG etc.) is no 
different from that in other scientific contexts with the usual assumptions required, e.g. 
for normal distribution of data where parametric tests are used.  
 
However, statistical analyses of functional imaging data are complicated by two features 
inherent to their structure. Firstly, fMRI data that reflects behavioral state A, say, is 
actually a spatial array of many individual measurements – voxels (of which there are ~ 
100,000 in a standard EPI volume) - each testing something meaningful in itself – 
namely, anatomical localization. The simplest way of comparing activation states 
therefore between A and B, say, while preserving anatomical information, is to take each 
voxel as an independent measure of states A and B, and to perform statistical tests within 
its own data series, and then to repeat this process for each voxel. However, this ‘mass 
univariate approach’ unavoidably presents the problem of multiple comparisons – i.e. that 
significant effects appear to occur by chance alone given enough things being measured 
(since significance is just the occurrence of things less commonly than five, or one, in a 
hundred). In order to correct for false-positives, whilst still enabling sensitivity to 
cognitive effects, is therefore one of the statistical adaptations that functional imaging 
methodology has had to develop.  
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The second structural feature of functional imaging data that statistical tests need to take 
account of is that it reflects a time series. This issue is more relevant in event-related 
fMRI where each scan is considered one of many separate time points, than in block-
related fMRI or PET studies, in which only one data point is obtained per testing session, 
per voxel, per subject. Consequently, the various questions that naturally arise with time 
series analysis of any sort become applicable to fMRI. For example if each instance of 
behavioral state A is measured as 10 consecutive time points, how can we reasonably 
pool those data points to provide an accurate reflection of brain activity?  Furthermore, 
given that time series are inherently autocorrelated, how should we adjust the degrees of 
freedom to allow for the fact that these 10 data points are not independent? These 
considerations are further motives for the particular machinery used to implement fMRI 
statistical analyses that shall be discussed. 
 
Generalised Linear Model (GLM)
Many common statistical tests are examples of a basic principle: that a dependent 
variable is related to one or more independent variables according to a simple linear 
dependency. This can be stated more formally by the terms of a general linear model: 
 
     yj =  x1j β1 +  x2j β2 +  … xij βi … xIjβI  +  εj
 
where yj is the jth observation, of a total of J observations, of the dependent variable y, 
that can be expressed in terms of I independent variables x1j, x2j … xIj, also measured at 
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the jth observation, by multiplication of each with a set parameter β1, β2 … βI, 
respectively, plus an error term for the jth observation. The system of J equations can be 
rewritten in matrix notation: 
 
      y = Xβ +  ε 
where: 
I explanatory effects 
  
y=   y1                   X =             x11, x21 … xi1 … xI1                           β =  β1                       ε =   ε1
       y2                                      x12, x22 … xi2 … xI2                                      β2                                   ε2 
       …                                                …                                         …                      ... 
       …                                                …                                         βi                                 … 
        yj                                                        x1j, x2 j … xij  …  xIj                                        …                                 εj
           …                                               …                                         βI                                  … 
        …                                              …                                                                    … 
        yJ                                     x1J, x2J … xiJ  … xIJ                                                                               εJ J
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X is also referred to as the design matrix specifying as it does a model of the entire data 
set by decomposing it in terms of explanatory variables. It should be noted that the GLM 
equation is equivalent to that used in multiple regression, in which the x terms represent 
various explanatory variables or regressors, the β terms the effect sizes, and the 
dependent variable y is a continuous parameter. Statistical tests such as t-tests or 
ANOVAs represent particular examples of this relationship. For example, a t-test reflects 
the special case when there is only one explanatory variable and for each case, this is 
either present or absent (i.e. x = 0 or 1).  
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Let us return again to one of the main purposes of functional imaging: typically, this can 
be phrased as a wish to determine whether 1) certain behavioral states, A or B say, are 
associated significantly with changes in brain activation, and 2) and to see how this 
relationship changes from region to region. Leaving aside the latter spatial issues for one 
moment, this purpose can be framed in terms of the GLM by substituting different 
behavioral states, A,B…, into different explanatory variables x1, x2 etc, and by 
substituting the level of BOLD intensity (for a particular spatial location or voxel) into 
the dependent variable y. As can now be seen, one of the advantages of the GLM is that 
multiple explanatory variables, related to discriminable components of the experiment or 
performance, can be modeled and estimated simultaneously. Furthermore, possible 
confounding factors, e.g. fatigue, reaction times, head movement, can also be measured 
and included as separate explanatory variables. This way changes in brain activity due to 
the behavioural / cognitive effects of interest can be determined, while partialling out 
possible confounds. 
 
In order to determine the significance of each behavioral state (i.e. explanatory variables 
x1j, x2j … xIj) in terms of their contribution to variation in brain activity at each voxel (i.e. 
dependent variable y) we need to calculate the effect sizes (β1, β2 … βI,) for each 
behavioural state, for each voxel. Thus we need to solve a system of simultaneous GLM 
equations for the unknown β parameters. In order to do this, we must first ensure that 
there are at least as many observations (j1, j2,…jJ), as explanatory variables (β1, β2 … βI,). 
Usually, in experiments, observations far outnumber explanatory variables. Secondly, the 
explanatory variables need to be made independent of one another so β that can be 
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uniquely estimated for each. In a complex design matrix this sometimes requires a 
mathematical adjustment in which the columns are orthogonalised with respect to one 
another. Finally, we wish to solve the set of equations in such a way that the error terms 
(ε1, ε2,… εJ) are minimised – this being the condition under which the estimated 
parameters provide the best prediction of the measured signal (y1, y2,… yJ). 
 
Solving a system of GLM-type linear equations, while minimizing their error terms, is 
achieved through the ‘ordinary least squares method’. This method can be derived by 
rearranging the GLM equation so as to express the sum of squared errors Σε2 (= E) in 
terms of β, and subsequently differentiating this with respect to each β. Knowing that the 
sum of squared errors term is minimal when dE/dβ = 0, we can then directly derive a set 
of ‘normal equations’ that relates the estimates of β under this condition (now referred to 
as the least squares, or maximum likelihood, estimates ) to y and X:  βˆ
 
       = (Xβˆ TX)-1XTy 
 
Since XTX is only invertible if X is of full rank - which is rarely ever the case - in practice 
the pseudoinverse, or pinv, of XTX is used.  Thus: 
 
      = pinv(Xβˆ TX)XTy,                          which resolves to: 
 
      = pinv(X)y βˆ
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Having calculated the effect sizes for each effect of interest one can perform statistical 
tests on these parameters, e.g. comparing them to zero, or comparing between different 
effect types, or between different sessions. This step is described later on (Contrasts). It 
should also be noted that the fitted response is defined as Y = Xβ, and the residual errors 
are given by ε = y – Y. 
 
So far, we have modeled the BOLD activity for just one spatial location, or voxel. Our 
second main aim is to show how this relationship varies between regions. This can be 
incorporated easily within the GLM equation by making Y a J x N matrix, where each 
column reflects the J data-points acquired from a separate voxel, for a total of N voxels. 
Correspondingly we need to make β a I x N matrix in which a different set of s are 
specified for each of N voxels, and ε a J x N matrix reflecting error terms for each data-
point for each voxel. Note that the design matrix X is not affected by voxel number, since 
X reflects a constant model applied to every voxel. Also note that an inherent assumption 
of the GLM, as with all parametric statistical methods, is that all error terms are 
independent from one another and identically distributed in a normal fashion. 
βˆ
 
Haemodynamic Response Function and its Neural Equivalent  
The design matrix approximates to a model of the underlying brain processes proposed to 
be activated during an experiment. However, since the data acquired with event-related 
fMRI is not a direct measure of neural activity we adjust the model to account for factors 
that intervene between hypothesized neural activity and actual measured signal intensity. 
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Specifically, each occurrence of a modeled ‘neural event’ (e.g. stimulus or movement 
onset) is modeled within the design matrix as a time-locked ‘haemodynamic response 
function’ (HRF) that reflects the recognized pattern of BOLD increase following a unit 
increment in regional neural activity.  
 
The temporal profile of BOLD signal change following neural stimulation reflects its 
metabolic - vascular origins, with a relatively gradual onset; a peak several seconds later, 
and an even more gradual decay. The entire duration of the BOLD signal, even following 
the briefest of evoking stimuli (or movements) lasting tens of milliseconds, is in the order 
of 10 – 20 seconds. Each behavioral or experimental event that is considered momentary 
is therefore modeled as a stick (or delta) function convolved with a canonical HRF. As 
the duration of the modeled event increases, the resultant HRF is assumed to be a 
convolution of a suitably-lengthed boxcar with the canonical HRF. Similarly, if multiple 
brief events occur within the time of one canonical HRF (e.g.. if the stimulus-onset 
asynchrony, SOA, is < 20 s), then the modeled signal is a convolution of multiple stick 
functions with the HRF. In other words, it is assumed that HRFs can be linearly 
superposed and scaled, and that the convolution is linear time invariant. This assumption 
has been found to be approximately true for SOAs as low as 1 – 2 s (Boynton et al, 1996; 
Friston et al, 1998). 
   
 
Figure 4.10. BOLD response (dots) to visual stimuli (boxcar) of differing duration and 
contrast in primary visual cortex (Boynton et al, 1996). 
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At short event durations the assumption of linearity breaks down, with stimuli of ~500ms 
resulting in HRFs upto 10x larger than that extrapolated from a linear projection of longer 
duration stimuli HRFs (Birn et al, 2001). Moreover, events spaces apart by short intertrial 
intervals (~5s) show ~20% reduction in HRF amplitude relative to those with greater 
spacing (~20s) (Miezin et al, 2000). A breakdown in linearity is also believed to occur 
with high stimulus intensities causing saturation (Howseman & Bowtell, 1999). 
 
Differences in HRF profile exist between brain regions, with for example, the peak of 
activation in anterior prefrontal cortex occurring 4s after that in visual cortex (Schacter et 
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al, 1997). Whether such variability arises from hemodynamic rather than neural effects is 
unclear. Furthermore, the dependency between event duration, or neurophysiological 
intensity (e.g. visual contrast), and HRF also varies between brain regions (Birn et al, 
2001). Variations in the HRF to a given level of neural activation are also likely to occur 
under any circumstance in which changes in vascular, haemodynamic or oxygenation 
properties occur, including with disease and drugs. Given the importance of this matter to 
the present thesis, this is discussed later.      
  
One of the mechanisms by which we can adjust for small variations in the onset timing, 
and temporal dispersion, of the HRF is to model, separately from the HRF, its first and 
second temporal derivatives, respectively.   
 
Finally, it should be noted that there have been attempts to model the HRF according to 
the various properties of underlying neural processes. By simultaneous neural and BOLD 
measurements (Logothetis et al, 2001; Goense & Logothetis, 2008; Rauch et al, 2008) it 
is found that the BOLD response most closely parallels local field potentials (LFP). This 
follows from the fact that LFP often reflects the sum of regional synaptic activity, which 
has its own metabolic footprint (due to transmitter release and uptake). BOLD responses 
are less related to the rate of regional cell-firing, or mean unit activity (MUA). Given the 
spatial resolution of fMRI, this indicates that the level of BOLD signal from a single 
voxel reflects a summation of inputs - regardless of whether excitatory or inhibitory in 
nature – rather than the output or rate of cell firing, the latter of which reflects the 
spatiotemporal integration of neural inputs. Nevertheless, since transmitter release is 
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directly related to spiking activity, a relationship between neuronal spike frequency and 
BOLD is also often apparent (Smith et al, 2002). In some circumstances - especially 
within hippocampus - dissociations between BOLD and LFP, or MUA, can occur that 
might be due to such regions having similar numbers of inhibitory and excitatory 
synapses, which when active, result in increased BOLD but no net increase in LFP or 
MUA. Such dissociations may also occur in regions such as hippocampus that have a 
sparse and less-well autoregulated blood-supply (Ekstrom, 2010).    
 
Design Matrix Specification in event-related fMRI 
In event-related fMRI the time resolution with which we are able to observe changes in 
neural activity is far superior – in the order of seconds, to that achievable in epoch-related 
methodologies such as PET, for which the datum reflects neural activity averaged over 
many minutes. One of the main advantages of this finer temporal resolution is that we can 
model phasic cognitive processes – that vary trial-to-trial, or even within the same trial – 
and distinguish these from tonic processes occurring over the course of a session, each of 
which are likely to have distinct neural bases (e.g. Forster et al, 2000; Marklund et al, 
2007). The ability to model separable behavioral / cognitive components, occurring at 
different times, and on different time-scales, is achievable by virtue of the versatility of 
design matrix specification as defined above. Furthermore, we are also able to model 
potential confounds such as reaction time or fatigue as extra terms within the GLM.  
 
A typical design matrix for an event-related fMRI experiment is partitioned into multiple 
factors, each represented by a separate column in the matrix, that provide the best 
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characterization of processes underlying variations in the BOLD signal time-series. The 
other constraint that we impose is that partitions are independent of each other; as we 
have seen this is required in order for the  estimates to be solved in the GLM.  βˆ
 
The usual components of a design matrix are: 
1. Effects of interest. These are distinguishable components of the experiment such 
as stimuli (e.g. houses versus faces); tasks (e.g. passive viewing versus ‘look for a 
target’); response type (e.g. move right versus left hand); response meaning (e.g. 
correct verus incorrect); and repetition (e.g. first versus second stimulus 
presentation or movement). Some effects may be categorizable only through 
testing in sessions before or after the scanning session itself, e.g. priming (e.g. 
word studied earlier versus novel word); introspective evaluation (e.g. pleasant 
versus unpleasant); or subsequent memory (e.g. correctly recognized versus 
incorrectly rejected). 
 
In general, each event type is modeled as a separate explanatory variable, and 
each event occurrence is modeled as a canonical HRF. Exceptions to this are 
where there may be insufficient trial types and where sub-classification of 
variables is not directly relevant to the research question. By modeling more then 
one factor the possibility of interactions can be tested.  
 
            The duration of each event type can be modeled by convolving the HRF with a 
suitably lengthed boxcar. This enables us to distinguish tonic from phasic 
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processes even where they are occurring concurrently (e.g. Otten et al, 2002). 
Furthermore, by orthogonally manipulating the duration of trial subcomponents 
we can distinguish different cognitive processes that may act together within a 
single trial (Zarahn et al, 1999; Rowe et al, 2001). For example in Experiment 3 in 
this thesis, stimulus-related activations are distinguished from attention and 
working memory-related activations by varying the duration of an intervening 
maintenance period during which sensory and motor requirements are held 
constant between conditions. 
 
            A further way in which effects of interest can be modeled, is to scale the HRF by 
a physiologically-meaningful variable. In this way a series of events can be 
contained within the same column of the design matrix, with each being assigned 
a parametric modulator. The nature of the parametric modulation can be linear, 
quadratic, logarithmic etc., depending on the model (Buchel et al, 1998). For 
example, in Experiment 1 of this thesis, different stimuli and task types were 
modeled both as time-invariant, and time-dependent, factors. The latter were 
specified as a time series of HRFs convolved with a linearly decreasing function. 
Responses found to decrease (or increase) over the session may capture time-
dependent component of the task such as habituation or learning.     
  
2. Error Trials. Trials in which the subject committed an error (whether of 
commission or omission) are often modeled separately to reduce possible variance 
within the effects of interest themselves. 
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3. Movement Parameters. The initial spatial registration step generates for each 
scan an estimate of the rigid-body parameters required to realign the scan to the 
reference scan (i.e. the first scan in a session). These six parameters are included 
within the design matrix to account for movement-related activations, or failure of 
activations.  
 
4. High-Pass Filter. A set of time-varying cosine regressors may be added to the 
model to remove a large component of noise that occurs at low temporal 
frequencies (Zarahn et al, 1997). Low-frequency noise originates from 
physiological effects (e.g. respiratory and cardiac high-frequency cycles being 
sampled slowly, and thus aliasing); slow movements of the head, and scanner B0 
magnetic field drift. An alternative correction method used in this thesis is to 
transform the time series into its frequency-power profile and to remove all 
components below a threshold (usually set at 1/256 Hz).  
 
5. Temporal Autocorrelation. A significant problem with the GLM approach to 
fMRI time-series analysis is that the error term does not contain independent 
residuals. This is because each data point (matrix row) is inherently correlated 
with data before and after it in time – i.e. is temporally autocorrelated. This occurs 
partly because each event is associated with a long HRF duration (10-20 s) that 
will be sampled multiple times by an fMRI acquisition run (TR ~ 3 s).   One of 
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the effects of this problem is that the actual number of degrees of freedom is less 
than the number of scans.  
 
            Several strategies have been proposed to correct for this problem. In the “pre-
whitening” method, the autoregression between each data-point and its immediate 
temporal neighbour is used to estimate an AR(1) model which can correct the data 
(Bullmore et al, 1996). A more robust, but arguably less sensitive, way of 
rendering residuals independent of each other is to use a Gaussian low-pass filter 
matched to the HRF, in addition to the previously mentioned, high-pass filter, 
which together swamps any intrinsic autocorrelation (Friston et al, 1995b).  
 
            Notwithstanding the above account of autocorrelation adjustment, it turns out that 
the problem of temporal autocorrelation is not too problematic if experiments are 
designed to make inferences at a random-effects level (see below). This is 
because such analyses compare only the parameter estimates of the first-level 
analyses, and not the error terms about those estimates. For this reason, 
Experiments 1 and 2 in this thesis (analysed using SPM99 software) did not 
perform any autocorrelation correction. In Experiments 3, 4 and 5, residual 
temporal autocorrelation is estimated using a one-step restricted maximum 
likelihood (ReML) estimation (Kiebel et al, 2003). In this method, the covariance 
of residuals (i.e. correlation of each datum with each other data-point, for each 
voxel) is modeled as a set of variance components, and the solution to the GLM 
proceeds by estimation of both GLM parameters and variance components’ 
169 
Chapter 4 
hyper-parameters. The advantage of this method is that it acts as a general method 
for non-sphericity correction, rather than being specific for temporal 
autocorrelation.    
 
6. Session Effects. Each session within the scanner is modeled by its own constant, 
this reflecting the average, or baseline, BOLD signal for each voxel. This factor 
may or may not be important depending on whether any effects of interest are 
separated as session-specific. However since it is likely that non-cognitive factors 
– such as magnetic field, head position, or subject fatigue – are also likely to vary 
between sessions, then estimation of session effects are likely to be inefficient 
(including extra noise) or confounded.  
 
Data Scaling 
It is possible that from session to session the level of signal received from the brain as a 
whole varies e.g. because the head is more or less optimally sited in the head coil. This 
grand mean reflects the mean over all voxels, and all scans of a session. This value is 
automatically removed by grand mean scaling, i.e. multiplying each voxel’s value at each 
acquired time-point by 100/grand mean.  
 
Extending the logic of grand means, it is also possible that the global signal varies from 
scan to scan (and not just session to session). This may reflect uninteresting variations in 
head or scanner properties from scan to scan, e.g. head movement, or even physiological 
effects e.g. arousal or drug effects that may affect the whole brain in one go. The global 
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mean is defined as the mean of voxel signal intensity for any one scan. This can be 
removed by global scaling in which each voxel for a given scan is multiplied by the 
100/global mean for that scan.  
 
In this thesis, both grand and global scaling were applied to eliminate effects of drug or 
disease on whole-brain mean activation that may have arisen from changes in the neural-
BOLD relationship (see below), rather than through changes in neural activity. We could 
afford to apply this correction because the hypotheses tested were concerned with drug or 
disease interactions with region-specific activations. 
 
One of the problems with global scaling is that if a large number of voxels become 
activated then regions which become activated less than the average may appear as 
deactivations. Furthermore, to the extent that global changes usually reflect gradual 
changes over the course of a session, global scaling is unnecessary as high-pass filtering 
(see above) effectively serves the same purpose.   
       
Hypothesis Testing 
By reviewing the GLM equation (Y = Xβ +  ε), and recalling that the design matrix, X, 
specifies a series of HRFs for each effect of interest, it can be seen that the size of β, 
estimated for each explanatory variable, reflects the strength of the HRF that best 
accounts for the measured BOLD time-series Y. Having estimated the size of each 
explanatory variable’s effect (β1, β2 … βI,), for each voxel, we subsequently wish to make 
inferences regarding them in relation to pre-specified experimental hypotheses. This step 
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involves comparing effect sizes with the variance of the data set, and assessing the 
statistical significance of this ratio. Usually these hypotheses takes the form of comparing 
one condition to another (e.g. β1 versus β2), or of comparing several conditions 
concomitantly (e.g. β1 versus β2 versus β3). Comparing only one effect to baseline (e.g. β1 
versus 0) is not often performed owing to the ambiguity over what the baseline state is, 
especially since it cannot be assumed that this is synonymous with ‘rest’. Thus for each 
subject tested, we usually perform either two-sample t-tests or F-tests that compare 
conditions of interest as described by the experimental hypotheses.  
 
T-tests or F-tests are performed on specific combinations of GLM regressors by the 
conventional method. Mathematically, the contrasts of interest can be specified by a 
pattern of 1s and 0s within a row-vector c, which then multiplies into the β matrix so as 
to perform a simple linear combination of the estimated parameters. When the effects of 
interest are replicated in more than one session, this involves adding the β  contrast of 
interest over all relevant sessions.      
 
The t-statistic reflects the size of the effect of interest (β) as a ratio with the standard error 
of the associated dataset (SE(ε)). In other words, using the c vector to specify a contrast 
of interest: 
 
          T = c β / stdev(c β) =  c β / sqrt(σ2 c pinv(XTX) cT) 
 
in which the estimated error variance is given by: 
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               σ2 = εTε / df,           and               df = J – rank(X)       (where J = no. of scans) 
 
assuming iid (i.e. residual errors are independently and identically distributed). 
 
The t-statistic can then be compared to reference t values at which the null hypothesis 
(i.e. that c β = 0) would be falsely rejected with no more than α probability. If the t-
statistic is greater than this cut-off then the null hypothesis can be rejected.  
 
An F-statistic can also be estimated in conditions where more than 2 conditions of 
interest are present. The hypothesis in this case is that any combination of a number of 
simple contrasts of βs is significant. An F-contrast is formulated as a matrix specifying a 
multitude of contrasts that together span the experimental space – i.e. all possible linear 
combinations of contrasts. The F-statistic is derived from the ratio of variance accounted 
for by the experimental model to the total amount of variance. This too can be compared 
to an F-distribution of probabilities reflecting the null hypothesis. 
 
The estimation of t or F-statistics proceeds for all voxels resulting in a statistical 
parametric map (SPM(t) or SPM(F)). These can be thresholded at a level set for rejection 
of the null hypothesis and then rendered into a 3D image to form an ‘activation map’. It 
should be emphasized that the analysis, as described, reflects a fixed-level, or first-level, 
analysis performed on individual subjects, and is to be distinguished from a random-
effects, or second-level analysis (see below).    
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Correction for Multiple Comparisons  
So far it has been described how a statistic – t or F – that relates modeled effects X to a 
data-series Y is estimated, for a single voxel. With functional imaging we are of course 
interested in generating such a statistic for as many locations that can be spatially 
resolved by the particular scanning technique used. This introduces two sorts of problems 
that act in opposite directions.  
 
Firstly, there is the well-known problem of multiple comparisons by which the 
probability α of a particular occurrence increases in proportion to the number N of times 
this occurrence is allowed to happen. Specifically, if α is the probability that we falsely 
reject the null hypothesis for a single statistical test (i.e. commit a type 1 error), then if we 
repeat the test N times: 
 
         P(no type 1 error is committed on any test) = (1 – α)N
 
Therefore 
 
         P(at least one error occurs) = P(Family-Wise Error) = 1 - (1 – α)N
 
When α is small the binomial expansion can be approximated by just the first two terms: 
 
         P(Family-Wise Error) ≤  Nα 
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If we consider P(FWE) to be the acceptable error threshold over all N tests –  
conventionally set as 0.05 or 0.01 - then we need to adjust α for each individual test. The 
most stringent but simplest means of correction is the Bonferroni method by which, 
rearranging the above equation, we set α for each individual test to be P(FWE) / N. Since 
N for fMRI is in the order of 100,000, this would entail a very high level of statistical 
significance required for the null hypothesis to be rejected at any single voxel, and so this 
correction method is too conservative.  
 
The second problem with sampling over many voxels is that they do not reflect 
independent samples by virtue of their spatial nature. In other words we would generally 
expect measurements that come from samples spaced closely together to be more 
correlated than samples taken from highly separated locations. (This is likely to be true 
for any kind of geographical survey). Spatial autocorrelation in fMRI originates from 
both inherent smoothness (owing to neural, vascular and MRI spatial properties) and 
applied smoothness (performed for reasons described earlier). Principles for estimating 
and correcting spatial autocorrelations are similar to those used for temporal 
autocorrelations discussed above. 
 
Although spatial autocorrelation is a problem in the sense that it means our spatial 
resolution is not as good as the number of voxels sampled suggests, it actually mitigates 
the first problem of multiple comparisons. This is because the number of independent 
comparisons that we need to correct for is significantly less than the number of voxels. 
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For example, if the smoothness of the dataset is governed solely by the applied 
smoothing kernel of full-width half maximum (FWHM) then the number of independent 
observations approximates to the total volume divided by the number of cubes of FWHM 
side length. In this situation, each FWHM-characterised cube is the true spatial resolution 
element (known as a ‘resel’) (Worsley et al, 1992). However, since we do not know the 
extent of spatial correlation before smoothing is applied it is necessary to estimate 
smoothness, which is derived from the residual error images (Kiebel et al, 1999).   
 
Having estimated the number of resels that our dataset is composed of, we can calculate 
the probability that a subset of resels will exceed a statistical threshold by chance. This 
relationship is derived from an equation of random field theory, which states that the 
average number of suprathreshold clusters - also referred to as the expected Euler 
characteristic, or E(EC) - is a function of resel number and the statistical threshold Z. For 
Z values greater than 1, E(EC) decreases exponentially, and for E(EC) values less than 1, 
E(EC) approximates to the probability of finding a suprathreshold cluster by chance. In 
practice, this equation is used in reverse, whereby we set the probability of observing a 
suprathreshold cluster by chance, E(EC), to be equivalent to P(FWE). Thus we derive the 
statistical threshold Z we should set for each voxel to assure ourselves of a P(FWE) of 
<0.05 (or 0.01). Note that this estimated Euler characteristic method is more accurate 
than the classical Bonferroni method of correction by which Z would simply equal 
P(FWE) / number of resels. 
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While using resel number, rather than voxel number, allows us to use a lower statistical 
threshold, and thus increase sensitivity, the method of correction as described is still 
relatively conservative. In order to improve sensitivity, or decrease the likelihood of type 
2 errors (i.e. false negatives), two alternative methods are sometimes used (including 
within experiments in this thesis). The first of these methods controls for false-discovery 
rate (FDR) (Genovese et al, 2002). The critical distinction here is that the FDR refers to 
the rate of false positives among only those tests which are all ready positive (i.e. null 
hypothesis is rejected), whereas with Bonferonni correction the FWE refers to the rate of 
false positives over all tests performed regardless of their result. Consequently, with the 
FDR method, for a given FDR value (e.g. 0.05), the α level for individual voxels will 
differ between statistical contrasts, depending on the overall spatial pattern of activity. In 
particular, it allows us to be more lenient with our thresholding in contrasts when only a 
small proportion of voxels have relatively low p values. By contrast, when a large 
number of voxels have low p values, the correction becomes more conservative and 
approximates a Bonferroni method.  
 
The second method by which we can improve statistical sensitivity is to restrict the 
search volume to that framed by the experimental hypothesis. Reducing the number of 
resels decreases the chance of finding a false cluster, E(EC), for a given statistical 
threshold Z. Given the inverse relationship between E(EC) and Z for Z>1 (see above), 
this entails that as resel number decreases, Z can be decreased while keeping E(EC) at a 
pre-specified level (usually, 0.05). In SPM software, a region of interest (ROI) can be 
defined by creating a ‘mask’ of voxels, thereby restricting statistical parameter estimation 
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to a subset of brain voxels. This mask can be defined anatomically, e.g. based upon 
recognized cerebral sulci or fissure landmarks, or functionally, e.g. a sphere centred upon 
activation coordinates quoted in a previous study, and of diameter equal to the smoothing 
FWHM.  
 
Sometimes an ROI is derived from a separate contrast performed in the same study. 
However, for statistical validity, and avoidance of bias, this ROI should be derived from 
separate trials, or separate subjects, than those from which the test is based upon, even if 
the contrasts are orthogonal (Mitsis et al, 2008). Rather, the main advantage of spatially 
masking contrasts with other contrasts is to enable functional characterization of regions, 
and interpretation of interactions between factors. This is elaborated in the Methods 
subsections for each experiment.  
 
In this thesis, results are reported at a statistical threshold of p < 0.05 corrected for whole 
brain, or corrected for small-volume as defined by the above methods. Additionally, 
voxels are reported at thresholds of p < 0.001, uncorrected, in anatomical regions 
considered to be relevant to the behavioral paradigm based upon previous work.   
  
Random-Effects Analysis  
The statistical values estimated from one subject’s dataset relate the experimental effect 
of interest to the variance of this particular subject’s dataset. Since the number of degrees 
of freedom from which the statistic is computed is based upon the number of 
measurements, i.e. scans, which is in the order of ~100, the statistical significance of 
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effects is often found to be very high. Usually the variances of different sessions are 
pooled, which is acceptable providing there are no good reasons for believing that the 
within-session variance is different from the between-session variance (acceptable, for 
example, if they are separated by only a short period of time). However, this fixed-effects 
method of analysis means that our inference regarding the experimental effect is confined 
to the subject under study.  
 
Usually, we are interested in making inferences about an experimental effect in a 
population – for example, of healthy adults. However, it is likely that variance between 
subjects is different from that within subjects, necessitating a random-effects analysis. In 
this analysis, the size of an experimental effect – averaged over a number of tested 
subjects – is compared to the variance between, rather than within, individuals. 
Accordingly, in SPM, the results of a contrast performed over a single subject’s GLM are 
reported (and saved) both in terms of effect size (difference between βs; referred to as 
“con-images”), and t- (or F-) statistics, the latter of which incorporates both effect size 
and within subject variance. Of these two types of result, it is the effect size alone that is 
utilized for a random-effects analysis, through pooling or comparison with the equivalent 
effect sizes from other subjects.       
 
Depending on what type of question we are asking at the population level, a random-
effects analysis proceeds as one of several types of GLM. This is the second time we 
construct a GLM – explaining why random-effects is also called a second-level analysis - 
but now we take subjects’ pooled effect size, rather than scans, as each datapoint 
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(modeled by individual rows of the design matrix). This often means that the degrees of 
freedom, and therefore sensitivity is reduced. 
 
If the question is what regions is BOLD greater during state A than state B, then the 
contrast of A – B generates a single effect size for each subject, which can then be 
analysed at the second level by a one-sample t-test. This would identify those regions in 
which (A-B) > 0, inferred upon the population of which the tested subjects were 
representative. If we are interested in comparing the responses between two conditions, 
or two groups of subjects (for example between patients and age-matched controls: see 
Experiments 4 and 5), then the second-level GLM is constructed so as to perform a two-
sample t-test. In these situations, the two explanatory variables (i.e. columns of the 
design matrix) reflect the two types of condition or subject. If more than two explanatory 
variables are represented within the second-level GLM, then an ANOVA can be 
performed. Alternatively, as in Experiment 2, we can perform a conjunction analysis, in 
which we estimate the probability of two or more contrasts being jointly significant 
(Price & Friston, 1997). The utility of a conjunction is that it isolates cognitive 
components common to two sets of conditions (and hence is an alternative approach to 
subtraction methodologies). The conjunction analysis proceeds as a split t-test, and its 
results can be incorporated within random field theory (Worsley & Friston, 2000).   
 
Sometimes we are interested in correlating an independently-derived parameter with 
individual subject effect sizes, in which case this parameter is modeled as a separate term 
within the GLM, allowing for an ANCOVA. For example, in Experiment 5, effects of 
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drug on a particular functional contrast of BOLD activations were correlated between 
subjects with the drug-effect on each subject’s subsequent recognition performance. 
Sometimes the modeled parameter is a ‘covariate of no interest’. For example, in 
Experiment 4, drug-effects on reaction times were included within the GLM so that the 
effects of drug on the functional contrast of interest (e.g. deep versus superficial 
encoding) could be determined separately from the effects of drug on RT. Finally, the 
parameter of interest can be set to be the effect size for another type of contrast in another 
brain region – enabling testing of hypotheses regarding functional connectivity. For 
example, in Experiment 5, the effect of task on stimulus-selectivity is modeled both as a 
constant term, and as a variable term based upon the size of individuals’ task-effects 
within right parietal cortex.  
 
In estimating the parameters of a GLM, where more than one condition is specified as in 
repeated measures ANOVA, we assume that variance is identical between conditions. 
Furthermore, we assume that the sizes of effects between orthogonal contrasts are 
independent. Since these assumptions are often unlikely to hold, we apply a non-
sphericity correction that is equivalent to a Greenhouse-Geisser correction. In SPM this 
occurs by deriving the error variance-covariance structure over all voxels showing a 
significant ‘effects of interest’ F-contrast. This enables estimation of voxel-specific 
hyperparameters controlling the nonspherical variance components, which themselves 
can be used to correct for the appropriate statistic and degrees of freedom (Glaser & 
Friston, 2004). 
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Experimental Design  
The experiments within this thesis are based predominantly upon a factorial design. By 
this we mean that the behavioural paradigm can be divided into two or more factors that 
act orthogonally with respect to each other. For example, in Experiments 1 and 2, stimuli 
were arranged in such a manner as to be distinguishable along three dimensions: attention 
(faces in attended vs unattended locations); emotional valence (fearful vs neutral faces, 
irrespective of face location), and repetition (first vs second exposure to face). This is 
considered to be a 2 x 2 x 2 factorial design in which each factor has two levels. Note that 
these factors are presented to each subject, enabling within-subject comparisons, whereas 
treatment (drug vs placebo) in Experiments 1 and 2 was a further factor that acted 
between subjects.  
 
The main advantage of the factorial approach is that it enables manipulation of several 
factors that may interact. By this is meant that effect of one factor (e.g. A1-A2) is 
modulated by whether another factor is operating or not (e.g. B1-B2). For example, in 
Experiment 4 we note that face, relative to building, stimuli activate fusiform cortex 
regardless of task (shallow vs deep), whereas the same stimulus comparison activates 
posterior superior temporal sulci significantly greater during a deep than shallow task. 
The other advantage of factorial designs is that they enable multiple factors to be 
investigated within the same experiment. However, whenever an extra factor, F say, has 
been included within the experimental design, this should be modeled so as to allow for 
the possibility that it is actually F that is the strongest driver of an effect, rather than a 
factor A represented in the original model. In this situation, we say that the main effect of 
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A is being driven by its interaction with F. The problem with modeling too many factors 
though (especially 4 or more) is that one may be left with too few event types per 
condition to enable reasonable parameter estimation, and interpretation of interactions 
becomes complicated. In order to deal with the latter problem, the approach used here is 
to mask interactions (e.g. stimulus x task x drug) with more rudimentary contrasts (e.g. 
main effect of stimulus). This avoids having to interpret so-called cross-over interactions 
in which a region shows opposite effects, rather than different sizes of an effect, under 
different conditions.  
 
Design Efficiency  
The design of a functional imaging experiment, in terms of trial numbers, spacings, 
durations, and order, affects the efficiency with which an underlying neural signal can be 
detected. At the simplest level, the more trials we measure the better our estimate of the 
the signal, meaning that we should try to cram in as many trials (i.e. have short stimulus 
onset asynchronies) as we can per experimental session. However, as well as possibly 
interfering with the psychological process that we wish to study, having too short SOAs 
is not efficient in fMRI because of the sluggishness and long duration of the HRF. For 
example, if we wish to observe the main effect of photic stimulation on visual cortex, 
then we need to wait for the HRF to rise and then fall over about 20s for each trial. Were 
we to space trials too close together (e.g. < 10s), the effect would be to elevate the 
baseline – that is not sampled because of the high-pass filter - while making individual 
trials indiscernible. Extending this logic entails that the most efficient protocol for main 
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effect contrasts (i.e. condition A -  0) are blocked designs in which A can be successively 
repeated, and then alternated with rest (0), in cycles with periods of ~20s.  
 
Usually our interest is in comparing two conditions rather than performing solely a main 
effect. Furthermore, blocked designs are problematic from a psychological standpoint 
since factors of interest may be confounded by time. Moreover the neural processes that 
we wish to probe are often phasic, rather than tonic, in nature, and in some cases we wish 
to classify trials according to post-scanning information (e.g. subsequent memory as in 
Experiment 5). Fortunately, if we wish to compare two trial types the signal difference 
between them can be discerned in the early parts of the HRF and we are not forced to 
wait 20s as with main effect discrimination. This fact allows us to perform event-related 
fMRI in which different trial types are mixed up within a block. The optimal SOA in this 
situation is determined by the ordering of the two trial types. If the two trial types simply 
alternate, then placing these together closer in time (e.g. < 3 s apart) than the peak of the 
HRF, will lead to a poorer discrimination than if we waited about 5 – 10s to sample each 
trial type. However, if we were to pseudorandomise the order in which the trial types 
occur, thereby allowing some runs in which the same trial occurs repeatedly, we can 
allow for a shorter SOA. This is because in runs with identical trial types, there is a 
summation of overlapping HRFs, during which we can observe more readily differences 
between trial types. Consequently, for a pseudorandomised design if SOAs are long (e.g. 
6 – 25 s) then sensitivity decreases because low-frequency components resulting from 
long runs of one event type are attenuated by the high-pass filter.   
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More formally, the ways in which variations in trial ordering, or SOA, affect signal 
estimability can be simulated with running estimates of the HRF (Josephs & Henson, 
1999). The estimated measurable power is equivalent to the total energy (sum of squared 
signal across scans) divided by the number of scans. This shows that the most powerful 
designs for experiments that contrast more than one trial type are those in which there is a 
short SOA (~3s), and a pseudorandomised ordering of trial types. At too short SOAs 
(<2s), the linear time-invariant assumption for BOLD responses breaks down, and 
efficiency becomes compromised. If both main and differential effects are desired, then 
insertion of ‘null events’ that are not distinguishable to the subject, but serve merely as 
spacers between events, enable sensitivity to both at short SOAs (Dale & Buckner, 1997).  
 
The experiments in this thesis generally adopt a mixed fMRI design in which task 
conditions are blocked, and stimuli types are assorted as ‘events’ within each block. 
Blocking tasks is often performed to reduce the likelihood that subjects make mistakes 
(especially important in Experiments 4 and 5 involving dementia patients). Within the 
blocks, event types are pseudorandomised, and SOAs are varied with a mean of ~ 3s. The 
use of jittering for the intertrial interval both reduces the likelihood of slice-timing 
confounding, and increases sensitivity for short SOA designs (Burock et al, 1998).  
 
Finally, it should be noted that efficiency of signal comparison between two conditions or 
more, is related to the relative timings and orderings of events between the condition 
types. In general, the greater the orthogonality (i.e. independence) between conditions, 
the more accurate is the parameter estimation for each condition. This is because with 
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orthogonal designs all the variance of the dataset can be divided up between the 
conditions, whereas with non-orthogonal designs some of the variance is common to 
multiple conditions and so cannot be utilised for parameter estimation. More formally, 
efficiency for a single contrast is proportional to the variance of a column in a design 
matrix, and for multiple contrasts, efficiency can be characterised by the trace of the 
covariance of the contrasted design matrix: 
 
         Efficiency(X)    = Var(X) =  XTX 
 
         Efficiency(c,X) = {cT(XTX) -1c}-1
 
Pharmacological and Clinical fMRI 
 
Confounding Effects of Drugs and Disease in fMRI  
A particular methodological concern to the experiments of this thesis is that drugs (Burke 
& Buhrle, 2006; Stefanovic et al, 2007; Pattinson et al, 2007) and disease - in this thesis, 
Alzheimer’s disease (Rombouts et al, 2005; Rombouts et al, 2007), as well as ageing 
(D’Esposito et al, 1999), alter the neurovascular coupling relationship. As discussed 
above, our assumption that fMRI is a reliable indicator of neural activity is predicated 
upon the assumption that there is a fairly constant relationship between neural activation 
on the one hand, and changes in regional blood flow and oxygenation, on the other. Thus 
any fMRI investigation into how a factor X influences neural activations needs to first 
question whether X also influences the neural-BOLD relationship. In other words, if X 
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reduces BOLD activations, this might be because X reduces neural activity, or it could 
mean that neural activity remains the same, but that the BOLD signal generated for the 
same amount of neural activity is lessened. It should be noted that this concern is distinct 
from that which questions whether there is a linear time-invariant relationship between 
evoked neural activity and BOLD response. Rather, the question is whether the function 
that maps neural activity to BOLD signal – be it linear or non-linear – differs under 
different physiological conditions, some of which may happen to encompass the 
manipulation of interest.  
 
Variations in physiology may alter neural-BOLD coupling at four theoretical stages 
(Iannetti & Wise, 2007):  
 
1. Neural. Whilst pharmacological or disease-associated changes in evoked neural 
responses are usually the subject of interest, it needs to be considered whether the 
experimental factor also alters the level of baseline neural activity. Studies 
measuring combined neural and metabolic parameters in rats have shown that 
different baseline firing patterns (invoked by differing degrees of anesthesia) can 
alter both the magnitude and spatial pattern of BOLD responses (Hyder et al, 
2002). For example, for a given stimulus, a low baseline state produces a higher 
evoked response than a high-baseline state, suggesting that function arises from 
an absolute, rather than relative, level of neural activity. Furthermore, 
observations that high-baseline relative to low-baseline states manifest evoked 
BOLD responses that are spatially more diffuse, but weaker, may reflect a higher 
187 
Chapter 4 
relative proportion of fast-firing (γ-range) to slow-firing (α-range) neurons (van 
Eijsden et al, 2009). In Alzheimer’s disease, background alpha-activity is 
impaired, which is predicted to reduce evoked BOLD responses according to a 
unified EEG-fMRI model (Sotero & Trujillo-Barreto, 2008). It is also possible 
that both drugs and disease alter the spatial distribution of default networks 
characterized by spatially-correlated baseline activity (e.g. Greicius et al, 2004).   
 
2. Metabolic signaling and blood flow. Changes in neural activity - whether 
ultimately originating from synaptic processes or action potential generation – 
necessitate changes in metabolic, especially oxygen, flux. The main way in which 
oxygen supply is varied is through modulation of regional cerebral blood flow 
(CBF), rather than adjusting the rate of cerebral metabolic oxygen consumption 
(CMRO2). This is because merely increasing CMRO2 following increased neural 
activity would rapidly become ineffective since a requisite oxygen concentration 
gradient from vessel to cell would be removed. Consequently, neuronal activity 
results in arteriolar vasodilatation and a fractional increase in CBF several times 
greater than any increase in CMRO2, thereby sustaining a high partial pressure of 
capillary oxygen.  
 
Coupling between neural activity and vascular tone may occur homeostatically 
through neural or glial-associated changes in the local concentrations of 
metabolites, including nitric oxide and oxygen. Alternatively, it may be controlled 
indirectly through vascular sensitivity to neurotransmitter release e.g. glutamate 
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and GABA (Drake & Iadecola, 2007). Which ever pathway is dominant, it is 
likely that efficiency of neurovascular signaling is susceptible to disease and 
drugs. Furthermore, in a similar vein to the confound of neural baseline 
previously mentioned, the values of basal metabolism, blood flow and volume, 
will also determine the incremental changes of each parameter, that ultimately 
determines BOLD signal (see below). For example, states in which there is a 
greater basal blood volume, e.g. due to vasodilator drugs or diseases characterized 
by angiogenesis, will exhibit a greater BOLD signal simply by virtue of a linear 
gain factor. Conversely, increasing basal cerebral blood flow, for example by 
inducing hypercapnia or administering acetazolamide, reduces the BOLD 
response to a constant stimulus (Cohen et al, 2002; Brown et al, 2003).       
 
3. Vascular Reactivity. Whereas with PET functional imaging, the measured signal 
is a direct reflection of regional metabolic activity, with fMRI, the BOLD signal 
is a more derived measure. Specifically, as previously discussed, BOLD 
ultimately depends upon  the ratio of oxyHb to deoxyHB, in a given volume, 
which is only partially a function of metabolic demand. Changes in BOLD are 
directly related to changes in CBF and changes in cerebral metabolic rate, or 
consumption of oxygen (CMRO2) according to the scaling parameter M, 
described by the relationship: 
 
            ∆BOLD = M (1 – (∆ CBFx. ∆ CMRO2y))   
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            where x relates cerebral blood flow to blood volume, and y is a physiological 
constant (Davis et al, 1998). M reflects the amount of deoxyHb in the baseline 
state, and defines the maximum possible BOLD signal change for a particular 
region. The value of M is inversely proportional to venous blood volume and 
flow, either of which, as well as parameter y, may alter according to physiological 
or pathological state. For example, drugs that lower systemic blood pressure are 
associated with increased venous volumes, due to a cerebral autoregulatory reflex, 
and thus a reduced BOLD signal (Kalisch et al, 2001). M is also inversely 
proportional to arterial oxygenation which may be reduced under certain 
conditions, e.g. smokers, sedating drugs.    
 
        4. BOLD signal. The relationship between changes in the deoxyHb content of a 
given voxel and recorded BOLD signal change is governed by factors that 
influence proton T2* relaxivity. Most of these – e.g. B0 magnet strength, pulse 
sequence – are clearly unrelated to drugs or disease. However, certain exceptions 
may exist: such as if bulk head motion were to be increased in dementia patients, 
or under drug state, then the efficiency of signal measurement would be reduced. 
Furthermore, disease-associated anatomical differences such as of grey matter 
density, or microhemorrhages, may alter MR signal-related factors, such as proton 
density and T2* susceptibility, respectively. 
 
Variations in hemodynamic response to evoked activity have been investigated in elderly 
people since a major application of fMRI is exploring the cognitive disorders of patients 
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with neurodegenerative diseases as well as of healthy ageing. For the same stimulus 
intensity, elderly subjects are found to show greater intersubject and intrasubject 
variability in the evoked haemodynamic response function, leading to smaller signal to 
noise ratios, and smaller clusters of significant activation (Fig. 4.12; Huettel et al, 2001).  
 
Figure 4.11. BOLD responses in primary visual cortex show less variance in young (A) 
than old humans (B), with consequent higher signal-to-noise ratio (C) (Huettel et al, 
2001). CC = calcarine cortex; Max = maximum signal voxel. 
C
 
 
 Whether effects of age on the BOLD response are due to alterations in the neural  - 
BOLD relationship, rather than neural differences per se, has been explored by studies 
measuring both cerebral blood flow (CBF) and BOLD (Ances et al, 2009). Since it was 
found that ∆BOLD was diminished in elderly under circumstances where both ∆CBF and 
∆CMRO2 remained constant, it appears that one reason for the age-related difference in 
BOLD response is a difference in the coupling relationship expressed by the parameter M 
in the 'Vascular Reactivity' equation described above (Figure 4.12; Ances et al, 2009). 
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Figure 4.12. Old and young subjects show similar visual cortex blood flow changes (A) 
in response to a stimulus, but decreased BOLD amplitude (B). This suggests a reduction 
in the neural – BOLD relationship with age (Ances et al, 2009). 
  
 
It is likely that certain drugs also have the potential to modulate the constants of the 
neural-BOLD relationship. This can been demonstrated by noting an electrohysiological-
BOLD dissociation, such as with the drug 7-nitroindazole (Burke & Buhrle, 2006). 
 
Figure 4.13. Pharmacological decoupling of the neural – vascular – BOLD relationship 
by 7 nitroindazole demonstrated by separate measurements of somatosensory evoked 
potentials (C, D) and somatosensory evoked BOLD (A) and blood flow (B) in rats (Burke 
& Buhrle, 2006).  
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It is possible that concerns about drug effects on the neural-BOLD relationship are 
limited to only a few particularly vasoactive drugs. Simultaneous BOLD – neural 
sampling in monkeys has shown no significant variation in correlations between the two 
measures comparing anaesthetized and awake monkeys, at least in primary visual cortex 
(Goense & Logothestis, 2008). It is noteworthy that this result appears to downplay the 
importance of differences in baseline energy in determining evoked BOLD responses 
(Hyder et al, 2002). Furthermore, the tight coupling known to occur between local field 
potential and BOLD is unaffected by direct injection of a serotonergic agonist into visual 
cortex (Rauch et al, 2008), in spite of this drug having vasoconstrictive properties (e.g. 
Hamel et al, 1989). Even where a drug significantly affects cerebral blood flow, as shown 
for cocaine using flow-sensitive inversion recovery MRI sequence, this does not 
necessarily alter the BOLD response (Gollub et al, 1998).  
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Measures to Control for Confounding in Clinical and Pharmacological fMRI 
As we have reviewed, in the handful of studies that jointly measure BOLD and another 
dependent physiological parameter – such as neural firing, evoked electrophysiological 
responses, or metabolic consumption – there are both examples and counterexamples of 
drugs and clinical states causing interference of the fundamental neural – BOLD 
relationship. However, in the absence of any such studies for the particular drug regime, 
patient population, and regions of interest relevant to the current experiments, we remain 
uncertain whether the disease or drug of interest affect the measured BOLD signal 
separately from any effect these factors have on underlying neural activations. 
Nevertheless, certain measures exist that enable us to control for potential confounds, and 
to verify whether the BOLD effects observed are likely to have been primarily neural, 
rather than vascular, in origin (Iannetti & Wise, 2007). A subset of these were employed 
in this thesis.  
 
1. Systemic Physiological Parameters. In the current experiments, pulse, capillary 
oxygen and blood pressure were measured immediately before and after scanning. 
The first two parameters were also monitored throughout scanning by means of 
MRI-compatible telemetry. 
 
2. Subjective Indices. Psychologically-validated questionnaires (e.g. Bond & Lader, 
1974) can be provided to subjects to assess states such as awareness and mood, as 
well as side-effects. These can provide surrogate markers of the baseline state 
194 
Chapter 4 
(especially arousal) which as discussed can influence magnitude of BOLD signal 
change.  
 
3. Global Scaling. As described above, two types of data scaling were performed so 
as to eliminate any global (i.e. whole-brain) effects of drug or disease. These 
operations served to correct both for the session and individual scan global means. 
It should be noted that the mean corrections are multiplicative, meaning that it 
corrects for main effects or interactions that are driven by a simple gain factor 
applying between sessions. Furthermore, the mean values are calculated 
independently of whether a particular scan samples a baseline period or an 
‘event’. However, as discussed, we cannot assume that the baseline and evoked 
responses scale equivalently; in fact, experiments suggest the opposite: viz. that as 
baseline decreases, the size of the evoked response increases (Hyder et al, 2002). 
Therefore in order to test for the possibility that changes in global mean may 
confound changes in event-related signal, including via a relationship other than 
simple scaling, we can derive the global mean for each session and subject and 
perform statistical tests on these. For example, we can test for absolute differences 
in mean BOLD between two pharmacological states with a t-test, or we can 
correct for a particular comparison in evoked responses between two states by 
including the global mean as a covariate of no interest in an ANCOVA.   
 
4. Voxel Session Effects. The arguments in favour of performing scaling also apply 
to region-specific effects. In other words, a disease or drug may enhance or 
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depress the overall level of BOLD signal, independent of event-related 
activations, in a particular region rather than over the whole brain. Such an effect 
can be corrected for over a session by the constant term that is included in every 
design matrix. Note that this serves to subtract the mean, rather than scale by the 
mean as performed on the global mean value. Furthermore, the possibility that the 
mean session activity, specific for each voxel, may influence the size of the 
evoked response in that particular voxel, and hence confound an apparent effect, 
can be tested for with either t-tests or ANCOVA, as described above.  
 
5. Task Dissociations. If a systemic drug or a diffuse brain disease, such as 
Alzheimer’s disease, affects the neurovascular coupling relationship, we would 
expect consistent alterations in BOLD signal intensity for a given level of neural 
activation, regardless of task. Conversely, if we were to find that a drug, or 
disease, results in a modulation of BOLD response for one behavioral condition 
but not another, where both conditions otherwise result in equivalent BOLD 
responses, this would be strong evidence for an interaction of the drug, or disease, 
with neural activity.  
 
Figure 4.14.  Hypothetical effects of drug on BOLD response between three 
different behavioral conditions A, B and C (control). Both drug effects result in a 
task-by-drug interaction, but only the first type suggests a neural effect 
specifically. Task C can also be replaced by the baseline providing this has been 
shown to be unaffected by drug.  
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Figure 4.14.   
                  
 
 
 
                       A         B       C                    A        B       C                   A        B       C              
                            Placebo                                   Drug                                 Drug 
             - Dissociation                  - General Effect 
                                                                    (neural effect)                       (neural or  
                     hemodynamic effect 
 
Ideally, the two behavioral conditions for which there is a BOLD dissociation 
should activate the same, or similar anatomical regions because of the possibility 
of region-specific neurovascular BOLD relationships (e.g. Schacter et al, 1997).   
 
6. Cross-Over Interactions. A further reason why the presence of a task-by-drug 
(or disease) interaction on BOLD response does not assure us of a neural 
interpretation is that the interaction may arise from a difference in the level of 
BOLD response between tasks in the normal state. For example, if the drug (or 
disease) in question acted to decrease blood flow changes, and hence BOLD 
excursions, it would limit any apparent effect of the drug to tasks that already 
generate large changes in BOLD. However, if the drug was found to decrease 
BOLD responses during certain tasks, but to increase it during others – i.e. show a 
cross-over interaction – then it is difficult to explain this without resource to the 
differential neural effects of these tasks.  
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Figure 4.15.  Hypothetical effects of drug on BOLD response between two 
different behavioral conditions A, B. Both drug effects result in a drug-by-task 
interaction, but only the latter is immune from haemodynamic confound. 
 
 
 
 
                   A        B                             A        B                            A       B 
                   Placebo                                 Drug                                 Drug 
                                                            ‘Flattening’                    ‘Cross-Over’ 
                                                           (ambiguous)                     (neural effect) 
 
7. HRF Variation. Differences in the shape of the hemodynamic response function 
– in addition to its magnitude, may alter the apparent effect size for a condition 
modelled with an inflexible HRF. Since evidence exists for age, and disease-
related differences in HRF profile (D’Esposito et al, 1999), these may result in 
spurious interpretations regarding effects of such clinical states on neural 
activations. Hence inspection of the raw signal, and comparison of this between 
physiological states of interest is required. One formal method by which this can 
be done is to decompose different aspects of the HRF into different regressors all 
of which are included in modeling the data, and orthogonalised hierarchically. In 
this thesis, the first differential of the HRF was added to the design matrix for 
every modeled condition, which effectively accounts for HRF delay. A more 
comprehensive HRF shape characterization can be achieved by inclusion of more 
regressors. For example, differences in HRF between mild cognitive impairment 
patients and healthy controls have been observed specifically for fast-BOLD 
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responses in a model that included seven HRF modeling regressors of different 
delay (Rombouts et al, 2005).  
 
Finally, methods exist that do not require explicit modeling of the HRF, but rather 
measure timing properties of the evoked BOLD response. For example, BOLD 
responses to alternating blocks of photic stimulation / rest in individual visual 
cortex voxels were classified according to one of two possible phase relationships 
(positive / negative) relative to a sinusoid fitted to the stimulus. The effects of 
donepezil on visual cortex activity were then calculated as changes in the 
proportions of positive versus negative-responding voxels (Silver et al, 2008). 
 
8. Behavioral Correlations and Confounds. In some settings, behavioral effects of 
a  drug or disease provide circumstantial support for a neural-based interpretation 
of imaging data. For example, if an interaction of a drug is observed with a 
behavioral contrast of BOLD activations, then a correlation of the same 
interaction with a relevant behavioral effect across subjects would be supportive 
of the claim that the drug interacted with neural, rather than vascular, processes. 
Furthermore, group effects at combined BOLD - behavioral levels are mutually 
supportive if there are prior reasons to expect parallel changes, e.g. sensory cortex 
activation and detectability, or hippocampal activation and memory performance.     
 
Saying this, behavioral differences between treatments or clinical groups act as 
double-edged swords in neurophysiological studies. This is because although such 
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differences suggest that the pharmacological, or pathological, factor of interest 
interacts with the neurophysiological process being investigated, there is a danger 
that performance differences can confound the results. As applied to functional 
imaging this implies that where we observe changes in brain activation due to a 
drug or disease, we would like to know whether this neuromodulation is the cause 
of a behavioral difference, or whether it is merely the effect of a behavioral 
difference - itself caused by some other process. Trying to disentangle the two 
cannot always be done, but some of the strategies that can be used are: using low 
drug doses or mild disease cases to minimize performance effects (while still 
observing neural effects); including performance effects (e.g. RT differences 
secondary to drug) as a covariate of no interest into the imaging ANCOVA; 
identifying neural – performance dissociations (e.g. under some circumstances a 
drug causes both neural and performance effects, but under other circumstances, 
the same neural effects but not performance effects are seen); choosing regions of 
interest, e.g. visual cortices, that are unlikely to be influenced by limb movements 
e.g. due to button presses; and separating scanning from sessions measuring 
performance effects, e.g. on subsequent memory (see Experiment 5). 
 
9. Multi-modal Imaging. Interpretation of BOLD effects can be enhanced by 
simultaneously employing methods that assess cerebral blood flow (e.g. arterial-
spin labeling MRI or contrast-based perfusion MRI); cerebral oxygen metabolism 
(e.g. PET); or vascular reactivity and cerebral blood volume (BOLD-MRI in 
combination with CO2 or acetazolamide challenge). Additionally, techniques e.g. 
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EEG or MEG that measure neural activity directly, without any metabolic or 
vascular confounds, can check for consistencies with BOLD effects, or 
alternatively flag up dissociations (Fig. 4.14). 
   
Evidence for Cholinergic Modulation of the Neural - BOLD Relationship 
  
No studies to date have directly measured cholinergic effects on neural and BOLD 
parameters within the same experiment. However, several lines of evidence exist to 
suggest that fMRI is vulnerable to confounding by cholinergic drugs.  
 
Endogenous control mechanisms underlying changes in regional cerebral blood flow 
(rCBF) following neural activity are complex (Drake & Iadecola, 2007), and involve 
multiple neurotransmitter systems including acetylcholine (Edvinsson et al, 1987). This is 
suggested by studies showing that cholinergic fibres interact with cortical capillaries and 
small arterioles (Arneric et al, 1989a), as well as perivascular astroglia or pericytes 
(Chedotal et al, 1994; Wu et al., 2003). In general, ACh dilates cerebral arterioles, via 
activation of nitric oxide (NO)-containing endothelial cells, neurons or glia (Parnavelas et 
al, 1985; Uchida & Hotta, 2009). Thus stimulation of basal forebrain neurons produces 
vasodilatation, and increases rCBF, without changes in systemic blood pressure (e.g. Sato 
et al, 2002). Cholinergic-dependent increases in rCBF are predominantly mediated by 
nicotinic receptors within both cerebral cortex and nucleus basalis (Uchida & Hotta, 
2009), although this response decreases with age (Uchida & Hotta, 2009).  
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Critically, abolition of cortical cholinergic neurotransmission impairs the normal pattern 
of functional hyperaemia without impairing cerebral glucose metabolism (Kimura et al, 
1990; Ogawa et al, 1994), suggesting that this is a vascular, not a neural mechanism. In 
support of this, nucleus basalis stimulation increases both cortical extracellular ACh 
release and rCBF, without increasing local lactate concentration (Hallstrom et al, 1990), 
or changes in electrocorticogram responses (Lacombe et al, 1989). Similarly, cholinergic 
enhancement with physostigmine increases rCBF without altering cerebral oxygen 
consumption (Scremin et al, 1982). However, in other circumstances, cholinergic lesions 
of the basal forebrain impair cortical cerebral glucose metabolism without affecting 
rCBF, suggesting a specific neural effect (Ouchi et al, 1996; Ogawa et al, 1996). Direct 
influences of ACh on rCBF occur either through cholinergic cortical interneurons 
(Fukuyama et al, 1996), or via stimulation of the nucleus basalis (Uchida et al, 1997).  
 
Increases in brain blood flow following nucleus basalis stimulation show regional 
specificity (Adachi et al, 1990), with neocortical targets showing most response, 
hippocampus less response (Sato et al, 2004), and subcortical nuclei showing virtually no 
response. Within neocortices, cholinergic stimulation increases rCBF and oxygen 
concentration more in prefrontal than parietal regions (Lacombe et al, 1989).  
 
The significance of these findings to the present thesis is that drugs acting on cholinergic 
neurotransmission may alter the size of rCBF change for a given level of neural 
activation. Given that ACh increases rCBF (Sato et al, 2004), which itself increases 
oxyHb:deoxyHb ratio (Davis et al, 1998), we might physostigmine to result in a greater 
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BOLD response for a fixed level of neural activation. Supporting this assertion, it has 
been found that cholinesterase inhibitors can reverse scopolamine-induced or age-
associated impairments in rCBF response to vibrotactile stimulation in monkey 
somatosensory cortex (Tsukada et al, 1997; Tsukada et al, 2000). Because these drug 
effects occurred in the absence of changes in cerebral glucose metabolism, the rCBF 
modulation appears to be directly due to vascular actions of the drug, rather than 
indirectly due to neural modulation. Furthermore, physostigmine uncouples the normal 
relationship between cerebral blood flow and glucose consumption, by increasing global 
cerebral flow, while decreasing regional glucose metabolism (Blin et al, 1997), or failing 
to alter oxygen consumption (Scremin et al, 1982). These effects are greater in 
Alzheimer’s disease patients than aged controls (Blin et al, 1997).  
 
The relevance of direct cholinergic influences on rCBF as regards its impact on BOLD is 
unclear. Although nicotine has been found not to alter the normal photic-driven BOLD 
response in visual cortex, suggesting relative immunity of BOLD recordings from 
cholinergic vascular effects (Jacobsen et al, 2002), it cannot be assumed that this holds 
for other cholinergic drugs such as physostigmine, or in other brain regions. For all of 
these reasons, wherever significant effects of physostigmine on BOLD responses are 
observed it is necessary to consider whether these may be because of direct 
pharmacological influences on vascular properties, rather than because of neural 
modulation as is intended.   
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5. EXPERIMENT 1:  
Effects of ChEI on Attention and Emotion
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Introduction 
Numerous lines of evidence indicate that corticopetal cholinergic projections originating 
in nucleus basalis may modulate attention, through influences both on a frontoparietal 
network thought to mediate “top-down” control and on sensory cortices subserving 
“bottom-up” stimulus processing (Sarter et al, 2001; Muir et al, 1996; Robbins, 1998). 
Cholinergic inputs to frontoparietal cortex have been associated with performance on 
sustained and selective attention tasks (McGaughy et al, 1996; Himmelheber et al, 2001), 
with attention-correlated-neural activity (Gill et al, 2000), and covert attentional shifts 
(Davidson & Marrocco, 2000). On the other hand, cholinergic neurotransmission within 
primary and secondary sensory cortices can facilitate stimulus processing via positive 
effects on signal-to-noise ratio (Sato et al, 1987), information flow (Hasselmo, 1995; 
Xiang et al, 1998), and response selectivity (Murphy & Sillito, 1991). Cholinergic 
influences on attention are also suggested by the fact that attentional deficits found in 
dementias associated with cholinergic degeneration (Perry & Hodges, 1999; Ballard et al, 
2001) are more amenable to correction with anticholinesterases than other cognitive 
deficits (Lawrence & Sahakian, 1995; McKeith et al, 2000). A recent fMRI study (Furey 
et al, 2000a) suggested that effects of acetylcholine on stimulus-processing regions might 
occur selectively during particular stages of a task e.g., encoding into working memory. It 
has not yet been shown, however, that cholinergic manipulation can modify activity in 
sensory cortices specifically attributable to attention, rather than to concomitant changes 
in stimulus or task (Lawrence et al, 2002). 
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Other research suggests a role for neocortical cholinergic modulation in emotional 
processing (e.g., conditioning, fear responses, anxiety). Cholinergic inputs have been 
shown in rodents to facilitate conditioning via effects on sensory cortices (Weinberger, 
1998; Delacour et al, 1990), while cholinergic blockade has recently been shown with a 
human fMRI study to inhibit conditioning-related responses in auditory cortex (Thiel et 
al, 2002a). Such data complement anatomical (Kapp et al, 1990; Amaral et al, 1992), 
neurophysiological (Weinberger et al, 1990; Wilson and Rolls, 1990), and computational 
(Friston et al, 1994) studies suggesting a role for nucleus basalis cholinergic fibres in 
relaying evaluative processing within regions such as the amygdala to selection and 
learning mechanisms in the thalamus and cortex. Increased cholinergic tone in the 
prefrontal cortex may also be expressed for behaviorally, significant or novel stimuli 
(Acquas et al, 1996; Pirch et al, 1992; Wilson and Rolls, 1990), which when continually 
hyperactive may engender clinical anxiety (Berntson et al, 1998; Hart et al, 1999). These 
findings suggest that cholinergic afferents to specific sensory and prefrontal regions may 
contribute to “automatic” enhancement of emotional stimulus processing, independently 
of whether such stimuli are attended. 
 
The present study crossed factors of selective attention and emotion within a fully 
orthogonal design to examine modulation of condition-specific fMRI responses by 
cholinergic enhancement with the centrally acting anticholinesterase physostigmine. The 
paradigm was similar to that of recent functional MRI studies with untreated human 
subjects, in which the response of the fusiform gyrus to faces was found to be increased 
by both selective spatial attention and emotional expression (Wojciulik et al, 1998; 
 206
Chapter 5 
Vuilleumier et al, 2001). Since acetylcholine has been found in animals to benefit 
selective attention and emotional processing, we predicted that the differential response 
of the fusiform cortex to both factors would be independently enhanced with 
physostigmine. We also assessed whether regions of the extrastriate cortex preferentially 
activated for attending houses versus faces—parahippocampal and posterolateral 
occipital cortices (Vuilleumier et al, 2001)—might also show a greater differential effect 
under physostigmine. Finally, as cholinergic afferents to parietal (Holland & Gallagher, 
1999) and orbitofrontal (Cavada et al, 2000; Aou et al, 1983) cortices have been proposed 
to mediate attentional recruitment by emotional stimuli, we predicted that these regions 
would show modulation by physostigmine specifically when emotional faces were task-
irrelevant. On the other hand, task-relevant emotional stimuli, being already attended, 
would not be expected to engage this cholinergic facilitated circuit. 
 
Methods 
Subjects 
Thirty healthy right-handed volunteers with no history of medical or psychiatric disease 
gave written informed consent. They were divided into two groups of 15 (placebo, 7 
female, 8 male; mean age, 26.8 ± 2.3; physostigmine, 8 female, 7 male; mean age, 23.5 ± 
2.0). No subject was taking active medication. While 2 subjects were mild smokers, they 
were in different groups and refrained from smoking on the test day. A between-subjects 
design was chosen for the pharmacological manipulation, to avoid habituation effects that 
may occur in within-subjects designs following repeated exposure to emotional stimuli 
(Breiter et al, 1996; van Turrennout et al, 2000). 
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Drug treatment 
A double-blind placebo-controlled drug administration technique was used. Each subject 
received an intravenous cannula into the left cubital fossa and an infusion of either 
physostigmine or saline. Dosage and rate of physostigmine infused were identical to 
those used in a recent study (Furey et al, 2000b), which demonstrated significant and 
stable levels of plasma drug concentration and butyrylcholinesterase inhibition, as well as 
a significant and stable effect on cognitive performance for 40 min, following a 40-min 
loading period. The same protocol has also been found to result in changes in both 
regional cerebral blood flow (rCBF) and blood oxygenation level-dependent (BOLD) 
activity, during visual working memory tasks (Furey et al, 1997; Furey et al, 2000a). 
 
Subjects in the drug group first received 0.2 mg of intravenous glycopyrrolate—a 
peripheral muscarinic receptor antagonist—to reduce peripheral side effects. The placebo 
group were injected with an equivalent volume of saline. Both groups then received an 
intravenous infusion. For the drug group this consisted of physostigmine at a rate of 1.93 
mg/hour for 10 min, followed by a constant rate of 0.816 mg/hour for 40 min, before 
scanning. The same rate was then continued until the end of study so that each subject 
received no more than 1.3 mg of physostigmine in total. The placebo group received an 
equivalent volume of saline over the same time course. Both groups of subjects had their 
blood pressure checked before and at 40 min into infusion; pulse oximetry was performed 
continuously throughout the experiment. Subjects were also given questionnaires at these 
two time points to document side effects and subjective ratings (Bond & Lader, 1974). 
 208
Chapter 5 
 
Cognitive task 
Subjects performed a matching task (Vuilleumier et al, 2001) for two black and white 
photographs situated in either the north–south or east–west positions of a cross-format 
display that comprised four concurrent photographs (3° × 5° visual angle each), arranged 
into a cross around a central fixation point (Fig. 5.1). At the start of each block, subjects 
were cued (for 2 s) to attend selectively to either the two vertically arranged or two 
horizontally arranged positions, while the alternative two locations were to be ignored 
throughout the block. In total, there were four blocks of 40 trials each. Each trial 
consisted of a central fixation cross (1 s) followed by the four-picture display for 250 ms. 
Subjects were required to indicate, as accurately and rapidly as possible, whether the two 
stimuli at task-relevant locations were the same or different, by either of two possible key 
presses with the right hand. Reaction time (RT) and accuracy were recorded. 
 
Figure 5.1: A stimulus example is shown. Before each block the subject was cued to 
attend either the two horizontal or the two vertical locations via a pair of highlighted 
frames. During the block subjects were required to perform a same/different judgment for 
the pair of stimuli at just the task-relevant locations; the other pair of stimuli were task-
irrelevant. Each display contained one pair of faces and one pair of houses, with either 
type equally likely to be at the relevant or irrelevant locations, in an unpredictable 
sequence. The pair of faces could both be fearful (emotional trial) or both neutral.  
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Figure 5.1 For legend see above. 
 
 
Within each trial, either the two attended or the two unattended locations were occupied 
by two faces, in an intermingled and unpredictable sequence. The remaining two 
locations were occupied by two houses. Hence each trial could be classified as faces-
attended (A) or faces-unattended (U) in this sense (with the type of attended stimulus thus 
being determined by spatial location). Furthermore, faces could have either a fearful 
emotion (E) or a neutral (N) expression, independently of whether they were at task-
relevant locations. Thus four conditions existed. AE, AN, UE, and UN (where AE, for 
example, would represent trials where fearful faces appeared at attended task-relevant 
locations). The four trial types, and pair identities (i.e., same/different, which was 
independent between the attended and unattended pair in each trial), were randomly 
counterbalanced throughout each block. The order of task-relevant locations (i.e., either 
vertical or horizontal) between blocks was randomly selected from one of four 
alternatives (HVHV, VHVH, HVVH, VHHV) and counterbalanced across subjects 
within each group. 
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Although the task design was identical to that used in our recent study of untreated 
subjects (Vuilleumier et al, 2001), there were four differences in details: (1) the median 
intertrial interval (2.5 s; range, 1.5–14.4 s) was half that used previously; (2) the number 
of trials of each type was reduced from 52 to 40; (3) an alternative set of pictoral stimuli 
were used (faces taken from The Karolinska Directed Emotional Faces set; (Lundqvist, et 
al, 1998), with each being repeated only once; (4) 40 “null” trials were included in which 
a blank screen occurred, following a 1-s central fixation cross (thus enabling 
measurement of any attentional activity in the absence of stimulation: see (Chawla et al, 
1999). The first two changes were implemented because of time constraints imposed by 
drug administration. 
 
The cross-format spatial array and brief exposure time have previously been shown to be 
effective at engaging covert attention to the relevant pair of locations without saccades 
(Vuilleumier et al, 2001; Wojciulik et al, 1998), as well as enabling emotional processing 
without awareness of unattended fearful faces (Vuilleumier et al, 2001). We nevertheless 
monitored eye movements throughout the task with an infrared eye tracker (ASL Model 
540, Applied Science Group Co., Bedford, MA; refresh rate, 60 Hz). For technical 
reasons, eye-position data were lost for six subjects (two placebo and four from drug 
group). 
 
Imaging and image processing 
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MRI data were acquired from a 2-T VISION system (Siemens, Erlangen, Germany) 
equipped with a head coil. Functional images were acquired with a gradient echo–planar 
T2* sequence using BOLD contrast. The acquired image consisted of 32 × 3 mm 
thickness axial slices that covered the entire brain. Volumes were acquired in a single 
continuous session with an effective repetition time of 3.26. The first eight volumes were 
discarded, to allow for T1 equilibration effects. Images were realigned, time corrected, 
normalized to a standard echo–planar image template, and smoothed with a Gaussian 
kernel of 8 mm full-width half-maximum. 
 
Statistical analysis of images 
Data were analyzed with a general linear model for event-related designs (SPM99; 
Wellcome Dept. of Cognitive Neurology, London, UK; (Friston et al, 1995) using a 
random effects analysis. Data were globally scaled and high-pass filtered at 1/120 Hz. 
Individual events were modeled by a canonical synthetic hemodynamic response function 
and its temporal derivative, aligned with the onset of the picture array. Time-related 
changes specific to each event type were included using a linear trend model, after being 
orthogonalized with respect to time-constant effects (Buchel et al, 1999). The six head 
movement parameters were included as confounds, and incorrect responses were modeled 
separately. Since face stimuli were presented twice, and repetition effects may themselves 
be cholinergically modulated (Thiel et al, 2002b), a second model was generated in which 
repetition effects were included as a separate factor. None of the drug-by-condition 
interactions presented here could be accounted for by repetition effects (see Experiment 
2). 
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Linear contrasts of parameter estimates for each subject were used to generate statistical 
parametric maps (SPMs) of the t statistic. We first examined regions specific to attended 
stimulus type (i.e., attending faces minus attending houses or vice- versa) in the placebo 
and physostigmine groups separately. We next performed t-tests that directly compared 
drug and placebo groups for the same contrasts across the whole brain. Similarly, we 
identified regions activated by emotional versus neutral faces (independent of attention) 
in each group separately, before comparing drug and placebo groups for this. For all drug 
× condition interactions, only regions showing a significant effect of face or house 
attention, or of emotion (P < 0.001, uncorrected), in either group are noted. Finally, to 
characterize the nature of any three-way interactions of attention, emotion, and drug, we 
performed post hoc ANOVAs on signal estimates of drug x emotion interactions, 
separately for trials with faces relevant versus irrelevant. Results are listed according to 
which of the two levels of attention showed a significant drug × emotion interaction (P < 
0.05); regions in which a significant interaction occurred under both levels of face 
attention are noted separately. 
 
Since one major issue concerned any cholinergic modulation of fusiform face-responsive 
areas in the present paradigm, we derived two regions of interest (ROI) from the bilateral 
fusiform areas identified from our previous study, which had demonstrated attentional 
modulation to faces in untreated subjects using a similar paradigm (thresholded at P < 
0.05, uncorrected; (Vuilleumier et al, 2001). We report areas that achieved significance 
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after correction either within these prespecified ROIs (Worsley et al, 1996) or for the 
entire brain volume, plus activations that reached P < 0.001, uncorrected. 
 
Results 
 
Physiological data, subjective reports, and eye tracking 
Questionnaires detailing possible side effects and subjective feelings as well as measures 
of blood pressure and pulse were recorded before infusion and just prior to scanner 
entrance, when a steady state of physostigmine would be expected (Furey et al, 2000b). 
Although subjects given physostigmine with glycopyrrolate were more likely to 
experience a dry mouth (U = 62, P < 0.05) and dizziness (U = 68, P < 0.01), the mean 
intensity of these symptoms was small (1.3 ± 0.95 and 0.5 ± 0.40, respectively, on a scale 
of 0 to 6). Two subjects given physostigmine who vomited were excluded and replaced 
with alternative subjects. A pooled measure of subjective alertness (Bond & Lader, 1974) 
suggested that the physostigmine group felt more drowsy at test relative to preinfusion 
(mean percentages of difference between preinfusion and prescan, −1.3 ± 2.2% for 
placebo and +8.8 ± 3.7% for physostigmine; F(1,28) = 6.4; P < 0.05), although the simple 
effects of group for absolute subjective alertness at each time point were insignificant. 
There were no significant cardiovascular main effects or interactions. 
 
The frequency of saccades and median angular deviation of the eye were measured 
during 250-ms epochs before and after the onset of each stimulus. These measurements 
were entered into a three-way ANOVA with factors of group, attention, and emotion. The 
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mean percentages of trials with saccades over both epochs were 3.2 and 3.0 under 
placebo and physostigmine, respectively. There were no reliable group differences during 
either of the two peristimulus epochs, either as a main effect or as an interaction with 
condition, for either saccade number or median ocular position. Finally, the same two 
measurements were compared within the first block only, given some group differences 
found in task performance for this block (see below). Once again, no significant main 
effects or interactions with condition were found. 
 
Behavioural 
A nonsignificant trend for faster responses was evident with physostigmine (mean RTs, 
844 ± 62 ms, 915 ± 62 ms, under drug and placebo, respectively; t(28) = 1.4; P < 0.1, 
one-tailed based on (Furey et al, 1997), but there was no difference in accuracy between 
groups (mean scores, 85 ± 3.2 % and 83 ± 3.2 %, under drug and placebo, respectively; 
t(28) = −0.7; ns; two-tailed hereon). There were no significant effects of group as a 
function of condition (attention, emotion, or their interaction) for either measure. 
 
It has previously been shown that the effect of emotional and distracting stimuli can 
habituate with time (Breiter et al, 1996 and Lorch et al, 1984). Consequently, the RT 
difference between emotional and neutral trials was calculated separately for each of the 
four successive blocks, with planned group comparisons made in the first block. During 
face-attended trials, both groups showed a trend to a time-dependent effect of emotion 
(F(3,27) = 2.7; P < 0.1), with a significant slowing of RTs to emotional stimuli within the 
first block only (t(28) = 2.6; P < 0.05; Fig. 5.2). There were no between-group RT 
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differences for these face-attended trials. However, during face- unattended trials, the 
physostigmine group showed significant slowing relative to the placebo group by the 
presence of an emotional expression in the first block (t(28) = 2.1; P < 0.05; Fig. 5.2). 
Because of these behavioral patterns, block sequence was also considered in time-related 
fMRI analyses. 
 
Figure 5.2: Plots show differences in RT (in milliseconds) between emotional minus 
neutral trials over block number for placebo and physostigmine groups separately for 
attended (A) and unattended (B) faces. An asterisk denotes significant between-group 
difference (P < 0.05) for the planned comparison in the first block when emotional effects 
would be expected to be greatest. Bars denote standard errors.  
 
 
 * 
 216
Chapter 5 
fMRI data: effects of physostigmine on attentional modulation 
We first aimed to replicate the findings from two previous studies using a similar 
paradigm but with untreated subjects (Wojciulik et al, 1998; Vuilleumier et al, 2001) by 
examining the placebo group for responses dependent on whether faces or houses fell in 
the task-relevant locations (i.e., attending faces minus attending houses and vice versa). 
As in those previous studies, we found bilateral mid-fusiform gyrus activation when faces 
appeared at task-relevant locations, while bilateral parahippocampal and posterolateral 
occipital cortices were activated when houses appeared at task-relevant locations (Figs. 
5.3A and 5.3B, respectively; all Z ≥ 4.29; P < 0.05, corrected for fusiform ROIs or whole 
brain). These regions were also all found to be activated by the same contrasts in the 
physostigmine group (all Z ≥ 3.30; P < 0.001, uncorrected). 
 
We next identified regions whose differential activity for faces relative to houses (or vice 
versa) was greater under physostigmine relative to placebo (or vice versa; Table 5.1). 
With faces versus houses in attended locations, physostigmine enhanced differential 
activation in left anterior fusiform gyrus (Fig. 4.3C) relative to placebo. This region failed 
to show a significant effect of face attention under placebo. The only regions showing 
less differential activity under drug, relative to placebo, for faces in attended versus 
unattended locations were bilateral insula. 
 
With houses versus faces in attended locations there were no enhancements of activity 
due to physostigmine. However, physostigmine reduced differential activity in the right 
posterolateral occipital cortex relative to placebo (Fig. 5.3D). Thus, physostigmine 
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engendered an opposite attentional effect depending on either the stimulus-processing 
region or the stimulus type falling within attended locations: fusiform gyrus showed 
increased attentional enhancement (for attending faces minus houses), while 
posterolateral occipital cortex showed reduced modulation by attention (for attending 
houses minus faces) under physostigmine relative to placebo. 
 
To unconfound the effect of drug on extrastriate region (fusiform and posterolateral 
occipital cortices) from stimulus type (faces and houses), we further tested whether the 
observed region-specific effects of physostigmine might correspond to a modulation of 
activity even in the absence of stimuli. We tested for this by comparing activations 
between groups in occipitotemporal regions on “null trials,” when subjects were cued but 
no stimulus appeared (Chawla et al, 1999). Note that these null events were modeled 
separately from, and hence are orthogonal to, session mean activity (thus any drug-
induced changes cannot reflect overall changes in mean activity throughout a session for 
particular brain areas). Comparing groups, this contrast (Table 5.2) showed that 
physostigmine, relative to placebo, resulted in greater null trial activity in anteroinferior 
temporal regions (Figure 4.3E), including left anterior fusiform, which showed the drug-
by-face attention interaction described above (t(28) = 2.3, P < 0.05; Fig. 5.3C). 
Conversely, physostigmine, relative to placebo, resulted in reduced activity in posterior 
occipital regions (Fig. 5.3F), although this failed to reach significance in that region 
showing less differential activity for house attention under physostigmine (Fig. 5.3D). 
These results indicate that the effects of physostigmine on selective attention may partly 
reflect region-specific changes in activity, independently of stimulus (but related to 
 218
Chapter 5 
 219
spatial cueing), which may then either increase or decrease the differential response to 
attended versus unattended stimuli that are selectively processed in these regions. 
Furthermore, these drug-induced changes occurred only when attention was spatially 
cued, as shown by the fact there were no between-group differences in session means for 
either the inferior temporal or posterior occipital regions identified by the group-by-
attention and group-by-null trial interactions. 
 
Figure 5.3. (See next page): Regions of inferotemporal cortex showing differing effects 
of physostigmine on attentional processing in face (A,C,E) and house-selective regions 
(B,D,F). Red represents regions that in the placebo group showed an increased response 
to faces (A) or to houses (B) in attended versus unattended locations; the physostigmine 
group displays similar effects in both fusiform and parahippocampal areas. Yellow 
represents regions in which physostigmine, relative to placebo, modulated the attentional 
effect by either increasing the differential response to faces in attended versus unattended 
locations (C) or decreasing the differential response to houses in attended versus 
unattended locations (D). Cyan represents regions in which physostigmine, relative to 
placebo, resulted in increased (E) or decreased (F) responses to null trials, i.e., when 
subjects were cued, but no stimulus appeared. Contrasts are thresholded at P < 0.001, 
uncorrected. Regions in E and F also showed selectivity for face and house attention, 
respectively, over both groups (P < 0.01, uncorrected). Activation maps are superimposed 
on a single-subject T1-weighted MRI brain. Graphs show percentages of signal change 
from baseline with faces in attended locations, houses in attended locations, and null 
trials for drug and placebo groups, mean-corrected between regions.  
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Figure 5.3: For legend see previous page.
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Table 5.1. Effects of drug on attentional modulation of face and house processing 
 
  
 
 
 
Table 5.2. Effect of drug on the occipitotemporal cortex during null trials 
 
 
 
 
 
 
 
fMRI data: effects of physostigmine on response to fearful expression 
The orthogonal contrast of fearful minus neutral faces was performed, independently of 
whether faces were attended or unattended, on each trial. Within extrastriate cortices, the 
placebo group demonstrated heightened activity to fearful relative to neutral faces in left 
mid-fusiform cortex (−40, −48, −24; Z = 3.27; P < 0.001, uncorrected). In addition, the 
same voxel in right mid-fusiform cortex (44, −52, −20) that showed emotion modulation 
in our previous study (Vuilleumier et al, 2001) demonstrated a similar effect in our data, 
but at a lower significance (Z = 2.64; P < 0.01, uncorrected; Fig. 5A). These areas were 
also activated by emotional stimuli under physostigmine (all Z > 3.09, P < 0.001, 
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uncorrected). The main effect of emotion over all subjects also identified a region 
extending between the hypothalamus and posterior medial amygdala (10, −8, −16; Z = 
3.49; P < 0.001, uncorrected; and 12, −10, −16; Z = 3.06; P < 0.05 corrected for right 
amygdala volume identified in (Vuilleumier et al, 2001), thresholded at P < 0.01, 
uncorrected). Furthermore, a more lateral amygdala-centred activation was activated just 
below threshold (30, −6, −18; Z = 2.45; P = 0.007, uncorrected). Activity in both of these 
areas was independent of attention (in keeping with Vuilleumier et al, 2001) and group. 
 
Comparing drug and placebo groups for the effect of emotion, we found regions in left 
middle fusiform (−48, −52, −22; Z = 2.85; P < 0.05, corrected for ROI; Figure 4.4B) and 
inferior occipital cortex (−24, −94, −8; Z = 3.37; P < 0.001, uncorrected) that showed a 
greater differential response to emotional versus neutral stimuli under physostigmine, 
relative to placebo. Furthermore, by examining emotional effects in the extrastriate cortex 
that habituated with time (Buchel et al, 1999, Morris et al, 2001; Rotshtein et al, 2001)—
in keeping with the time-dependent patterns observed behaviorally—we found that left 
mid-fusiform cortex also showed a stronger relative response to emotional stimuli with 
drug relative to placebo, as a function of time (−34, −52, −6; Z = 3.26; P < 0.001, 
uncorrected). There were no regions in which an emotional activation under placebo was 
significantly reduced by physostigmine. 
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Figure 5.4. (See next page): (A) Regions of the inferotemporal cortex showing the effect 
of physostigmine on emotional processing. Red represents regions in the placebo group 
that showed an increased response to emotional versus neutral faces, the physostigmine 
group can be seen to display similar effects here (A). Yellow represents regions in which 
physostigmine, relative to placebo, resulted in an enhanced differential response to 
emotional versus neutral faces (B). Both contrasts are thresholded at P < 0.01, 
uncorrected (so as to illustrate less significant activation of the right fusiform in the 
placebo group—in the same region previously showing emotional modulation in 
untreated subjects: (Vuilleumier et al, 2001). Activation maps are superimposed on a 
single-subject T1-weighted MRI brain, pitched to visualize both contrasts. Graphs 
represent percentages of signal change from baseline during emotional and neutral trials 
with faces in attended (AE and AN) or unattended (UE and UN) locations for drug and 
placebo groups, mean-corrected between regions. The voxels chosen are based upon the 
two voxels in our previous study (Vuilleumier et al, 2001) showing the most significant 
modulation of the fusiform cortex by attention. In the right fusiform (A), both groups 
show a positive main effect of emotion (P < 0.01); in the left fusiform, physostigmine 
shows a main effect of emotion (P < 0.005), but not placebo; a group by emotion 
interaction was also observed here (P < 0.005).  
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Figure 5.4.  For legend see previous page. 
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fMRI data: effects of physostigmine on the interaction of attention with emotion 
Finally, we examined physostigmine modulation of emotional responses as a function of 
whether emotional faces were task-relevant or task-irrelevant. The majority of effects 
were in regions previously found to exhibit an attention x emotion interaction 
(Vuilleumier et al, 2001, Armony and Dolan, 2002; Perlstein et al, 2002). Thus 
physostigmine versus placebo showed enhanced differential activity for emotional faces, 
specifically when task-irrelevant (i.e. (UE-UN)-(AE-AN)), in left lateral orbitofrontal 
cortex, temporal pole, and anterior cingulate, while decreasing activity in the right 
intraparietal sulcus for the equivalent contrast (Table 5.3; Fig. 5.5A). 
 
Areas where physostigmine, relative to placebo, showed enhanced differential activity for 
emotional faces when task-relevant (i.e. (AE-AN)-(UE-UN)), faces were seen in the left 
dorsolateral prefrontal and medial prefrontal cortex (Table 5.3). The only areas where 
physostigmine reduced activity related to the emotion of task relevant faces were in the 
ventral striatum and medial orbitofrontal cortex. 
 
To complement our RT findings of physostigmine-induced, time-dependent effects for 
fearful faces in task-irrelevant locations, we also examined fMRI data for an interaction 
of drug × task-irrelevant emotion that habituated over the course of the experiment (using 
a linearly decreasing time model (Buchel et al, 1999). Results of this analysis were 
broadly similar to those of the time-independent fMRI effects. Thus left lateral 
orbitofrontal cortex (−38, 32, −8), adjacent inferior frontal cortex (−44, 38, 6), right 
temporal pole (48, 8, −20), plus left intraparietal sulcus (−40, −58, 46; Z ≥ 3.85 for all 
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above; Fig. 5.5B) showed stronger time-dependent effects for task-irrelevant emotional 
versus neutral faces under physostigmine relative to placebo, while left superior parietal 
(−14, −56, 68) and right occipital cortices (32, −82, 36; Z ≥ 3.36; P < 0.001, uncorrected 
for all above) showed a reduced effect with physostigmine for the equivalent contrast. 
 
Figure 5.5. (See next page): Regions showing modulation of emotional responses by 
physostigmine selectively when faces were task-irrelevant on examination of both time-
independent (A) and time-dependent (B) effects. (A) The lateral orbitofrontal and right 
intraparietal regions showing a significant drug by emotion by attention interaction, due 
to a predominant effect within face-unattended trials. Statistical maps are overlaid on a 
single-subject T1-weighted MRI Graphs represent percentages of signal change from 
baseline during face-attended emotional and neutral trials (AE and AN) and face-
unattended emotional and neutral trials (UE and UN) for drug and placebo groups. The 
orbitofrontal cortex demonstrated a significant enhancement to task-irrelevant emotional 
stimuli under physostigmine only (*P < 0.005 for post hoc contrast of UE–UN), whereas 
the right intraparietal sulcus demonstrated reduced activity to task-irrelevant emotional 
stimuli under physostigmine only (**P < 0.001 for post hoc contrast of UN–UE). (B) A 
representative profile of activity in the lateral orbitofrontal and left intraparietal regions 
identified in the interaction of drug x emotion is shown examining condition-specific 
effects modeled with a linear time-dependent response function, specifically for trials 
when faces were task-irrelevant. Plots depict the best fitting peak canonical response over 
trial number of the subject from each of the placebo (dashed) and physostigmine (solid) 
groups showing the median effect size of task-irrelevant emotion for fearful (red) and 
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neutral (green) trials. There were no drug by emotion interactions in these two regions for 
task-relevant faces.  
 
Figure 5.5: For legend see above.
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 Table 5.3: Areas showing effects of drug on interaction of attention with emotion 
 
 
 
 
 
 
 
 
 
Discussion 
Cholinergic modulation of attentional effects within visual cortex 
The task employed here has previously been shown in untreated subjects to activate face-
related and house-related regions of extrastriate cortex differentially, depending solely on 
endogenous spatial attention (i.e., when both types of stimuli are presented on every trial, 
but with only one type falling at the currently attended locations; (Vuilleumier et al, 
2001; Wojciulik et al, 1998). We now show that physostigmine enhanced the anterior 
fusiform gyrus (a region linked to higher level processing of faces: George et al, 1999) 
for attended versus unattended faces, but suppressed differential responses in 
posterolateral occipital cortex for attended versus unattended houses. These results 
suggest that while physostigmine enhances the effect of selective attention within the 
extrastriate visual cortex, not all stimulus processing regions, or stimulus types, are 
affected in a similar fashion. The cortical cholinergic system may thus facilitate selective 
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attention not only via general influences on “top-down” processes within frontoparietal 
cortices (Sarter et al, 2001; Himmelheber et al, 2001)—which would predict parallel 
effects for face and house-selective regions—but also through region-specific effects in 
sensory perceptual areas. The fact that anterior fusiform cortex showed this drug 
interaction rather than mid-fusiform is possibly because mid-fusiform was already 
maximally modulated by selective attention.  
 
To distinguish whether these distinct effects of physostigmine on attentional processing 
were a function of extrastriate cortical region (fusiform or posterolateral occipital cortex) 
or stimulus type attended (faces or houses), we examined activity in these same regions 
on null trials, when subjects were cued but no stimulus appeared. This showed that event-
related activity in anterior fusiform cortex was enhanced, while that in occipital cortex 
was decreased by physostigmine, even in stimulus absence. Thus, drug-induced changes 
on null trials occurred in the same direction as when a stimulus was present and were 
associated with similar changes in the differential responses caused by attention. This 
may suggest that physostigmine modified the general responsiveness of extrastriate 
cortex according to region, rather than stimulus type. Importantly, these drug-induced 
regional modulations were observed only to the event related responses to cued trials and 
were not seen as group differences in baseline (mean session) activity. Furthermore, the 
profile of response in many regions e.g. left anterior fusiform cortex, cannot be modelled 
by a simple scaling factor in the presence of drug.  
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It is noteworthy that similar regional effects of cholinergic modulation have been found 
in previous functional imaging studies, across a wide variety of tasks. Thus while 
posterolateral occipital areas have been associated with cholinergic-induced activity 
decreases (Mentis et al, 2001; Grasby et al, 1995; Thiel et al, 2001), fusiform cortex has 
been associated with cholinergic-induced increases (Furey et al, 1997; Furey et al, 2000a, 
Rosier et al, 1999; Thiel et al, 2002b); some of these studies employed cholinergic 
antagonists to demonstrate the converse effects). Our data extend these findings by 
showing regional differences in cholinergic modulation for effects of selective attention, 
when stimuli and task are kept constant. 
 
A further interpretation of the extrastriate region-specific effects of physostigmine 
observed here was that they were dependent on the stimuli expected. Hence cholinergic 
enhancement may have biased activations in advance of any stimulation (Chawla et al, 
1999) to favor enhancements of face attention (in fusiform) and reductions of house 
attention effects (in posterolateral occipital cortex). However, any biasing cannot have 
taken the extreme form of the physostigmine group always attending to the faces, 
regardless of whether these were task-relevant. This could only have reduced differential 
activation for task-relevant versus irrelevant faces in the fusiform cortex, whereas in fact 
physostigmine either enhanced this effect (left anterior fusiform) or did not diminish it 
(bilateral mid-fusiform). Thus, in terms of brain responses, top-down selection continued 
to operate under physostigmine, but with task-relevant faces becoming particularly 
dominant, in keeping with the anteroinferior temporal activations. 
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Neuropharmacological studies have found that acetylcholine can result in differing 
relative levels of activation versus inhibition in the visual cortex depending on local 
factors (Xiang et al, 1998; Muller & Singer, 1989; Sillito & Kemp, 1983). Within the 
inferior temporal cortex, cholinergic stimulation has been proposed to underlie the diffuse 
activation seen at the start of new delayed-match-to-sample trials when attention is 
heightened (Sohal & Hasselmo, 2000; Furey et al, 2000a). Furthermore, the anteroinferior 
temporal cortex represents a unique sensory region in having projections both to and from 
the nucleus basalis (Mesulam & Mufson, 1984) and so may influence its own activation 
through a cholinergic-dependent feedback loop (Sohal & Hasselmo, 2000). Conversely, 
early visual cortical areas have been found to be inhibited by acetylcholine in all layers 
except layer IV (Kimura et al, 1999), which may favor feedforward over feedback 
activity (Hasselmo, 1995) and enhance direction and orientation specificities (Murphy & 
Sillito, 1991). Consequently, the contrasting activity profile between inferior temporal 
and occipital cortices observed here in response to systemically administered 
anticholinesterase may reflect such regional differences of net neural activation versus 
inhibition. Moreover, our finding that such changes in activity were trial specific may 
relate to the fact that endogenous cholinergic release elevates with attentional demand 
(Gill et al, 2000). 
 
Cholinergic modulation of emotional effects within visual cortex 
Corticopetal cholinergic fibers appear to be involved in both filtering out distractors (Gill 
et al, 2000), consistent with the modulation of attentional effects reported here, and 
enhancing responses to stimuli of emotional significance (Acquas et al, 1996). One 
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mechanism for this may involve direct cholinergic modulation of the visual cortex, 
similar to that found in the auditory (Weinberger, 1998) and somatosensory cortices 
(Delacour et al, 1990) during conditioning in rodents. Moreover, connections between the 
amygdala, nucleus basalis, and sensory cortical regions may provide one pathway 
(Amaral et al, 1992) by which emotional discriminations within the amygdala can 
facilitate relevant stimulus processing (Wilson & Rolls, 1990, Kapp et al, 1990, 
Weinberger et al, 1990, Friston et al, 1994; Morris et al, 2001). 
 
The results of our placebo group, and those of a previous report employing the present 
study design (without drug: Vuilleumier et al, 2001) found that the right mid-fusiform 
gyrus was modulated by both attention and emotion separately (i.e., additively; Figure 
4.4A). We now demonstrate that cholinergic enhancement can increase the extent of 
emotional modulation within the left mid-fusiform gyrus (Figure 4.4B), as well as the 
posterior occipital cortex. As with the enhancement of face attention discussed earlier, the 
left laterality of this drug effect may arise because the right fusiform is already highly 
sensitive to faces and their emotion, while the left fusiform becomes more so with 
cholinergic enhancement. The fact that left fusiform cortex also showed enhanced 
responses to emotional stimuli when we modeled time habituating effects (akin to those 
seen in behavior; see also (Buchel et al, 1999, Breiter et al, 1996, Morris et al, 2001 and 
Rotshtein et al, 2001) is consistent with cell recordings in the substantia innominata 
suggesting that cortical cholinergic stimulation occurs selectively with novel, 
behaviorally relevant stimuli (Wilson & Rolls, 1990). 
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Finally, we note that in addition to enhancing fusiform gyrus activity, the main effect of 
fearful versus neutral faces activated a region around the right hypothalamus–
dorsomedial amygdala, with only a trend for activation centred on the right amygdala 
proper. In this respect, our findings in the placebo group did not entirely replicate those in 
our earlier study (Vuilleumier et al, 2001). However, this difference might be attributable 
to a change in several parameters, including stimulus set, number of events, interstimulus 
interval, statistical analysis (see Methods), as well as the stress of venipuncture and 
infusion. We note that the two amygdala-related regions showing fear-related activations 
were unaffected by either attention (as in Vuilleumier et al, 2001) or drug (consistent with 
the amygdala being upstream of nucleus basalis activation). 
 
Cholinergic modulation of attention–emotion interactions in frontoparietal cortex 
Cholinergic projections from the nucleus basalis to the frontoparietal cortex and thalamus 
may provide a means by which emotional processing engages attention (Holland & 
Gallagher, 1999; Friston et al, 1994); when overactive, this may contribute to clinical 
anxiety (Berntson et al, 1998; Hart et al, 1999). Previous functional imaging studies have 
identified distinct frontoparietal regions that respond to emotional stimuli in a manner 
that depends on the degree to which the stimuli are task-relevant (Vuilleumier et al, 2001, 
Armony & Dolan, 2002; Perlstein et al, 2002). By examining areas that showed an 
interaction of attention by emotion by drug, we found that many of these regions also 
displayed a cholinergic-induced modulation of responses to emotional faces that 
depended on whether the faces were task relevant. 
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Physostigmine, relative to placebo, resulted in an enhancement to task-irrelevant fearful 
faces in the lateral orbitofrontal cortex (OFC), anterior cingulate, and temporal pole, 
whereas the right intraparietal sulcus showed a decrement in response for the equivalent 
contrast (Fig. 5.5A). The lateral OFC and left intraparietal sulcus also showed 
physostigmine-specific enhancements to task-irrelevant fearful faces that decreased with 
time (Fig. 5.5B), in line with a parallel impairment in RTs under physostigmine that was 
similarly time-dependent (Fig. 5.2). These data support the view (Armony & Dolan, 
2002; Elliott et al, 2000) that this network of areas relays information about the affective 
value of background stimuli to attentional processes and, furthermore, they show an 
increase in this effect with cholinergic enhancement. Animal studies have previously 
shown that the OFC is intimately connected with cholinergic fibers of the nucleus basalis 
(Cavada et al, 2000) and is activated by acetylcholine during reinforcement (Aou et al, 
1983), while cholinergic modulation of the parietal cortex influences covert spatial 
attention (Davidson & Marrocco, 2000; Cavada et al, 2000), including that toward 
reward-associated stimuli (Chiba et al, 1995; Bucci et al, 1998). Here we have 
demonstrated that cholinergic enhancement both modulated activity in the OFC and 
parietal cortex, and resulted in impairment of performance, specifically under the 
condition of task-irrelevant fearful faces (in a time-dependent manner for both). 
 
By contrast, physostigmine increased responses to task-relevant fearful faces in 
dorsolateral and medial prefrontal cortices, which have previously shown emotion-
sensitive task-relevant activity (Simpson et al, 2000, Gray et al, 2002; Perlstein et al, 
2002). These regions have also been found to depend on cholinergic afferents for both 
 234
Chapter 5 
selective attention (Muir et al, 1996; Gill et al, 2000) and enhancement of cortical 
responses to emotional stimuli (Mark et al, 1996; Acquas et al, 1996; Thiel et al, 1998; 
Pirch et al, 1992). The pattern of activity in prefrontal areas under physostigmine seen 
here is particularly in keeping with a model of anxiety which proposes excessive 
cholinergic stimulation of the prefrontal cortex as a means by which fearful stimuli are 
processed excessively (Hart et al, 1999; Berntson et al, 1998). In contrast to the case with 
task-irrelevant emotional stimuli, RTs were impaired with task-relevant emotional stimuli 
to a similar extent under physostigmine and placebo, suggesting a ceiling effect in 
placebo. 
 
Conclusion 
Our study has shown that neural correlates of both selective attention and emotional 
processing can be independently enhanced by physostigmine in the fusiform gyrus. By 
contrast, physostigmine decreased differential activation due to attention in the 
posterolateral occipital cortex. As these changes occurred even in the absence of stimuli 
we suggest that acetylcholine may modulate attention according to extrastriate region, 
rather than stimulus type. Physostigmine also modulated responses to emotional stimuli 
depending on whether they were task-irrelevant (in orbitofrontal and intraparietal 
cortices) or task-relevant (in dorsolateral and medial prefrontal cortices). These results 
demonstrate that despite their diffuse neocortical innervation, cholinergic projections may 
modulate attention-related and emotion-related activity in distinct parts of extrastriate and 
frontoparietal cortices. 
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6. EXPERIMENT 2: 
Effects of ChEI on Repetition Priming
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Introduction 
Stimulus repetition is associated with decreases in cortical activity (Buckner et al, 
1998), which may reflect more efficient stimulus processing and underlie perceptual 
priming -  a type of implicit memory (Schacter & Buckner, 1998). The present study 
sought to determine whether cholinergic enhancement with the anticholinesterase 
physostigmine.would modulate behavioural and fMRI repetition effects. Behavioural 
and haemodynamic measures of priming have both previously been found to be 
impaired by cholinergic blockade with scopolamine (Thiel et al, 2001, Thiel et al, 
2002a), in line with known effects of acetylcholine on cortical plasticity and learning 
(e.g. Rasmusson, 2000). By contrast, cholinergic enhancement improves an fMRI 
measure of perceptual processing in extrastriate cortex, selectively for stimuli that 
must be remembered (Furey et al, 2000a). Cholinesterase inhibition also increases the 
proportion of studied words used on a subsequent (incidental) word-completion task, 
in Alzheimer’s disease (Riekkinen & Riekkinen, 1999). On this basis, plus the fact 
that cholinergic modulation is thought to favour processing selectively of attended 
stimuli (Sarter et al, 2001), we hypothesised that physostigmine should result in 
greater neural and behavioural repetition effects specifically for attended (task-
relevant) stimuli. Furthermore, since acetylcholine has been shown to enhance cortical 
plasticity specifically for emotional stimuli, as in fear-conditioning (Weinberger et al, 
1998; Ji et al, 2001; Thiel et al, 2002b), we predicted that priming effects to fearful, 
relative to neutral, faces would be greater under physostigmine.  
 
The investigation of cholinergic modulation of repetition effects in the current study is 
embedded within the design of Experiment 1. As such, the dataset also permits 
analysis of possible interactions between attention, emotion and repetition, within the 
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placebo-treated group. This is interesting in itself because the degree to which 
repetition priming and/or suppression operates automatically (Wiggs & Martin, 1998; 
Desimone, 1996), versus being influenced by top-down factors (Henson et al, 2002) 
remains unclear. This is especially so in sensory-perceptual areas, where repetition 
suppression occurs most robustly (Badgaiyan, 2000). Similar repetition decreases for 
both target and foil faces have been observed in extrastriate visual cortex during a 
working memory task (Jiang et al, 2000), and in superior temporal gyrus to written 
words following both divided and full attention study phases using spoken words 
(Badgaiyan et al, 2001). On the other hand, some differences in face-repetition effects 
in visual cortex have been observed depending on task (Henson et al, 2002; Reber et 
al, 1998), in keeping with electrophysiological data (Puce et al, 1999; Dale et al, 
2000) suggesting that sensory repetition effects may be influenced by re-entrant 
signals from regions involved in higher levels of processing. If repetition effects in 
sensory cortex are entirely dependent on task-related processing, e.g. in prefrontal 
cortex, then it might be expected that stimuli which are completely irrelevant to the 
task (at both study and test) would not engender repetition effects. Our first aim in the 
current experiment was to determine whether repetition effects in extrastriate visual 
cortex as measured by fMRI, would be observed for faces both when selectively 
attended and ignored as distractors.  
 
A further factor that may influence priming, independently of attention, is the 
emotional value of a stimulus. Emotional stimuli can enhance activity within 
extrastriate visual areas separately from an effect of attention (Vuilleumier at al, 
2001), which appears to be involved in association learning in the context of fear 
conditioning (Morris et al, 2001). Since priming may represent a similar form of 
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perceptually-based implicit memory (Schacter & Buckner, 1998), it might also be 
expected to be enhanced by emotion. Behavioural studies have suggested a priming 
benefit for emotional stimuli in healthy adults (LaBar and Phelps, 2002), as well as 
depressed and social phobic patients (Watkins et al, 2000; Lundh and Ost, 1997). On 
the other hand, unpleasant (versus neutral) faces have been found in one fMRI study 
to result in less of a repetition decrease in temporo-occipital cortex, which was 
interpreted in terms of reduced adaptation to negative valence stimuli (Rotshtein et al, 
2001). An alternative explanation, however, was that the critical faces in this 
particular study were not just unpleasant but also bizarre (i.e. mouth and eyes were 
inverted), which could have influenced repetition effects through indirect attentional 
factors. In the present experiment we examined the effect of face-emotion on 
repetition effects, orthogonally from any effect of attention, by using an event-related 
design which repeated faces only once so as to minimise habituation (Brown and 
Xiang, 1998).  
 
Methods 
Subjects 
As for Experiment 1. 
 
Drug treatment 
As for Experiment 1. 
 
Cognitive task 
Subjects performed the same matching task as described in Experiment 1 (after 
Vuilleumier et al., 2001). However, now the critical factor lay in analysis of stimulus 
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order since each stimulus was shown twice (Fig. 6.1). At the start of each block, 
subjects were cued (for 2 secs) to attend selectively to either the two vertically-
arranged or two horizontally-arranged positions, while the alternative two locations 
were to be ignored throughout the block. In total, there were four blocks of forty trials 
each. Each trial consisted of a central fixation cross (1 sec) followed by the four-
picture display for 250 ms. Subjects were required to indicate, as accurately and 
rapidly as possible, whether the two stimuli at task-relevant locations were the same 
or different, by either of two possible key presses with the right hand. Reaction time 
(RT) and accuracy were recorded. The median intertrial interval was 2.5 secs (range: 
1.5 – 14.4 secs). 
 
Within each trial, either the two attended or the two unattended locations were 
occupied by two non-famous faces (taken from The Karolinska Directed Emotional 
Faces set; Lundqvist et al, 1998), in an intermingled and unpredictable sequence. The 
remaining two locations were occupied by two house pictures. Hence a trial could be 
classified as faces-attended (A) or faces-unattended (U) in this sense, depending on 
where the faces were placed with respect to the currently attended locations. 
Furthermore, both faces could either have a fearful emotion (E) or neutral (N) 
expression, independent of whether they were at task-relevant locations. This resulted 
in four conditions (AE,AN, UE and UN faces); these conditions plus the pair 
identities (i.e. same/different, which was independent between the attended and 
unattended pair in each trial), were randomly counterbalanced throughout each block. 
The order of task-relevant locations (i.e. either vertical or horizontal) between blocks 
was randomly picked from one of four alternatives (HVHV, VHVH, HVVH, VHHV), 
and counterbalanced across subjects within each group. 
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Stimulus repetition only occurred for particular face stimuli. Every first presentation 
of a pair of faces (suffixed 1 henceforth) was followed by only one other repetition of 
the same pair of faces (suffixed 2) that occurred after an interval of two to five 
intervening trials (equally distributed across each block). Thus eight conditions 
existed: AE1, AE2, AN1, AN2, UE1, UE2, UN1 and UN2 (where AE1, for example, 
would represent first presentation of a particular pair of fearful faces appearing at 
task-relevant locations, and AE2 would represent their subsequent repetition). There 
were twenty trials of each condition per subject. Owing to the small number of 
intervening stimuli between first and second repetitions, the influence of any time 
confound would be minimal (< 5% trials fell outside of the time window in which 
stimulus order was fully counterbalanced with respect to time). 
 
The cross-format spatial array and brief exposure time has previously been shown to 
be effective at engaging covert attention to the relevant pair of locations without 
saccades (Vuilleumier et al, 2001; Wojciulik et al, 1998), and without awareness of 
identity, gender or expression of faces when these appear in task-irrelevant locations 
only (Vuilleumier et al, 2001). Nonetheless, to exclude possible between-group 
differences in saccade frequency or compliance with the requirement for central 
fixation, we monitored eye movements throughout the task using an infra-red eye 
tracker (ASL Model 540, Applied Science Group Co., Bedford, MA; refresh rate = 60 
Hz). For technical reasons, eye-position data were lost for six subjects (2 placebo, 4 
from drug group). 
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Figure 6.1. Stimulus format. Each block started with cue stimulus that indicated 
whether subjects must attend to horizontal or vertical locations in cross-array for 
performance of subsequent matching task (in this example, this would be horizontal 
locations). Each trial consisted of a pair of faces that may be either in task-relevant 
(A) or taskirrelevant (U) locations; together with a pair of houses occupying alternate 
2 locations. Face pairs were repeated with lag of 2 to 5 intervening trials; houses were 
never repeated. Face pairs could be either fearful and thus emotional (E) or neutral 
(N). Experiment thus had a 2 x 2 x 2 factorial design, with factors of face-repetition, 
attention (toward or away from faces), and emotion. 
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Imaging and image processing 
As for Experiment 1. 
 
Statistical analysis of images 
Data were analyzed with a general linear model for event-related designs, using a 
random-effects analysis, as in Experiment 1. However, in Experiment 2, eight event 
types were defined for each subject (see above). Data were globally scaled and high-
passed filtered at 1/120 Hz. Individual events were modelled by a canonical synthetic 
hemodynamic response function and its temporal derivative (Friston et al, 1998). The 
six head movement parameters were included within the model as before.   
 
Linear contrasts of parameter estimates were made for each subject and used to 
generate statistical parametric maps (SPMs) of the t-statistic. In order to test for 
regions showing face-repetition effects common to different conditions (i.e. to both 
attended and unattended faces; or to both emotional and neutral faces), contrasts of 
first versus second presentation under each condition were performed for each subject 
and entered into a repeated-measures ANOVA corrected for non-sphericity (Glaser et 
al, 2002). A conjunction analysis was then performed over contrasts from both 
conditions (Price & Friston, 1997). In order to test for regions showing a different 
magnitude of repetition decrease between conditions, contrasts representing the 
repetition x condition interaction for each subject were entered into a one-sample t-
test; only regions showing a significant repetition decrease (p < 0.001, uncorrected) in 
at least one of the tested conditions are reported. Regions found to show repetition x 
condition interactions that also showed a significant three-way interaction (repetition 
x attention x emotion; thresholded at p < 0.001, uncorrected) are noted. 
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Repetition x drug interactions were analysed separately for attended and unattended 
faces by comparing between-subject repetition effects with t-tests. Repetition x 
condition x drug interactions were similarly assessed by comparing the repetition x 
condition interactions, for each subject, between groups, but only the volume of 
voxels showing a repetition main effect or repetition x condition interaction in the 
placebo group was searched (masks thresholded at p < 0.001, uncorrected). Effects of 
physostigmine on attention and emotion, independent of repetition, are considered in 
Experiment 1. We emphasise that the drug effects reported here are condition-
specific, as mean session-effects are modelled separately. All regions that showed 
significant repetition x drug, or repetition x condition x drug, interactions were found 
to show insignificant between-group session effects (p > 0.05, uncorrected). 
Furthermore, the global session mean activity did not differ between groups (p > 
0.05), suggesting that physostigmine did not engender significant general vascular 
effects.  
 
We report areas that achieve significance either after correction for whole brain (or 
effective search volume in the case of repetition x condition x drug interactions; see 
above), or regions of interest (ROI) where indicated (Worsley et al, 1996). Two ROI’s 
of approximately 20 cm3 each were defined (Rorden & Brett, 2001) in right and left 
inferior temporo-occipital cortices so as to encompass coordinates previously found to 
show repetition decreases in event-related fMRI designs for repetition of unfamiliar 
faces (Henson et al, 2002; Jiang et al, 2001). Regions surviving a threshold of p < 
0.001, uncorrected, are also reported descriptively. Any activations smaller than 5 
contiguous voxels were discounted.  
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Results 
 
Physiological data, subjective reports, and eye tracking 
Side-effects and subjective reports are described in Experiment 1. 
 
The frequency of saccades and median angular deviation of the eye were measured 
also as in Experiment 1. However, these parameters were now entered into a four-way 
ANOVA with factors of group, attention, emotion and repetition,. There were no 
significant effects or interactions for either saccade number, or median ocular position 
(all F’s < 1.8; p ≥ 0.2).  
 
Behavioural  
Behavioural effects of priming were determined by calculating median RT and mean 
accuracy differences between the first and second presentations for each face pair, 
separately for each of the four conditions in each participant. In the placebo group, a 
significant speeding of responses when attended neutral (AN) faces were repeated 
(mean RT difference between first and second presentation = 30.3 ± 17.5ms, t(14) = 
3.5, p <0.005), plus a trend for more accurate performance with repeated stimuli 
(mean accuracy difference = 5.3 ± 5.8 %; t(14) = 1.8, p < 0.1) was evident, consistent 
with previous studies of repetition priming (e.g. Henson et al, 2002).  
 
To ascertain any effects of condition (attention and emotion) and group (cholinergic 
enhancement versus placebo), we entered RT and accuracy differences (between first 
and second presentation) for each subject, for each condition, into a repeated-
measures, mixed ANOVA. While there was no main effect of group on the RT 
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priming effect, there were significant group x attention (F(1,28) = 4.4; p <0.05) and 
group x emotion interactions (F(1,28) = 4.3; p <0.05; Fig. 6.2A). These effects can be 
explained by a significant reduction of the RT priming effect for emotional versus 
neutral trials under placebo (F(1,14) = 11.7; p <0.005), but not under physostigmine 
(F(1,14) = 0.7; ns); while the RT priming effect was significantly greater for attended 
versus unattended faces under physostigmine (F(1,14) = 12.8; p <0.005), but not 
under placebo (F(1,14) = 0.3; ns). A separate ANOVA comparing absolute RTs 
between groups over condition (attention x emotion x stimulus order) did not reveal 
any between-group differences, although there was a trend to faster overall RTs in the 
physostigmine group (t(28) = 1.4, p < 0.1, one-tailed based on Furey et al, 1997).   
 
There was no group x condition interaction for priming in accuracy measures, but a 
trend for greater primimg with attended repeated faces versus unattended repeated 
faces (F(1,14) = 3.0; p < 0.1; Fig. 6.2B). Overall accuracy (mean score = 85 ± 3.2 %, 
and 83 ± 3.2 %, under drug and placebo respectively) was comparable to a previous 
study using the same task in which limited awareness of task-irrelevant compared 
with task-relevant faces was demonstrated (Vuilleumier, et al, 2001). There were no 
behavioural effects of specific attended location (i.e. horizontal or vertical pair), or 
interactions of location x group.  
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Figure 6.2:. A: median RT for each of 8 conditions (AE, Attended Emotional faces; 
AN, Attended Neutral; UE, Unattended Emotional; UN, Unattended Neutral; 1: 1st 
presentation; 2: 2nd presentation), separately for placebo and physostigmine groups. 
Second graph shows itemwise differences in RTs to novel minus primed stimuli for 
each of 4 main conditions (hence positive values represent repetition advantage). B: 
mean accuracy for same 8 conditions. Second graph shows itemwise differences of 
accuracy to primed minus novel stimuli for each of 4 main conditions (hence positive 
values represent repetition advantage). SE bars are shown. Note that statistical 
inferences concerning priming are based on subject-specific differences, and that 
inferences on behavioral effects are based on item-specific repetition (not conveyed 
by error bars on group means). 
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fMRI data: Effects of selective attention on face-repetition 
The main effect of faces presented in task-relevant, versus task-irrelevant, locations 
(i.e. independent of repetition) identified bilateral mid-fusiform regions (44, -50, -24 
and –42, -44, -28; Z ≥ 4.29; p < 0.001, uncorrected; Fig. 6.3A), while the opposite 
contrast (houses in task-relevant, versus task-irrelevant, locations) identified bilateral 
parahippocampal cortex (16, -52, 6 and –24, -36, -14; Z ≥ 5.50; p < 0.01, corrected for 
whole brain). This replicates previous results using a similar task (Vuilleumier et al, 
2001; Wojciulik et al, 1998) and demonstrates that subjects selectively processed the 
pair of stimuli at cued locations.  
 
We next identified areas that showed fMRI face-repetition effects common to both 
attended and unattended face stimuli, by performing a conjunction analysis across 
contrasts comparing first and second presentations of both attended-face and 
unattended-face trials in the placebo group. Areas showing repetition decreases under 
both levels of attention were bilateral inferior temporo-occipital cortex, left inferior 
prefrontal gyrus and premotor areas (Table 6.1A, Figure 6.3B). These regions were 
distinct from those that showed greater repetition decreases for attended versus 
unattended faces,  viz. superior temporal sulcus, middle occipital gyrus, and striatum 
(Table 6.1C). We note that the inferior temporo-occipital regions showing a repetition 
effect independent of attention did not show a main effect of face-attention (Fig. 
6.3B), and, conversely, the mid-fusiform peaks showing a main effect of attention did 
not show any repetition effects (Fig. 6.3A). Repetition effects in these inferior 
occipital regions are likely to reflect processing of stimulus features more general than 
those encoded by the face-selective mid-fusiform regions, that were located more 
anteriorly. Areas that showed repetition increases across both levels of attention 
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included bi-parietal cortex and posterior cingulate (Table 6.1B), both of which 
showed likewise increases to repeated faces in Henson et al, 2002.  
 
Finally, as our behavioural data suggested a performance advantage on house 
judgements when faces were repeated at irrelevant locations, we examined the 
contrast of first versus second presentations of task-irrelevant faces (i.e. when house 
judgements were performed), and restricted the analysis to house-selective regions 
(by masking with the main effect of house-attention, thresholded at p < 0.001, 
uncorrected). This identified a left parahippocampal region (-22, -32, -10; Z = 4.09, p 
< 0.05, corrected) that showed increased activity with repetition of unattended face 
stimuli, presumably as the houses became more dominant when the same faces were 
ignored. This repetition enhancement was indeed specific to trials when house 
judgements were required (and faces ignored), as shown by a significant repetition x 
attention interaction (F(1,14) = 5.0; p < 0.05).  
 
Figure 6.3. (See next page): Regions of inferior temporo-occipital cortex showing 
main effect of faces in attended vs. unattended locations, independent of repetition 
(mauve; A), and conjunction of repetition decreases to faces in both attended and 
unattended locations (yellow; B); both contrasts P < 0.001, uncorrected. Activation 
map is superimposed on single-subject T1-weighted MRI brain, pitched to visualize 
inferior cortical surface. Graphs show percentage signal change from baseline in right 
mid-fusiform (A) and inferior occipital cortex (B) during first and second 
presentations of faces from each of 4 conditions (AE, AN, UE, UN). On right are 
plots of mean subject-specific signal differences between first and second 
presentations for each of 4 conditions (positive values represent repetition decreases; 
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negative values represent repetition enhancements). Regions showing main effect of 
face-attention (P < 0.001) did not show a significant effect of repetition (P > 0.05), 
whereas regions showing repetitions to both attended and ignored faces (P < 0.001) 
did not show a significant effect of face-attention (P > 0.05). Placebo and 
physostigmine groups are shown separately. Left-sided plots are corrected for mean 
over all conditions between groups (no significant main effect of drug). 
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Table 6.1: Common and differential effects of attention on priming in placebo group 
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fMRI data: Effects of emotion on face-repetition 
Comparison of signal estimates between emotional and neutral face conditions at the 
peak of the conjunction of face-repetition effects across attended and unattended 
contrasts suggested a similar repetition decrease in occipital cortex for both emotional 
and neutral faces (Fig. 6.3B). This was confirmed formally by performing the 
conjunction of priming effects between fearful and neutral-face trials, independent of 
attention (Table 6.2, yellow area in Fig. 6.4A). The same posterior visual (and 
premotor) areas that showed face-repetition decreases for both levels of attention thus 
also showed repetition decreases to both neutral and emotional faces.  
 
We next examined for repetition effects that were significantly modulated by emotion 
(i.e. repetition x emotion interaction). This showed that left postero-inferior occipital 
cortex, as well as a region at posterior amygdala-hippocampal border, exhibited a 
greater repetition decrease for emotional, relative to neutral, stimuli (Table 6.2; cyan 
area in Figs. 6.4A, 6.4B). Conversely, the only area showing a greater repetition 
decrease to neutral, relative to emotional, faces was lateral orbitofrontal cortex (OFC: 
red area in Fig. 6.4A). The pattern of repetition decreases in this region across 
conditions (Fig. 6.4B) parallels the RT priming effects observed behaviourally. 
Furthermore, a correlation analysis comparing the size of the emotional effect on RT 
priming with the size of the emotional effect on BOLD repetition decreases at the 
OFC peak showed a positive trend (r = 0.46, p = 0.08): i.e. subjects showing the 
greatest attenuation of RT priming with emotional faces also tended to show the 
greatest diminuition of repetition decreases in OFC towards emotional faces.  
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We note that none of the extrastriate areas exhibiting repetition effects showed a main 
effect of emotion, but such a main effect of emotion, independent of attention, was 
found in left fusiform (-40, -48, -24, Z = 3.27, p < 0.001, uncorrected), and medial 
amygdala-substantia innominata (10, -8, -16, Z = 3.09, p = 0.001, uncorrected), in 
keeping with Vuilleumier et al, 2001. 
 
Figure 6.4. (See next page): Regions of inferior temporo-occipital and orbitofrontal 
cortex showing conjunction of repetition decreases for both emotional and neutral 
faces (yellow; activity plot similar to that shown in Figure 6.3B; a left inferior 
occipital cluster occurred on lower slice); or greater repetition decreases to neutral, 
relative to emotional, faces (red; A); or greater repetition decreases to emotional, 
relative to neutral, faces (blue; B); all contrasts thresholded at P < 0.001, uncorrected. 
Activation maps are superimposed on single-subject T1-weighted MRI brain (z = -
14). Graphs show percentage signal change from baseline in right lateral orbitofrontal 
cortex (OFC: A), and left posterior occipital (B) regions during first and second 
presentations of faces from each of 4 conditions (AE, AN, UE, UN). Scales differ 
between regions. On right are plots of mean subject-specific signal differences 
between first and second presentations for each of 4 conditions (positive values 
represent repetition decreases; negative values represent repetition enhancements). 
Placebo and physostigmine groups are shown separately for each contrast. Left-sided 
plots are corrected for mean over all conditions between groups (no significant main 
effect of drug). 
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Figure 5.4. For legend see above. 
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Table 5.2: Common and differential effects of emotion on priming in placebo group 
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fMRI data: Effects of cholinergic enhancement on repetition  
Given the role of cholinergic inputs on selective attention, we had hypothesised that 
physostigmine might enhance repetition suppression effects (see Thiel et al, 2001; 
Thiel et al, 2002a) specifically for attended faces (see also Furey et al, 2000a). 
Therefore we examined group x repetition interactions for attended and unattended 
trials separately. With faces attended, this interaction identified left inferior occipital 
cortex as showing a greater repetition decrease under physostigmine relative to 
placebo (-32, -66, -22; Z = 3.91; p < 0.05, corrected for ROI; Fig. 6.5). This occipital 
area also showed a repetition x attention x drug interaction (F(1,28) = 4.0; p < 0.05) 
that reflected physostigmine, but not placebo, engendering a greater repetition 
decrease for attended, versus ignored, faces (physostigmine: F(1,28) = 7.0; p < 0.05; 
placebo: F(1,28) = 0.6; ns). Furthermore, in the same region, we note that 
physostigmine, versus placebo, resulted in reduced activity to the repeated face (t(28) 
= 2.4; p < 0.05), but did not change activity to the first face (t(28) = 1.1; ns). These 
results complement previous findings of modulation of repetition effects within left 
inferior occipital cortex by cholinergic blockade, when scopolamine resulted in a 
reduced repetition decrease, due specifically to an elevation in activity to the repeated 
stimulus (Thiel et al, 2001). 
 
No regions showed less repetition decreases to attended faces under physostigmine, 
relative to placebo, and no regions showed a significant drug x repetition interaction 
for unattended faces.  
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Figure 6.5: Regions of inferior temporo-occipital cortex showing greater repetition 
decreases for physostigmine than placebo, specifically for faces in attended locations 
(P < 0.001, uncorrected). Area showing this significant interation was close to region 
previously showing repetition decreases in face priming study (Henson et al. 2002), 
and also showing diminution of repetition decrease under cholinergic blockade (Thiel 
et al. 2001). Activation map is superimposed on single-subject T1-weighted MRI 
brain. Transverse slice taken at z = -22; coronal slice taken at y =-68. Graph shows 
percentage signal change from baseline in left inferior occipital cortex during first and 
second presentations of faces from each of 4 conditions (AE, AN, UE, UN). On right 
are plots of mean subject-specific signal differences between first and second 
presentations for each of 4 conditions, at the same point. Placebo and physostigmine 
groups are shown separately for each contrast, and are not mean-corrected.  
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Three-way interactions of drug x repetition x condition (for conditions of attention 
and emotion, separately) were also tested, given that these interactions showed 
significant effects in the RT data. We restricted our search volumes to those voxels 
showing a main effect of repetition-decrease (regardless of attention and emotion 
condition) or a repetition x condition interaction in the placebo group (thresholded at 
p < 0.001, uncorrected). Importantly, no areas showed a repetition x drug interaction 
over all conditions (i.e. there was no main effect of physostigmine on repetition 
independent of conditions). 
 
In the repetition x drug x attention interaction, we found that the right inferior 
occipital region which had shown the maximum repetition decrease common to both 
attended and unattended faces (as well as to both emotional and neutral faces) under 
placebo, was found under physostigmine, to show a repetition decrease selectively for 
attended faces only (i.e. repetition x attention x drug interaction: F(1,28) = 5.5; p < 
0.05; a similar interaction was found in the left inferior occipital region showing a 
repetition x drug interaction for attended faces – see above). As shown in Fig. 6.3B, 
under physostigmine, the right inferior occipital region manifested a similar degree of 
repetition decrease to attended faces as under placebo, but showed a trend for 
repetition increases to unattended faces (t(14) = 1.7; p = 0.1), in contrast to the 
placebo group. There were no regions in which this interaction survived correction for 
search volume. 
 
Finally, the repetition x drug x emotion interaction revealed that the lateral 
orbitofrontal region (38, 38, -12), previously found in the placebo group to display 
less repetition effects with emotional, relative to neutral, faces, was not associated 
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with this pattern under physostigmine (Z = 4.51; p < 0.05, corrected; Fig. 6.4B). In 
fact, physostigmine produced the opposite effect at this point, viz. greater repetition 
decreases with emotional than neutral faces (F(1,28) = 10.3; p < 0.01).   
 
Discussion 
 
Effects of cholinergic enhancement on repetition priming and its neural correlates 
Since cholinergic blockade with scopolamine has previously been found to inhibit 
both behavioural and neuronal correlates of repetition priming to attended stimuli 
(Thiel et al, 2001; Thiel et al, 2002a), we expected to find an increase of both 
measures with the cholinergic enhancer physostigmine. Consistent with this 
prediction, physostigmine produced a greater repetition decrease in left inferior 
occipital cortex (selectively with attended face-repetition), although this did not 
benefit RT or accuracy significantly. This occipital area was close to those previously 
showing repetition decreases to faces (Henson et al, 2002; Jiang et al, 2000), or 
showing an elimination of repetition effects following cholinergic blockade (Thiel et 
al, 2001). The fact that no RT improvement was observed with physostigmine 
suggests that an additional rate-limiting step of the task may lie downstream from 
perceptual processes in occipital cortex, e.g. response-related.   
 
The nature of the physostigmine interaction with repetition was closely 
complementary to that previously found with scopolamine (Thiel et al, 2001) in 
another respect: both cholinergic manipulations only affected response to the repeated 
occurrence of an item, not to the initial presentation. This contrasts with other drugs, 
e.g. GABAergic modulators, that disrupt cortical repetition effects and priming 
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through effects on novel stimulus processing (Thiel et al, 2001; Vidailhet et al, 1999). 
Our results may also be relevant in the context of Alzheimer’s disease (AD), in which 
perceptual priming is impaired (Shimamura et al, 1987; Schwartz et al, 1996). Since 
AD patients have shown paradoxical repetition enhancements in inferior occipital 
cortex, in contrast to healthy age-matched subjects who show repetition decreases 
(Backman et al, 2000), we speculate that the beneficial effect of anticholinesterases on 
priming observed in AD (Riekkinen & Riekkinen, 1999) may arise from an 
enhancement of repetition effects in inferior occipital cortex, as observed here in 
healthy subjects. 
 
In contrast to the placebo group, who showed similar repetition decreases to both 
attended and ignored faces in inferior occipital regions, we found in the 
physostigmine group that repetition decreases occurred preferentially to attended 
stimuli (Figs. 6.3B, 6.5B). These results complement our RT data in showing that 
physostigmine, but not placebo, induced a repetition benefit selectively with attended 
stimuli. Such an effect would be consistent with studies showing the importance of 
cortical cholinergic modulation on selective attention (Sarter et al, 2001), noise 
filtering (Sato et al, 1987), and selective perceptual processing of stimuli that need to 
be remembered (Furey et al, 2000). 
 
Cholinergic modulation has also been shown to enhance processing of emotional 
stimuli (Holland & Gallagher, 1999), and facilitate experience-dependent cortical 
plasticity specifically to fear-conditioned stimuli (Weinberger et al, 1998; Ji  et al, 
2001; Thiel et al, 2002b). Our results extend the role of acetylcholine in emotional 
learning by showing that physostigmine favoured repetition decreases to emotional, 
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relative to neutral, faces in orbitofrontal cortex (thus reversing the normal pattern); 
and eliminated the detrimental effect of emotion on primed RTs seen under placebo. 
The OFC has especially strong interconnections with cholinergic neurons of the 
nucleus basalis (Cavada et al, 2000) and is modulated by acetylcholine during 
reinforcement learning in animals (Aou et al, 1983).  
 
A discussion of the other findings of this Experiment – on attentional and emotional 
interactions with repetition, independent of cholinergic modulation – is made 
elsewhere (Bentley et al, 2003). 
 
Conclusion 
Experiment 2 demonstrates that cholinergic enhancement can augment the size of 
repetition effects in inferior occipital cortex, and favour behavioural and neural 
priming effects for both attended and emotional stimuli (the latter being due to a 
reversal of the emotion-selective impairment of priming in untreated subjects). The 
experiment also showed that repetition priming, and its associated haemodynamic 
marker of extrastriate cortex repetition decrease, can occur by a similar amount for 
stimuli appearing at task-relevant or irrelevant locations. In contrast, emotional 
stimuli reduced behavioural priming, associated with an attenuation of repetition 
decreases in lateral orbitofrontal cortex. These results suggest that cortical 
mechanisms underlying priming may occur automatically (in extrastriate areas) and 
yet be influenced by intrinsic stimulus value (in orbitofrontal cortex) and cholinergic 
modulation (in both regions).  
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7. EXPERIMENT 3: 
Effects of ChEI on Visual Stimulation, 
Visuospatial Attention and  
Spatial Working Memory 
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Introduction 
 
 
The integrity of cholinergic afferents to cerebral cortex is necessary for normal 
stimulus discrimination, selection and vigilance (Robbins, 1998). During periods of 
high attentional demand, acetylcholine is released diffusely throughout neocortex 
(Phillis & Chong, 1965) and modulates processing within both sensory and prefrontal-
parietal cortices (Sarter & Bruno, 1997). Thus, cholinergic input to visual or auditory 
cortices has been shown to sharpen stimulus representations through a combination of 
signal amplification and noise suppression (e.g. Sato et al, 1987, Hars et al, 1993). 
Additionally, cholinergic afferents to prefrontal and parietal areas have been shown to 
be critical for spatial orientation (Davidson & Marrocco, 2000; Chiba et al, 1999) and 
sustained attention (McGaughy & Sarter, 1998), especially in the presence of 
distractors (Gill et al, 2000).  
 
The above effects have been characterised in terms of cholinergic modulation of 
bottom-up and top-down processes, respectively (Sarter et al, 2001). An issue that 
remains unaddressed is the manner in which cholinergic modulation of these two 
types of processes combine. There remains uncertainty as to whether top-down 
modulation of sensory cortices is enhanced with cholinergic stimulation (as might be 
expected given the facilitatory effects of acetylcholine on attention generally – Sarter 
et al, 2001) or whether it is suppressed, so as to favour bottom-up activity (suggested 
by cell-layer recording studies in sensory cortices – Hasselmo & Cekic, 1996; Kimura 
et al, 1999, and computer modelling of cholinergic effects – Yu & Dayan, 2002). 
 
One method by which this issue can be investigated is with functional imaging which 
has reliably demonstrated neural correlates of both bottom-up and top-down activity 
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within human visual cortex (e.g. Chawla et al, 1999, Hopfinger et al, 2000). While 
previous studies report modulation of visual cortical activity as a result of cholinergic 
drug administration, none have compared effects of cholinergic modulation on 
occipital activation evoked by stimulus, as compared to that due to attention. The 
anticholinesterase physostigmine has been found to increase extrastriate cortex 
activity selectively during the encoding-phase of a face working memory task (Furey 
et al, 2000). However, a more recent fMRI study (Lawrence et al, 2002) failed to find 
selective cholinergic effects, observing that nicotine (a more selective pro-cholinergic 
agent) enhanced occipital activity during both easy and difficult versions of a 
sustained attention (rapid visual information-processing) task. Consequently, the 
enhancement of occipital cortices may have been a direct effect of nicotine on visual-
evoked responses. It is worth noting that both studies employed tasks that involved 
both attention and working memory components, which themselves may be 
independently modulated by acetylcholine (Everitt & Robbins, 1997; Ernst et al, 
2001a; Heishman et al, 1994). Furthermore, Experiment 1 demonstrated that 
physostigmine may modulate neural correlates of attention differently between face 
and non-face, stimuli, which may reflect a bias of acetylcholine towards processing 
stimuli of high intrinsic valence (e.g. Holland & Gallagher, 1999; Wilson & Rolls, 
1990; Acquas et al, 1996).  
 
In the present study, we aimed to distinguish effects of physostigmine on occipital 
cortex activation attributable to attention from that due to stimulus. We also assessed 
whether the differential occipital activation engendered by selective spatial attention 
(e.g. Hopfinger et al, 2000) is itself modulated by physostigmine. This question is 
motivated by a recent model predicting that excess acetylcholine reduces the degree to 
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which top-down influences, such as selective attention, modulate activity in sensory 
cortices (Yu & Dayan, 2002). Finally, to unconfound effects of acetylcholine on 
attention and working memory (Furey et al, 2000; Lawrence et al, 2002), and mindful 
that both types of task may engage similar processes or brain areas (LaBar et al, 1999; 
Awh & Jonides, 2001), we compared physostigmine modulation of cortical activity 
between spatial attention and spatial working memory.  
 
Methods 
Subjects 
Eighteen right-handed volunteers (13 female; 5 male; mean age = 23.4 ± 1.0) with no 
history of medical or psychiatric disease gave written informed consent. No subject 
was on medication or a smoker. Each subject participated in two sessions separated by 
7 – 10 days, performed at similar times of the day. Subjects received physostigmine or 
placebo (saline infusion) on different sessions, with treatment order counterbalanced 
across subjects. Three further subjects scanned were excluded due to excessive 
saccades (> 50% trials). 
 
Drug treatment  
A double-blind placebo-controlled drug administration technique was used. Each 
subject received an intravenous cannula into the left cubital fossa and an infusion of 
either physostigmine or saline, depending on session. Dosage and rate of 
physostigmine infused was identical to that used in a recent study (Furey et al, 2000b) 
providing stable levels of plasma drug concentration and butyrylcholinesterase 
inhibition, as well as a significant and stable effect on cognitive performance for 40 
minutes, following a 40 minute loading period. The same drug protocol has also been 
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found to result in changes in task-specific occipital activity using fMRI or PET 
techniques, using working memory (Furey et al, 1997; Furey et al, 2000a) and 
perceptual-attention (Experiment 1) tasks. 
 
During the drug-session, subjects were first given 0.2 mg intravenous glycopyrrolate 
(peripheral muscarinic receptor antagonist), before an intravenous infusion of 
physostigmine was commenced (1.93 mg / hour for 10 minutes, followed by 0.816 mg 
/ hour for 40 minutes). Subjects then performed the task in the scanner while 
receiving a constant rate of drug for a further 40 minutes (< 1.3mg physostigmine in 
total delivered). In the placebo-session, an equivalent volume of saline was 
administered in all steps. On both sessions, blood pressure was checked before, and at 
40 minutes into infusion, whilst pulse-oximetry was performed continuously. Subjects 
were given a questionnaire at 0 and at 40 minutes post-infusion that allowed a ranked 
measurement (0 – 6 scale) of seven recognised adverse reactions to physostigmine 
and glycopyrrolate, as well as a list of visual analogue scales for estimating subjective 
feelings (Bond & Lader, 1974).  
 
Cognitive task 
On each session, subjects performed three tasks (spatial attention, spatial working 
memory, and visual control: Fig. 7.1) in different blocks, and repeated once (e.g. 
AWCAWC). To minimise order effects, treatment and task order were completely 
counterbalanced across subjects, with task-order being repeated across sessions. 
Furthermore, on each session, subjects were given half-hour practice with feedback, 
outside the scanner, prior to drug delivery. There were fifty-two trials of each 
condition per session, with an ITI of 0.5 – 3.5 seconds. 
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In the attention task, subjects were cued to either right or left visual hemi-fields (for 
2.1 seconds), before being presented with a 12 Hz alternating, polarised chequerboard 
(18° height x 22° width; vertical wedges removed) for 3 –14 seconds (mean = 7.8 
secs; approximate Poisson distribution). After this delay period, two adjacent 
‘squares’ on either right or left side of the chequerboard (6° eccentricity; 3° wide) 
reversed in polarity (the target, appearing as a ‘hole’) for 84 ms, before being replaced 
by the normal chequerboard for a further 2.5 seconds. Subjects were required to 
attend to the cued side covertly (i.e. while fixating centrally), and to press either right 
or left buttons, depending on target-side, immediately on seeing the target. By only 
including responses within 1.5 seconds of target (accounting for > 95% responses), a 
measure of accuracy could be obtained (since only < 27 % accuracy could occur by 
subjects simply pressing after the commonest delay period). Targets either appeared 
on the same (valid trials: 80%) or opposite (invalid trials: 20%) side to that cued.  
 
Working memory trials began with three points presented successively (for 700 ms 
each), each in one of twenty-four, equally-spaced locations in either right or left 
visual hemi-fields (equivalent to half the chequerboard area). Subjects were than 
required to rehearse the locations of the three points, while fixating centrally, during 
presentation of a 3 – 14 seconds, alternating chequerboard (parameters as for 
Attention task). Following this period, a probe point appeared anywhere in the display 
(for 2.5 seconds), and subjects had to indicate whether its location was the same as 
one of the three studied points.       
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Visual control trials resembled attention and WM trials in temporal composition, with 
a 3 – 14 second delay period of alternating chequerboard, during which subjects 
fixated centrally. However, trials began with a central cue for 2.1 seconds, and ended 
with a large, central triangle for 2.5 seconds, at which subjects had been instructed to 
press the first key, with no emphasis on speed (hence requiring minimal attention).   
 
The use of variable-duration delay periods enabled us to model delay-period brain 
activity (in which the stimulus remained identical across conditions, and there was no 
motor response), separately from transients at either end of the delay-period (that 
varied between conditions and group – the latter due to effects on response by drug), 
while minimising the potential correlation between these task components (see Rowe 
at al, 2001). Furthermore, by monitoring saccades and median eye position during 
each delay period (using an infra-red eye tracker: ASL Model 540, Applied Science 
Group Co., Bedford, MA; refresh rate = 60 Hz), we were able to discount those trials 
in which central fixation did not occur from the behavioural and imaging analysis.    
 
Figure 7.1:. (See next page): Task design and peristimulus- evoked BOLD responses. 
(A) Schematic time course of three tasks. Each task type consisted of task-specific 
stimuli at the beginning and end of every trial and a variable intervening delay period 
(3–14 s of alternating checkerboard) that was identical in stimulus across tasks and in 
which no motor response occurred. Transients at trial start and end were modeled 
separately from delay period for each task type, with each task phase being convolved 
with its own canonical hemodynamic response function. (B) Adjusted data from 
occipital cortex (averaged over bilateral peaks plotted in Figure 7.5, under placebo) 
showing changes in BOLD response across attention trials for varying delay periods, 
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temporally realigned to each trial onset. Trials were divided according to whether the 
initial cue was in the visual hemifield contralateral or ipsilateral to the occipital side 
from which the data was acquired. Note the increasing amplitude and duration of 
BOLD activity with delay duration reflects delay period activity (higher for attention 
to contralateral than ipsilateral space), unlike responses to cue or target that are delay 
independent. Effects reported here reflect the degree to which data fits a standardized 
delay-dependent regressor for each trial type, similar to the actual profile of activity 
observed here for contralateral attention. 
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Imaging and image processing 
MRI data were acquired from a 2T VISION system (Siemens, Erlangen, Germany) 
equipped with a head coil. Functional images were acquired with a gradient echo-
planar T2* sequence using BOLD (blood-oxygenation level dependent) contrast. The 
acquired image consisted of 33 x 3 mm thickness axial slices that covered the entire 
brain. Within each session (drug or placebo), volumes were acquired in two sub-
sessions, with an effective repetition time (TR) of 2.51 seconds; echo time (TE), 
50ms, and flip angle 90º. The first six volumes were discarded, to allow for T1 
equilibration effects. Images were realigned to the first scan of the first session, time-
corrected, normalised to a standard echo-planar image template, and smoothed with a 
Gaussian kernel of 8-mm full-width half-maximum. 
 
Statistical analysis of images 
Data were analyzed with a general linear model for blocked, event-related designs 
(SPM99; Wellcome Dept. of Cognitive Neurology, London, UK; Friston et al, 1995) 
using a random-effects analysis. Data were globally scaled and high-passed filtered at 
1/256 Hz. For each subject, treatment and sub-session, the following events and epoch 
types were modelled: attention-cue (R and L, separately), attention-delay (R and L), 
attention-target (R and L, and for both, valid and invalid), WM-study (R and L), WM-
delay (R and L), WM-probe, control-cue, control-delay, control-target (all control 
trials were arbitrarily divided into two to allow for independence in a conjunction 
analysis of attention and working memory versus control), false alarms, and saccades 
or eye-deviation (R and L). In those attention trials in which the target was missed, 
the modelled delay period was extended until the end of chequerboard presentation. 
All modelled events and epochs were convolved by a canonical hemodynamic 
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response function; temporal derivatives of these functions were modelled separately 
(Friston et al, 1998). The six head movement parameters were included within the 
model as confounding covariates.  
 
In order to minimise the effect of sensorimotor differences between conditions, and 
performance between treatments, only contrasts of delay period activity were made. 
Differences of activity between delay period types of interest (and with respect to 
baseline) were calculated for each subject and treatment (i.e. parameter estimates), 
before being submitted to one-sample t-tests and generation of statistical parametric 
maps (SPMs) of the t-statistic. Comparisons of these contrasts were then made 
between treatments (group-by-condition interactions). Regions showing significant 
group-by-condition interactions were only reported if activation clusters at least 
partially overlapped with clusters showing a significant effect of the relevant 
condition within either treatment group (thresholded at p < 0.001, uncorrected). In 
order to test for regions showing both attention and working memory activity, 
contrasts of each condition versus its own set of control trials, under placebo, for each 
subject, were submitted to repeated-measures ANOVA corrected for non-sphericity 
(Glaser et al, 2002). A conjunction analysis was then performed over contrasts from 
both conditions (Price & Friston, 1997). We report areas that achieve significance 
after correction for whole brain, as well as those surviving a threshold of p < 0.001, 
uncorrected (qualified by previous fMRI studies employing similar tasks). 
 
We emphasise that the drug effects reported here are task-specific, as mean session-
effects are modelled separately. All regions that showed significant treatment-by-
condition interactions were found to show insignificant between-treatment session 
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effects (p > 0.10, uncorrected). Furthermore, the global session-mean activity did not 
differ between treatments (p > 0.10), suggesting that physostigmine did not engender 
significant general vascular effects.  
 
Results 
 
Physiological data, subjective reports, and eye tracking 
Subjects were less alert after physostigmine relative to placebo, comparing subjective 
rating scores (Bond & Lader, 1974) between 0 and 40 minutes post-infusion (68% vs. 
75% alert, respectively; p < 0.01). This replicates an effect observed in Experiment 1 
and 2. Subjects were also more likely to develop dry mouth (n = 8), dizziness (n = 8) 
and nausea (n = 6; all p < 0.05; mean intensity out of 6 = 1, 0.6, 0.4, respectively) 
under drug. There were no significant effects of drug on cardiovascular measures. 
Mean saccade frequency was 8% in attention; 3% in working memory, and <1% in 
control delay periods; median eye position was <0.5° from fixation in all sessions. 
There were no treatment effects for either eye position measure.  
 
Behavioural 
RT and accuracy measures for each subject were submitted to repeated-measures 
ANOVA with factors of group (drug or placebo) and condition (attention, WM and 
control; Fig. 7.2). Subjects were faster under physostigmine relative to placebo over 
all conditions (F(1,17) = 4.6; p < 0.05; RT’s, comparing drug to placebo, for attention, 
WM and control, were 428 vs. 443 ms; 1014 vs. 1047 ms, and 435 vs. 457, 
respectively; paired t-tests of this comparison were only significant in the case of 
attention task). There was no main effect of group for accuracy. Conversely, there was 
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no group-by-condition interaction for RT, but a group-by-condition interaction was 
evident for accuracy (F(1,17) = 5.7; p < 0.05). This interaction reflected 
physostigmine improving accuracy in attention (86 vs. 79 %; p < 0.05), but not in 
WM (86 vs. 87 %) or control conditions (98 vs. 98 %). Differences in performance 
across task were also found in the following orders: For RT: WM was slower than 
attention and control (p < 0.01). For accuracy: attention and WM scored less than 
control (p < 0.01); attention also scored less than WM (p < 0.05; accountable by an 
effect in the placebo group alone).  
 
Within the attention condition, a selective spatial processing bias towards cued, versus 
uncued, hemifields, was indicated by a faster performance (RT = 435 vs. 678 secs.; p 
< 0.01) and greater accuracy (83.3 vs. 62.6; p < 0.01) during validly versus invalidly-
cued trials. There was no group-by-validity interaction. Finally, we found no 
difference in false alarm rate between groups (mean across groups = 4.6%; 1.1 %, and 
1.6%, for attention, WM and control, respectively).  
 
Figure 7.2. (See next page): Performance compared across conditions (attention, 
working memory, and control; valid and invalid cue trials are shown separately) and 
treatments (placebo and physostigmine). For RTs, a main effect of group existed, 
suggesting faster responses under physostigmine (individual paired t tests for each 
task revealed a significant effect only for attention). For accuracy, subjects performed 
better under physostigmine during attention but not working memory or control (at 
ceiling), as suggested by a treatment x condition interaction. *p < 0.05. 
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Figure 7.2. For legend see previous page 
 
 
 
 
 
 
 
 
 
fMRI data: Effects of physostigmine on visual stimulation 
The first fMRI contrast performed was for visual regions showing stimulus-evoked 
activation to the alternating chequerboard across all three tasks (attention, working 
memory and control) versus baseline. Under both placebo and physostigmine, robust 
activations were evident in primary visual (9, -84, -6, Z = 5.91, p < 0.01, corrected) 
and lateral occipital (42, -72, 0; -42, -75, 6, Z ≥ 4.24, p < 0.001, uncorrected) cortices. 
A treatment effect was evident in primary visual cortex, with physostigmine reducing 
delay-period activations compared to placebo (i.e. main effect of drug, with no 
interaction: Fig. 7.3, graph 1). Lateral occipital cortices did not show a treatment 
effect (Fig. 7.3, graph 2; group-by-region interaction for primary visual and lateral 
occipital regions was p < 0.005), suggesting that physostigmine did not simply change 
the haemodynamic response function across occipital cortex. 
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 Fig. 7.3. Effect of physostigmine on visual stimulation. Regions within occipital 
cortex showing main effect of visual stimulation (i.e., delay period activity across all 
tasks) versus baseline, under placebo, physostigmine, and when comparing treatments 
for this effect (no occipital areas were greater under physostigmine than placebo for 
the main effect of visual stimulation). Graphs plot % signal change from baseline for 
the three conditions (separating attend-right and attend-left conditions) in regions 
showing a main effect of visual stimulation under placebo. Primary visual cortex 
(calcarine sulcus) showed greater stimulus-evoked activity under placebo than 
physostigmine, which did not differ significantly across conditions. This effect was 
unlikely to be due to a general vascular effect of drug, as it was not seen in either 
lateral occipital cortex that also showed main effects of visual stimulation under 
placebo (these regions can also be seen to show an effect of condition due to failure of 
activation during WM but not attention or control).  
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fMRI data: Effects of physostigmine on spatial attention versus control 
Under placebo, spatial attention versus control activated prefrontal, superior parietal 
and superior occipital cortices (Table 7.1; Fig. 7.4). These same areas were also 
activated under physostigmine. The direct comparison (i.e. group-by-task interaction) 
revealed that these regions were differentially modulated by cholinergic enhancement. 
Specifically, bilateral occipital and prefrontal cortices showed enhanced differential 
activity (mauve in Fig. 7.3), while superior-medial parietal cortex (green in Fig. 7.3; 
yellow in Fig. 7.6) showed reduced differential activity, during spatial attention 
relative to control, under physostigmine versus placebo. We note that the drug-
induced increases in bi-occipital activity with attention occurred to an equivalent 
degree in both attend-right and attend-left trials (Fig. 7.4B).  
 
Table 7.1: Regions showing effect of attention versus control, under placebo, and 
interaction of this with physostigmine. 
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Figure 7.4. Effects of physostigmine on spatial attention versus control. Surface 
rendering of regions showing activity during delay periods of attention versus control 
tasks, under placebo, physostigmine, and when comparing the two treatments for this 
effect. Graphs plot %  signal change from baseline for each task (separating attend-
right and attend -left conditions) in right and left occipital regions showing 
enhancement of attention versus control under physostigmine. Both regions showed 
an enhancement of attention relative to control activity on both attend right and attend 
left trials (**p < 0.001, uncorrected). The superior parietal region showing less 
activation under physostigmine for the same contrast is also shown in Fig. 7.6A.
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fMRI data: Effects of physostigmine on right versus left-spatial attention 
We next addressed whether physostigmine influenced the differential activation of 
right-versus-left occipital cortices (and vice versa) as a function of attended location. 
Under placebo, attending to either hemifield (versus the opposite hemifield) activated 
contralateral occipital cortex, stronger for right-versus-left attention than vice versa 
(Table 7.2, Fig. 7.5A). Under physostigmine, activation of occipital cortex 
contralateral to attended hemifield was also evident, although the volume of activation 
for this right-versus-left attention contrast was notably less. The direct between-group 
comparison of right-versus-left attention, and vice versa, showed that contralateral 
occipital cortex was less differentially activated under physostigmine than placebo for 
both hemispheres. Inspection of signal estimates indicates that this interaction was 
driven by greater ipsilateral than contralateral occipital cortex activation under 
physostigmine (Fig. 7.5B). 
 
Consequently, the effect of physostigmine on superior-middle occipital cortex was 
two-fold: 1) it increased activity selectively during the Attention task (rather than WM 
or control tasks); 2) it decreased the differential retinotopic activation observed as a 
function of visual-hemifeld cueing (i.e. Rvs L and vice versa) during the unmedicated 
session. The latter effect occurred because physostigmine enhanced occipital 
activations more within the hemisphere representing the unattended visual hemifield. 
 
Since physostigmine decreased cue-driven spatial biasing of occipital cortex, we 
determined whether there was an equivalent effect on performance. For the latter 
measure, we calculated the difference in accuracy between validly and invalidly cued 
trials ('invalidity effect') for each subject. There was a highly significant correlation 
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between drug-induced impairment of the invalidity effect and drug-induced 
attenuation in occipital activity lateralisation reported above (r = 0.70; p = 0.001; Fig. 
7.5C). In other words, where physostigmine decreased the spatial biasing of BOLD 
activity between right and left occipital cortices, there was a proportionate reduction 
in the differential processing of task-relevant versus task-irrelevant stimuli.  
 
Furthermore, those occipital regions manifesting a physostigmine-induced 
enhancement specifically during ipsilateral attention (versus control) showed a 
correlation of this effect with drug-induced improvement in accuracy of invalid trials 
(r = 0.51, p < 0.05; Fig. 7.5C; effect averaged over bilateral occipital peaks showing 
treatment × task interaction: −33, −87, 0 and 30, −81, 18). These BOLD-behavioral 
correlations, together with the fact that the peak signal estimates of both superior 
occipital regions in Fig. 7.5A were less (p < 0.05) than those observed elsewhere in 
superior occipital cortex (e.g.,  Fig. 7.4), argues against the possibility that a ceiling in 
the hemodynamic response could explain the treatment × laterality interactions. 
 
Table 7.2: Regions showing effect of lateralized attention, under placebo, and 
interaction of this with physostigmine
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Figure 7.5. (See next page): Effects of physostigmine on right versus left spatial 
attention and vice versa. (A) Surface rendering of visual regions showing activity 
during delay periods of attend-right versus attend-left and vice versa for placebo, 
physostigmine, and the difference between treatments for these effects. Graphs plot 
percent signal change from baseline for the three conditions (separating attend-right 
and attend-left conditions) in regions from right and left occipital cortices showing 
reduced differential activity to attend-left versus right (and vice versa) under 
physostigmine relative to placebo. The physostigmine-induced reductions in 
differential activity occurred as a result of physostigmine increasing activity during 
ipsilateral attended trials (*p < 0.05)  rather than due to drug-induced effects during 
contralateral attended trials (not significant). Dashed line indicates peak activity 
observed in right superior occipital region from Fig. 7.4 (which was significantly 
greater than the peak activity depicted here). RVF, right visual field; LVF, left visual 
field. (B) Scatter plot illustrates relationship between physostigmine-induced 
reduction in occipital lateralization and a behavioral measure of physostigmine-
induced reduction in stimulus selectivity. Values on x axis calculated as 
Placebo[contralateral - ipsilateral activity] - Physostigmine[contralateral - ipsilateral 
activity], averaged over both occipital peaks showing treatment x laterality 
interaction. Values on y axis calculated as Placebo - Physostigmine Invalidity Effect, 
where Invalidity Effect = valid trial - invalid trial accuracy. (C) Scatter plot illustrates 
relationship between physostigmine-induced enhancement of delay period activity in 
occipital cortex ipsilateral to cue location and accuracy on invalid trials. Values on x 
axis calculated as Placebo[ipsilateral - control activity] - Physostigmine[ipsilateral - 
control activity], averaged over both occipital peaks showing equivalent treatment x 
condition interaction.   
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Figure 7.5. For legend see previous page. 
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fMRI data: Effects of physostigmine on working memory 
The effect of working memory versus control task, under placebo, engendered 
activation in superior parietal and prefrontal cortices (Table 7.3). A similar network of 
fronto-parietal areas was also activated by the attention task, under placebo, as shown 
by a conjunction analysis over the two tasks (i.e. regions significantly active in both 
attention and working memory: red in Fig. 7.6). However, in contrast to the case in 
the attention task where superior-medial parietal cortex showed attenuated responses 
under physostigmine (yellow in Fig. 7.6), there was no drug-induced modulation of 
this area in the working memory task. The difference in drug effect on this region 
between attention and working memory conditions (i.e. group-by-task interaction) just 
fell short of conventional significance (6, -63, 60; Z = 2.77; p < 0.005, uncorrected; 
first graph). The only area showing an effect of drug on working memory activity 
(versus control) was in left inferior prefrontal cortex that showed less differential 
activation under physostigmine. There was no group-by-task interaction in this region.  
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Table 7.3: Regions showing effect of working memory versus control, under placebo, 
and interaction of this with physostigmine and showing the effects of both lateralized 
attention and lateralized working memory, under placebo, and interaction of these 
with physostigmine. 
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Fig. 7.6. Dissociation and commonalities of physostigmine effects on spatial attention 
and WM. (A) Regions within superior parietal and prefrontal cortices showing 
increased activity to the conjunction of attention and working memory, 
relative to control, under placebo (red). Superimposed  is that parietal region showing 
greater differential activity to attention versus control, under placebo relative to 
physostigmine (yellow). This region was not modulated by physostigmine during 
WM in spite of showing an even greater effect of WM relative to control under 
placebo. Graph plots percent signal change from baseline for the three conditions in 
superiormedial parietal region showing a treatment x condition (attention or WM) 
interaction (p < 0.005). Values have been mean corrected with respect to occipital 
regions (across groups) to facilitate interregional comparison. (B) Surface rendering 
of visual regions showing activity during delay periods of both WM-right versus left 
(i.e., whether study items were presented in right or left visual field) and attend-right 
versus left and vice versa, as revealed by a conjunction analysis of laterality effects 
over both tasks, for placebo, physostigmine, and the between-treatment effect. Graphs 
plot percent signal change difference between trials in which attention or WM were 
directed contralaterally versus ipsilaterally to each occipital side. Plots are from those 
coordinates showing the maximal treatment x laterality interaction (ringed) and 
demonstrate similar physostigmine-induced reductions in selective occipital 
activation with both attention and WM. (C) Surface rendering of visual regions 
showing physostigmine-induced enhancement of both attention delay (versus control 
delay) and WM encode (versus WM test) contrasts. Graphs plot percent signal change 
difference for both contrasts under placebo and physostigmine, in those occipital 
coordinates showing the maximal treatment effect on both contrasts (ringed).
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 Figure 7.6. For legend see previous page. 
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Discussion 
The present study sought to dissociate cortical effects of cholinergic enhancement on 
attention, from those on visual stimulation and working memory, by employing a 
design that minimised sensorimotor confounds between tasks and treatments (see 
Rowe et al, 2000). Physostigmine increased differential activity in bilateral superior 
occipital cortex during spatial attention, relative to both control and working memory 
conditions, but decreased differential activity in superior parietal cortex selectively 
with spatial attention. Physostigmine also modulated prefrontal cortex differently for 
attention and WM tasks. In contrast to an increase in superior occipital activity with 
attention, physostigmine decreased activity in primary visual cortex evoked by visual 
stimulation. Finally, physostigmine-induced enhancement of superior occipital cortex 
activity was greater on the side ipsilateral, than contralateral, to that spatially 
attended, resulting in a net reduction in selectivity of visual cortex activation under 
attention. This finding is supportive of models (Yu & Dayan, 2002; Hasselmo & 
Cekic, 1996) that predict acetylcholine decreases top-down influences on stimulus 
processing.   
 
We discount any explanation of our findings in terms of general effects of drug on 
blood oxygenation level dependent (BOLD) responses. Firstly, all task effects were 
corrected for session means, which themselves did not differ by treatment across any 
of the areas highlighted (nor was there a treatment effect in global activity). Secondly, 
certain task-by-treatment interactions (apparent in Fig. 7.4, 7.5 and 7.6) can only be 
explained by recourse to an effect of drug on specific cognitive processes. In the case 
of drug effects across all tasks (Fig. 7.3), we note that the effect reported was specific 
to only one part of visual cortex, arguing against a general change in BOLD 
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responsiveness. While a BOLD response ceiling could potentially explain a reduced 
occipital lateralisation under drug, we observe that the peak response is different 
between contiguous occipital regions (that would be unlikely in the case of a vascular 
ceiling). Furthermore, the behavioural-BOLD correlation found strongly suggests that 
the BOLD effects observed indeed mirror population neuronal activity. Finally, the 
fact that subjects reported more sedation with physostigmine argues against an 
'arousal' explanation for enhanced performance and BOLD responses under drug. 
Conceivably this effect on subjective alertness might reflects influences of 
physostigmine on brainstem / reticular formation.  
 
Cholinergic modulation of attention relative to other cognitive processes  
Our results of physostigmine-induced enhancement of occipital cortex, selectively 
with attention, but reduction in primary visual cortex activity to visual stimulation, 
bear similarity to an fMRI study by Furey et al (2000). Using an identical drug 
protocol, this group demonstrated physostigmine-induced enhancement of extrastriate 
cortex selectively during study, versus test, phases of a face working memory task, 
but a decrease within inferior occipital cortex to non-face stimuli during a control 
task. The results of our study help to narrow the interpretation of Furey et al, 2000 by 
suggesting that it was increased attention to study-phase faces, rather than stimulus-
related properties (e.g. first presentation of a face; see Experiment 1), or working 
memory demand, that accounted for the selective facilitation of occipital activity by 
physostigmine.  
 
One explanation for the specific effects of physostigmine on occipital activity is that 
more acetylcholine was released during attention, than other, conditions (see 
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Himmelheber et al, 2000), allowing physostigmine to have a greater local effect. 
Although the response profile in calcarine sulcus argues against this (by showing non-
selective physostigmine modulation: Fig. 7.3), this may reflect the fact that primary, 
relative to higher, sensory areas possess greater concentrations of cholinergic 
receptors (Mash et al, 1988; Prusky et al, 1988), and hence their cholinergic 
responsiveness may occur at lower concentrations of acetylcholine. An alternative 
explanation for the attention-specificity of physostigmine on extrastriate cortex is due 
to an effect of drug on higher processing centres (as we found in superior parietal and 
prefrontal cortices), which may have then indirectly augmented activations in sensory 
regions (see Sarter et al, 2001). The behavioural consequences of cortical cholinergic 
deafferentation have suggested that cholinergic inputs to rat prefrontal (Gill et al, 
2000), but not visual (Sarter et al, 2001), cortices are necessary for normal sustained 
attention. A future method by which direct versus indirect effects of cholinergic 
modulation on sensory cortices may be addressed is through connectivity analyses of 
human functional imaging data (Friston et al, 2002). 
 
Physostigmine decreased activity over all conditions in primary visual cortex, 
consistent with previous studies showing cholinergic reductions in posterior occipital 
cortices (Experiment 1; Mentis et al, 2001;Grasby et al, 1995; Thiel et al, 2001), and 
indicating that attention-specific cholinergic enhancement of occipital activity is 
limited to higher parts of the visual stream. We suggest that acetylcholine decreases 
net neuronal activity in early visual areas due to both noise suppression (e.g. Sato et 
al, 1987, Murphy & Sillito, 1991) and reduced feedback from higher centres 
(Hasselmo & Cekic, 1996; Kimura et al, 1999). In so doing, cholinergic modulation 
of early visual processing may both facilitate a feedforward direction of information-
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flow (Hasselmo & Cekic, 1996) and potentiate higher visual processing (as indexed 
by greater activation under physostigmine in higher visual areas in the present study, 
or in Furey et al, 2000; Experiment 1).  
 
In contrast to the wide effects of physostigmine on attention-associated activity, 
physostigmine’s modulation of working memory responses was restricted to inferior 
prefrontal cortex (similar to Furey et al, 2000). Notably, physostigmine decreased 
attention, but not WM-related, activity in superior parietal cortex, in spite of both 
conditions activating this region under placebo. This pattern of activity could be 
explicable, as for occipital cortex, either in terms of differing acetylcholine release 
between conditions, or as a difference in input to parietal cortex from other cortical 
regions (occipital and prefrontal cortices were more widely activated under attention 
than WM). We also note a parallel dissociation of drug effect on accuracy between 
attention (improved) and WM (no effect), in spite of the tasks being similarly difficult 
(under placebo, attention was performed slightly less accurately, but faster than WM). 
Such attention-specific effects of cholinergic manipulation mirror animal studies that 
de-emphasise the role of cortical acetylcholine in modulating short-term memory (e.g. 
Chappell et al, 1998; Baxter et al, 1996). We suggest that behavioural and neuronal 
effects of cholinergic drugs observed in human WM tasks (e.g. Furey et al, 2000; 
Lawrence et al, 2002; Ernst et al, 2001b; Kumari et al, 2003) act primarily through 
attentional components within these tasks.  
 
Cholinergic modulation of selective attention  
A most significant finding of our study was that, within the attention condition, 
physostigmine decreased the selectivity of visual cortex activation, through increasing 
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activation disproportionately on the occipital side ipsilateral (representing the 
irrelevant visual field), rather than contralateral, to the attended direction. 
Furthermore, subjects in whom this effect was greatest showed the least performance 
discrepancy between valid and invalid trials (the fact that this correlation crossed the 
abscissa suggests an additional factor, e.g. observed drug-induced fatigue, may have 
worked against the behavioural effect). This data supports psychopharmacological 
studies showing that cholinergic levels inversely correlate with the detriment 
engendered by invalid cues (Stewart et al, 2001; Witte et al, 1997; Chiba et al, 1999), 
and that the hypercholinergic state may be associated with heightened processing of 
irrelevant information, e.g. as in anxiety (Bernston et al, 1998). Our imaging results 
suggest a neural substrate for such enhanced processing of task-irrelevant stimuli. 
Interestingly, we note a similar effect of physostigmine on auditory cortical responses 
was observed in Thiel et al (2002), when responses to a behaviourally-irrelevant tone 
were increased disproportionately relative to a relevant (conditioned) tone. 
 
Summarising, we note that while cholinergic enhancement increases selectivity of 
occipital activation comparing tasks of different attentional demand (see also Furey et 
al, 2000), and increase selectivity of stimulus-evoked responses (e.g. Sato et al, 1987, 
Murphy & Sillito, 1991), it appears to decrease the selectivity of attention-driven 
modulation of occipital cortices. These findings are in keeping with two recent 
models (Hasselmo & Cekic, 1996; Yu & Dayan, 2002) which suggest that neocortical 
acetylcholine favours feedforward over feedback, processes. Such models propose 
that ACh is preferentially released under conditions of high uncertainty, e.g. sustained 
attention, with the effect of suppressing top down modulation of stimulus processing. 
Since such top down modulations of sensory cortices may involve a biasing between 
290 
Chapter 7 
 
mutually-inhibitory areas (e.g. Chelazzi et al, 2001), our results could be explained in 
terms of Yu & Dayan’s model (2002) by assuming that the disproportionate 
enhancement of occipital cortex, ipsilateral to attention, represented a disinhibition of 
attentional influences on the spatially-irrelevant side. This account may still be 
compatible with findings that ACh enhances signal-to-noise ratio (Sato et al, 1987), in 
that physostigmine increased task-related activations over a wider set of visual areas 
than placebo, and therefore enhance signal processing generally rather than 
selectively.   
 
Conclusion  
Physostigmine was found to improve subjects’ accuracy on a spatial attention, but not 
spatial working memory, task, while producing modulations of occipital and parietal 
cortex under the former, but not the latter, condition. Occipital cortex also exhibited 
different responses to physostigmine comparing attention (drug enhanced superior 
occipital cortex) with visual stimulation (drug suppressed primary visual cortex over 
all conditions). Finally, the selectivity of occipital activation normally observed under 
spatial attention was diminished under physostigmine. These results support a central 
role for the cortical cholinergic system in specifically attentional processing (Everitt 
& Robbins, 1997), and suggest that acetylcholine may bias the interaction of top-
down with bottom-up processes.  
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8. EXPERIMENT 4: 
Effects of ChEI on Visual and Attentional 
Processing in Healthy Elderly and  
Alzheimer’s Disease  
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Introduction 
 
An understanding of how the cholinergic neuromodulatory system interacts with 
cerebral cortical processing represents an important step in elucidating 
neuropsychological conditions such as Alzheimer’s disease, cortical Lewy body 
disease, vascular dementia, and head injury (Auld et al, 2002; Tiraboschi et al, 2000; 
Wilkinson et al, 2005; Conner et al, 2005). Conversely, studies of brain diseases 
associated with damaged cholinergic structures inform the normal physiology of 
acetylcholine as a central nervous system neurotransmitter. In Alzheimer’s disease, 
the association of acetylcholine with cognitive impairment is suggested by three 
principal facts: cortical cholinergic neurons, along with medial temporal structures, 
are preferential victims of the degenerative process in AD (Geula & Mesulam, 1989); 
selective lesions of cortical cholinergic neurons in animals reproduce the memory and 
attentional deficits found in Alzheimer’s disease (Everitt & Robbins, 1997); and 
cholinesterase inhibitors by increasing concentrations of acetylcholine throughout the 
brain help to improve, or slow the deterioration, in cognitive performance in AD 
(Rogers et al, 1998).  
 
Experiments 1 and 3 investigated the effects of cholinesterase inhibition on stimulus 
processing and attention in healthy young adults using fMRI. A starting hypothesis 
was that attention-related activations of parietal and sensory cortices would be 
enhanced with raised levels of acetylcholine, since animal-lesion studies have shown 
that corticopetal cholinergic fibres are necessary for sustained and selective visual 
attention (Sarter & Bruno, 1997), and administration of cholinesterase inhibitors to 
healthy humans had been associated with improved performance and heightened 
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extrastriate cortex responses (Davis et al, 1978; Furey et al, 2000). However, across 
three different paradigms (Experiment 1 and Experiment 3; also Thiel et al, 2002) the 
opposite effect was found: parietal activation and the differential activation of sensory 
cortices as a function of task or emotional memory (i.e. top-down influences) was 
mostly decreased by physostigmine in spite of subjects tending to be faster. One 
explanation for this lay in the findings that cholinergic enhancement increased sensory 
cortex activity non-specifically which may have a greater relative effect during 
conditions that do not normally activate sensory cortices compared to those conditions 
that, in the healthy brain, are already activated near to maximum (Experiment 3; Thiel 
et al, 2002). This is consistent with neurobiological models predicting that 
acetylcholine favors bottom-up over top-down sensory processing (Hasselmo & 
Giocomo, 2006; Yu & Dayan, 2005), and with data suggesting that excessive 
cholinergic stimulation underlies heightened processing of irrelevant stimuli (Thiel et 
al, 2005), including in anxiety (Bernston et al, 1998). 
 
In Alzheimer’s disease degeneration of cholinergic neurons that connect substantia 
innominata with cerebral cortex is an early pathological finding, whereas the intrinsic 
structure of sensory cortices is relatively spared (Geula & Mesulam, 1989). Animal 
studies have demonstrated that cholinergic stimulation of sensory cortices has 
facilitatory effects on stimulus-processing parameters such as selectivity and signal-
to-noise ratio (e.g. Sato et al, 1987, Murphy & Sillito, 1991), while cholinergic inputs 
to frontoparietal cortices provide a necessary contribution to tasks requiring sustained 
or selective attention (Sarter & Bruno, 1997). Behavioral testing in mild-to-moderate 
Alzheimer’s disease have recognised defects in both early sensory processing e.g. 
visual contrast sensitivity (Tippett et al, 2003) as well as with attentional manipulation 
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of sensory information (Perry et al, 2000; Baddeley et al, 2001). Consequently, it is 
reasonable to hypothesise that at least part of both the visual and attentional deficits in 
AD are due to a reduction of cholinergic input to sensory and frontoparietal cortices 
(see also Perry & Hodges, 1999). Using fMRI this hypothesis was tested by firstly 
examining differences in both visual and attentional processing between AD and 
healthy controls, and secondly by enquiring as to whether a restoration of normal 
activity can be achieved following administration of a cholinesterase inhibitor. 
Following on from the results of Experiments 1 and 3 in healthy young adults, the 
following predictions were made for an fMRI study comparing AD patients with 
healthy age-matched controls:  
 
1) Stimulus-selectivity in extrastriate cortex (BOLD-responses to face versus building 
visual stimuli, and vice versa) would be decreased in AD relative to controls, but this 
would be corrected with cholinesterase inhibition. 
 
2) Attention-dependent activations of frontoparietal cortex with attention would be 
diminished in Alzheimer’s disease relative to controls, but this would, at least 
partially, be reversed by cholinesterase inhibition. The direction of this 
pharmacological effect would therefore be opposite to what we expected in controls 
(see also Experiment 3; Furey et al, 2000; Thiel et al, 2005).  
 
3) Attention-driven modulation of extrastriate cortex (stimulus-selectivity compared 
between high and low attention-demanding tasks) would be decreased in AD relative 
to controls due to impaired recruitment of sensory cortex in the more attention-
demanding condition. Furthermore, this failure would be remedied by cholinesterase 
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inhibition. In other words, cholinesterase inhibition would produce the opposite 
attentional effect in AD as that seen in controls: an increase in stimulus-selectivity 
under the harder condition (in AD), rather than an increase in stimulus-selectivity 
under the easier condition (in controls). 
 
Methods 
 
Subjects 
Sixteen right-handed patients with newly-diagnosed Alzheimer’s disease and MMSE 
of 21 – 26 were recruited from the Dementia Research Group, National Hospital for 
Neurology and Neurosurgery (London, United Kingdom) over a fifteen month period. 
Seventeen right-handed healthy subjects, matched for age and sex, were recruited over 
the same period. No subjects were active smokers. Characteristics of the two groups 
are listed in Table 8.1. All subjects gave written informed consent. The inclusion 
criteria for patients were: (i) probable Alzheimer’s disease according to international 
criteria (National Institute of Neurological and Communication 
Disorders/Alzheimer’s Disease and Related Disorders Association (NINCDS-
ADRDA) and the Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition (DSMIV). Exclusion criteria for patients were: (ii) alternative or additional 
diagnosis contributing to cognitive symptoms considered possible; this was assessed 
following a full neuropsychological, neurological and  general clinical examination, 
as well as dementia-screening blood tests, chest x-ray, brain MRI, 
electroencephalography, and cerebrospinal fluid examinations (where felt to be 
appropriate for diagnosis); (iii) mild cognitive impairment; (iv) major visuospatial or 
visuo-perceptual impairment or severe apraxia; (v) coexistent significant central 
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nervous system disease, e.g. no epilepsy, movement disorder, head injury, drug nor 
alcohol abuse; (vi) receiving psychoactive drugs, including cholinesterase inhibitors, 
N-methyl-D-aspartate antagonist, or antidepressants. Patients or healthy subjects 
found to have significant lesions on brain MRI (other than Alzheimer’s disease-
associated changes in the case of the Alzheimer’s disease group) such as ischemic 
changes, were excluded. 
 
All patients were started on therapeutic oral cholinesterase inhibitor following the 
second experimental session, and were followed up for a minimum of one year to 
ensure that no other features developed that would suggest an alternative cause for 
dementia. 
 
Table 8.1: Characteristics of control and Alzheimer disease subjects (±95% 
confidence intervals). 
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Drug-treatment 
A double-blind placebo-controlled drug administration technique was used. Each 
subject received an intravenous cannula into the left cubital fossa and an infusion of 
either physostigmine or saline, depending on session. In the drug-session, subjects 
first received 0.2 mg intravenous glycopyrrolate (peripheral muscarinic receptor 
antagonist) before being administered an infusion of physostigmine at a rate of 1mg / 
hr. Testing took place at 25 minutes from the start of the infusion. In the placebo-
session, an equivalent volume of saline was administered in all steps. We employed a 
lower dosage of physostigmine relative to Experiments 1, 2 and 3 that had used 
subjects aged between 20 and 30, since a pilot study showed an unacceptably high 
level of adverse effects (predominantly nausea and vomiting in 4/6 subjects) in the 
age-range of the present study. The dosage and timing schedule of physostigmine that 
we used was based upon previous studies in which performance improvements were 
observed over a range of tasks in Alzheimer’s disease (Christie et al, 1981; Asthana et 
al, 1995; Davis &Mohs, 1982; Muramoto et al, 1984). 
 
Cognitive task 
On each of two sessions (placebo / physostigmine), subjects performed two tasks 
(Colour and Age: Figure 8.1) separated into blocks of 48 trials each, and repeated 
once in one of the following orders: CACA, ACAC, CAAC, or ACCA. Treatment and 
task order were counterbalanced across subjects, with task-order being repeated across 
sessions. The two sessions were separated in time by 1 – 2 weeks. Both tasks 
comprised serial presentation of either faces or buildings with no image being 
repeated across both sessions. The images for both tasks were presented in 
isoluminant red or green monochrome. The Colour task required an indication as to 
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whether an image was red or green; the Age task required a judgment as to whether 
the featured face or building was old or young (the latter choice denoting ‘modern’ in 
the case of buildings).  
 
The stimulus set comprised an equal number of ‘young’ (individuals aged 21-35) and 
‘old’ faces (individuals aged over 65), as well as the same and an equal number of 
modern (e.g. office-blocks) and old buildings (e.g. castles). We excluded faces and 
buildings that were famous or depicted from a non-canonical view, and faces with 
overtly emotional expressions. The particular stimuli comprising any session were 
counterbalanced for task, treatment and group between subjects. Responses were 
recorded by one of two possible button-presses made with the right-hand. The SOA 
was 4.05 seconds with images being presented for 1 sec. A reminder of the button 
meanings for that block preceded each image. Subjects were taught and practiced the 
tasks with repeating stimuli sixty minutes prior to scanner entry (at each session) for 
as long it took them to achieve a stable performance. A short practice run was also 
performed before each block in the scanner. Subjects were informed that a recognition 
test of faces was to be carried out after scanning but were told to perform their best on 
the judgements tasks and not to concentrate on memorising items. Images were 
presented at central fixation and subtended 5º vertically and 3º horizontally.  
 
Subjects were fitted with appropriate MRI-compatible refractive lenses where 
required. Eye movements were monitored with an infra-red eye tracker (ASL Model 
540, Applied Science Group Co., Bedford, MA; refresh rate = 60 Hz) in 16 control 
and 11 AD subjects.  
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Figure 8.1: Task design. In the scanner, subjects performed one of two tasks in block-
fashion: Colour task: subjects were prompted as to whether the image was red or 
green; Age task: subjects were prompted as to whether the depicted object was old or 
young /modern. Face and building-stimuli occurred with equal frequency in each task. 
Subjects were reminded of the key-press meanings prior to each stimulus.  
 
 
 
 
 
 
 
 
 
 
 
Imaging and image processing 
Data were collected on a 1.5 T MRI scanner (Siemens, Erlangen, Germany) using 
gradient echo T2*-weighted echo-planar images, with blood oxygenation level 
dependent (BOLD) contrast. Volumes consisted of 39 horizontal slices through the 
whole brain, each 2mm thick with a 1mm gap between slices (field-of-view, 192 x 192 
mm
2
; matrix size 64 x 64). In-plane resolution was 3mm×3mm; effective repetition time 
(TR), 3.51 s; echo time (TE), 50ms, and flip angle 90°. For each block 63 volumes were 
acquired, with the task only beginning after the sixth volume to allow for T1 equilibration 
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effects. Imaging data were pre-processed and analysed using SPM2 (Wellcome 
Department of Imaging Neuroscience, London; http://www.fil.ion. 
ucl.ac.uk/spm). Preprocessing consisted of determining and applying rigid affine 
transformations to the image series to realign the scans (Friston et al, 1995a), 
normalization (Friston et al, 1995a) to a standard EPI template in MNI space and 
smoothing with a three-dimensional 8mm Gaussian kernel to account for residual 
inter-subject anatomical differences.  
 
Statistical analysis of images 
Data were analyzed with a general linear model for blocked, event-related designs 
(SPM2; Wellcome Dept. of Cognitive Neurology, London, UK; Friston et al, 1995) 
using a random-effects analysis. Data were globally scaled and high-passed filtered at 
1/256 Hz. Events were modelled by delta functions convolved with a synthetic 
hemodynamic response function (Friston et al, 1998); temporal derivatives of these 
functions were modelled separately (Friston et al, 1998). Within-subject conditions of 
interest were stimulus-type, task, and treatment. Stimuli in different scanning-blocks 
were modelled separately to enable estimation of session effects. Six-dimensional 
head movement parameters derived from image-realignment were included within the 
model as confounding covariates.  
 
Differences of activity between conditions of interest (stimulus-type, task and their 
interaction) were estimated for each subject and treatment (i.e. parameter estimates), 
before being submitted to one-sample t-tests and generation of statistical parametric 
maps (SPMs) of the t-statistic. The analyses report effects for stimulus-selectivity, 
task and task x stimulus interactions in control subjects in the drug-free state where 
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voxels are significant at p<0.05, corrected (false-discovery rate) for a visual cortex 
mask for stimulus-dependent effects, or for whole-brain volume for task effect. The 
visual cortex mask was constructed manually using MRIcro software 
(www.mricro.com) and the combined-group mean EPI image so as to include the 
entire occipital, temporal and parietal lobes but excluding somatosensory and auditory 
cortices - thereby encompassing activations from Experiment 1 that employed similar 
stimulus classes. The interaction of task x stimulus was qualified by masking with 
simple effects of stimulus-selectivity at each task level (thresholded at p<0.01, 
uncorrected). In the task analysis, the threshold was dropped to p<0.001, uncorrected, 
in order to explore effects in prefrontal cortex that was an a priori region of interest 
and that did not show significance at the whole-brain level. Having identified regions 
showing the primary effects (stimulus, task and stimulus x task) in drug-free controls, 
we then interrogated within these areas (thresholded at p<0.01, uncorrected) for 
interactions of these primary effects with group; with treatment in each group 
separately, and with a treatment-by-group interaction (reported at p<0.001, 
uncorrected). We also report regions that showed enhanced stimulus and/or task-
effects in AD relative to controls and inspected for interactions with treatment (x 
group) within these regions (p<0.001, uncorrected). Group-effects were overlaid on 
mean-normalised functional images of the appropriate group(s) to enable anatomical 
localisation. 
  
Results
 
Physiological data, subjective reports, and eye tracking 
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On both sessions, blood pressure was checked before and after scanning, whilst pulse-
oximetry was performed continuously. Subjects were given a questionnaire before and 
after scanning that allowed a ranked measurement (0 – 6 scale) of seven recognised 
adverse reactions to physostigmine and glycopyrrolate, as well as visual analogue 
scales for alertness and physical wellbeing. For blood pressure, there were no effects 
of drug, time-point, or group, nor interactions between these factors (p>0.05). The 
only physical side-effects reported after the physostigmine (with glycopyrrolate) 
session, and documented in more than one subject, were nausea (controls: 4; AD: 4 
subjects; median severity 1.5/7 within these subjects) and dry mouth (controls: 8; AD: 
7; median severity 3/7). Subjective scores of alertness and physical wellbeing both 
showed an interaction of time-point with treatment (p<0.01) reflecting mean 
reductions over time by 0.14 and 0.15, respectively (on a scale of 0-1) under 
physostigmine, compared to 0.05 and 0.03, respectively under placebo. However, 
there was no effect of group or interaction of group with treatment and time (p>0.1) 
for either measure. The frequency and type of side-effects associated with 
physostigmine are similar to those reported in Experiments 1 and 3.  
 
Saccade frequency was 0.8% in controls and 1% in patients. There were no 
interactions of eye-movement with stimulus-type, task, treatment or group.   
 
Behavioural 
RT and accuracy were submitted to between-subject (controls versus AD) repeated-
measures ANOVAs with factors of stimulus (building, face), task (Colour, Age), and 
treatment (placebo, physostigmine) (Figure 8.2). For both RT and accuracy, there 
were main effects of task (F(1,31)>24, p<0.01),and group (F(1,31)>4, p< 0.05), as 
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well as a task x group interaction for accuracy (F(1,31)=9, p<0.01) reflecting a greater 
impairment of performance by AD relative to controls with Age task relative to 
Colour task (task effect in AD: F(1,15)=16, p<0.01; in controls: F(1,16)=8, p<0.05). 
The equivalent interaction for RT showed a non-significant trend (F(1,31)=2, p=1.3). 
The effect of treatment manifested itself as a strong interaction of treatment x group x 
task (F(1,31)=9, p<0.01) for RT. Hence whilst there was no treatment effect on 
performance in controls, physostigmine in AD shortened RTs during Age 
(F(1,15)=14, p<0.01) but not Colour (F(1,15)=0, ns) tasks (F(1,31)=10, p<0.01, for 
the treatment x task interaction). This effect was also present when face and house 
stimuli were analysed separately (p<0.05 for each stimulus-class; there was no 
treatment x group x task x stimulus interaction) even though Age judgements were 
more difficult for buildings than faces across all subjects (task x stimulus interaction 
(F(1,31)>4, p<0.05 for both measures).       
 
Figure 8.2: RT and accuracy responses separated by stimulus-type and task for each 
combination of group and treatment. * denotes significant task x treatment 
interactions for the AD group (p < 0.05). 
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fMRI data: Session effects 
Estimates of the mean BOLD signal across each session were obtained both for the 
whole-brain (global) and in regions described above showing stimulus and task effects 
in controls. These were subjected to between-group repeat-measures ANOVAs with 
group, task and treatment as factors. Both global and regional session BOLD 
estimates were influenced neither by a main-effect nor by an interaction between any 
of these factors (p>0.05).  
 
fMRI data: Effects of physostigmine on stimulus-selectivity 
We first identified regions of extrastriate cortex that were selective in their response to 
faces versus buildings, and to buildings versus faces. The main effects of stimulus 
type in controls under placebo are listed in Table 8.2 (1st column; also Figs. 8.3A, 
8.3G, 8.5A). The regions listed are similar to those found in numerous previous 
studies for corresponding contrasts of faces versus houses (instead of buildings, as 
here) and vice versa (see Experiment 1). AD activated a similar set of areas (8.3B, 
8.3H, 8.5B), but a direct comparison of stimulus-selectivity between groups in the 
drug-free state revealed a subset of these regions for which selectivity of both classes 
of stimulus was reduced in AD relative to controls (Table 8.2, 2nd column; Figs. 8.3E, 
I). There were no regions in which AD showed greater stimulus selectivity.  
 
Physostigmine was found to reduce both face and building selectivity in many of the 
regions identified in controls under placebo (3rd column; Figs. 8.3C, J). In AD (4th 
column), physostigmine modulated stimulus-selectivity in one of two ways that 
corresponded to whether there had been a difference in stimulus-selectivity between 
AD and controls in the drug-free state: in right fusiform cortex, the region showing 
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the strongest face-selectivity, and where there was no difference between groups in 
stimulus-selectivity (p>0.1; peak coordinate in AD being 40, -54, -24; Z = 4.26), 
physostigmine resulted in a similar decrease of stimulus-selectivity as had been 
observed in controls (Fig. 8.3D, M – 1st graph). By contrast, in another face-selective 
region, precuneus, and in one building-selective region, right posterior 
parahippocampal cortex, where AD had shown reduced selectivity relative to controls, 
physostigmine resulted in increased selectivity in AD (Figs. 8.3F, K, M – 2nd and 3rd 
graphs). Consequently, both regions responded to physostigmine in an opposite 
manner comparing controls and AD as demonstrated by the group x treatment x 
stimulus-selectivity interactions (Table 8.2, final column; Fig. 8.3L).   
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Figure 8.3: (See next page): A, B – Main-effect of face > building in controls (A) and 
AD (B) on placebo at the level of mid-fusiform cortex and precuneus (y = -50). C, D 
– Interaction of face-selectivity x treatment in controls (C) and AD (D) demonstrating 
reduced selectivity in right fusiform cortex with physostigmine in both groups (y = -
50 and -54, respectively). There was no between-group difference in face-selectivity 
or in the interaction of selectivity x treatment in the right fusiform cortex (p>0.1). E, F 
– E: interaction of face-selectivity x group (on placebo) demonstrating reduction of 
selectivity in AD relative to controls in precuneus. F: interaction of face-selectivity x 
treatment in AD demonstrating increased selectivity in precuneus with physostigmine 
relative to placebo. G, H, I – Main-effect of building > face in controls (G), AD (H) 
and the difference between them (I), on placebo, at the level of parahippocampal 
cortices (z = -16), demonstrating reduction of selectivity in AD relative to controls in 
posterior parahippocampal cortex. J, K, L – Interaction of building-selectivity x 
treatment in controls (J) and AD (K) demonstrating that physostigmine induces a 
reduction of selectivity in controls (J) but an increase in selectivity in AD (K) in right 
posterior parahippocampal cortex. L depicts the interaction of building-selectivity x 
treatment x group. M – Plots of %-signal change for face > building contrast in right 
fusiform cortex, and precuneus, and for building > face contrast in right posterior 
parahippocampal cortex, under each combination of treatment and group. Coordinates 
plotted are those at the maxima of selectivity x treatment interaction in controls (first 
graph); and selectivity x treatment in AD (second and third graphs). Activations are 
thresholded at p<0.001, uncorrected, and are superimposed on the mean normalised 
EPI of controls or patients as appropriate (group interactions are overlaid on patients’ 
mean).
Chapter 8 
Figure 8.3. For legend see previous page. 
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Table 8.2: Effect of stimulus-type on extrastriate cortex.  
Chapter 8 
fMRI data: Effects of physostigmine on task-related activity independent of 
stimulus type 
The contrast of Age – Colour in controls in the drug-free state yielded strong 
activations within right posterior parietal cortex (Table 8.3 – 1st column; Fig. 8.4A). 
At a less conservative statistical threshold (p < 0.001, uncorrected for whole-brain) 
there were also activations of right dorsolateral and left inferior prefrontal cortices; 
there was no effect of stimulus-type in any of these areas (p>0.5). In AD, Age – 
Colour activation was found most strongly in bilateral posterior parietal cortices (46, -
56, 52; -40 -70 42; Z>4.07; Fig. 8.4B). However, the right parietal and left prefrontal 
cortex activations were less in AD than in controls (group x task interaction under 
placebo; 2nd column: Figure 8.4C). There were no regions for which the task effect 
was greater under AD than controls. Physostigmine administered to controls resulted 
in a reduction of the task effect in both right parietal and left prefrontal cortex 
(treatment x task interaction; 3rd column: Fig. 8.4D); simple-effect analysis revealed 
that this was contributed to by both a drug-induced increase of activity in Colour task 
and decrease in Age task relative to placebo (p<0.05 for both). When administered to 
AD, physostigmine had the opposite effect: task-dependent activations increased in 
right parietal cortex (treatment x task interaction; 4th column; Fig. 8.4E; there was a 
trend for the same effect in left inferior prefrontal cortex at p = 0.006, uncorrected) 
although this was due exclusively to an effect during the Age task (p<0.5 in both 
regions). Therefore the regions that had shown decreases in task effect comparing AD 
with controls in the drug-free state were also those that showed enhancements of task-
related activity following physostigmine. The differences in response to 
physostigmine between groups were confirmed by significant group x treatment x task 
interactions at both points (5th column; Figure 8.4F). Furthermore, the drug-induced 
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increase in relative parietal activation in AD was not explained by the relative change 
in RT between tasks: the effect was still significant (Z = 3.49) when individual RT 
difference (between treatment and task) was modelled as a nuisance variable in an 
analysis of covariance. 
 
Figure 8.4. (See next page): A, B, C – Main-effect of task (Age > Colour) in controls 
(A), AD (B), and the difference between them (C), on placebo. There were no 
interactions with stimulus-type in regions shown (p>0.1). D, E, F – Interaction of task 
x treatment in controls (D), AD (E) and the difference between them (F): regions 
shown are those in which the task-effect is decreased by physostigmine relative to 
placebo in controls (D) but increased by physostigmine relative to placebo in AD (E).  
G – Plots of %-signal change for Colour and Age tasks, for each treatment and group 
at the maxima for the 3-way interaction (from F). Activations are thresholded at 
p<0.001, uncorrected, and are superimposed on the mean normalised EPI of controls 
or patients as appropriate (group interactions are overlaid on patients’ mean).  
Chapter 8 
Figure 8.4. For legend see previous page. 
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Table 8.3. Effects of task independent of stimulus-type (first row section) and task on stimulus-selectivity effects (second row section).  
Chapter 8 
fMRI data: Effects of physostigmine on task x stimulus-selectivity interaction 
The next analysis examined the interaction of stimulus-selectivity with task. In the 
control group, under placebo, face-selectivity was enhanced with Age versus Colour 
task in right posterior superior temporal sulcus (pSTS), while building-selectivity was 
increased in left posterior occipital cortex for the same task-comparison (Table 8.3 – 
1st column; Fig. 8.5C). There were no regions in which stimulus-selectivity was 
greater with Colour than Age. In AD, the effect of task on selectivity in these two 
regions was less than that in controls (2nd column; Fig. 8.5D, E). Physostigmine 
given to controls also lessened the effect of task on stimulus-selectivity in the same 
two areas (3rd column; Fig. 8.5F). However, the manner by which task-driven 
modulation of selectivity was lessened differed between effect of group and effect of 
treatment as revealed by separate analyses of each task. Hence for the factor of group, 
significant AD-associated diminutions of stimulus-selectivity were seen with Age task 
in both areas, although right pSTS also showed an additional AD-associated increase 
in selectivity with Colour task (p < 0.05 for all). On the other hand, the treatment x 
task x stimulus interactions in the control group were driven by increases in 
selectivity with the Colour task (p < 0.05) rather than by decreases in selectivity with 
the Age task (p > 0.1). In the AD group, physostigmine increased stimulus-selectivity 
in both areas comparing Age to Colour tasks (4th column; Fig. 8.5G), effectively 
restoring a similar relationship between task and selectivity as had been observed in 
controls in the drug-free state. This drug effect in AD was achieved through an 
increase in selectivity in Age tasks in both regions as well as a decrease in selectivity 
in Colour task in right pSTS (p<0.05 for all). The effect of physostigmine on the task 
x stimulus-selectivity interaction was therefore opposite between controls and AD, 
showing itself as strong group x treatment x task x stimulus interactions in both 
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regions (p<0.0001, uncorrected; Fig. 8.5H). A subject-based correlation analysis of 
the task x stimulus x treatment interaction in the above two extrastriate regions with 
the task x treatment interaction identified in right parietal cortex, in AD, identified a 
significant correlation with the right pSTS (r = 0.50, p<0.05); but not left posterior 
occipital region (r = -0.05).   
 
The AD group showed alternative patterns of stimulus-selectivity x task interactions 
compared to controls. Left lateral occipital cortex showed enhanced face-selectivity 
under Age versus Colour (-38, -74, 8; Z = 4.93; p<0.05, corrected; Fig. 8.5I), whilst 
right superior occipital cortex showed enhanced house-selectivity under Age versus 
Colour (36, -86, 18; Z = 3.90; p<0.0001, uncorrected). The former region differed 
significantly from controls who did not demonstrate task-modulation of selectivity in 
this area (group x task x stimulus interaction: Z = 5.79; p<0.05 corrected). When 
physostigmine was administered to AD this region just lost its task-dependency 
(treatment x task x stimulus interaction: Z = 3.01; p = 0.001 uncorrected) and so 
reverted to the control pattern. Controls were uninfluenced by physostigmine in this 
area (treatment x task x stimulus interaction: Z = 3.87; p < 0.001 uncorrected; Fig. 
8.5J; third graph). 
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Figure 8.5. (See next page): A, B – Main-effect of face > building (first slice) and 
building > face (second slice) stimuli in control (A) and AD (B) subjects on placebo. 
The slices chosen include regions which additionally show interactions with task, 
treatment and group as illustrated below. Regions shown for face-selectivity are 
bilateral posterior STS (z = +12); and for building-selectivity are lateral occipital and 
retrosplenial cortices (z = +2).  C, D, E – Interaction of stimulus-selectivity x task in 
controls (C), AD (D) and the difference between them (E) on placebo: regions shown 
are those in which Age relative to Colour task results in greater face-versus-building 
(first slice) and building-versus-face (second slice) responses. F, G, H –  Interaction of 
stimulus-selectivity x task x treatment in controls (F), AD (G) and the difference 
between them (H): circled regions are those in which task-enhancements of face- and 
building- selectivity are decreased by physostigmine relative to placebo in controls 
(F) but increased by physostigmine relative to placebo in AD (G). I – Interaction of 
stimulus-selectivity (face > building) x task in controls (first slice) and AD (second 
slice); region circled shows greater task task-modulation of stimulus-selectivity in AD 
relative to controls, that itself is cholinergic dependent (z = +8; see text). J – Plots of 
%-signal change for face > building (first and third graphs) and building > face 
(second graph) contrasts, under each task, treatment and group at the maxima for the 
4-way interaction (from H; first two graphs) and at the maximum task x stimulus 
interaction in AD (from I; third graph). Activations are thresholded at p<0.001, 
uncorrected, except for F and G that are thresholded at p<0.01, uncorrected, and are 
superimposed on the mean normalised EPI of controls or patients as appropriate 
(group interactions are overlaid on patients’ mean).  
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Figure 8.5. For legend see previous page.  
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Discussion
 
The present experiment set out, firstly, to compare neurophysiological responses to 
stimulus and task-effects between Alzheimer’s disease and healthy age-matched 
controls and, secondly, to examine how cholinergic enhancement modulates these 
effects. Our results can be summarised as follows: 
 
1. Across two visual discrimination tasks Alzheimer’s disease patients performed 
poorer and showed weaker levels of stimulus-selectivity in several regions of 
extrastriate visual cortex than healthy age-matched controls; physostigmine improved 
selectivity in two of these regions specifically in AD. Right fusiform cortex, by 
contrast, showed an equivalent level of face-selectivity compared with controls, and 
was negatively modulated by physostigmine in a manner that matched controls.  
 
2. The performance of AD subjects relative to controls was more impaired in the Age 
than Colour discrimination task, which corresponded with AD relative to controls 
showing less task-dependent activity in right parietal and left prefrontal cortices. The 
administration of physostigmine to Alzheimer’s disease subjects resulted in both a 
task-specific improvement in performance and a relative increase in appropriate task-
related activity in right parietal cortex (and a trend for this effect in prefrontal cortex).  
 
3. Appropriate task-dependent modulations of stimulus-selectivity seen in controls in 
two extrastriate regions (i.e. greater for Age than Colour tasks) were reduced in AD. 
Physostigmine reversed this AD-associated impairment by enhancing stimulus 
selectivity during the Age task in both regions as well as reducing selectivity during 
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the Colour task in one region. Conversely, an additional extrastriate cortex region that 
showed maladaptive task-dependent modulation of stimulus-selectivity in AD 
reverted to the control pattern of being task-independent with physostigmine. 
  
4. In contrast to AD, when physostigmine was administered to healthy controls there 
were decreases in cortical stimulus-selectivity as well as reductions in task-dependent 
effects in frontoparietal cortex and in the interaction of task on stimulus-selectivity in 
extrastriate cortex. The effect of drug on task modulation of stimulus-selectivity in 
controls was primarily driven by enhancements in selectivity during the Colour task, 
although drug effects in frontoparietal cortex were contributed to by opposing effects 
in each task. 
 
Cholinergic modulation of stimulus-selectivity 
Psychophysical and functional imaging studies in mild-to-moderate Alzheimer’s 
disease have demonstrated defects in both early and late stages of visual processing 
(Tippett et al, 2003; Prvulovic et al, 2002), some of which correlate with the degree of 
cognitive impairment (Rizzo et al, 2000; Pietrini et al, 2000). However, given that 
sensory cortices are relatively spared from degeneration until the disease becomes 
advanced, one possible explanation for this impaired performance is that a deficiency 
of cholinergic input to sensory regions secondary to the recognised degeneration of 
basal forebrain in AD is responsible. Since stimulus-selective responses of occipital 
neurons have been shown to be influenced either positively or negatively by 
cholinergic enhancers or antagonists, respectively (e.g. Sato et al, 1987, Murphy & 
Sillito, 1991), we might expect AD to show an impaired level of stimulus-selectivity 
that is to some extent correctible with cholinergic enhancement. We tested this by 
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employing a comparison of ‘faces versus places’, which although differ from each 
other across numerous physical properties, nevertheless, offer a robust fMRI measure 
of high-order visual processing that is more likely to detect disparities between AD 
and controls than using simple visual stimuli (Mentis et al, 1998; Dannhauser et al, 
2005). Our results show that stimulus-selectivity of extrastriate cortical regions is 
diminished in AD relative to controls in a significant proportion of areas that are 
normally activated in controls. In two of these areas – precuneus (face-selective) and 
posterior parahippocampal cortex (building-selective) - cholinergic enhancement 
increased selectivity in AD, thereby supporting the proposal that a cholinergic 
deficiency is, in part, responsible for the visual processing deficit in AD.  
 
A further notable aspect of our data is that whereas superior occipital, precuneus and 
parahippocampal cortices showed impaired stimulus-selectivity in AD relative to 
controls, right fusiform cortex – the region showing the strongest face-selective 
responses - was unaffected. The finding is consistent both with previous functional 
imaging studies in AD that demonstrate a relatively greater attenuation of activations 
in dorsal parieto-occipital (Prvulovic et al, 2002) and medial parietal (Bradley et al, 
2002) than temporo-occipital areas, and with the association of AD with atrophy in 
medial relative to lateral temporal structures (Chan et al, 2003). Additionally, the fact 
that functionally-impaired parahippocampal and precuneus regions showed stimulus-
selectivity increases with physotigmine, while functionally-intact fusiform cortex 
showed the control pattern of a decrease, is evidence for a selective, rather than 
uniform, loss of cortical cholinergic inputs in AD. Of relevance to our findings is that 
precuneus was also the region most strongly enhanced by the cholinesterase inhibitor 
galantamine in a visual working memory task in patients with mild cognitive 
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impairment (MCI) (Goekoop et al, 2004). The fact that physostigmine reduced 
stimulus selectivity in many visual extrastriate regions, in healthy elderly, may reflect 
electrophysiological findings from non-human studies showing that acetylcholine 
potentiates responses more to inputs that prior to drug are non-dominant, relative to 
those that were dominant (Kuo et al, 2010); or reflect acetylcholine inducing increases 
in sensory responsiveness at the cost of reducing stimulus selectivity (e.g. Sato et al, 
1987a; Zinke et al, 2006; Herrero et al, 2008; but see also Murphy & Sillito, 1991). 
 
Cholinergic modulation of attention: frontoparietal effects 
Whilst amnesia is the hallmark of Alzheimer’s disease, attentional impairments are 
well described even in early stages of the disease (Perry et al, 2000; Baddeley et al, 
2001). Furthermore, whereas the memory impairment of AD seems to derive largely 
from selective atrophy of medial temporal structures (Chan et al, 2003), the 
attentional defects of AD most likely reflect a deficiency of input – both cortico-
cortical and cholinergic – to areas that are relatively structurally intact (Perry & 
Hodges, 1999). This is consistent with the observations that cholinesterase inhibitors 
improve attention more than memory scores in AD (Lawrence & Sahakian, 1995; Blin 
et al, 1998) and that lesions to basal forebrain cholinergic neurons induce deficits in 
visual-attention more than memory tasks (Everitt & Robbins, 1997). One of the 
principal aims of our study was to test whether AD-associated impairments in 
attention, at combined behavioral and neurophysiological levels, are cholinergic 
dependent. We found that AD patients compared to healthy age-matched controls 
showed relatively greater impairment of both performance and frontoparietal 
responses with a more attention-demanding task, and that both relative differences 
decreased following administration of a cholinergic enhancer.  
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The strongest task-related activation in our design was right parietal cortex – a region 
that has previously been found to show impaired activation in AD during attentional 
paradigms (Hao et al, 2005; Prvulovic et al, 2002; Parasuraman et al, 1992; Buck et 
al, 1997). We expected this region to manifest cholinergic sensitivity given a wealth 
of animal studies, largely using visuospatial paradigms, that show a critical 
dependency of attention on cholinergic inputs to parietal cortex (see Sarter & Bruno, 
1997 for review). As well as replicating the previous finding of impaired task-related 
attention in right parietal cortex in AD, we have shown that cholinergic enhancement 
can partially restore the normal pattern of task-dependent parietal activation. This 
result still stood even after controlling for drug effects on reaction time, suggesting 
that the drug-induced differences in BOLD activity were not merely caused by 
differences in motor activity (Honey et al, 2000). Equally, however, it suggests that 
the drug-induced differences in BOLD activity cannot be the sole cause of the 
behavioural improvement.    
 
Control subjects were also found to activate two prefrontal regions, one of which – 
left inferior prefrontal cortex - was underactivated in AD. Recent fMRI studies in 
mild AD / MCI have also found hypoactivation of left prefrontal regions during 
divided attention (Dannhauser et al, 2005) and visual search (Hao et al, 2005) tasks. 
Physostigmine showed a non-significant trend to enhance left prefrontal cortex in our 
study, that may reflect the weak activation of this region in controls. By contrast, an 
fMRI-study employing a working memory task that engaged prefrontal cortex 
strongly in controls but not MCI, demonstrated enhancement within this region 
following a six-week course of donepezil (Saykin et al, 2004).   
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Cholinergic modulation of attention: extrastriate effects 
A central role of the cortical cholinergic system is in balancing executive-attentional 
control of sensory processing with stimulus-driven sensory activity (Sarter & Bruno, 
1997). Cholinergic inputs to frontoparietal cortex are necessary for selective visual 
attention, by which is meant a preferential facilitation of task-relevant stimulus-
encoding neurons. Since frontoparietal activity in AD is impaired during attentional 
tasks (see above), we predicted a ‘knock-on’ detrimental effect in the attentional-
modulation of extrastriate cortex; furthermore, we predicted that this would be 
sensitive to cholinergic manipulation. In order to test for this we chose two tasks that 
differed from each other in the required level of visual processing while using the 
same two types of visual stimuli between tasks. The difference between stimulus 
types – face versus building - was incidental in the Colour task, but contained feature 
information critical to performance in the Age task. We avoided adopting a selective 
spatial attention task as had been employed in our previous studies as we anticipated 
AD patients would have difficulty maintaining central fixation.  
 
The results in healthy elderly subjects showed that face-selectivity was modulated by 
task in right pSTS, while right fusiform cortex was unaffected – in keeping with the 
distinct roles ascribed to face-sensitive regions of extrastriate cortex (Haxby et al, 
2000). Building-selectivity was modulated by task in early visual regions 
(approximately V2/3) that encode for features such as orientations and angles, and are 
strongly activated by houses versus faces (e.g. Experiment 1). While the overall level 
of stimulus-selectivity did not differ significantly in these two regions between 
controls and AD, the influence of task on selectivity in these areas was impaired in 
323 
Chapter 8 
AD. Importantly, physostigmine given to AD enhanced the degree to which stimulus-
selectivity was favored with Age relative to Colour tasks in the same regions that AD 
had exhibited an impairment of this effect. Hence the action of cholinesterase 
inhibition within these extrastriate regions was neither on baseline activity, nor on the 
main-effect of stimulus selectivity, but specifically on the executive-attentional 
control of stimulus selectivity. Given the diffuse innervation pattern of cortical 
cholinergic neurones (Sarter & Bruno, 1997), this may have been due to either (or 
both) a direct facilitation of top-down inputs within these sensory regions, or due to an 
indirect action within frontoparietal cortex. The facts that the drug- and group-
dependent profile of task-related activity in frontoparietal regions was so similar to 
that seen in extrastriate regions, and that the response of one extrastriate region 
(pSTS) correlated in its response profile with right parietal cortex (across AD 
subjects), support the latter explanation. Furthermore, as well as enhancing the normal 
pattern of task-influence on sensory cortex, physostigmine reduced an abnormal 
pattern of the same effect (in left lateral occipital cortex) in AD, suggesting a 
coordinated response to cholinergic modulation between regions.  
 
In a recent fMRI study comparing face-encoding to a simple baseline task, Kircher et 
al (2005) reported hypoactivation of fusiform cortex in AD that reversed following a 
10-week course of donepezil. Rombouts et al (2002) similarly found rivastigmine-
induced enhancement of fusiform cortex activity in seven AD patients on comparing a 
similar pair of tasks. Both results may have been due to cholinergic modulation of 
either stimulus-processing or attentional recruitment of sensory cortices. Our study 
distinguishes these possibilities by finding that face-selectivity of fusiform cortex, 
independent of attention, was not impaired in AD and showed negative modulation by 
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cholinesterase inhibition. However, where face-selectivity was dependent on attention 
(in our task, pSTS) there was an AD-associated impairment, and a positive 
modulation with cholinesterase inhibition.  
 
Cholinergic modulation in healthy elderly relative to Alzheimer’s disease 
A striking aspect of our results was the consistent finding that the influence of 
physostigmine on stimulus-selectivity and/or task-related responses was opposite 
between AD and controls. The pattern we observed in controls of reduced task-
dependent activity in parietal and sensory cortices following cholinergic enhancement 
is in keeping with several previous studies (Experiments 1 and 3; Thiel et al, 2005). 
Physostigmine-induced reduction of sensory cortex modulation by task or 
conditioning have been attributable to disproportionate enhancement of sensory cortex 
processing during conditions in which sensory cortex is normally at a low activity 
level (Experiment 3; Thiel et al, 2002). Similarly, reduction of parietal activation with 
pro-cholinergic treatment has been interpreted in terms of ‘broadening of attention’ to 
include stimuli that normally are processed only weakly (Thiel et al, 2005). In the 
current study, we found that the reduction of task-modulation of sensory cortex by 
physostigmine was predominantly due to an enhancement of stimulus-selectivity 
during the low-attention task, although drug-induced reduction of task-dependent 
parietal activity was due equally to levelling effects in both tasks. By contrast, AD 
patients compared to controls showed impaired attentional responses primarily due to 
defective differential activation during the high-attention task in frontoparietal and 
extrastriate areas, and physostigmine had its impact in these areas primarily during 
this condition. Combining both results, it would seem that a normal level of 
acetylcholine is required both for frontoparietal activation and for stimulus-selectivity 
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enhancement specifically during attention-demanding conditions; whereas excessive 
acetylcholine enhances parietal and selective extrastriate responses during low-
attention conditions that do not normally engage such areas. The facts that 
physostigmine in controls also tended to reduce parietal and sensory effects during the 
high-attention task, and that elsewhere, stimulus-selectivity was reduced, suggests that 
there are also costs to visual processing with excessive cholinergic stimulation. 
Findings or reduced stimulus selectivity following acetylcholine application to 
sensory cortices has been found in non-human studies (e.g. Zinke et al, 2006; Herrero 
et al, 2008). Furthermore, the finding that similar deficits of cortical function may 
occur with both deficient and excessive levels of neuromodulator (depicted by an 
‘inverted-U’ function) is well recognised in another instance – namely, dopaminergic 
modulation of prefrontal cortex in working memory performance (Williams & 
Castner, 2006).      
 
Limitations 
We draw our conclusions from the effect of disease and drug on event-related BOLD 
responses, rather than neural activity directly. Consequently, the results are potentially 
susceptible to confounds that derive from differences in metabolism, blood-flow and 
neurovascular coupling between the two groups and two treatments, independent of 
cognitive factors (Blin et al,1997; Tsukada et al, 2000). In our study we found that 
baseline BOLD levels did not differ between treatments or between groups at the level 
of whole brain or within the regions that exhibited task x group and/or treatment 
interactions. Furthermore, the profile of drug effects on event-related BOLD activity 
that we found – mostly increases and one decrease in AD, and decreases in control – 
cannot be explained merely on the basis of a unidirectional influence of 
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physostigmine on baseline metabolism or cerebral blood-flow as recorded by Blin et 
al In fact, the pattern of ‘cross-over’ effects – i.e. where drug enhanced activity during 
one condition but decreased it in during another in the same voxel – that we observed 
in several regions, necessarily involves an explanation in terms of the cognitive factor 
of interest. We also discount explanations in terms of drug-induced reductions in 
alertness or side-effects such as nausea because both groups were affected equally 
along these dimensions (in contrast to the effects of interest that were opposite 
between groups), and because these factors would be expected to act in an opposite 
direction to the attention-enhancing results found in AD. 
 
Conclusion 
Experiment 4 aimed to study the neural correlates of two fundamental cognitive 
categories known to be impaired in Alzheimer’s disease – visual processing and 
attention – and their sensitivity to cholinergic manipulation, by employing a task that 
enabled orthogonal manipulation of each variable. The study showed that AD patients 
manifest deficits in cerebral activations associated with both types of process, as well 
as their interaction, compared to age-matched controls. Many of these deficient 
activations were reversed by cholinesterase inhibition thus providing novel insights 
into how cortical-cholinergic deficiency contributes to the neurophysiological and 
performance impairments of mild-to-moderate AD. Finally, we have demonstrated 
that excessive cholinergic stimulation in controls also disrupts the normal pattern of 
visual-attentional processing, although the mechanisms by which these occur differ 
from those of AD.  
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9. EXPERIMENT 5: 
Relationship between Effects of ChEI on 
Visuo - Attentional Processing and 
Subsequent Memory 
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Introduction 
 
Among its numerous cognitive impacts, the basal forebrain - neocortical cholinergic 
system exerts important influences on sensory processing (Everitt & Robbins, 1997; 
Sarter et al, 2005a). For example, acetylcholine release in sensory cortices enhances 
stimulus-evoked responses (Sato et al, 1987); modifies stimulus-selectivity (Sillito & 
Kemp, 1983), and alters the configurations of sensory representation maps 
(Weinberger, 2007). Indeed, the ability of acetylcholine to influence plasticity 
mechanisms within sensory cortices during stimulus-encoding – in addition to its 
separate actions on the hippocampus – has been proposed to contribute to the well-
established effects of acetylcholine on memory (Kirkwood et al, 1999; Boroojerdi et 
al, 2001; Gu, 2003; Hasselmo & McGaughy, 2004; Schon et al, 2005). The present 
study was designed to test this hypothesis by examining whether effects of 
cholinesterase inhibitors on processing in higher sensory cortex processing, for 
healthy subjects and in mild Alzheimer’s disease (Furey et al, 2000; Rombouts et al, 
2002), may be directly related to its effects on subsequent memory (Davis et al, 1978; 
Davis & Mohs, 1982).  
 
Previous functional imaging studies using visual paradigms have shown that pro-
cholinergic drugs increase stimulus-driven extrastriate visual cortex responses in a 
task-dependent fashion (Furey et al, 2000; Lawrence et al, 2002; Experiments 1 and 
3). In a similar way, we note from psychopharmacological studies that the pro-
mnemonic effects of cholinergic-enhancing drugs are also related to encoding-task, 
with a greater memory improvement noted for stimuli that have undergone ‘deep’ 
relative to ‘shallow’ processing (Rusted & Warburton, 1992; Warburton et al, 2001; 
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Fitzgerald et al, 2008). In other words, cholinergic manipulation interacts with the 
well-recognised depth-of-processing effect on memory (Craik & Tulving, 1975; 
Baddeley, 1990). Here we sought to bridge these two effects, by testing whether 
cholinergic enhancement of task-dependent activity in visual extrastriate cortex relates 
to the impact on subsequent memory. We predicted that the cholinergic enhancer 
physostigmine would increase memory selectively for deeply relative to shallowly 
encoded faces, and, critically, that this would correlate with the degree to which 
physostigmine enhances face-selective fusiform cortex activity during the deep 
relative to shallow encoding task.  
 
A further question we addressed was whether effects of cholinesterase inhibition on 
the relationship between face-encoding and subsequent recognition differ between 
healthy older subjects and Alzheimer’s disease. Previous studies in Alzheimer’s 
disease have shown impaired extrastriate visual cortex activation during memory 
tasks, associated with poor subsequent recall (Golby et al, 2005; Gron & Riepe, 2004; 
Machulda et al, 2003; Rombouts et al, 2005); while cholinesterase inhibition may 
reverse impairments in sensory cortex activity (Rombouts et al, 2002; Kircher et al, 
2005; Gron et al, 2006). No studies however, have shown or assessed any direct 
relationship between enhanced extrastriate cortex activity following cholinesterase 
inhibitor treatment in Alzheimer’s disease and improved subsequent recognition. 
Furthermore, it remains unknown whether impairments in depth of processing 
(Beauregard et al, 2001; Bird & Luszcz, 1991) or task-modulation of sensory cortex 
activity (Mandzia et al, 2004; Gazzaley A, D'Esposito M, 2007) seen in Alzheimer’s 
disease and ageing, are reversible with pro-cholinergic treatments. Since both 
pathological (Mesulam et al, 2004) and pharmacological (Lawrence & Sahakian, 
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1995) studies have suggested that cholinergic deficits or manipulation produce more 
impact upon attentional than memory processes, and given that stimulus depth-of-
processing effects may partly depend upon attentional processes (Baddeley, 1990), we 
tested whether effects of cholinesterase inhibition on memory in Alzheimer’s disease 
are dependent upon encoding task.  
 
Finally, given the likely importance of sensory- frontoparietal – hippocampal cortex 
interactions in memory and depth-of-processing (Celone et al, 2006; Rissman et al, 
2008), we tested in both healthy and Alzheimer’s disease groups the relationship 
between activity in fusiform cortex with that in wider brain regions, and the effects of 
cholinergic manipulation on such co-variations between areas. 
 
It should be noted that this experiment involves a secondary analysis of data acquired 
from Experiment 4, but now incorporating the additional factor of subsequent (i.e. 
post-scanning) memory performance that was ignored previously.  
 
Methods 
 
Subjects 
Eighteen right-handed healthy older subjects (mean age 64.8 ±4.2; hereon referred to 
as ‘healthy subjects’) participated, plus thirteen right-handed patients with newly-
diagnosed Alzheimer’s disease (MMSE of 20 – 26; mean age 64.8 ±4.4) who were 
recruited from the Dementia Research Group, National Hospital for Neurology and 
Neurosurgery (London, UK) over a sixteen month period. Data sets were from fifteen 
of the healthy controls and twelve of the patients included in Experiment 4 (additional 
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subjects were recruited to make up for subjects in Experiment 4 who did not complete 
the post-scan memory task). No subjects were active smokers. Summary 
characteristics of the two groups are listed in Table 9.1. We used the NART-R test to 
assess IQ in healthy subjects as previous studies have shown that its score correlates 
robustly with verbal and performance IQ scores from the WAIS-R (e.g. Schretlen et 
al, 2005) that Alzheimer’s disease subjects underwent as part of their clinical 
management. All subjects gave written informed consent. Inclusion and exclusion 
criteria for patients were the same as for Experiment 4.  
 
Table 9.1: Summary characteristics of healthy elderly and Alzheimer disease subjects 
(±95% confidence intervals). 
 
 
 
 
 
 
 
 
IQ scores in controls are estimated from National Adult Reading Test (NFER-
NELSON Publishing Co. Ltd., Berkshire, England, 2nd Edition, 1991). 
* P < 0.01 between-group difference. 
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Drug-treatment 
A double-blind, placebo-controlled drug administration technique was used. Details of 
the physostigmine challenge are described in Experiment 4. The encoding task took 
place at 25 minutes from the start of the infusion. The infusion was continued until the 
end of the encoding phase, (i.e. ~45 minutes from the start of the infusion), but then 
terminated in order to minimise drug side-effects and permit subject mobility. The 
recognition task took place 10 minutes after termination. Since previous data (Asthana 
et al, 1995; Christie et al, 1981; Muramoto et al, 1984) indicate a pharmacodynamic 
half-life for intravenous physostigmine of ~60 minutes, there will have been 
significant cholinesterase inhibition during both encoding and recognition phases 
here. 
 
Blood pressure was checked before and after scanning, and pulse-oximetry was 
performed continuously. Subjects were given a questionnaire before and after 
scanning that allowed a ranked measurement (0 – 6 scale) of seven recognised adverse 
reactions to physostigmine and glycopyrrolate, as well as visual analogue scales for 
alertness and physical wellbeing. 
 
Cognitive task 
The task performed within the scanner is identical to that described in Experiment 4. 
To recap, on each of two sessions (placebo or physostigmine), subjects performed two 
tasks of varied processing depth. For the shallow task they judged the Colour (C) of 
colour-washed red or green faces or building stimuli. For the deep task they judged 
instead the Age (A; young/old) of comparable face or building stimuli. Subjects were 
informed that a recognition test of faces would be carried out after scanning but were 
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instructed simply to perform their best on the within-scanner colour or age tasks, 
rather than trying specifically to memorise items. A short practice run (without 
scanning) was also performed before each block in the scanner. Subjects wore 
appropriate MRI-compatible refractive lenses if required to correct their visual acuity 
(i.e. for individuals who would normally wear spectacles).  
 
Eye position was monitored during scanning and task performance, with a remote 
infra-red eye tracker (ASL Model 540, Applied Science Group Co., Bedford, MA; 
refresh rate = 60 Hz) for 16 control and 11 Alzheimer’s disease subjects.  
 
Recognition memory for exposed faces (versus foils) was tested 10 minutes following 
the end of the encoding. Subjects were removed from the scanner for testing and sat in 
front of a laptop computer. Test stimuli were presented singly, and together consisted 
of the 96 faces that had appeared during the encoding task (presented in the same 
colour used for either the colour- or age-task during exposure), randomly intermixed 
with 96 foils (equally divided into red and green) that were also presented singly. 
Thus each trial comprised either a previously shown face or a foil face. These 
recognition probe stimuli subtended ~7 º x ~4 º visual angle. Subjects were prompted 
on the screen to say whether they had seen each face or not during the encoding 
phase, and whether they were confident or not of this judgement. Subjects’ verbal 
responses were recorded by an examiner blind to the test stimuli. Recognition 
accuracy was scored using a discrimination index (DI) calculated as p(hit) minus 
p(false alarm); see Snodgrass & Corwin (1988).  
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Figure 9.1: Schematics of tasks performed during fMRI scanning (encoding) and 
afterwards (recognition task).  
 
Colour task: Green or Red?
…
…
Age task: Old or Young?
Imaging Tasks (Encoding)
…
Post-Imaging Task (Recognition)
Have you seen the face earlier? & 
Sure or Unsure?
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Imaging and imaging processing 
fMRI data were collected during the encoding tasks on a 1.5 T MRI scanner 
(Siemens, Erlangen, Germany) using gradient echo T2*-weighted echo-planar images, 
with blood oxygenation level dependent (BOLD) contrast. Volumes consisted of 39 
horizontal slices through the whole brain, each 2mm thick with a 1mm gap between 
slices (field-of-view, 192 x 192 mm2; matrix size 64 x 64). In-plane resolution was 
3mm×3mm; effective repetition time (TR), 3.51 s; echo time (TE), 50ms, and flip 
angle 90°. For each block 63 volumes were acquired, with the task only beginning 
after the sixth volume to allow for T1 equilibration effects.  
 
Imaging data were pre-processed and analysed using SPM2 (Wellcome Centre for 
Neuroimaging at UCL; http://www.fil.ion.ucl.ac.uk/spm). This consisted of 
determining and applying rigid affine transformations to the image series to realign 
the scans with respect to the first scan (Friston et al., 1995). Scans were then 
normalized to a standard EPI template (Montreal Neurological Institute) with a 
resampled voxel size of 3 x 3 x 3mm (Friston et al., 1995), and smoothed using a 
Gaussian kernel with a full width at half maximum (FWHM) of 8 mm. The same 
template was used for healthy subjects and Alzheimer’s disease in order to allow for 
unbiased between-group comparison. 
 
Statistical analysis of behaviour 
Behavioural data were analysed with SPSS software (v16.0). DI scores were entered 
into mixed ANOVAs, with task (shallow or deep), treatment (physostigmine or 
placebo) and recognition confidence (confident or not) as repeated-measure factors, 
and group (healthy or Alzheimer’s disease) as a non-repeat factor. For completeness, 
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performance during initial encoding (RT and accuracy for colour or age tasks) 
underwent comparable ANOVAs with the same factors. Treatment order 
(physostigmine given in first or second session) produced neither main effects nor 
interactions with other factors, so was not considered further.  
 
Statistical analysis of images 
Imaging data were analyzed with a general linear model for combined blocked (here, 
colour- or age-task at encoding) and event-related (here, face or building stimuli in a 
randomly intermingled sequence within each block) factors, using SPM2 with a 
random-effects approach. Data were globally scaled so as to remove the possibility 
that between-treatment or between-group effects were caused by any differences in 
baseline BOLD values, and high-passed filtered at 1/256 Hz. Events were modeled by 
delta functions convolved with a synthetic hemodynamic response function (Friston et 
al., 1998); temporal derivatives of these functions were modelled separately for 
completeness (Friston et al, 1998). Within-subject conditions of interest were 
stimulus-type, task, and treatment. Stimuli in different scanning-blocks were modelled 
separately to enable estimation of any session effects. Six-dimensional head 
movement parameters derived from image-realignment were included within the 
model as confounding covariates of no interest.  
 
For each of 31 subjects, BOLD differences were estimated for the following contrasts 
of interest: i) face-selectivity under placebo, i.e. face > building; ii) physostigmine-
induced enhancement of face-selectivity, i.e. two-way interaction of  treatment x 
stimulus [physostigmine (face >building)] > [placebo (face > building)]; iii) task-
modulation of face-selectivity under either treatment, i.e. two-way interaction of 
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stimulus x task under placebo, or physostigmine [age (face >building)] > [colour (face 
> building)], and iv) physostigmine-induced enhancement of task-modulation of face-
selectivity, i.e. three-way interaction of treatment x task x stimulus, 
{physostigmine[age (face > building)] > [colour (face > building)]} > {placebo[age 
(face > building)] > [colour (face > building)]}.  
 
We next calculated depth-of-processing effects on later behavioural recognition scores 
for each subject (i.e. DI for deep- minus shallow-encoded faces) under placebo, and 
the change in this score when comparing physostigmine with placebo. These values 
for each subject were then correlated respectively with each subject’s own BOLD-
derived measure of the task x stimulus (under placebo) (contrast iii, above) and 
treatment x task x stimulus (contrast iv, above) interactions, separately for the two 
groups. Since the Alzheimer’s disease group showed a treatment effect on memory 
that was independent of task, we also correlated subjects’ treatment effects on 
recognition score (i.e. DI for all faces) with subjects’ treatment x stimulus BOLD 
effect (contrast ii, above), separately for healthy  and Alzheimer’s disease subjects. 
Group comparisons of correlation coefficients were performed at the peak estimates 
for each group using Fisher’s Z-test (i.e. for balance we compared between groups the 
strongest correlations found within each group, rather than the strongest within one 
against an unselected score for the other). We were guided by behavioural effects of 
drug on recognition at the group level in deciding whether to use all recognition 
responses, or instead just confident recognition responses, as the covariate with 
BOLD activity during the encoding-phase. In order to facilitate interpretation of 
interactions we limited the search volume to those regions also showing a main effect 
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of face-selectivity in the appropriate subject group under placebo (thresholded at p < 
0.001, uncorrected). 
 
In a separate model, for each subject incorporating the same factors as before 
(stimulus, task, treatment), we re-classified face stimuli according to whether they 
were later recalled confidently, recalled non-confidently, or forgotten. In this way we 
could identify any areas that showed heightened BOLD responses at initial exposure 
for faces that were later recognised or forgotten - i.e. a ‘subsequent-memory’ analysis 
(Rugg et al, 2002). This was performed for all recognised faces in healthy subjects, 
but with a focus on confidently-recalled faces in Alzheimer’s disease patients, given 
the specific physostigmine effect that we found on later recognition confidence for 
this patient group (see below). Interactions of a subsequent-memory effect with task, 
treatment and group were also performed within those regions also showing a main-
effect of subsequent memory (thresholded at p < 0.001, uncorrected). 
 
Face-selective regions were initially identified by performing a one-sample t-test in 
healthy or Alzheimer’s disease subjects separately to generate corresponding 
statistical parametric maps (SPMs), thresholded at p < 0.05, corrected for whole-brain 
volume (false-discovery rate). Behavioural – BOLD correlations and subsequent 
memory effects were first explored within 8mm (i.e. the smoothing kernel) of the 
fusiform peaks of face-selectivity (as identified initially without considering 
behaviour) for each group. We then explored face-selective regions of interest more 
widely – namely fusiform gyri and superior temporal sulci (Haxby et al, 2000) – that 
were defined functionally from the face > building SPM contrast in the corresponding 
subject group under placebo, itself thresholded at p < 0.001, uncorrected (Worsley et 
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al, 1996). The medial temporal lobes were also interrogated as regions of interest 
given their central role in episodic memory (Rugg et al, 2002), and were defined 
anatomically here (see Rorden & Brett, 2000). We used a conventional statistical 
threshold of p < 0.001 (uncorrected) within these regions of interest. The rest of the 
brain was also examined for these correlations and contrasts, but for those areas we 
applied a threshold of p < 0.05 (false-discovery rate; corrected for whole-brain). 
Group-effects were overlaid on mean normalised T1 structural images of the 
appropriate group(s) to enable anatomical localisation.  
 
In order to ascertain whether those regions implicated in differences for behavioural – 
BOLD correlations between healthy subjects and Alzheimer’s disease groups also 
differed in grey matter volume, we analysed T1 structural images with voxel-based 
morphometry using SPM5 software (see Mechelli et al, 2005). Essentially, this 
process involves segmenting volumes to extract grey matter; normalising to an 
asymmetric T1-weightedtemplate in Montreal Neurological Institute (MNI) 
stereotactic space; modulating for total volume changes; smoothing (by 8mm kernel), 
for each subject’s scan, before applying a 2-sample t-test to compare healthy subjects 
with Alzheimer’s disease. 
 
Finally, we tested for relationships between right-fusiform effects of task x stimulus, 
and stimulus, and inter-regional covariation with wider brain regions showing task-
effects and subsequent-memory effects respectively. For the first of these connectivity 
analyses, we first identified regions showing a task-effect (Age > Colour) under 
placebo over all healthy subjects (and separately for Alzheimer’s disease), thresholded 
at p < 0.001 uncorrected, and smoothed with a 8mm kernel. Within this predetermined 
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area we then tested for subregions in which this task effect for individual subjects 
covaried with task modulation of face-selective fusiform activity (contrast iii, above) 
sampled from the peak of the pharmacological behavioural – BOLD correlation, 
separately for subject group and treatment. We then compared differences in 
correlation coefficients between treatments for each group. Similarly we tested for 
regions that showed covariation of a subsequent-memory effect (see above) with face-
selective fusiform activity (contrast i, above) also sampled from the peak of the 
pharmacological behavioural – BOLD correlations. These results are reported at p < 
0.001 uncorrected, within regions showing a main effect of task, or in medial 
temporal lobe regions of interest (no other brain areas exhibited these correlations 
when thresholding at p < 0.05, whole-brain corrected). 
 
The influence of physostigmine on group effects of stimulus-selectivity and task-
modulation independent of subsequent recognition are reported in Experiment 4. 
 
Results
 
Physiological data, subjective reports and eye-tracking 
The only side-effects reported in the treatment group in more than one subject were 
nausea and dry mouth. Blood pressure was unaffected. Subjective scores of alertness 
and physical wellbeing reduced between beginning and end of session somewhat 
more for physostigmine than placebo (time x treatment interaction p < 0.05). There 
was no effect or interaction concerning group (healthy or Alzheimer’s disease) for any 
of these measures (all p > 0.1). Saccades arose on only 0.8% of trials in controls and 
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only 1% in patients. Moreover, there were no interactions of saccade-rate with 
stimulus-type, task, treatment or group, so eye position was not considered further.  
 
Behavioural 
The expected difference in attentional demand for deep versus shallow encoding tasks 
was found in controls and Alzheimer’s disease groups, expressed as slower RTs and 
decreased accuracy for the Age versus Colour task (p < 0.01 for each measure and 
group). Alzheimer’s disease subjects performed worse than controls for both tasks in 
RT and accuracy (both F(1,28) > 4, both p < 0.05). A task x group interaction arose 
for accuracy, due to Alzheimer’s disease patients showing a greater difference 
between the two tasks than controls (F(1,28) = 5.5, p < 0.05). Physostigmine led to 
faster RTs selectively in Alzheimer’s disease but not healthy subjects, during the Age 
but not the Colour task (F(1,28) = 9.0, p < 0.01).   
 
Recognition memory performance is shown in Fig. 9.2, separately for all responses 
and for just confident responses. Healthy subjects demonstrated superior memory to 
Alzheimer’s disease patients (main effect of group (F(1,29) = 5.4, p < 0.05); dividing 
up recognition score by encoding task identified a selective group difference for Age-
encoded (t(29)= 3.0; p < 0.01), but not Colour-encoded faces (p = 0.13). Furthermore, 
healthy subjects showed a strong benefit in memory when comparing Age with 
Colour encoding tasks (F(1,17) = 14.2; p<0.01; also significant at p < 0.05 under each 
treatment), whereas there was no such effect in Alzheimer’s disease patients (F(1,12) 
= 0.3, n.s; no task effect under either treatment) leading to a significant task x group 
interaction for recognition memory scores (F(1,29) = 4.4, p < 0.05). Among 
Alzheimer’s disease subjects, there was a trend for a correlation between MMSE 
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scores and recognition memory of deep- versus shallow-encoded faces (r(12) = 5.3; p 
= 0.06). There was also a confidence x task x group interaction (F(29,1) = 4.9; p < 
0.05), that reflected healthy subjects showing a task effect for confident (p < 0.01), 
but not un-confident judgements, while Alzheimer’s disease subjects showed no task-
effect for either. 
   
Physostigmine had distinct influences on the impact of encoding-task upon memory 
for healthy subjects versus Alzheimer’s disease patients, leading to a three-way group 
x task x treatment interaction (F(1,29) = 4.5, p < 0.05). In healthy subjects, 
physostigmine increased the difference in memory between the two types of 
encoding-task, relative to placebo, specifically enhancing the depth-of-processing 
effect (F(17,1) = 4.7, p < 0.05). This effect occurred regardless of recognition 
confidence. By contrast in Alzheimer’s disease patients, there was no effect (p > 0.1) 
of physostigmine on task-dependent memory, relative to placebo, i.e. no tendency for 
it to restore the depth-of-processing effect found in healthy subjects. However, when 
analysing only those recognition judgements that Alzheimer’s disease patients rated 
with confidence (see Fig. 9.2, rightmost graph), we found that physostigmine exerted 
a beneficial effect on their memory (F(12,1) = 5.2; p < 0.05), although this was 
equivalent for faces encoded during the Age and Colour task (i.e. there was no task x 
treatment interaction for the Alzheimer’s disease group, p > 0.1).  
 
Analyses of false-alarm rates showed an effect of group (higher for Alzheimer's 
disease: t(29)=2.44, p < 0.05), but not treatment, either as a main-effect, or as an 
interaction with group or task (Table 9.2). 
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Figure 9.2: Behavioural recognition results for each group. Discrimination indices 
[P(hit) – P(false alarm)] plotted separately for faces that had earlier been encoded 
during ‘shallow’ colour task, or encoded during ‘deep’ age task, under placebo or 
physostigmine, in control or AD subjects. The left graph scores all recognition 
responses as hits, while the right graph scores only confident recognition judgements 
as hits.  
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Table 9.2: Probabilities of correct hits and false alarms (with standard errors) 
All Responses 
Healthy Alzheimer's Disease
  Placebo Physostigmine   Placebo Physostigmine 
Colour 
P(Hit) 
Age 
P(Hit) 
 
P(FA) 
Colour 
P(Hit) 
Age 
P(Hit) 
 
P(FA) 
Colour 
P(Hit) 
Age 
P(Hit) 
 
P(FA) 
Colour 
P(Hit) 
Age 
P(Hit) 
 
P(FA) 
0.43 
(0.03) 
0.48 
(0.02) 
0.29 
(0.03) 
0.39 
(0.04) 
0.52 
(0.04) 
0.31 
(0.03) 
0.47 
(0.06) 
0.50 
(0.05) 
0.40 
(0.05) 
0.49 
(0.05) 
0.49 
(0.05) 
0.41 
(0.05) 
 
Confident Responses 
Healthy   Alzheimer's Disease
  Placebo Physostigmine   Placebo Physostigmine 
Colour 
P(Hit) 
Age 
P(Hit) 
 
P(FA) 
Colour 
P(Hit) 
Age 
P(Hit) 
 
P(FA) 
Colour 
P(Hit) 
Age 
P(Hit) 
 
P(FA) 
Colour 
P(Hit) 
Age 
P(Hit) 
 
P(FA) 
0.18 
(0.02) 
0.24 
(0.02) 
0.11 
(0.02) 
0.16 
(0.02) 
0.26 
(0.02) 
0.11 
(0.02) 
0.18 
(0.04) 
0.18 
(0.04) 
0.15 
(0.04) 
0.24 
(0.05) 
0.23 
(0.05) 
0.16 
(0.05) 
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fMRI data: Session effects 
We obtained estimates of the mean BOLD signal per session for the whole-brain 
(global) and in functionally-defined (face>house) face-selective extrastriate cortical 
regions. Importantly, neither global (whole-brain) nor regional (face-selective areas) 
session BOLD estimates were influenced by group or treatment overall, and there was 
no significant interaction between these factors. This means that the specific results 
reported later below cannot be a trivial outcome of any non-specific drug or group 
influences on whole brain or face-selective BOLD signals.  
 
fMRI data: Face-selectivity, subsequent memory and depth of processing 
Extrastriate cortical regions showing higher BOLD-signals for face than building 
stimuli in healthy subjects were most apparent in right fusiform cortex (Fig. 9.3A; 
Table 9.3). In Alzheimer’s disease patients, the same contrast showed activation of 
bilateral fusiform cortices (Fig. 9.4A; Table 9.3), with no significant group-
differences in face-selectivity (i.e. no interaction of face>building with group, all p > 
0.1) for fusiform cortex in either hemisphere. Effects of task, treatment and group on 
face-selective responses that do not take into account individuals’ subsequent 
recognition performance are described in Experiment 4.  
 
We next investigated the relationship between face-selective fusiform cortex 
activations during encoding with memory performance post-scanning. Specifically, 
we tested: i) whether the strength of fusiform responses to faces was associated with 
subsequent successful recognition, and ii) whether task-modulation of face-selective 
responses in this region was associated with task-dependent recognition scores – i.e. 
the depth of processing memory effect. For the first question, we compared responses 
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to faces that were later correctly recognised to those which were incorrectly rejected 
later as foils. This ‘subsequent-memory’ contrast in healthy subjects under placebo 
showed higher BOLD for faces later recognised than forgotten in anterior right 
fusiform cortex (Fig. 9.3B; Table 9.3). The right hippocampus, as an a priori 
anatomical region of interest (Rugg et al, 2002), also showed this subsequent memory 
effect at a lower statistical threshold (28, -4, -24; Z = 2.10; p < 0.05, uncorrected). In 
Alzheimer’s disease subjects under placebo, there was no such subsequent-memory 
effect in fusiform cortex for either hemisphere, leading to a between-group difference 
for this in right fusiform cortex (44, -38, -18; Z = 3.95; p < 0.001, uncorrected). 
However, on comparing faces later recognised confidently by Alzheimer’s disease 
patients to those forgotten by them (for which a drug-effect had been observed 
behaviourally – see above), a subsequent-memory effect did emerge for this patient 
group under placebo in left fusiform cortex, within 8mm of the local peak of face-
selectivity for the Alzheimer’s disease group (Fig. 9.4B). The Alzheimer’s disease 
group also showed a subsequent-memory effect in left hippocampus (-18, -16, -8; Z = 
3.35; p < 0.001, uncorrected) but only under physostigmine. Apart from the right 
fusiform cortex region mentioned showing a greater subsequent-memory effect for 
healthy subjects than Alzheimer’s disease, there were no other interactions of 
subsequent-memory with task, treatment or group (thresholded at p < 0.001, 
uncorrected in regions of interest; p < 0.05 corrected in other brain regions). 
 
For the second question, we examined whether the behavioural improvement in 
recognition for faces encoded deeply (Age task) relative to faces encoded shallowly 
(Colour task) found in healthy subjects would correlate in a subject-by-subject manner 
with task-modulation of face-selective responses extrastriate cortex at encoding. Right 
347 
Chapter 9 
fusiform cortex, at the peak of face-selectivity identified above in a behaviour-
independent manner for healthy subjects under placebo, showed a correlation between 
task-modulation of BOLD signal at exposure, and the behavioural depth-of-
processing effect on later recognition (r(30) = 0.49; Z = 2.82, p < 0.01), with no 
difference between patients and controls (p > 0.1). Left fusiform cortex did not show a 
significant correlation in either group. We note that the extrastriate regions showing 
the strongest effects for this correlation in healthy subjects were in bilateral superior 
temporal sulci (60, -38, -2; r(17) = 0.86, Z = 4.52; and -44, -48, -8; r(17) = 0.80, Z = 
3.93; both p < 0.0001, uncorrected). For these superior temporal regions, Alzheimer’s 
disease subjects failed to show positive correlations (r(12) = -0.25 and -0.12, n.s.) 
leading to between-group differences in this respect ( Z = 2.56 or 1.65, p < 0.05 or p < 
0.1, respectively). 
 
Summarising this section, we found that fusiform cortices in both healthy and 
Alzheimer’s disease groups showed activations that were: i) greater for faces than 
buildings; ii) greater for faces subsequently remembered than forgotten, and iii) 
greater for faces shown during the deep, relative to the shallow, encoding task in 
subjects showing a greater depth-of-processing subsequent memory effect.  
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Figure 9.3. (See next page): BOLD responses obtained from fMRI scanning during 
encoding in healthy control participants. A) Face-selective responses (faces>houses) 
regardless of task during encoding, under placebo, and physostigmine, show strongest 
activation in right mid-fusiform gyrus. B) Regions where higher BOLD signals during 
face encoding (independent of task or drug) predict subsequent recognition (i.e. faces 
reclassified as later recognised or forgotten), under placebo and physotigmine. C) 
Regions where physostigmine-induced enhancements of task-modulation at encoding 
(i.e. face-selective BOLD responses for deep minus shallow task) correlate with 
physostigmine-induced enhancements of depth-of-processing effect on later 
recognition (i.e. discrimination indices for deeply minus shallowly encoded faces), 
across healthy participants. Graphs show individual subject scatterplots for this 
relation in right fusiform cortex, which was significant in healthy (scatter plot shown 
at left, with diamond symbols for each healthy participant) but not for the Alzheimer 
patients (scatter plot shown centrallym with open-circle symbols for each Alzheimer 
patient). The BOLD-behavioral relation found for healthy controls in right fusiform 
cortex can also be seen (right bar graph) by dividing subjects into tertile sub-groups 
according to the degree that physostigmine increased memory for Age-encoded 
relative to Color-encoded faces. The extent to which physostigmine increased face-
selective responses during encoding, specifically for the Age relative to Color tasks, 
mirrored the degree to which physostigmine induced enhancements in the depth-of-
processing effect for subsequent memory. SPM contrasts shown are thresholded for 
display purposes at p<0.001 uncorrected, in A and C, or p < 0.01, uncorrected, in B, 
and overlaid on mean T1-weighted MRI of the healthy subjects. Percent BOLD signal 
changes for the conditions making up each contrast are plotted for the peaks in each 
circled cluster. 
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Figure 9.3: For legend see previous page. 
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a The AD group only showed subsequent memory effects using the contrast of confidently recognised – forgotten faces (for which the healthy 
group did not show effects).     
Significance values are corrected for whole-brain volume (false-discovery rate) except * that are reported uncorrected for completeness.   
Table 9.3: Coordinates in fusiform cortex showing maxima of face-selective and subsequent- memory effects. 
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fMRI data: Effects of physostigmine on task-dependent encoding in health  
The principle hypothesis of this experiment was that physostigmine-induced 
enhancement of extrastriate visual cortex activations during encoding would relate 
systematically to effects of physostigmine on subsequent recognition performance. 
Since in healthy subjects, the behavioural effect of physostigmine on recognition was 
dependent upon encoding task (i.e. greater improvement for deeply- than shallowly-
encoded faces) we assessed whether this effect related to physostigmine-induced 
enhancements of face-responses, during the deep relative to the shallow-encoding 
tasks. As predicted, we found in healthy controls a correlation of exactly this type - 
i.e. higher subject-by-subject recognition for deeply-studied, relative to superficially-
studied, faces under physostigmine, associated with higher face-selective BOLD 
responses during deep versus superficial encoding tasks, under physostigmine in right 
mid-fusiform cortex (peak at 46, -48, -26, this being within 8mm of the peak for face-
selectivity reported above in healthy subjects; r(17) = 0.79; Z = 4.22; p < 0.0001, 
uncorrected; Fig. 9.3C). The impact of this relationship can also be seen by ordering 
healthy subjects into tertile sub-groups, according to the degree to which 
physostigmine increased memory of deeply-encoded faces relative to shallow-
encoded faces, i.e. Physostigmine[DI (Age) > DI (Color)] > Placebo[DI (Age) > DI 
(Color)]; see Fig. 9.3C. While all 3 subgroups showed positive face-selective 
responses at this fusiform peak under both placebo and drug, the relative strength by 
which face-selective fusiform responses were increased by physostigmine during Age 
versus Colour tasks paralleled the drug’s enhancement of memory for faces presented 
during the Age relative to Colour tasks. There were no other face-selective regions 
showing this BOLD-behavioural correlation (p > 0.05).  
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The equivalent correlation analysis for Alzheimer’s disease subjects showed no such 
relationship at the right fusiform peak identified above (r(12) = -0.13, n.s.), leading to 
a reliable between-group difference there in this respect (Z(12) = 3.71, p < 0.01). The 
Alzheimer’s disease group did not show such a correlation in any other face-selective 
area, whether using all recognition responses or only those judged as being confident. 
A voxel-based morphometric analysis showed that there was no significant structural 
difference (p > 0.05 uncorrected) in grey matter density at this right fusiform peak 
between groups. 
 
fMRI data: Effects of physostigmine on task-independent encoding in Alzheimer’s 
disease 
Since the behavioural influence of physostigmine in the Alzheimer’s disease group 
had arisen specifically for confident recognition of faces, regardless of encoding task 
(see above), we next examined in this patient group whether physostigmine-induced 
enhancements of face-selective BOLD signals (at exposure) correlated with 
physostigmine-induced increases in later confident recognition, regardless of task. 
This analysis revealed such a positive BOLD-behaviour correlation for the patient 
group in left fusiform cortex (peak at -40, -54, -20; r(12) = 0.89; Z = 4.44; p < 0.0001, 
uncorrected) within 8mm of the left fusiform peak effect of face-selectivity already 
described above for the Alzheimer’s disease-group (see Fig. 9.4B, circled); as well as 
in right fusiform cortex, (34, -40, -24; r(12) = 0.89; Z = 4.06; p < 0.001, uncorrected), 
and posterior hippocampus (24, -24, -20; r(12) = 0.81; Z = 3.50; p < 0.001, 
uncorrected). The impact of this relationship in left fusiform can also be appreciated 
by dividing up patients into three ordered tertile sub-groups, according to the degree 
to which physostigmine increased confident face recognition; see Fig. 9.4C. 
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Physostigmine increased face responses selectively in the sub-group showing the 
greatest drug-induced enhancement of subsequent memory.  
 
The equivalent analysis for healthy subjects found no reliable correlation of 
physostigmine-modulation of face-selective BOLD responses with physostigmine-
modulation of later confident recognition, regardless of task, in any region (all r ≤ 
0.104, n.s.). This led to reliable between-group differences between all the brain-
regions showing a significant brain-behaviour correlation of this type for the 
Alzheimer’s disease patients (as listed above) but not for the healthy participants (all 
Z ≥ 2.56, all p ≤ 0.01). Voxel-based morphometric comparison of grey-matter density 
between groups showed no significant structural differences at any of these these 
voxels (p > 0.05, uncorrected). 
 
There were no correlations between drug modulation of task-independent face-
selectivity and subsequent recognition for healthy subjects if using all recognition 
judgements, rather than just confident responses.  
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Figure 9.4. (See next page): BOLD responses obtained from fMRI scanning during 
encoding in Alzheimer patients. A) Face-selective responses (faces>houses) 
regardless of task during encoding, under placebo and physotigmine, show strongest 
activations in bilateral mid-fusiform gyri. B) Regions where heightened BOLD signal 
during face encoding (independent of task or drug) predict subsequent confident 
recognition in AD patients under placebo and drug. C) Regions where physostigmine-
induced enhancements of face-selective BOLD responses (independent of task) 
correlate with physostigmine-induced enhancements of confident recognition 
performance, across AD patients. Regions showing a significant BOLD-behaviour 
relation of this specific type included middle left fusiform, anterior right fusiform and 
right hippocampal cortex. Graphs show subject-by-subject scatterplots for this relation 
in left fusiform gyrus, separately for controls (scatterplot shown at left with diamond 
symbols for each healthy participant, no significant relation) and for Alzheimer 
patients (scatterplot shown centrally, with open-circle symbols for each patient, 
illustrating the significant relationship found only for this pathological group). The 
rightmost bar graph further illustrates the relation in left fusiform cortex by dividing 
patients into three tertile sub-groups, ordered by the effect of physostigmine on 
confident recognition. The upper-tertile subgroup shows the strongest impact of 
physostigmine on left fusiform at encoding. SPM contrasts shown are thresholded for 
display purposes at p<0.001 uncorrected, in A and C, or p < 0.01, uncorrected, in B, 
and overlaid on mean T1-weighted MRI of the AD patients. Percent signal changes of 
the conditions making up each contrast are plotted for the peaks in each circled 
cluster. 
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Figure 9.4: For legend see previous page. 
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fMRI data: effects of physostigmine on fusiform-parietal and fusiform-
hippocampal functional coupling 
Finally, remote brain regions whose task-related, or memory-related, activity co-
varied (in a subject-by-subject manner) with the relevant fusiform activations 
described above as showing BOLD-behavioural correlations (i.e. at 46, -48, -26 for 
healthy subjects; plus at -40, -54, -20 and 34, -40, -24 for Alzheimer’s disease) were 
explored. Whether physostigmine impacts on any such inter-regional relationships 
was also assessed. In healthy subjects, the main-effect of task (Age versus Colour) 
under placebo activated right superior parietal cortex (peak: 48, -42, 58; Z = 5.46; p < 
0.001, corrected; Fig. 9.5A); no other regions were significant after whole-brain 
correction. We found that the task effect within this right parietal region also 
correlated with the task-modulation of face-selective responses in right fusiform 
cortex under both placebo (66, -36, 40; Z = 3.37; p<0.001, uncorrected) and 
physostigmine (38, -40, 56; Z = 3.49; p<0.001, uncorrected). Comparing each of these 
two parietal peaks with the equivalent two voxels under the alternative treatment 
showed a significant between-treatment difference only for the latter peak, i.e. at 38, -
40, 56 there was a greater correlation coefficient under physostigmine than under 
placebo (Z(17) = 1.96, p < 0.05; Fig. 9.5B). In Alzheimer’s disease, task-related 
regions beyond fusiform cortex did not show correlations with task-modulation of 
face-selective fusiform cortex under either treatment. 
 
We next investigated any association of fusiform face-selective responses with 
regions showing a subsequent-memory effect (i.e. higher responses for faces during 
encoding that were subsequently recognised relative to those forgotten). This showed 
that healthy subjects showing greater face-selective responses at the right fusiform 
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peak (46, -48, -26) also showed a greater subsequent memory effect in bilateral 
amygdala (36, 6, -42, Z = 3.42; -30, -4, -24; Z = 3.31; p < 0.001, uncorrected) under 
placebo, and in right hippocampus (24, -8, -16; Z = 3.85; p < 0.0001, uncorrected) 
under physostigmine. The latter region also showed a greater correlation coefficient 
under physostigmine than under placebo (Z(17) = 2.07; p < 0.05; Fig. 9.5C). In 
Alzheimer’s disease, correlations were found between left fusiform face-selective 
responses and a subsequent-memory effect in right amygdala (24, 2, -36; Z = 3.62; p 
< 0.0001, uncorrected) under placebo, and in extensive regions of bilateral 
hippocampus - amygdala under physostigmine (-26, -12, -18; Z = 4.03; 26, -8, -14; Z 
= 3.83; p < 0.0001, uncorrected; Fig. 9.5D; note that confident responses only were 
included, in line with the preceding results for the Alzheimer’s disease group). Each 
of these Alzheimer’s disease fusiform – medial temporal correlations as specified 
were greater than under the alternative treatment (all Z(12) > 2.08; p < 0.05). Face-
selective activations in right fusiform cortex did not show correlations with 
subsequent memory responses in any brain region in Alzheimer’s disease under either 
treatment.  
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Figure 9.5. (See next page): Regions showing main effect of Age>Color task (A) or 
correlations of task effects (B), or subsequent-memory effects (C, D), with task-
modulation and face-selective responses of fusiform cortex, respectively. A) SPM 
depicting regions in the whole brain showing a main-effect of task (shown at p < 
0.001 uncorrected, depicted as a maximum-intensity projection), within which were 
found sub-regions where that effect correlated on a subject-by-subject basis with task-
modulation of face-selective responses in right fusiform cortex (at peak of treatment 
effect: 46, -48, -26) under both placebo and drug conditions. The cross indicates the 
voxel showing the greatest fusiform – parietal covariation under physostigmine, at 
which there was a significantly greater correlation coefficient than under placebo as 
shown (B) in the scatterplot; C) Medial temporal regions in which a subsequent 
memory effect (i.e. recognised versus forgotten faces) correlated with face-selective 
responses in right fusiform cortex (peak: 46, -48, -26) under placebo and 
physostigmine in healthy subjects; scatterplot at right depicts fusiform – hippocampal 
covariance for the hippocampal site showing the greatest difference in correlation 
coefficients between treatments (p < 0.05); D) As for C, except now in Alzheimer 
disease subjects, with correlations of medial temporal regions’ subsequent memory 
effect (for confident judgements) with face-selective responses in left fusiform cortex 
(at peak of treatment effect: -40, -54, -20) under placebo and physostigmine. 
Scatterplot at right depicts fusiform – hippocampal covariance at a hippocampal 
region showing greater correlation coefficient under physostigmine than placebo (p < 
0.05).  
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Figure 9.5: For legend see previous page. 
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Discussion
 
Cholinesterase inhibitors are one of the most widely used symptomatic treatments for 
dementia (Gruber-Baldini et al, 2007), but the physiological basis for their 
performance benefits are unclear. We show here for the first time a direct relationship 
between the behavioural and neural effects of a single challenge with a cholinesterase 
inhibitor in both health and dementia. The principal findings are: i) the cholinesterase 
inhibitor physostigmine produced small overall improvements in face-recognition 
memory, that in healthy subjects but not Alzheimer’s disease were dependent upon 
encoding-task; ii) in healthy subjects, the degree to which physostigmine improved 
the memory of faces studied deeply (relative to those studied shallowly) correlated 
with the degree to which physostigmine enhanced face-selective fusiform cortex 
activity during the deep- (relative to the shallow-) encoding task; iii) in Alzheimer’s 
disease, improvements in confidently-judged face recognition caused by 
physostigmine correlated with drug-induced enhancements of fusiform face-selective 
responses during encoding, that unlike the case for healthy subjects, were independent 
of encoding task; iv) the fusiform cortex regions showing these neural-behavioural 
correlations also showed increases in their functional coupling with parietal and 
hippocampal regions following physostigmine. We discuss the results of the healthy 
and Alzheimer’s disease groups in turn.         
 
Cholinergic modulation of encoding in healthy subjects 
A recent integrative model of memory suggests that the physiological actions of 
acetylcholine on both sensory and entorhinal cortices enable the cortical dynamics 
necessary for new memory formation (Hasselmo, 2006). For example, acetylcholine 
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increases both sensitivity and specificity of stimulus-evoked visual cortical responses 
(Sato et al, 1987; Murphy & Sillito, 1991), while suppressing feedback connections to 
the same areas (Kimura et al, 1999), thereby potentiating the formation of novel input 
associations (Hasselmo & McGaughy, 2004). Additionally, plastic changes in the 
response pattern of sensory cortices to specific stimuli (e.g. as seen with fear-
conditioning) are dependent on cholinergic inputs from basal forebrain to sensory 
cortices (Weinberger, 2007; Gu, 2003). In the current study we sought to bridge the 
neurophysiological actions of acetylcholine on sensory cortices with the well-
recognised influences of cholinergic-enhancing drugs on memory performance (Gron 
et al, 2005) through the use of functional imaging.    
 
The design of our study married together two previous sets of observations. First, 
previous experiments (e.g. Experiment 3; Furey et al, 2000; Lawrence et al, 2002) 
have shown that pro-cholinergic drugs can increase visual-evoked responses in visual 
extrastriate cortex, with this effect appearing to be greater for stimuli that are attended 
than for those that are incidental to the task. For example, in Experiment 1, in a 
healthy, young adult population, physostigmine increased fusiform cortex responses 
for faces that were task-relevant, rather than those that were task-irrelevant, thereby 
enhancing the usual pattern by which task demands, independent of stimulus changes, 
can modify sensory cortex activity (Vuilleumier et al, 2001). Secondly, 
psychophysical studies in humans suggest that nicotine or cholinesterase inhibitors 
enhance memory through effects during the encoding phase when stimuli are first 
presented (Ghoneim & Mewaldt, 1977; Wetherell, 1992; Rusted & Warburton, 1992), 
rather than during consolidation or recall, when they may exert a negative effect 
instead (Edginton & Rusted, 2003; Gais & Born, 2004). Moreover, the pro-mnemonic 
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actions of these drugs are experienced more for stimuli that are presented during deep, 
than shallow, encoding tasks (Warburton et al, 2001; Fitzgerald et al, 2008) – thereby 
mirroring the pattern of extrastriate cortex modulation found in functional imaging 
studies. Consequently, we predicted that physostigmine would increase memory more 
for faces studied during a deep task (of judging age) than during a shallow task in 
which the particular facial characteristics were incidental to the task (of ascertaining 
picture colour). Critically, we hypothesised that this behavioural effect (measured at 
later recognition) would correlate with enhancements in face-selective activity of 
fusiform cortex (measured during initial encoding), that should also be more 
pronounced during the Age than the Color tasks. As Fig. 9.3C illustrates such a 
BOLD-behavioural correlation was found to occur very close to the peak of face-
selective responses in right fusiform cortex. In other words, in those subjects for 
whom physostigmine improved memory more for faces studied deeply than 
shallowly, physostigmine was also found to increase fusiform face-responsiveness 
during the encoding phase when the faces were first presented, more during the deep 
than shallow task.  
 
Several features of our results suggest that the observed pharmacological modulation 
of fusiform cortex was instrumental to the drug’s effects on subsequent memory 
performance. First, although our conclusion rests in part on a brain-behaviour 
correlation, it should be noted that this relationship was directional in time - i.e. 
physostigmine enhancement of face-responses during encoding predicted later effects 
on memory. Since the behavioural performance of healthy subjects during the 
encoding tasks was unaltered by physostigmine our results at that time are 
unconfounded by performance considerations. Furthermore, although physostigmine 
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would have been present during both encoding and recognition phases, the 
pharmacological effect observed here in healthy subjects occurred as an interaction 
with task that differed only during encoding. Second, both the data from our subjects 
in the placebo condition, and those from several previous studies (Grady et al, 1998; 
Bernstein et al, 2002; Otten et al, 2002; Mandzia et al, 2004) show that task-
modulation of face-selective responses of fusiform cortex during encoding correlates 
with a subsequent depth-of-processing (i.e. encoding-task-dependent) effect on 
memory. Third, a separate ‘subsequent-memory’ analysis of the same subjects 
showed that faces later recognised, ascompared to faces subsequently forgotten, 
elicited higher activity in right fusiform cortex during the encoding task (now 
independent of task or treatment) - again indicating the crucial role of fusiform 
activity at encoding for subsequent face memory. Previous (but non-drug) studies 
have analogously observed a subsequent memory effect to visual stimuli in fusiform 
cortex (Wagner et al, 1998; Kirchhoff et al, 2000; Golby et al, 2001; Sperling et al, 
2003; Dickerson et al, 2007; Kircher et al, 2007). Fourth, we found a correlation of 
face-selective activity in right fusiform cortex with a subsequent-memory effect in 
hippocampal/amygdala regions that was enhanced under physostigmine specifically in 
right hippocampus (Fig. 9.5C). Thus the observed effects of drug on memory here 
may arise from a combination of enhanced fusiform responses, specific to the 
encoding task, and increases in functional connectivity between sensory cortex and 
the medial temporal cortices that are thought to be critical for memory formation 
(Rissman et al, 2008).  
 
It is important to distinguish physostigmine-induced response increases in fusiform 
cortex shown here that are task-dependent (and which mirror subjects’ greater depth 
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of processing memory effects), from physostigmine-induced decreases in fusiform 
activity that are task-independent (as reported in Experiment 9.4, and which did not 
take into account subsequent memory effects). This combination of findings seems 
consistent with previous fMRI studies showing that, on the one hand, physostigmine 
increases visual cortex BOLD activity selectively during encoding (Furey et al, 2000) 
or high-attention tasks (Experiments 1 and 3); but, on the other hand, that the same 
treatment causes decreases, or no change, in activity in the same regions during low-
attention (Experiment 3: visual stimulation main-effect) or passive viewing tasks 
(Furey et al, 2000; Silver et al, 2008). This profile of functional imaging results 
parallels observations made using more basic neurophysiological techniques: viz. 
direct acetylcholine application to visual cortex decreases the net stimulus-driven field 
potential of cortical columns (Kimura et al, 1999) due to suppressed intracortical 
signalling (Levy et al, 2006), while increasing differential activity in visual cortical 
units as a function of spatial attention (Herrero et al, 2008). 
 
A likely source for task-driven as opposed to stimulus-driven activation changes in 
sensory cortex would seem to be frontoparietal regions within the so-called dorsal 
attention network (Kastner et al, 1999). Hence one possible explanation for the depth-
of-processing memory effect is an enhancement of resource allocation through 
attentional mechanisms (Baddeley, 1990; Chun & Turk-Browne, 2007). Given that 
attention is critically dependent on cholinergic innervation to frontoparietal cortices 
(Sarter et al, 2005a), we explored the possibility that the modulation of task-effects by 
physostigmine in fusiform cortex (seen here as correlating with drug effects on 
subsequent memory) may reflect an impact of the drug on functional coupling 
between fusiform cortex and regions traditionally associated with attention. The main 
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effect of task in our study (i.e. Age > Colour task) activated right parietal cortex most 
strongly (Fig. 9.5A). We found that this task effect in parietal cortex correlated across 
subjects with task-modulation of face-selective right fusiform cortex under both 
placebo and physostigmine, supporting the idea of a functional connection between 
these regions. The strength of this relationship was greater under physostigmine than 
placebo, suggesting that cholinergic modulation of task-responses in fusiform cortex, 
along with associated depth of processing subsequent memory effects, may involve 
cholinergic modulation of influences from regions such as parietal cortex that can 
exert top-down influences on sensory cortices. We note that drug-induced changes in 
the correlation coefficients for subject-by-subject effect sizes in fusiform and parietal 
cortex are distinct from drug-effects on mean task-related parietal activity (which is 
depressed by the drug overall: see Experiment 4). Similar physostigmine-induced 
reductions in task-related activity in frontoparietal cortices, associated with 
performance improvements, have been reported before (Experiment 3; Furey et al, 
2000) and may reflect either a reduced demand for resource allocation in the face of 
enhanced sensory processing (Furey et al, 2000) or improved parietal –sensory 
coupling as suggested here.  
   
Cholinergic modulation of encoding in Alzheimer’s disease 
Cholinesterase inhibitors enable modest improvements in memory performance in 
Alzheimer’s disease (Almkvist et al, 2004), although whether these occur primarily 
through direct effects on memory processes (Gron et al, 2005; Gron et al, 2006), or 
via indirect actions on executive - attentional processes (Alhainen et al, 1993; 
Lawrence & Sahakian, 1995) is unclear. In our study, we were able to address this 
issue at both behavioural and neural levels by testing for interactions between drug-
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induced memory enhancement and the encoding task. Contrary to what might be 
expected from a purely attentional account, we found in the Alzheimer’s disease 
group that physostigmine-induced memory improvement was both independent of 
encoding task, and did not correlate with task-modulations of face-selective 
extrastriate cortex. Instead we found that physostigmine-induced improvement in 
recognition performance correlated with enhancement of face-selectivity in left 
fusiform cortex, that was also independent of encoding-task. Importantly therefore we 
show that both behavioural and physiological consequences of cholinesterase 
inhibition may differ between healthy subjects and dementia patients. 
 
In contrast to healthy subjects, Alzheimer’s disease subjects did not benefit from a 
depth-of-encoding manipulation in their subsequent recognition performance (as also 
shown behaviourally in Beauregard et al, 2001; Bird & Luszcz, 1991). In our 
situation, this was not due merely to Alzheimer’s disease patients failing to follow 
task instructions, because Alzheimer’s disease patients actually showed a greater 
performance difference between tasks during encoding than healthy subjects. A 
possible neurophysiological basis for this lack of depth-of-processing in Alzheimer’s 
disease may lie in impaired top-down modulation of sensory cortices by frontoparietal 
regions (Gazzelley & D’Esposito, 2007; Walla et al, 2005). We found some support 
for this from our data in two respects: first we found that healthy subjects showed 
correlations between depth-of-processing memory effects and task modulation of 
face-selective cortices (in superior temporal sulci) that were reduced in the 
Alzheimer’s disease group. Second we also found some correlations between task-
modulation of face-selective fusiform cortex and task effects in right parietal cortex in 
healthy subjects that were absent in dementia patients. A similar pattern of 
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correlations arising between encoding-related activity and subsequent recognition in 
healthy subjects, but not in mild cognitive impairment patients, has recently been 
reported (Mandzia et al, 2007). Although in the latter study the main between-group 
differences arose in parahippocampal and hippocampal regions, the contrasts in 
Mandzia et al (2007) were based upon stimulus-related activations, as opposed to 
task-related modulations as we report here which more closely reflect the depth-of-
processing effect.   
 
In Experiment 4, that employed the same task, but analysed responses without taking 
into account subsequent memory performance, physostigmine partially reversed 
Alzheimer’s disease-associated deficits in task-related frontoparietal activity, that was 
associated with a lesser performance impairment during the encoding task (of visual 
discrimination). However, by directly correlating task-related responses with effects 
on subsequent memory, the current results show that even under circumstances where 
physostigmine enhances frontoparietal task-related activity - as in Experiment 4 – this 
may be insufficient to restore a depth-of-processing effect on subsequent memory. 
Two previous fMRI studies in mild cognitive impairment patients have similarly 
shown enhancements of task-related frontoparietal activity following cholinesterase 
inhibitor therapy that were associated with improvements in working memory / 
attention, but not in episodic memory (Goekoop et al, 2004; Saykin et al, 2004). 
Taken together, these observations argue for the existence of dissociable effects for 
cholinesterase inhibitors on episodic memory versusattention (Sahakian et al, 1993; 
Lindner et al, 2006), that parallel dissociable pathological correlates of episodic 
memory and attention impairments in Alzheimer’s disease (Perry & Hodges, 1999; 
Perry et al, 2000; Buckner, 2004). One possible reason for the pharmacological / 
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functional dissociation observed is that memory, and especially depth of processing 
memory effects, rely on frontoparietal-extrastriate-hippocampal functional 
connections (Grady et al, 2001; Celone et al, 2006; Bokde et al, 2006), whose 
impairments in dementia may be less reversible by physostigmine than strength of 
activation for each of these regions considered in isolation. Our finding that 
physostigmine did not impact on  fusiform – parietal functional coupling in 
Alzheimer’s disease subjects, unlike in healthy subjects, is consistent with this.  
 
Although physostigmine did not influence depth- of-processing recognition-memory 
effects in our Alzheimer’s disease patients, the drug did exert a significant benefit in 
(confident) recognition that was independent of encoding task (Fig. 9.4C). Moreover, 
this behavioural memory effect of the drug in Alzheimer’s disease correlated with 
physostigmine-induced enhancements of bilateral face-selective fusiform cortices at 
initial encoding, but did so regardless of encoding task. Left fusiform cortex also 
showed a subsequent memory effect for faces in Alzheimer’s disease, suggesting that 
enhancement of activity in this region by physostigmine was related to subsequent 
recognition in these patients. This aspect of our results suggest that Alzheimer’s 
disease-associated impairments in fusiform cortex activity (see also Golby et al, 2005; 
Gron & Riepe, 2004; Machulda et al, 2003; Rombouts et al, 2005) may not only be 
reversible with cholinergic enhancement (see also Rombouts et al, 2002; Kircher et al, 
2005), but that a functional consequence of this can be a proportionate improvement 
in subsequent recognition memory. The fact that, unlike healthy subjects, the effects 
of physostigmine on encoding-related activity in Alzheimer’s disease patients was 
independent of task also seems consistent with reports that cholinesterase inhibition 
may modulate sensory cortices in Alzheimer’s disease under both low and high-
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attention conditions (Rombouts et al, 2002; Teipel et al, 2006). Our findings also 
complement studies showing that cholinergic antagonism in healthy subjects impairs 
both encoding-related activity in fusiform cortices, and recognition performance 
(Schon et al, 2005; Sperling et al, 2002; Rosier et al, 1999; Thiel et al, 2002).  
 
We found that Alzheimer’s disease patients only showed a treatment effect on 
memory when selectively analysing confident judgements. To the extent that 
confident judgements can be thought of as indexing hippocampus-based recollection 
memory, as opposed to familiarity (see Hudon et al, 2009; Wais, 2008), this 
behavioural result complements studies showing that Alzheimer’s disease memory 
impairment is relatively specific for the former type of memory process (Dalla Barba 
et al, 1997; Rauchs et al, 2007). Indeed, we found that the drug-induced (confident) 
memory improvement in Alzheimer’s disease correlated with activation enhancement, 
not only in fusiform cortex but also in hippocampus (Fig. 9.4C), as well as increasing 
functional coupling between these two regions (Fig. 9.5D). These findings 
complement a recent study showing that scopolamine reduces perirhinal activations 
specifically during contextual recollection, rather than for familiarity judgements 
(Bozzali et al, 2006), as well as supporting behavioural evidence suggesting a 
specificity of cholinergic actions for explicit relative to implicit memory (Knopman, 
1991; Kopelman & Corn, 1988). 
 
Conclusion 
The current study unifies three previous sets of results: first, for behavioural studies 
showing that the memory-enhancing effects of pro-cholinergic drugs interact with 
encoding task (Warburton et al, 2001; Fitzgerald et al, 2008); second, functional 
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imaging studies showing that cholinergic-enhancing drugs increase visual extrastriate 
cortex activity in a task-dependent pattern (Furey et al, 2000; Lawrence et al, 2002; 
Experiments 1 and 3); and third, a range of studies showing that cholinergic 
antagonism of higher sensory cortices (as well as perirhinal-entorhinal cortices) 
correlates with impaired encoding (Kirkwood et al, 1999; Boroojerdi et al, 2001; 
Dotigny et al, 2008; Sperling et al, 2002; Schon et al, 2005). Here we show that the 
improvement in face-recognition memory induced by a cholinesterase inhibitor 
challenge directly correlates with drug-induced increases in visual extrastriate cortex 
activity during encoding, that in healthy subjects, but not Alzheimer’s disease, are 
task-dependent. As well as lending further support to theoretical models that integrate 
cholinergic actions on sensory, attentional and memory processes (Sarter et al, 2003; 
Hasselmo & McGaughy, 2004), the BOLD-behavioural relations that we present here 
support aspirations to apply functional imaging technology to predict treatment 
responses in patients in future (Matthews et al, 2006).  
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10. General Discussion 
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 Summary of Experimental Findings 
 
The experiments of this thesis explore how a hypercholinergic state (as induced by a 
single-challenge with the cholinesterase inhibitor physostigmine) interacts with brain 
activation patterns observed under specific sensory, attentional and memory paradigms, 
and how this relates to behavioural effects. Given a theoretical neurobiological 
framework of cholinergic function, as discussed in Chapter 2, specific hypotheses were 
generated regarding how elevation of ACh levels would interact with patterns of cerebral 
processing measurable with human functional neuroimaging. The experiments also 
complement an expanding literature of human cholinergic functional imaging studies 
reviewed in Chapter 3. The main findings are as follows (listed thematically to assist 
interpretation): 
 
1. Stimulus-evoked activity within higher (extrastriate) and lower (striate) visual cortices 
is diminished with physostigmine where there is no prior interaction of attention with 
sensory response and /or during low-attention. This is seen most clearly in Experiment 3 
where physostigmine decreases striate cortex activity response to a flashing visual 
chequerboard regardless of task, and decreases superior and lateral occipital activity 
during low-attention conditions. Experiment 4 also showed that face-evoked fusiform 
cortex activity is generally decreased by physostigmine - during a depth-of-processing 
manipulation that did not itself modulate fusiform cortex activity.       
 
2. By contrast, stimulus-evoked activity within higher visual cortex is enhanced with 
physostigmine selectively during tasks demanding high attention and where there is 
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already an interaction of attention with sensory response. This is seen in Experiment 3 
where superior-lateral occipital visual-evoked responses are increased by physostigmine 
selectively during a demanding visual orienting task; and in Experiment 4 where occipital 
regions already demonstrating task-by-sensory interactions showed an overall 
enhancement of stimulus-evoked activity by physostigmine. Experiment 1 too showed an 
enhancement of fusiform cortex activity with physostigmine - this region also showing an 
interaction with attention (unlike the paradigm of Experiment 4 in which fusiform cortex 
activity did not apparently interact with task, and in which physostigmine decreased 
activations in this region). Experiment 1 also revealed a drug-induced enhancement of 
fusiform activations specifically to emotional, relative to neutral valence, stimuli, 
suggesting that physostigmine can also boost responses to bottom-up forms of attention, 
e.g. as elicited by stimulus salience.  
 
3. Although physostigmine enhances sensory cortex activations during attention-
demanding tasks (see above), this enhancement is often greater for task-irrelevant than 
task-relevant stimuli. Consequently, top-down differential activation of sensory cortices 
may actually be reduced. This is seen in Experiment 3 where physostigmine 
preferentially increased occipital activations on the hemisphere side opposite to that 
expected from the cue direction. A functional correlate of this was also expressed in that 
treated subjects also tended to show faster responses to targets in the visual hemifield 
opposite to that cued. Experiment 1 showed similarly a reduction in selective attention-
driven modulation of lateral occipital cortex with physostigmine. Furthermore, 
Experiment 4 demonstrated a reduction in task-dependent differential modulation of 
sensory cortices with physostigmine, due primarily to a drug-induced enhancement of 
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sensory activations during a ‘superficial encoding’ task, in which higher sensory 
processing was irrelevant to task.     
 
4. One of the functional consequences of physostigmine increasing higher sensory cortex 
activations, selectively under attention-demanding conditions, is that it may enhance 
stimulus encoding, as measured by a subsequent recognition memory test. Hence in 
Experiment 5, a strong positive correlation was found between physostigmine-induced 
enhancement of fusiform cortex activity and the extent to which physostigmine enhanced 
subsequent recognition memory scores.  
 
5. Repetition suppression - a well-recognised neural correlate of repetition priming – is 
increased by physostigmine in early sensory cortices, although only for attended, rather 
than unattended, stimuli (Experiment 2). In so doing, physostigmine shifted the normal 
pattern of repetition decreases – in which they occur equally for all stimuli regardless of 
task relevance, to one in which repetition decreases occurred selectively for task-relevant 
stimuli. A concordant behavioural effect was also observed, in that priming (i.e. faster 
responses to repeated stimuli) became under physostigmine confined to trial pairs in 
which repeated stimuli were task-relevant, rather than occurring to repeated stimuli 
regardless of task relevance, as seen under placebo.  
 
6. Cerebral responses to physostigmine differed importantly and consistently between 
healthy elderly people and age-matched Alzheimer’s disease patients. Specifically, where 
physostigmine had decreased differential activations in healthy subjects, e.g. in sensory 
or frontoparietal cortices as a function of depth of processing, the same manipulation in 
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Alzheimer’s disease had caused increases in these same contrasts (Experiment 4). 
Furthermore, whereas correlations between drug-induced fusiform cortex enhancements 
and recognition memory improvements had in healthy subjects been found to interact 
with depth of processing (in that physostigmine preferentially increased both fusiform 
responses and recognition to ‘deeply encoded’ stimuli), in Alzheimer’s disease, where 
BOLD – memory correlations did occur, these were not related to depth of encoding 
(Experiment 5).   
 
Interpretation 
 
1. Directionality of sensory cortex modulations depends upon task or stimulus type  
The general findings of Experiments 1, 3 and 4 that probed interactions of physostigmine 
with sensory cortex function are in line with previous functional imaging studies, and 
accounts of cholinergic modulation of sensory and attentional functions described earlier. 
Thus, cholinergic stimulation enhanced sensory cortex activation, but only under high- 
attention conditions where there is already evidence for top-down modulation of sensory 
activations. In other words, physostigmine does not enhance sensory cortex activity 
generally, or even enhance stimulus-evoked responses, but instead enhances top-down 
recruitment of sensory regions. This is entirely in keeping with a key postulated role for 
the nucleus basalis - neocortical system - namely, to enhance sensory and attentional 
processes in posterior regions during periods of performance challenges - for example 
with distracter insertion, or with sustained attention paradigms when performance 
typically declines with time (Sarter et al, 2006).   
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Experiments 3 and 4 also concur with another general point noted in the earlier review of 
human cholinergic functional imaging studies (Chapter 3) - that during periods of low-
attention or rest, cholinergic stimulation decreases sensory cortex activity (or conversely, 
cholinergic antagonists increase sensory cortex activity). This was interpreted with 
reference to cortical-slice studies, showing that ACh decreases overall activation of 
cortical columnar activity, by virtue of decreasing transmission in all cortical layers, 
except in input layer IV (e.g. Kimura et al, 1999). Since the functional effect of this 
laminar-selective suppression by ACh is to enhance feedforward, relative to feedback, 
information flow (Hasselemo & McGaughy, 2004), the general neuroimaging finding that 
cholinergic-stimulating drugs decrease sensory cortex activity, might be regarded as 
indicating enhanced bottom-up processing. In other words, rises in ACh levels in sensory 
cortex, when top-down signalling is at a low level, result in a processing mode favouring 
input potentiation, although the observed effect is a net suppression of feedback synapses. 
 
That effects of physostigmine in higher sensory regions interact with attention is 
highlighted by comparing the results of Experiments 1 and 4. Thus in Experiment 1, 
physostigmine increased attentional modulation of fusiform cortex, whereas in 
Experiment 4, the same drug caused a general decrease in stimulus-evoked activations of 
fusiform cortex, there being no effects of task (attention) in this region, for this 
experimental design. This difference in fusiform cortex drug response parallels the 
region-specific responses found in Experiment 3, whereby striate cortex –which showed 
no task-modulation – was suppressed by physostigmine, whereas lateral occipital cortex – 
which did show task-modulation – showed task-selective enhancement under 
physostigmine. Thus physostigmine appears to enhance attention-driven modulations of 
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(higher) sensory cortex, while decreasing sensory-driven modulations of sensory cortex; 
although, as discussed, this latter neuroimaging finding may still be compatible with a 
model in which bottom-up processing is enhanced with acetylcholine.   
 
As well as enhancing attention-dependent activations of sensory cortex, Experiment 1 
demonstrated that physostigmine can enhance fusiform cortex activations driven by the 
emotional valence of a stimulus type. This is perhaps not too surprising given that 
stimulus salience can act as a source of ‘bottom up’ attention, and may employ common 
downstream machinery to that recruited by top-down forms of attention. Two types of 
experiments in rodents have demonstrated analogous effects. In the first, cholinergic 
lesions in rodents disrupt attentional increments to conditioned stimuli secondary to 
stimulus contingency violations (Chiba et al, 1995). In this particular paradigm, attention 
shifting is found to be critically dependent upon a circuit comprising amygdala central 
nucleus (Holland & Gallagher, 1993), substantia innominata – nucleus basalis, and 
posterior parietal cortex (Bucci et al, 1998). In the second set of experiments, fear-
conditioning-induced remapping of tone-specific representations within auditory cortex is 
similarly found to depend upon both amygdala, nucleus-basalis and neocortical 
cholinergic integrity (Weinberger et al, 2007). The results of Experiment 1 accord with 
these two sets of findings since the valence of the stimuli employed activated both 
amygdala, and higher sensory cortex, with physostigmine increasing emotion-driven 
responses in the latter. Hence Experiment 1 supports a model by which either top-down 
or motivation-driven recruitment of sensory processing is mediated, at least partially, by 
the nucleus basalis – neocortical cholinergic system (Sarter et al, 2006). Moreover it 
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shows that cholinesterase inhibition can increase both attention-driven and salience-
driven activations of higher sensory cortex.  
 
2. Sensory cortex modulations may depend upon anatomical region 
 A further factor that may determine responsiveness of sensory regions to cholinergic 
stimulation is anatomical location. In Experiment 3, physostigmine decreased stimulus-
induced visual striate cortex activations regardless of task, whereas higher visual regions 
e.g. lateral occipital cortex, showed the task-dependent pattern of drug-induced 
modulation discussed above. Other functional neuroimaging studies have also suggested 
that cholinergic stimulation increases activation in higher more than lower visual 
processing regions. For example, cholinesterase inhibition suppressed stimulus-evoked 
activations in striate cortex, (Silver et al, 2007), while increasing them in a task-
dependent fashion in higher extrastriate visual regions (Furey et al, 2000a). Nicotine also 
is found to decrease posterior visual cortical activations while increasing those in more 
anterior visual regions (Thiel et al, 2005; Hahn et al, 2009). Furthermore, scopolamine 
decreases activations in extrastriate visual cortex specifically during face-name learning, 
whereas no modulation is observed in striate cortex (Sperling et al, 2002). Such 
anatomical variations of cholinergic response would be in keeping with a model (Fig. 3.1) 
in which cholinergic stimulation modifies both bottom-up effects (recorded as net 
deactivation of early sensory cortices) and top-down effects (recorded as net 
enhancements of higher sensory cortices); as in most of these studies top-down effects 
were seen more readily in higher visual regions. One of the ways by which such 
anatomical-specificity of ACh effects occurs is through receptor segregation. For 
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example, a preferential expression of muscarinic receptors in V2 relative to V1 cortex 
parallels a spatial gradient in attentional modulation (Disney et al, 2006). 
 
A further consistent anatomical division by which visual regions differ according to 
cholinergic response is that between ventromedial and posterolateral visual regions, with 
the former showing increased, and the latter decreases, in activity secondary to 
cholinergic stimulation. This dichotomous pattern of responses is seen most readily in 
Experiment 1, where neural correlates of spatial attention were increased by 
physostigmine in fusiform cortex, but decreased in posterolateral occipital cortex. 
Experiment 2 and 4 also found that physostigmine decreased task-related differential 
responses in posterolateral occipital cortex, while Experiment 5 found evidence for 
physostigmine-induced increases in task-related activations within fusiform cortex 
(apparent only on correlating with subsequent recognition performance). It is striking that 
a very similar anatomical dissociation in responses to physostigmine has also been 
observed by a separate group using a face working memory paradigm – with 
physostigmine increasing stimulus-induced, ventromedial extrastriate activations 
(including fusiform gyrus), while decreasing activations in posterolateral occipital 
regions (Furey et al, 2000b; Furey et al, 2008a; Ricciardi et al, 2009; Mentis et al, 2001). 
A similar profile of modulations is also seen with nicotine in higher visual areas (Thiel et 
al, 2005; Hahn et al, 2007). Conversely, muscarinic blockade results in activation 
decreases in fusiform cortex (Thiel et al, 2002c; Sperling et al, 2002; Schon et al, 2005; 
Rosier et al, 1999) but activation increases in lateral occipital cortices (Grasby et al, 
1995; Bahro et al, 1999; Mentis et al, 2001; Thienel et al, 2009b).  
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Cholinergic-induced enhancements of inferior-medial temporal cortex might relate to this 
region’s critical role in encoding. Since activations in inferior temporal cortex may index 
subsequent memory (Grady et al, 1998), cholinergic-induced enhancements here may 
reflect facilitation of encoding (Experiment 5), possibly due to processes such as 
sustained-spiking (Schon et al, 2005). This might explain why cholinergic modulation of 
medial, but not lateral, occipital regions is delay-dependent (Furey et al, 2008a). 
Conversely, lateral occipital cortex, that is heavily influenced by top-down or lateral 
connections (Vinberg & Grill-Spector, 2008), might be expected to show depressed 
activity following cholinergic stimulation, given that ACh generally inhibits intracortical 
transmission (Roberts et al, 2005). It is also noteworthy that cholinergic innervation to 
human occipital cortex segregates into medial and lateral pathways (Selden et al, 1998).  
  
3. Effects on top-down modulation of sensory activations  
Given that ACh plays a key role in selective attention (Sarter et al, 2006), with evidence 
from single-unit studies of ACh potentiating attentional modulation of visual (Herrero et 
al, 2008) and parietal (Broussard et al, 2009) responses, it was initially hypothesized that 
pro-cholinergic drugs would enhance selectivity of sensory processing. Thus an 
unexpected finding across several experimental paradigms is that cholinesterase 
inhibition reduces top-down selectivity of sensory cortices. This is seen for both spatial 
attention (Experiment 1; Experiment 3) and depth-of-processing (Experiment 4) visual 
tasks, in which physostigmine reduces task-driven (as opposed to stimulus-driven) 
differential modulation of extrastriate visual cortices. Similarly, in a fear-conditioning 
paradigm, physostigmine reduced the differential activation of auditory cortex to a 
conditioned stimulus (i.e. previously paired with a shock) relative to a non-conditioned 
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stimulus (i.e. no shock association) (Thiel et al, 2002b). Physostigmine has also been 
shown to increase the spatial extent of sensory activations during stimulus processing 
implying a reduction in stimulus-selectivity (Furey et al, 2000a). 
 
Importantly, in order to reconcile this set of findings with the previous observation that 
pro-cholinergic drugs elevate functional activations during attention-demanding tasks, 
these experiments also showed that a main reason for such decrease in attentional 
selectivity is because of a disproportionate increase in sensory activity for  task-
irrelevant, or non-conditioned, rather than task-relevant, or conditioned, stimuli. 
Moreover, accompanying behavioural data suggest that enhancement of irrelevant 
stimulus processing associated with a hypercholinergic state has functional correlates. For 
example, physostigmine-induced stimulation of visual cortex coding for the visual 
hemifield opposite to that cued correlates with speeding to invalidly-cued targets 
(Experiment 3). Furthermore, high-ACh states enhance behavioral (Holley et al, 1995) 
and autonomic (Quigley et al, 1994) responses to irrelevant or low salience (Furey et al, 
2008b) stimuli. Thus by heightening activity in sensory regions away from those 
favoured by top-down commands, a hypercholinergic state increases detectability of 
unexpected signals. Once again this fits with a model in which cortical ACh levels 
increase under conditions of high uncertainty by reducing internally-derived weighting of 
inputs (Yu & Dayan, 2005).  
 
Whether nicotine works in a similar regard to cholinesterase inhibition is unclear. 
Behaviourally, nicotine reduces the penalty incurred by invalid cueing, suggesting that - 
like physostigmine - it counteracts selective attention by balancing out competing inputs 
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(Witte et al, 1997; Thiel et al, 2005). Furthermore, nicotine reduces a correlation between 
occipital deactivations and increasingly precise spatial cueing, suggesting that it enhances 
activity in task-irrelevant retinotopic areas (Hahn et al, 2007).  However, nicotine does 
not consistently modulate cue-driven sensory cortex selectivity (Thiel et al, 2008), 
suggesting that more regionally abundant muscarinic receptors may account for the 
profile seen with physostigmine (Paterson & Nordberg, 2000; Zilles et al, 2002).       
 
Does evidence from other sources indicate that a hypercholinergic state can decrease 
sensory cortex selectivity? As mentioned earlier, local ACh application in visual cortex 
increases the difference in firing rates between cells coding for task-relevant versus task-
irrelevant locations (Herrero et al, 2008). However, the same study also found that ACh 
increased the overall firing rate, and, moreover, in some neurons increased it 
disproportionately more for stimulus-attribute values (e.g. bar length) that were non-
optimal. Other studies have also noted ACh-induced reductions in selectivity to stimulus 
features (Zinke et al, 2006) or spatial coding (Kuo et al, 2009), at the same time as 
enhancing overall activity. This concords with functional imaging findings of enhanced 
sensory cortex activations following cholinergic stimulation, concomitantly with reduced 
selectivity (Figure 3.1).  
 
Conceivably, under hypercholinergic conditions – i.e. those achievable 
pharmacologically, but not encountered under usual physiological states – weak top down 
signals are boosted more than strong ones, because the latter have all ready reached a 
ceiling. This may explain why some cholinergic-functional imaging results seem 
maladaptive in the sense that they favour task-irrelevant over task-relevant stimulus 
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processing. Support for this interpretation comes from an animal model of anxiety and 
psychosis, in which excessive ACh neurotransmission produces a hypervigilant state - 
including heightened sensitivity to distractor and irrelevant stimuli (Berntson et al, 1998).     
 
4. Frontoparietal modulations  
Since physostigmine was found to reduce top-down modulation of sensory cortices (see 
above), we might also expect the same drug to modulate those frontoparietal regions – 
especially right parietal cortex - that are believed to exert top-down control (Yantis et al, 
2002). Consistent with this, Experiment 3 demonstrated that physostigmine reduced right 
superior parietal cortex activity (as well as left inferior prefrontal cortex) during 
maintenance of orienting, coincident with a reduction in occipital cortex selectivity. In 
Experiment 4 too, healthy subjects responded to physostigmine with a decrease in task-
related right parietal activity, while also showing decreases in task-dependent differential 
modulation of extrastriate visual cortex. The interpretation of these findings is that 
physostigmine enhances sensory processing generally during tasks requiring high 
attention, whilst reducing selectivity of sensory processing during these very conditions – 
thus enhancing activity relatively more in occipital regions coding for task-irrelevant 
visual locations (Experiment 3), or in regions processing facial characteristics where this 
is irrelevant to task (Experiment 4). To the extent that right parietal activation might 
reflect the source of selective attention it is conceivable that the reductions in sensory 
cortex selectivity secondary to physostigmine were themselves due primarily to 
cholinergic effects in parietal cortex.    
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A related set of findings are from those studies investigating effects of nicotine on a 
spatial (Posner) cueing task, in which nicotine decreased parietal activation, at the same 
time as speeding responses to invalidly cued targets (Phillips et al, 2000; Thiel et al, 
2008; see Chapter 3). In this context, nicotinic stimulation was proposed to increase 
sensory processing in general (‘vigilance’), whilst diminishing the selectivity of sensory 
processing induced by spatial cueing. Both this interpretation and that advanced for 
Experiments 3 and 4, are in line with a model by which acetylcholine increases the 
influence of bottom-up relative to top-down processing (Yu & Dayan, 2005). 
 
5. Memory-associated modulations  
Experiments 2 and 5 tested effects of physostigmine on behavioural and neural measures 
of one form of implicit memory – repetition priming, and one form of explicit memory – 
recognition memory. Hypotheses motivating these experiments spawned from studies 
demonstrating multiple memory mechanisms susceptible to cholinergic manipulation (see 
Chapter 2). 
 
Repetition priming – the phenomenon by which repeated stimuli are processed more 
efficiently than unprecedented ones – is believed to be strongly related to the neural 
phenomenon of repetition suppression – by which neural activity decreases specific to 
repeated stimulus details (see Henson et al, 2002). The cellular processes that underlie 
repetition suppression are likely to be sensitive to a range of neuromodulatory influences 
(Rasmusson, 2000), including acetylcholine that is known to interact with sensory 
cortices, where most sensory-related repetition decreases are observed. Consistent with 
this, two previous human fMRI studies employing scopolamine showed a diminution of 
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both repetition priming and neural repetition decreases in prefrontal and visual 
extrastriate cortices to either word or face stimuli (Thiel et al, 2001; Thiel et al, 2000a).  
Although repetition suppression in monkey inferior temporal cortex has not, by contrast, 
been found to be cholinergic-dependent (Miller & Desimone, 1993), it is possible that 
this discrepancy may have arisen because of restricted neural sampling or shorter lag 
times in the latter case.  
 
Given that scopolamine suppresses functional imaging signatures of repetition priming, 
and given that cholinesterase inhibition improves repetition priming in Alzheimer’s 
disease (Riekkinen and Riekkinen, 1999), it was hypothesised that physostigmine would 
enhance neural correlates of repetition priming. This prediction was borne out in 
Experiment 2 in which physostigmine reduced neural activity to the repeated item more 
than was already the case without drug, thereby enhancing the repetition decrease effect. 
This result stands in contrast to effects of physostigmine on conditioning-associated 
sensory cortex remapping (Thiel et al, 2002b), in which physostigmine increased neural 
activity to unconditioned stimuli, effectively decreasing the neural conditioning effect. 
Thus the neural and behavioural influences of physostigmine are not always the opposite 
of those induced by cholinergic-blocking drugs, even within the restricted set of neural 
mechanisms underlying implicit memory within sensory cortices.  
 
Experiment 5, in testing effects of physostigmine on recognition memory, also 
corresponded with previous functional imaging studies investigating effects of 
scopolamine on recognition memory, and its neural correlates (Sperling et al, 2002; 
Bullmore et al, 2003; Schon et al, 2005). These studies had shown that cholinergic 
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antagonism reduces visual extrastriate, as well as perirhinal, cortex activations during 
encoding, which itself correlated with reduced subsequent memory. In so doing, such 
studies had corroborated studies in monkeys demonstrating a dependency of recognition 
memory on cholinergic inputs to equivalent higher sensory regions during encoding (e.g. 
Tang et al, 1997). Conversely, pro-mnemonic effects of cholinesterase inhibition and 
nicotine, having also been expressed selectively during encoding (Warburton et al, 2001; 
Fitzgerald et al, 2008), led to the prediction that task-specific enhancements of sensory 
cortical processing by physostigmine – as witnessed in Experiments 1 and 3, as well as in 
the context of a working memory task (Furey et al, 2000b) – would be associated with 
enhanced subsequent memory. Experiment 5 was able to confirm this prediction by 
demonstrating positive correlations between effects of physostigmine on face-selective 
responses in fusiform cortex at encoding, and effects of the same drug on subsequent 
recognition, at the subject level, in both healthy elderly and mild Alzheimer disease.  
 
An interesting commonality in the results of Experiments 2 and 5 (healthy subjects 
group), is that the positive effects of physostigmine on memory-associated sensory cortex 
activity were expressed only through an interaction with attention (or task requirements). 
In other words, physostigmine enhanced visual cortex repetition decreases, but only for 
attended, not unattended, repeated stimuli; and correlations between physostigmine-
associated increases in fusiform cortex activity, and subsequent recognition, were only 
apparent for the contrast of deeply-encoded versus superficially-encoded stimuli. Such 
data concord well with the notion that pro-attentional affects of ACh in sensory cortices 
are conducive to effective encoding (Warburton et al, 2001; Sarter et al, 2005a). For 
example, selective effects of ACh on sensory cortical laminae encourage a feedforward 
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relative to feedback direction of inputs, and as such are likely to enhance both stimulus 
processing during attention-demanding conditions, and the formation of novel associative 
connections required for effective encoding (Hasselmo & McGaughy, 2004).  
 
Combining results of Experiments 4 and 5, it is apparent that physostigmine can enhance 
both non-specific visual processing (in sensory regions showing task-specific activity 
initially) and task-specific visual processing (in sensory regions not showing task effects 
initially), and as such support a model by which ACh potentiates both bottom-up and top-
down processes (Sarter et al, 2001). This observation may be related to the general 
anatomical point made earlier (based upon Experiments 1, 3 and 4) that physostigmine 
enhances task-related effects in ventromedial occipital-temporal regions (including 
fusiform cortex) while decreasing them in posterolateral occipital regions. The findings 
from Experiments 2 and 5 suggest a functional consequence of this anatomical 
dissociation in responses to physostigmine: namely, that the drug-induced increases in 
task- (or attentional-)dependent differential responses in ventral extrastriate cortex are 
hallmarks of cholinergic influences on sensory cortex-based memory mechanisms. 
 
6. Differences between health and Alzheimer’s disease in response to physostigmine  
The use of cholinesterase inhibitors in Alzheimer’s disease (AD) followed logically from 
two sets of facts: firstly, from the pathological insight that the AD brain is distinguished 
by loss of cortical cholinergic innervation; and secondly, from appreciating that similar 
profiles of cognitive dysfunction could be induced by selective cholinergic lesions in 
animals (Bartus et al, 1982). Consequently, drugs that enhance, and therefore which may 
partially restore, cholinergic neurotransmission might be expected to reverse AD-
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associated patterns of neural activation. This prediction was directly tested in Experiment 
4, in which each AD patient was scanned both on and off drug (counterbalanced for 
order), and compared with healthy subjects. As expected from the AD ‘cholinergic 
hypothesis' (Mesulam et al, 2004), physostigmine partially restored patterns of stimulus 
or task-selective activations in AD patients that had differed significantly between 
groups. However, the same drug challenge in healthy subjects, rather than further 
increasing the differential responses to stimulus or task type (as might be expected for a 
monotonic relationship between ACh levels and cortical activations), actually decreased 
many of these differential responses. Consequently, both hypocholinergic states (i.e. as 
recognised in AD), and hypercholinergic states (as here induced by physostigmine), 
impaired the normal pattern of differential activations, in both sensory and frontoparietal 
regions – implying an ‘inverted-U shaped’ pattern of neuromodulation. 
 
A similar, more general finding summarises a range of other cholinergic functional 
imaging studies that have scanned subjects under different physiological or pathological 
states. Thus pro-cholinergic drugs normalise task-evoked activation levels in states - such 
as sleep-deprivation (Chuah & Chee, 2008), aging (Ricciardi et al, 2009) or disease (Blin 
et al, 1997; Jacobsen et al, 2004; Goekoop et al, 2006), or with certain genetic 
polymorphisms (Jacobsen et al, 2006) - where such activations are abnormally low or 
high to begin with. By contrast, many of these studies also show either no modulation, or 
a reverse pattern of modulation, in the same regions, under the same paradigm, in healthy 
controls tested with the same drugs (Fig. 10.1B). Furthermore, disparate neuromodulatory 
signatures between patients and controls may be matched by equivalent behavioural 
dissociations, with performance enhancements selectively in those with abnormal 
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physiological states to begin with, and deteriorations in controls (Jacobsen et al, 2004). 
This matches data demonstrating that performance benefits of pro-cholinergic drugs are 
inversely correlated with baseline performance (Ernst et al, 2001; Kukolja et al, 2009; 
Newhouse et al, 2004; Thiel et al, 2005; Beglinger et al, 2005).  
 
There are two further patterns of inverted-U response to cholinergic drugs that might be 
related (Fig. 10.1). Firstly, cortical response to a cholinergic drug often depends upon the 
level of regional activation prior to drug challenge (Figure 4A). Thus pro-cholinergic 
drugs enhance frontoparietal activity most readily under task conditions where such 
activity is relatively low under placebo, but decrease activity within the same regions, 
when activations are high to begin with (seen in Experiment 3 in parietal regions; also see 
Kumari et al, 2003; Hahn et al, 2007; Hahn et al, 2009). It is notable that the relative 
activation levels under placebo are not consistently related to the relative attentional 
demands, suggesting that the inverted U-shaped profile of cholinergic modulations may 
occur independently of the cognitive process tested. In fact, many examples of task-by-
drug interactions, where say cholinergic stimulation decreases activations in 
frontoparietal regions selectively during demanding conditions (Furey et al, 2008a; 
Ricciardi et al, 2009; Thiel et al, 2005), may relate to the height of activations at baseline, 
rather than because of a specific cognitive interaction per se. Similar baseline-dependent 
inverted-U shaped cholinergic responses have been observed in sensory (Hahn et al, 
2007) and hippocampal (Schon et al ,2005; Kukolja et al, 2009) regions.  
 
A related phenomenon consists of activation decreases under both cholinergic blockade 
and stimulation, for a given brain region and paradigm. As examples, working memory-
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associated prefrontal activity is suppressed by both physostigmine (Furey et al, 1997; 
Furey et al, 2000b), and scopolamine (Grasby et al 1995; Dumas et al, 2008), whilst 
stimulus-evoked activations of primary visual cortex are suppressed both by donepezil 
(Silver et al, 2008) and scopolamine (Mentis et al, 2001). 
 
One explanation for these phenomenona might relate to methodology. For example, if a 
drug reduces all activations by 10%, then this may be discerned only in conditions with 
high activations to begin with. Conversely, if the hemodynamic response to a particular 
condition is at ceiling, then drug-induced increases in neural activity may only be 
manifest in conditions where the hemodynamic response starts off low. Furthermore, we 
should be wary of ‘regression to the mean’ artefacts - arising from the fact that floor 
activations can only get higher, and ceiling activations can only get lower.  
 
However, there are several plausible neurobiological reasons why we might expect this 
profile. According to the ‘attentional effort’ hypothesis (Sarter et al, 2006), cholinergic 
stimulation activates both anterior and posterior cortical regions in response to 
performance challenges, which may explain why exogenous pro-cholinergic drugs 
elevate activations that begin low, typically in undemanding conditions. Conversely, the 
suppression of both frontoparietal task-dependent activity and sensory cortex task-
dependent selectivity with pro-cholinergic therapies may correspond to decreases in top-
down, or feedback, concordant with information-processing models of cholinergic 
function (Hasselmo & McGaughy, 2004; Yu & Dayan, 2005). This would explain why 
the pattern of impaired differential sensory cortex responses seen with physotigmine in 
healthy subjects is due to excess activation during task-irrelevant conditions 
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(Experiments 3, 4; also Thiel et al, 2000b); whereas the pattern of impaired differential 
sensory cortex responses observed during disease or with cholinergic antagonists, is 
accountable more through under-activation during task-relevant conditions. More 
generally, where cholinesterase inhibition or nicotine increases task-related cortical 
activity, or performance, this appears to reflect subject factors, e.g. due to genetic 
variation, disease, sleep-deprivation or task conditions, or task factors, e.g. with low 
attentional demands, where there is a relative reduction in ACh neurotransmission to 
begin with, and vice versa for subject groups or tasks in which there is a relatively high 
baseline level of cholinergic activation. 
 
It is noteworthy that inverted-U shaped functions of neuromodulation are also seen with 
dopamine (Williams & Castner, 2006), and norepinephrine (Introini-Collison & 
McGaugh, 1986). For instance, amphetamine increases performance and prefrontal 
activation in subjects with low baseline measures of each, but decreases both in subjects 
who begin with high values for each (Mattay et al, 2000). Thus a common property of 
neuromodulators is that their process-optimising capabilities exist within a narrow 
concentration range. Two practical implications of this are that ‘performance-enhancing’ 
drugs are unlikely to benefit high-performers, and that the effects of such drugs may be 
predictable from individuals' baseline behaviour or brain activity (Giessing et al, 2007). 
Furthermore, differences in performance accountable by genetic polymorphisms in 
dopaminergic neurotransmission produce an inverted-U pattern of response to nicotine 
(Jacobsen et al, 2006), providing further evidence for cholinergic - dopaminergic 
interactions (Dewey et al, 1993). 
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Figure 10.1 Responses to cholinergic drugs, both behaviourally and as recorded by functional imaging, may correspond to an inverted-U 
shaped pattern. Hence whether a pro-cholinergic drug increases or decreases performance / relative activity depends upon the value of either 
measure before drug is given, that itself depends upon task demands (A) and subject-specific factors (B). 
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Conclusion 
  
The physiological consequences of ingesting cholinergic-active substances have been 
observed since the Ancient Greek era, with scopolamine (bella donna), nicotine and 
physostigmine being recognised first as poisons, and only much more recently, as 
medicines. Applying these compounds to specific clinical scenarios, such as glaucoma, 
myasthenia gravis and Alzheimer’s disease, followed only after a basic 
pathophysiological appreciation of each condition, and from models of how such drugs 
act. Functional imaging promises to advance such understandings of disease and drug by 
relating traditional animal-based or post-mortem lines of enquiry with signatures of brain 
activity during real-time human performance.    
 
Focusing on cholinergic neurotransmission, the experiments of this thesis, and the 
subsequent review of like-minded studies, have shown how functional imaging can be 
used to inform, support or refute, existing accounts of neuromodulatory physiology. For 
example, although selective attention has previously been shown to be critically 
dependent upon an intact cholinergic system (Sarter et al, 2005a), functional imaging has 
shown that pharmacological elevation of cholinergic neurotransmission in healthy 
humans, cannot in general further improve this process (Experiment 1; Experiment 3; 
Experiment 4; Thiel et al, 2002c; Thiel et al, 2008). Rather, a range of studies has shown 
that such drugs modulate sensory and parietal cortex activity in a way that may enhance 
sensory processing of irrelevant items (Experiment 3; Thiel et al, 2002c; Thiel et al, 
2005; Vossel et al, 2008). From a pharmaceutical standpoint, such findings are useful in 
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showing why pro-cholinergic drugs may be limited in their use amongst relatively-well 
people, and contrast with ‘restorative’ patterns of neuromodulation in Alzheimer’s 
disease (Experiment 4). Furthermore, fMRI findings that cholinergic stimulation 
increases irrelevant sensory processing support independently-derived animal models 
which suggest that a hypercholinergic state contributes to ‘hypervigilant’ symptoms of 
anxiety and psychosis (Berntson et al, 1998; Sarter et al, 2005b). Consequently, a natural 
prediction from such results is that anti-cholinergic therapies may have a role in disorders 
characterised by distraction or hypervigilance.   
 
A further example by which functional imaging results may inform therapeutic pathways 
is suggested by the wealth of studies showing modulatory effects of pro-cholinergic drugs 
on parietal activations and attentional performance combined (see Table 2). These 
complement animal studies showing cholinergic dependence of parietal cortex for normal 
attentional orienting (Bucci et al, 1998; Davidson & Marrocco, 2000). Assuming 
therefore that parietal cortex is essential for the pro-orienting effects of cholinergic 
stimulation, a reasonable prediction is that patients with attentional neglect may benefit 
from pro-cholinergic drugs only if there is some sparing of (right) parietal cortex. A 
recent study seems to bear this out, with nicotine enabling reorienting away from 
invalid.cues, selectively in neglect patients with an intact parietal lobe (Vossel et al, 
2009).       
 
A different type of conclusion is suggested by those pharmacological functional imaging 
studies demonstrating correlations between drug-modulations and drug-associated 
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behavioural effects. In keeping with the observation that most pro-cholinergic drugs show 
only small or no behavioural effects, these studies demonstrate that subjects can differ 
widely in their neuromodulatory response to such drugs. Inspecting only group-effects of 
drugs on brain activations may ignore important neuromodulatory influences in a subset 
of subjects. For example, whereas group-level analysis suggested that physostigmine only 
decreases task-related activations in sensory cortex in healthy subjects (Experiment 4), a 
correlation analysis based upon subsequent memory scores revealed that in certain 
healthy subjects, physostigmine increases task-related responses (Experiment 5). Other 
cholinergic imaging studies have similarly shown a range of drug-associated 
neuromodulations associated with a spread of drug influences on performance (e.g. Ernst 
et al, 2001; Hahn et al, 2007).  
 
It is critical that drug-induced neural effects are not confounded by the subsequent 
behavioural influences, that in certain cases can be controlled methodologically, e.g. by 
restricting analyses to correct responses only (Kukolja et al, 2009) , or temporally 
separating neural sampling from performance effects (Experiment 5). However, even 
when such controls are made, it is difficult to know whether performance-correlated 
neural effects are causative, downstream or even epiphenomenal. For a more complete 
understanding therefore of variation in drug-responses, pharmacological functional 
imaging studies will need to be complemented by human studies employing factors such 
as genes, lesions or TMS, as well as more traditional animal experiments.  
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Yet, while functional imaging may point to neural processes of interest in accounting for 
performance effects, without actually proving causation, the same technology may also 
serve therapeutic innovation in other ways. For example, in separating drug-induced 
modulation of brain activity from performance effects, Experiment 5 demonstrates how 
functional imaging, in combination with a single drug-challenge, could be used as a 
predictive tool. A similar concept also underlies the finding that partial-least squares 
analysis of individual functional imaging data, prior to drug-use, can be used to predict 
subsequent behavioral effects of a drug, in this case, nicotine (Giessing et al, 2008). 
Furthermore, response to a cholinesterase inhibitor over a prolonged period has been 
correlated with both structural atrophy of substantia innominata, and baseline regional 
perfusion of frontal regions, as measured by baseline SPECT imaging (Kanetaka et al, 
2008). With increasing accuracy by which human cholinergic systems can be 
anatomically localized (Zaborsky et al, 2008; Selden et al, 1998), it is also possible that 
relationships between focal brain lesion site and drug response may emerge.  
 
One criticism often leveled against functional imaging is that its principle datum exists on 
a spatiotemporal scale, orders of magnitude greater than that at which neural processing 
occurs. This thesis has hopefully shown how in spite of this limitation, its results may still 
be both neuroscientifically meaningful, and offer the potential for clinical application.  
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